{"PMC7313479": [["The Journal reserves the right to edit all communications and requires that all letters be signed.", [["right", "ANATOMY_MODIFIER", 25, 30]]], ["You may submit your letter via e-mail in Word format to jadaletters@ada.org; by fax to 1-312-440-3538; or by mail to Letters to the JADA Editor, Publishing Division, American Dental Association, 211 E. Chicago Ave, Chicago, IL.", [["IL", "GENE_OR_GENE_PRODUCT", 224, 226]]], ["60611-2678.", [["60611-2678", "CHEMICAL", 0, 10]]]], "1a6365dc39a64aca823f69702986a2f78f021302": [["IntroductionCamillo Golgi (1844 Golgi ( -1926 not only discovered the Golgi apparatus (Golgi 1898) but also, in an unrelated set of experiments, provided the first description of a secretory process, namely acid secretion by gastric parietal cells (Golgi 1893) .", [["Golgi", "ANATOMY", 32, 37], ["Golgi apparatus", "ANATOMY", 70, 85], ["gastric parietal cells", "ANATOMY", 225, 247], ["Golgi", "ANATOMY", 249, 254], ["Golgi", "CELLULAR_COMPONENT", 20, 25], ["Golgi", "CELLULAR_COMPONENT", 32, 37], ["Golgi apparatus", "CELLULAR_COMPONENT", 70, 85], ["Golgi", "CELLULAR_COMPONENT", 87, 92], ["gastric parietal cells", "CELL", 225, 247], ["gastric parietal cells", "CELL_TYPE", 225, 247], ["a secretory process", "PROBLEM", 179, 198], ["acid secretion", "PROBLEM", 207, 221], ["gastric", "ANATOMY", 225, 232], ["parietal cells", "ANATOMY", 233, 247]]], ["Little did he know at the time, however, that his \"internal reticular apparatus\" was also intimately involved in a secretory pathway which was ubiquitous in eucaryotic cells.IntroductionThe electron microscopic studies of the 1950s provided convincing evidence for the existence of a Golgi organelle and the first detailed structural description of this complex organelle (see review by Farquhar and Palade 1981) .", [["reticular apparatus", "ANATOMY", 60, 79], ["cells", "ANATOMY", 168, 173], ["Golgi organelle", "ANATOMY", 284, 299], ["reticular apparatus", "CELLULAR_COMPONENT", 60, 79], ["eucaryotic cells", "CELL", 157, 173], ["Golgi organelle", "CELLULAR_COMPONENT", 284, 299], ["eucaryotic cells", "CELL_TYPE", 157, 173], ["his \"internal reticular apparatus", "PROBLEM", 46, 79], ["The electron microscopic studies", "TEST", 186, 218], ["reticular", "ANATOMY_MODIFIER", 60, 69], ["eucaryotic cells", "OBSERVATION", 157, 173]]], ["These early morphological studies initiated the challenge to biochemists and cell biologists to unravel the function of this organelle.", [["cell", "ANATOMY", 77, 81], ["organelle", "ANATOMY", 125, 134], ["cell", "CELL", 77, 81], ["organelle", "CELLULAR_COMPONENT", 125, 134], ["These early morphological studies", "TEST", 0, 33]]], ["In the 1960s the application of autoradiography demonstrated that secretory proteins moved through the Golgi apparatus and that this organelle was involved with glycoprotein biosynthesis.", [["Golgi apparatus", "ANATOMY", 103, 118], ["organelle", "ANATOMY", 133, 142], ["secretory proteins", "GENE_OR_GENE_PRODUCT", 66, 84], ["Golgi apparatus", "CELLULAR_COMPONENT", 103, 118], ["organelle", "CELLULAR_COMPONENT", 133, 142], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 161, 173], ["secretory proteins", "PROTEIN", 66, 84], ["autoradiography", "TEST", 32, 47], ["secretory proteins", "PROBLEM", 66, 84], ["glycoprotein biosynthesis", "TREATMENT", 161, 186]]], ["In particular, the classic studies of Leblond and co-workers (Neutra and Leblond 1996a, b) using electron microscopy combined with autoradiography demonstrated that the Golgi stack was the cellular site for the incorporation of various monosaccharides into glycoproteins (Fig. 1) .", [["Golgi stack", "ANATOMY", 169, 180], ["cellular site", "ANATOMY", 189, 202], ["monosaccharides", "CHEMICAL", 236, 251], ["Golgi", "CELLULAR_COMPONENT", 169, 174], ["cellular", "CELL", 189, 197], ["glycoproteins", "PROTEIN", 257, 270], ["electron microscopy", "TEST", 97, 116], ["autoradiography", "TEST", 131, 146], ["the Golgi stack", "PROBLEM", 165, 180], ["various monosaccharides into glycoproteins", "TREATMENT", 228, 270], ["cellular site", "OBSERVATION", 189, 202]]], ["The subsequent development of methods to isolate highly enriched Golgi membrane fractions led to the discovery that the glycosyltransferase responsible for the synthesis of N-acetyllactosamine, namely \u03b21,4-galactosyltransferase (\u03b21,4GalT), was highly enriched in Golgi membranes (Fleischer et al. 1969; Morr\u00e9 et al. 1969; Schachter et al. 1970) .", [["Golgi membrane fractions", "ANATOMY", 65, 89], ["Golgi membranes", "ANATOMY", 263, 278], ["N-acetyllactosamine", "CHEMICAL", 173, 192], ["N-acetyllactosamine", "CHEMICAL", 173, 192], ["Golgi membrane", "CELLULAR_COMPONENT", 65, 79], ["N-acetyllactosamine", "SIMPLE_CHEMICAL", 173, 192], ["\u03b21,4-galactosyltransferase", "GENE_OR_GENE_PRODUCT", 201, 227], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 229, 237], ["Golgi membranes", "CELLULAR_COMPONENT", 263, 278], ["glycosyltransferase", "PROTEIN", 120, 139], ["\u03b21,4-galactosyltransferase", "PROTEIN", 201, 227], ["\u03b21,4GalT", "PROTEIN", 229, 237], ["the glycosyltransferase", "TREATMENT", 116, 139], ["the synthesis of N-acetyllactosamine", "TREATMENT", 156, 192], ["Golgi membrane fractions", "OBSERVATION", 65, 89], ["Golgi membranes", "OBSERVATION", 263, 278]]], ["The presence of this membrane-bound enzyme specifically associated with Golgi fractions was a pivotal finding as it definitely showed that the Golgi apparatus had the enzymic machinery necesssary for glycosylation and, in addition, provided a marker enzyme to monitor cell fractionation, which remains the marker of choice today.", [["membrane", "ANATOMY", 21, 29], ["Golgi fractions", "ANATOMY", 72, 87], ["Golgi apparatus", "ANATOMY", 143, 158], ["cell", "ANATOMY", 268, 272], ["membrane", "CELLULAR_COMPONENT", 21, 29], ["Golgi", "CELLULAR_COMPONENT", 72, 77], ["Golgi", "CELLULAR_COMPONENT", 143, 148], ["cell", "CELL", 268, 272], ["membrane-bound enzyme", "PROTEIN", 21, 42], ["this membrane-bound enzyme", "PROBLEM", 16, 42], ["Golgi fractions", "PROBLEM", 72, 87], ["glycosylation", "TREATMENT", 200, 213], ["a marker enzyme", "TEST", 241, 256], ["cell fractionation", "TREATMENT", 268, 286]]], ["Moreover, these collective findings gave a cell biological focus to the biochemistry of glycosylation.", [["cell", "ANATOMY", 43, 47], ["cell", "CELL", 43, 47], ["glycosylation", "TREATMENT", 88, 101]]], ["We now know that the Golgi apparatus plays a major role in the biosynthesis of glycolipids, the glycan chains of glycoproteins and proteoglycans and polysaccharides of plant cells.IntroductionThe purification of glycosyltransferases allowed the production of specific antibodies for immunocytochemistry.", [["Golgi apparatus", "ANATOMY", 21, 36], ["cells", "ANATOMY", 174, 179], ["Golgi", "CELLULAR_COMPONENT", 21, 26], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 131, 144], ["plant cells", "CELL", 168, 179], ["glycoproteins", "PROTEIN", 113, 126], ["plant cells", "CELL_TYPE", 168, 179], ["glycosyltransferases", "PROTEIN", 212, 232], ["specific antibodies", "PROTEIN", 259, 278], ["the biosynthesis of glycolipids", "TREATMENT", 59, 90], ["glycoproteins and proteoglycans", "TREATMENT", 113, 144], ["polysaccharides of plant cells", "TREATMENT", 149, 179], ["The purification of glycosyltransferases", "TREATMENT", 192, 232], ["immunocytochemistry", "TEST", 283, 302], ["plant cells", "OBSERVATION", 168, 179]]], ["Immunocytochemical localisation of \u03b21,4GalT to the trans-Golgi (Roth and Berger 1982) and \u03b12,6-sialyltransferase (\u03b12,6ST) to predominantly the trans-Golgi network (TGN) (Roth et al. 1985) confirmed the view that the Golgi consists of multiple compartments and further demonstrated a relationship between the ordered sequence of reactions of the glycosylation pathway and the relative location of the enzymes within the Golgi stacks.", [["TGN", "ANATOMY", 164, 167], ["Golgi", "ANATOMY", 216, 221], ["Golgi stacks", "ANATOMY", 419, 431], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 35, 43], ["Golgi", "CELLULAR_COMPONENT", 57, 62], ["\u03b12,6-sialyltransferase", "GENE_OR_GENE_PRODUCT", 90, 112], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 114, 120], ["TGN", "CELLULAR_COMPONENT", 164, 167], ["Golgi", "CELLULAR_COMPONENT", 216, 221], ["Golgi stacks", "CELLULAR_COMPONENT", 419, 431], ["\u03b21,4GalT", "PROTEIN", 35, 43], ["trans-Golgi (Roth and Berger 1982", "PROTEIN", 51, 84], ["\u03b12,6", "PROTEIN", 90, 94], ["sialyltransferase", "PROTEIN", 95, 112], ["\u03b12,6ST", "PROTEIN", 114, 120], ["trans-Golgi network", "PROTEIN", 143, 162], ["TGN", "PROTEIN", 164, 167], ["enzymes", "PROTEIN", 400, 407], ["Immunocytochemical localisation", "TEST", 0, 31], ["the glycosylation pathway", "TREATMENT", 341, 366], ["Golgi stacks", "OBSERVATION", 419, 431]]], ["Subcellular fractionation of Golgi membranes also provided supporting evidence for the compartmentalisation of Golgi enzymes (Dunphy and Rothman 1983; Goldberg and Kornfeld 1983) .", [["Subcellular", "ANATOMY", 0, 11], ["Golgi membranes", "ANATOMY", 29, 44], ["Golgi", "ANATOMY", 111, 116], ["Golgi membranes", "CELLULAR_COMPONENT", 29, 44], ["Golgi", "CELLULAR_COMPONENT", 111, 116], ["Golgi enzymes", "PROTEIN", 111, 124], ["Golgi membranes", "PROBLEM", 29, 44], ["Golgi enzymes", "TEST", 111, 124], ["fractionation", "OBSERVATION", 12, 25], ["Golgi membranes", "OBSERVATION", 29, 44]]], ["The highly specific localisation of these membrane-bound enzymes raised fascinating questions about how these proteins were targeted and retained within specific regions of the Golgi apparatus.", [["membrane", "ANATOMY", 42, 50], ["Golgi apparatus", "ANATOMY", 177, 192], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["Golgi apparatus", "CELLULAR_COMPONENT", 177, 192], ["membrane-bound enzymes", "PROTEIN", 42, 64], ["these membrane-bound enzymes", "TEST", 36, 64], ["these proteins", "TEST", 104, 118], ["Golgi apparatus", "OBSERVATION", 177, 192]]], ["However, the ability to approach this intriguing question experimentally only became a reality after Golgi glycosyltransferases began to be cloned in the mid to late 1980s.IntroductionAt the same time that the first endogenous Golgi proteins were being cloned, an alternative approach to dis-sect the molecular basis for the localisation of resident Golgi proteins was developed through the study of enveloped viruses.", [["Golgi", "ANATOMY", 101, 106], ["Golgi", "ANATOMY", 227, 232], ["Golgi", "ANATOMY", 350, 355], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 101, 127], ["Golgi", "CELLULAR_COMPONENT", 227, 232], ["Golgi", "CELLULAR_COMPONENT", 350, 355], ["Golgi glycosyltransferases", "PROTEIN", 101, 127], ["endogenous Golgi proteins", "PROTEIN", 216, 241], ["resident Golgi proteins", "PROTEIN", 341, 364], ["Golgi glycosyltransferases", "PROBLEM", 101, 127], ["Golgi proteins", "TEST", 350, 364], ["the study", "TEST", 387, 396], ["enveloped viruses", "PROBLEM", 400, 417], ["mid", "ANATOMY_MODIFIER", 154, 157], ["viruses", "OBSERVATION", 410, 417]]], ["Enveloped viruses have proved very useful in understanding the pathways of intracellular transport in eucaroytic cells.", [["intracellular", "ANATOMY", 75, 88], ["eucaroytic cells", "ANATOMY", 102, 118], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 88], ["eucaroytic cells", "CELL", 102, 118], ["eucaroytic cells", "CELL_TYPE", 102, 118], ["Enveloped viruses", "PROBLEM", 0, 17], ["intracellular transport in eucaroytic cells", "TREATMENT", 75, 118], ["viruses", "OBSERVATION", 10, 17]]], ["A number of intracellular viruses acquire their envelopes by budding into the lumen of the Golgi apparatus, after which the mature virus is transported from the cell (Pettersson 1991; Griffiths and Rottier 1992) .", [["intracellular", "ANATOMY", 12, 25], ["lumen", "ANATOMY", 78, 83], ["Golgi apparatus", "ANATOMY", 91, 106], ["cell", "ANATOMY", 161, 165], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 12, 25], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 83], ["Golgi apparatus", "CELLULAR_COMPONENT", 91, 106], ["cell", "CELL", 161, 165], ["intracellular viruses", "PROBLEM", 12, 33], ["the mature virus", "PROBLEM", 120, 136], ["intracellular viruses", "OBSERVATION", 12, 33], ["lumen", "ANATOMY_MODIFIER", 78, 83], ["Golgi apparatus", "OBSERVATION", 91, 106], ["mature", "OBSERVATION_MODIFIER", 124, 130], ["virus", "OBSERVATION", 131, 136]]], ["Enveloped viruses from Golgi membranes have been shown to encode one or more membrane proteins which are specifically targeted to distinct regions within the Golgi apparatus.", [["Golgi membranes", "ANATOMY", 23, 38], ["membrane", "ANATOMY", 77, 85], ["Golgi apparatus", "ANATOMY", 158, 173], ["Golgi membranes", "CELLULAR_COMPONENT", 23, 38], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["Golgi apparatus", "CELLULAR_COMPONENT", 158, 173], ["membrane proteins", "PROTEIN", 77, 94], ["Enveloped viruses", "PROBLEM", 0, 17], ["Golgi membranes", "PROBLEM", 23, 38], ["more membrane proteins", "PROBLEM", 72, 94], ["viruses", "OBSERVATION", 10, 17], ["Golgi membranes", "OBSERVATION", 23, 38], ["Golgi apparatus", "OBSERVATION", 158, 173]]], ["Indeed, the first Golgi localisation signal was identified in the E1 or M glycoprotein of the coronavirus, avian infectious bronchitis virus (IBV).", [["Golgi", "ANATOMY", 18, 23], ["avian infectious bronchitis virus", "DISEASE", 107, 140], ["Golgi", "CELLULAR_COMPONENT", 18, 23], ["E1", "GENE_OR_GENE_PRODUCT", 66, 68], ["M glycoprotein", "GENE_OR_GENE_PRODUCT", 72, 86], ["coronavirus", "ORGANISM", 94, 105], ["avian infectious bronchitis virus", "ORGANISM", 107, 140], ["IBV", "ORGANISM", 142, 145], ["E1 or M glycoprotein", "PROTEIN", 66, 86], ["coronavirus", "SPECIES", 94, 105], ["avian infectious bronchitis virus", "SPECIES", 107, 140], ["infectious bronchitis virus", "SPECIES", 113, 140], ["IBV", "SPECIES", 142, 145], ["the coronavirus", "PROBLEM", 90, 105], ["avian infectious bronchitis virus", "PROBLEM", 107, 140], ["coronavirus", "ANATOMY", 94, 105], ["infectious", "OBSERVATION_MODIFIER", 113, 123], ["bronchitis", "OBSERVATION", 124, 134]]], ["Avian coronavirus M protein has three membrane-spanning domains and deletion analysis suggested that a Golgi localisation signal may be contained within the first membrane-spanning domain of IBV M protein (Machamer and Rose 1987) .", [["membrane", "ANATOMY", 38, 46], ["Golgi", "ANATOMY", 103, 108], ["membrane", "ANATOMY", 163, 171], ["Avian coronavirus", "ORGANISM", 0, 17], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["Golgi", "CELLULAR_COMPONENT", 103, 108], ["membrane", "CELLULAR_COMPONENT", 163, 171], ["IBV M protein", "GENE_OR_GENE_PRODUCT", 191, 204], ["Avian coronavirus M protein", "PROTEIN", 0, 27], ["membrane-spanning domains", "PROTEIN", 38, 63], ["first membrane-spanning domain", "PROTEIN", 157, 187], ["IBV M protein", "PROTEIN", 191, 204], ["Machamer", "PROTEIN", 206, 214], ["Avian coronavirus M", "SPECIES", 0, 19], ["Avian coronavirus", "SPECIES", 0, 17], ["Avian coronavirus M protein", "TEST", 0, 27], ["deletion analysis", "TEST", 68, 85], ["a Golgi localisation signal", "TEST", 101, 128], ["IBV M protein", "TEST", 191, 204], ["coronavirus", "OBSERVATION", 6, 17], ["may be", "UNCERTAINTY", 129, 135]]], ["The surprising finding that a hydrophobic sequence may contain a Golgi retention signal lay the foundations for the subsequent analyses of glycosyltransferases a few years later.IntroductionThe Golgi apparatus is not only a carbohydrate factory but also represents the hub of the secretory pathway where intense membrane traffic is controlled.", [["Golgi", "ANATOMY", 65, 70], ["Golgi apparatus", "ANATOMY", 194, 209], ["membrane", "ANATOMY", 312, 320], ["carbohydrate", "CHEMICAL", 224, 236], ["Golgi", "CELLULAR_COMPONENT", 65, 70], ["Golgi", "CELLULAR_COMPONENT", 194, 199], ["membrane", "CELLULAR_COMPONENT", 312, 320], ["glycosyltransferases", "PROTEIN", 139, 159], ["a hydrophobic sequence", "TEST", 28, 50], ["glycosyltransferases", "TREATMENT", 139, 159], ["Golgi retention", "OBSERVATION", 65, 80], ["intense", "OBSERVATION_MODIFIER", 304, 311], ["membrane traffic", "OBSERVATION", 312, 328]]], ["Vesicles are thought to bud from one compartment and then target and fuse with the next compartment (Rothman and Orci 1992; Rothman 1994 ).", [["Vesicles", "ANATOMY", 0, 8], ["bud", "ANATOMY", 24, 27], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8]]], ["An increasing number of structural and regulatory components have been identified which are involved in the orchestration of the complex and intriguing processes of budding, specific targeting, docking and fusion (Pryer et al. 1992; Rothman 1994; Schekman and Orci 1996 .)", [["structural and regulatory components", "PROBLEM", 24, 60], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["structural", "OBSERVATION_MODIFIER", 24, 34], ["regulatory components", "OBSERVATION", 39, 60], ["complex", "OBSERVATION_MODIFIER", 129, 136]]], ["Some of the components of this machinery are localised specifically to Golgi membranes and are thought to be specific for membrane transport through and from the Golgi apparatus.", [["Golgi membranes", "ANATOMY", 71, 86], ["membrane", "ANATOMY", 122, 130], ["Golgi apparatus", "ANATOMY", 162, 177], ["Golgi membranes", "CELLULAR_COMPONENT", 71, 86], ["membrane", "CELLULAR_COMPONENT", 122, 130], ["Golgi apparatus", "CELLULAR_COMPONENT", 162, 177], ["membrane transport", "TEST", 122, 140], ["components", "OBSERVATION_MODIFIER", 12, 22], ["Golgi membranes", "OBSERVATION", 71, 86], ["thought to be", "UNCERTAINTY", 95, 108]]], ["The restricted location of these components implies the presence of specific localisation signals.IntroductionA fundamental question currently being addressed in cell biology is how the Golgi apparatus is organised to achieve the demanding functions of glycosylation and membrane transport and how its structural integrity is maintained in spite of the intense membrane traffic which enters and leaves this organelle.", [["cell", "ANATOMY", 162, 166], ["Golgi apparatus", "ANATOMY", 186, 201], ["membrane", "ANATOMY", 271, 279], ["membrane", "ANATOMY", 361, 369], ["organelle", "ANATOMY", 407, 416], ["cell", "CELL", 162, 166], ["Golgi", "CELLULAR_COMPONENT", 186, 191], ["membrane", "CELLULAR_COMPONENT", 271, 279], ["membrane", "CELLULAR_COMPONENT", 361, 369], ["organelle", "CELLULAR_COMPONENT", 407, 416], ["glycosylation and membrane transport", "TREATMENT", 253, 289], ["restricted", "OBSERVATION_MODIFIER", 4, 14], ["localisation signals", "OBSERVATION", 77, 97]]], ["This review will focus on our understanding of the molecular signals and mechanisms for the retention of resident Golgi proteins which carry out these diverse functions.Compartmentalisation of the GolgiUnderstanding how resident Golgi proteins are localised requires an appreciation of the structure of this organelle and the mechanism by which newly synthesised proteins move through the Golgi apparatus.", [["Golgi", "ANATOMY", 114, 119], ["Golgi", "ANATOMY", 229, 234], ["organelle", "ANATOMY", 308, 317], ["Golgi apparatus", "ANATOMY", 389, 404], ["Golgi", "CELLULAR_COMPONENT", 114, 119], ["Golgi", "CELLULAR_COMPONENT", 229, 234], ["organelle", "CELLULAR_COMPONENT", 308, 317], ["Golgi apparatus", "CELLULAR_COMPONENT", 389, 404], ["resident Golgi proteins", "PROTEIN", 105, 128], ["GolgiUnderstanding", "PROTEIN", 197, 215], ["resident Golgi proteins", "PROTEIN", 220, 243], ["Golgi proteins", "TEST", 114, 128]]], ["The classic image of the Golgi is that of a set of flattened cisternae with dilated rims.", [["Golgi", "ANATOMY", 25, 30], ["cisternae", "ANATOMY", 61, 70], ["Golgi", "CELLULAR_COMPONENT", 25, 30], ["cisternae", "CELLULAR_COMPONENT", 61, 70], ["flattened cisternae with dilated rims", "PROBLEM", 51, 88], ["Golgi", "ANATOMY_MODIFIER", 25, 30], ["flattened", "OBSERVATION_MODIFIER", 51, 60], ["cisternae", "ANATOMY_MODIFIER", 61, 70], ["dilated", "OBSERVATION", 76, 83], ["rims", "OBSERVATION_MODIFIER", 84, 88]]], ["The organelle is organised into functionally distinct regions; the Golgi stack (consisting of cis, medial and trans cisternae) and two flanking tubular networks of membrane (Mellman and Simons 1992) .", [["organelle", "ANATOMY", 4, 13], ["Golgi stack", "ANATOMY", 67, 78], ["medial", "ANATOMY", 99, 105], ["cisternae", "ANATOMY", 116, 125], ["tubular networks", "ANATOMY", 144, 160], ["membrane", "ANATOMY", 164, 172], ["organelle", "CELLULAR_COMPONENT", 4, 13], ["Golgi stack", "CELLULAR_COMPONENT", 67, 78], ["medial", "CELLULAR_COMPONENT", 99, 105], ["cisternae", "CELLULAR_COMPONENT", 116, 125], ["tubular networks", "MULTI-TISSUE_STRUCTURE", 144, 160], ["membrane", "CELLULAR_COMPONENT", 164, 172], ["distinct", "OBSERVATION_MODIFIER", 45, 53], ["Golgi stack", "OBSERVATION", 67, 78], ["medial", "ANATOMY_MODIFIER", 99, 105], ["cisternae", "ANATOMY_MODIFIER", 116, 125], ["flanking", "ANATOMY_MODIFIER", 135, 143], ["tubular", "ANATOMY_MODIFIER", 144, 151], ["membrane", "OBSERVATION_MODIFIER", 164, 172]]], ["The cis-Golgi network (CGN), probably equivalent to the (ER)-Golgi intermediate compartment or salvage compartment, is considered to be the compartment which receives newly synthesised proteins from the ER.", [["cis-Golgi network", "ANATOMY", 4, 21], ["Golgi intermediate compartment", "ANATOMY", 61, 91], ["salvage compartment", "ANATOMY", 95, 114], ["ER", "ANATOMY", 203, 205], ["cis-Golgi", "GENE_OR_GENE_PRODUCT", 4, 13], ["CGN", "CELLULAR_COMPONENT", 23, 26], ["ER", "GENE_OR_GENE_PRODUCT", 57, 59], ["ER", "GENE_OR_GENE_PRODUCT", 203, 205], ["cis-Golgi network", "PROTEIN", 4, 21], ["CGN", "PROTEIN", 23, 26], ["ER", "PROTEIN", 57, 59], ["ER", "PROTEIN", 203, 205], ["cis-Golgi network", "OBSERVATION", 4, 21], ["probably", "UNCERTAINTY", 29, 37], ["equivalent", "OBSERVATION_MODIFIER", 38, 48], ["salvage compartment", "OBSERVATION", 95, 114]]], ["It is also involved in the recycling of lipids and ER-associated proteins, which have leaked out of the ER, by backward or retrograde transport.", [["ER", "ANATOMY", 104, 106], ["lipids", "SIMPLE_CHEMICAL", 40, 46], ["ER", "GENE_OR_GENE_PRODUCT", 51, 53], ["ER", "GENE_OR_GENE_PRODUCT", 104, 106], ["ER", "PROTEIN", 51, 53], ["associated proteins", "PROTEIN", 54, 73], ["ER", "PROTEIN", 104, 106], ["associated proteins", "PROBLEM", 54, 73]]], ["The highly dynamic nature of the CGN has resulted in considerable controversy as to to the exact relationship of this compartment with the ER and Golgi stack (Hauri and Schweizer 1992; Krijnse Locker et al. 1994a) .", [["ER", "ANATOMY", 139, 141], ["Golgi stack", "ANATOMY", 146, 157], ["CGN", "DISEASE", 33, 36], ["CGN", "CELLULAR_COMPONENT", 33, 36], ["ER", "GENE_OR_GENE_PRODUCT", 139, 141], ["Golgi", "CELLULAR_COMPONENT", 146, 151], ["ER", "PROTEIN", 139, 141], ["highly", "OBSERVATION_MODIFIER", 4, 10], ["dynamic", "OBSERVATION_MODIFIER", 11, 18]]], ["In view of this uncertainty, the CGN/intermediate compartment will be not be included in this review.", [["CGN", "CELLULAR_COMPONENT", 33, 36]]], ["The TGN is situated at the distal face of the Golgi stack, is functionally distinct from the trans-cisternae, and is the compartment where the secretory and endocytic pathways converge.", [["TGN", "ANATOMY", 4, 7], ["distal face", "ANATOMY", 27, 38], ["Golgi stack", "ANATOMY", 46, 57], ["cisternae", "ANATOMY", 99, 108], ["secretory", "ANATOMY", 143, 152], ["TGN", "GENE_OR_GENE_PRODUCT", 4, 7], ["Golgi", "CELLULAR_COMPONENT", 46, 51], ["cisternae", "CELLULAR_COMPONENT", 99, 108], ["TGN", "PROTEIN", 4, 7], ["TGN", "OBSERVATION_MODIFIER", 4, 7], ["distal", "ANATOMY_MODIFIER", 27, 33], ["face", "ANATOMY_MODIFIER", 34, 38], ["Golgi stack", "OBSERVATION", 46, 57], ["functionally", "OBSERVATION_MODIFIER", 62, 74], ["distinct", "OBSERVATION_MODIFIER", 75, 83], ["trans", "ANATOMY_MODIFIER", 93, 98], ["cisternae", "ANATOMY_MODIFIER", 99, 108], ["compartment", "ANATOMY_MODIFIER", 121, 132], ["endocytic pathways", "OBSERVATION", 157, 175]]], ["The TGN is the site where a number of late-Golgi post-translational modifications occur, for example sialylation, tyrosine sulphation and proteolytic processing.", [["TGN", "ANATOMY", 4, 7], ["Golgi", "ANATOMY", 43, 48], ["tyrosine", "CHEMICAL", 114, 122], ["tyrosine", "CHEMICAL", 114, 122], ["TGN", "GENE_OR_GENE_PRODUCT", 4, 7], ["Golgi", "CELLULAR_COMPONENT", 43, 48], ["tyrosine", "AMINO_ACID", 114, 122], ["TGN", "PROTEIN", 4, 7], ["example sialylation", "TREATMENT", 93, 112], ["tyrosine sulphation", "TREATMENT", 114, 133], ["proteolytic processing", "TREATMENT", 138, 160], ["TGN", "OBSERVATION_MODIFIER", 4, 7], ["post-translational modifications", "OBSERVATION", 49, 81]]], ["In addition, the TGN is the sorting station of the Golgi where proteins are packaged into vesicles and shipped to various destinations, including the cell surface (and either the apical or basolateral surfaces of polarised epithelial cells), lysosomes and secretory storage granules (Farquhar 1985; Griffiths and Simons 1986; Mellman and Simons 1992) .", [["TGN", "ANATOMY", 17, 20], ["Golgi", "ANATOMY", 51, 56], ["vesicles", "ANATOMY", 90, 98], ["cell surface", "ANATOMY", 150, 162], ["apical", "ANATOMY", 179, 185], ["basolateral surfaces", "ANATOMY", 189, 209], ["epithelial cells", "ANATOMY", 223, 239], ["lysosomes", "ANATOMY", 242, 251], ["secretory storage granules", "ANATOMY", 256, 282], ["TGN", "CELLULAR_COMPONENT", 17, 20], ["Golgi", "CELLULAR_COMPONENT", 51, 56], ["vesicles", "CELLULAR_COMPONENT", 90, 98], ["cell surface", "CELLULAR_COMPONENT", 150, 162], ["apical", "CELLULAR_COMPONENT", 179, 185], ["basolateral surfaces", "CELLULAR_COMPONENT", 189, 209], ["epithelial cells", "CELL", 223, 239], ["lysosomes", "CELLULAR_COMPONENT", 242, 251], ["granules", "ORGANISM_SUBSTANCE", 274, 282], ["TGN", "PROTEIN", 17, 20], ["polarised epithelial cells", "CELL_TYPE", 213, 239], ["the cell surface", "TEST", 146, 162], ["various", "OBSERVATION_MODIFIER", 114, 121], ["destinations", "OBSERVATION_MODIFIER", 122, 134], ["cell", "OBSERVATION_MODIFIER", 150, 154], ["surface", "OBSERVATION_MODIFIER", 155, 162], ["apical", "ANATOMY_MODIFIER", 179, 185], ["basolateral", "ANATOMY_MODIFIER", 189, 200], ["surfaces", "ANATOMY_MODIFIER", 201, 209], ["polarised epithelial cells", "OBSERVATION", 213, 239], ["storage granules", "OBSERVATION", 266, 282]]], ["Flanked by the CGN and TGN are the cis, medial and trans cisternae, which represent biochemically distinct subcompartments.Compartmentalisation of the GolgiSimultaneous localisation of N-acetylglucosaminyltransferase I (GlcNAc-TI) and \u03b21,4GalT by Warren and colleagues (Nilsson et al. 1993a) showed, as was expected, that the two enzymes had different distributions throughout the Golgi stack.", [["TGN", "ANATOMY", 23, 26], ["medial", "ANATOMY", 40, 46], ["cisternae", "ANATOMY", 57, 66], ["subcompartments", "ANATOMY", 107, 122], ["Golgi stack", "ANATOMY", 381, 392], ["GlcNAc", "CHEMICAL", 220, 226], ["CGN", "GENE_OR_GENE_PRODUCT", 15, 18], ["TGN", "CELLULAR_COMPONENT", 23, 26], ["medial", "CELLULAR_COMPONENT", 40, 46], ["trans cisternae", "CELLULAR_COMPONENT", 51, 66], ["N-acetylglucosaminyltransferase I", "GENE_OR_GENE_PRODUCT", 185, 218], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 220, 229], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 235, 243], ["Golgi", "CELLULAR_COMPONENT", 381, 386], ["CGN", "PROTEIN", 15, 18], ["TGN", "PROTEIN", 23, 26], ["N-acetylglucosaminyltransferase I", "PROTEIN", 185, 218], ["GlcNAc", "PROTEIN", 220, 226], ["TI", "PROTEIN", 227, 229], ["\u03b21,4GalT", "PROTEIN", 235, 243], ["enzymes", "PROTEIN", 330, 337], ["the two enzymes", "TEST", 322, 337], ["CGN", "OBSERVATION", 15, 18], ["TGN", "OBSERVATION_MODIFIER", 23, 26], ["medial", "ANATOMY_MODIFIER", 40, 46], ["trans", "ANATOMY_MODIFIER", 51, 56], ["cisternae", "ANATOMY_MODIFIER", 57, 66], ["biochemically", "OBSERVATION_MODIFIER", 84, 97], ["distinct", "OBSERVATION_MODIFIER", 98, 106], ["subcompartments", "OBSERVATION_MODIFIER", 107, 122]]], ["However, contrary to the simple models that had been proposed for Golgi compartmentalisation, the results showed that the distributions of the two enzymes were not discrete but overlapped considerably.", [["Golgi", "ANATOMY", 66, 71], ["Golgi", "CELLULAR_COMPONENT", 66, 71], ["enzymes", "PROTEIN", 147, 154], ["the two enzymes", "TEST", 139, 154]]], ["This was an important observation which was extended in a subsequent study to include a number of other glycosyltransferases.", [["glycosyltransferases", "PROTEIN", 104, 124], ["a subsequent study", "TEST", 56, 74], ["other glycosyltransferases", "TREATMENT", 98, 124]]], ["The overlapping distribution of glycosyltransferases demonstrates that different Golgi compartments have unique mixtures of enzymes rather than different sets of enzymes.", [["Golgi compartments", "ANATOMY", 81, 99], ["Golgi", "CELLULAR_COMPONENT", 81, 86], ["glycosyltransferases", "PROTEIN", 32, 52], ["enzymes", "PROTEIN", 124, 131], ["enzymes", "PROTEIN", 162, 169], ["The overlapping distribution of glycosyltransferases", "PROBLEM", 0, 52], ["enzymes", "TEST", 124, 131], ["enzymes", "TEST", 162, 169], ["overlapping", "OBSERVATION_MODIFIER", 4, 15], ["distribution", "OBSERVATION_MODIFIER", 16, 28]]], ["A further degree of flexibility is indicated by the differences in the distribution of particular glycosyltransferases between cell types.", [["cell", "ANATOMY", 127, 131], ["cell", "CELL", 127, 131], ["glycosyltransferases", "PROTEIN", 98, 118], ["A further degree of flexibility", "PROBLEM", 0, 31], ["flexibility", "OBSERVATION", 20, 31], ["cell types", "OBSERVATION", 127, 137]]], ["For example, \u03b12,6ST is found predominantly in the trans region of the Golgi apparatus in hepatocytes and intestinal goblet cells, whereas in absorptive cells from the large intestine \u03b12,6ST is found more extensively distributed throughout the stack (Roth et al. 1985; Taatjes et al. 1988 ).", [["Golgi apparatus", "ANATOMY", 70, 85], ["hepatocytes", "ANATOMY", 89, 100], ["intestinal goblet cells", "ANATOMY", 105, 128], ["absorptive cells", "ANATOMY", 141, 157], ["intestine", "ANATOMY", 173, 182], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 13, 19], ["Golgi apparatus", "CELLULAR_COMPONENT", 70, 85], ["hepatocytes", "CELL", 89, 100], ["intestinal goblet cells", "CELL", 105, 128], ["absorptive cells", "CELL", 141, 157], ["intestine", "ORGAN", 173, 182], ["\u03b12,6ST", "PROTEIN", 13, 19], ["hepatocytes", "CELL_TYPE", 89, 100], ["intestinal goblet cells", "CELL_TYPE", 105, 128], ["absorptive cells", "CELL_TYPE", 141, 157], ["intestinal goblet cells", "PROBLEM", 105, 128], ["predominantly", "OBSERVATION_MODIFIER", 29, 42], ["trans", "ANATOMY_MODIFIER", 50, 55], ["region", "ANATOMY_MODIFIER", 56, 62], ["Golgi apparatus", "OBSERVATION", 70, 85], ["hepatocytes", "ANATOMY", 89, 100], ["intestinal", "ANATOMY", 105, 115], ["goblet cells", "OBSERVATION", 116, 128], ["absorptive cells", "OBSERVATION", 141, 157], ["large", "OBSERVATION_MODIFIER", 167, 172], ["intestine", "ANATOMY", 173, 182], ["more extensively", "OBSERVATION_MODIFIER", 199, 215]]], ["Collectively, these results demonstrate a certain plasticity in the distribution of glycosylation enzymes throughout the Golgi stack, rather than a strict and discrete compartmentalisation of enzymes.", [["Golgi stack", "ANATOMY", 121, 132], ["Golgi", "CELLULAR_COMPONENT", 121, 126], ["glycosylation enzymes", "PROTEIN", 84, 105], ["enzymes", "PROTEIN", 192, 199], ["glycosylation enzymes", "TEST", 84, 105], ["a strict and discrete compartmentalisation of enzymes", "PROBLEM", 146, 199], ["glycosylation enzymes", "OBSERVATION", 84, 105], ["Golgi stack", "OBSERVATION", 121, 132]]], ["The basis for the differences between cell types is not known but may reflect the underlying dynamic behaviour of Golgi membranes.Compartmentalisation of the GolgiHow are proteins transported through the Golgi?", [["cell", "ANATOMY", 38, 42], ["Golgi membranes", "ANATOMY", 114, 129], ["Golgi", "ANATOMY", 204, 209], ["cell", "CELL", 38, 42], ["Golgi membranes", "CELLULAR_COMPONENT", 114, 129], ["GolgiHow", "GENE_OR_GENE_PRODUCT", 158, 166], ["Golgi", "CELLULAR_COMPONENT", 204, 209], ["GolgiHow", "PROTEIN", 158, 166], ["Golgi membranes", "OBSERVATION", 114, 129]]], ["Newly synthesised proteins are transported sequentially from the ER to the Golgi and then to their final destination.", [["ER", "ANATOMY", 65, 67], ["Golgi", "ANATOMY", 75, 80], ["ER", "GENE_OR_GENE_PRODUCT", 65, 67], ["Golgi", "CELLULAR_COMPONENT", 75, 80], ["ER", "PROTEIN", 65, 67], ["Newly synthesised proteins", "PROBLEM", 0, 26], ["proteins", "OBSERVATION", 18, 26]]], ["Until recently it was widely believed that, if correctly folded, newly synthesised proteins were transported from the ER, through the Golgi apparatus without the requirement for a specific transport signal (Pfeffer and Rothman 1987; Rothman and Orci 1992) .", [["ER", "ANATOMY", 118, 120], ["Golgi apparatus", "ANATOMY", 134, 149], ["ER", "GENE_OR_GENE_PRODUCT", 118, 120], ["Golgi", "CELLULAR_COMPONENT", 134, 139], ["ER", "PROTEIN", 118, 120], ["newly synthesised proteins", "PROBLEM", 65, 91]]], ["However, a variety of observations, including electron microscopic data that certain proteins become concentrated as they exit the ER (Balch et al. 1994; Balch and Farquhar 1995) , indicate that transport to the Golgi may be mediated by, as yet, undefined transport signals.", [["Golgi", "ANATOMY", 212, 217], ["ER", "GENE_OR_GENE_PRODUCT", 131, 133], ["Golgi", "CELLULAR_COMPONENT", 212, 217], ["ER", "PROTEIN", 131, 133], ["electron microscopic data", "TEST", 46, 71]]], ["On the other hand, current evidence indicates that forward transport of newly syntheised proteins through the Golgi apparatus constitutes a signal-independent or default pathway.", [["Golgi apparatus", "ANATOMY", 110, 125], ["Golgi", "CELLULAR_COMPONENT", 110, 115], ["syntheised proteins", "PROTEIN", 78, 97], ["newly syntheised proteins", "PROBLEM", 72, 97]]], ["Despite this extensive flux of proteins, the Golgi apparatus must maintain a set of resident proteins which define its unique structural and functional properties.Compartmentalisation of the GolgiHow are proteins transferred from one Golgi compartment to the next?", [["Golgi apparatus", "ANATOMY", 45, 60], ["Golgi compartment", "ANATOMY", 234, 251], ["Golgi", "CELLULAR_COMPONENT", 45, 50], ["GolgiHow", "GENE_OR_GENE_PRODUCT", 191, 199], ["Golgi", "CELLULAR_COMPONENT", 234, 239], ["resident proteins", "PROTEIN", 84, 101], ["GolgiHow", "PROTEIN", 191, 199], ["this extensive flux of proteins", "PROBLEM", 8, 39]]], ["A widely held view is that transport vesicles bud from the dilated rims of one cisternae and then target and fuse with the next Golgi compartment (Rothman and Orci 1992; Rothman 1994; Rothman and Warren 1994) .", [["vesicles bud", "ANATOMY", 37, 49], ["cisternae", "ANATOMY", 79, 88], ["Golgi compartment", "ANATOMY", 128, 145], ["vesicles bud", "CELLULAR_COMPONENT", 37, 49], ["cisternae", "CELLULAR_COMPONENT", 79, 88], ["Golgi compartment", "CELLULAR_COMPONENT", 128, 145], ["transport vesicles bud", "PROBLEM", 27, 49], ["dilated", "OBSERVATION", 59, 66], ["rims", "ANATOMY_MODIFIER", 67, 71], ["one", "ANATOMY_MODIFIER", 75, 78], ["cisternae", "ANATOMY_MODIFIER", 79, 88]]], ["Highly defined in vitro reconstitution systems argue for a role of transport vesicles in intra-Golgi transport (Rothman and Orci 1992; Rothman 1994) .", [["vesicles", "ANATOMY", 77, 85], ["intra-Golgi", "ANATOMY", 89, 100], ["vesicles", "CELLULAR_COMPONENT", 77, 85], ["vitro reconstitution systems", "TREATMENT", 18, 46], ["vitro reconstitution", "OBSERVATION", 18, 38]]], ["However, in vivo evidence for intracisternal transport remains largely indirect (Mellman and Simons 1992) .", [["intracisternal transport", "PROBLEM", 30, 54]]], ["Furthermore, it is unclear whether the coated buds associated with the Golgi apparatus represent small vesicles (Orci et al. 1986 ) or cross-sections through the peripheral tubules of the Golgi (Morr\u00e9 and Keenan 1994) .", [["buds", "ANATOMY", 46, 50], ["Golgi apparatus", "ANATOMY", 71, 86], ["vesicles", "ANATOMY", 103, 111], ["sections", "ANATOMY", 141, 149], ["peripheral tubules", "ANATOMY", 162, 180], ["Golgi", "ANATOMY", 188, 193], ["Golgi apparatus", "CELLULAR_COMPONENT", 71, 86], ["small vesicles", "CELLULAR_COMPONENT", 97, 111], ["peripheral tubules", "MULTI-TISSUE_STRUCTURE", 162, 180], ["Golgi", "CELLULAR_COMPONENT", 188, 193], ["the coated buds", "PROBLEM", 35, 50], ["small vesicles", "PROBLEM", 97, 111], ["cross-sections", "TEST", 135, 149], ["coated buds", "OBSERVATION", 39, 50], ["small", "OBSERVATION_MODIFIER", 97, 102], ["vesicles", "OBSERVATION", 103, 111], ["peripheral", "ANATOMY_MODIFIER", 162, 172], ["tubules", "ANATOMY_MODIFIER", 173, 180]]], ["In view of the lack of direct evidence for vesicular transport it is perhaps not surprising that alternative models based on non-vesicular mechanisms of transport are currently attracting renewed attention, in particular, transport by cisternal progression (Mironov et al. 1997) and via membrane tubules (Morr\u00e9 and Keenan 1994; Weidman 1995) .Compartmentalisation of the GolgiFundamental to the understanding of membrane transport throughout the Golgi is whether the Golgi subcompartments are indeed physically distinct entities or whether they are continuous.", [["vesicular", "ANATOMY", 43, 52], ["cisternal", "ANATOMY", 235, 244], ["membrane tubules", "ANATOMY", 287, 303], ["membrane", "ANATOMY", 412, 420], ["Golgi", "ANATOMY", 446, 451], ["Golgi subcompartments", "ANATOMY", 467, 488], ["vesicular", "MULTI-TISSUE_STRUCTURE", 43, 52], ["membrane tubules", "CELLULAR_COMPONENT", 287, 303], ["membrane", "CELLULAR_COMPONENT", 412, 420], ["Golgi", "CELLULAR_COMPONENT", 446, 451], ["Golgi", "CELLULAR_COMPONENT", 467, 472], ["vesicular transport", "PROBLEM", 43, 62]]], ["Golgi stacks have been shown to be linked by lateral connections to form a single network Clermont 1990, 1997) .", [["Golgi stacks", "ANATOMY", 0, 12], ["Golgi stacks", "CELLULAR_COMPONENT", 0, 12], ["Golgi stacks", "PROBLEM", 0, 12]]], ["Although transmission electron microscopy indicates that the cisternae of individual stacks are physically distinct entities, by scanning electron microscopy tubular continuities have been observed between cisternae within a stack (Tanaka and Fukudome 1991) .", [["cisternae", "ANATOMY", 61, 70], ["stacks", "ANATOMY", 85, 91], ["tubular", "ANATOMY", 158, 165], ["cisternae", "ANATOMY", 206, 215], ["cisternae", "CELLULAR_COMPONENT", 61, 70], ["cisternae", "CELLULAR_COMPONENT", 206, 215], ["transmission electron microscopy", "TEST", 9, 41], ["physically distinct entities", "PROBLEM", 96, 124], ["scanning electron microscopy", "TEST", 129, 157], ["distinct", "OBSERVATION_MODIFIER", 107, 115]]], ["Tubular connections between and within stacks could provide structural continuity for non-vesicular transfer of membrane bound and soluble molecules through the Golgi.", [["Tubular", "ANATOMY", 0, 7], ["membrane", "ANATOMY", 112, 120], ["Golgi", "ANATOMY", 161, 166], ["Tubular", "MULTI-TISSUE_STRUCTURE", 0, 7], ["membrane", "CELLULAR_COMPONENT", 112, 120], ["Golgi", "CELLULAR_COMPONENT", 161, 166], ["membrane bound and soluble molecules", "PROTEIN", 112, 148], ["Tubular connections between and within stacks", "PROBLEM", 0, 45], ["non-vesicular transfer of membrane bound", "TREATMENT", 86, 126]]], ["Clearly, the precise three-dimensional structure of the Golgi warrants further investigation and the relative contribution of vesicular and non-vesicular transport needs to be resolved.", [["Golgi", "ANATOMY", 56, 61], ["vesicular", "ANATOMY", 126, 135], ["non-vesicular", "ANATOMY", 140, 153], ["Golgi", "CELLULAR_COMPONENT", 56, 61], ["vesicular", "MULTI-TISSUE_STRUCTURE", 126, 135], ["further investigation", "TEST", 71, 92], ["vesicular and non-vesicular transport", "PROBLEM", 126, 163], ["vesicular", "OBSERVATION_MODIFIER", 126, 135]]], ["This issue is likely to be fundamental for understanding why resident Golgi proteins are retained whereas proteins in transit pass through.Resident Golgi proteinsThe proteins that reside in the Golgi carry out functions associated with post-translational modifications, including glycosylation and proteolytic processing, membrane transport, recycling of ER proteins and maintainance of the structural organisation of the organelle itself.", [["Golgi", "ANATOMY", 70, 75], ["Golgi", "ANATOMY", 148, 153], ["Golgi", "ANATOMY", 194, 199], ["membrane", "ANATOMY", 322, 330], ["organelle", "ANATOMY", 422, 431], ["Golgi", "CELLULAR_COMPONENT", 70, 75], ["Golgi", "CELLULAR_COMPONENT", 148, 153], ["Golgi", "CELLULAR_COMPONENT", 194, 199], ["membrane", "CELLULAR_COMPONENT", 322, 330], ["ER", "GENE_OR_GENE_PRODUCT", 355, 357], ["organelle", "CELLULAR_COMPONENT", 422, 431], ["resident Golgi proteins", "PROTEIN", 61, 84], ["Resident Golgi proteins", "PROTEIN", 139, 162], ["ER proteins", "PROTEIN", 355, 366], ["post-translational modifications", "TREATMENT", 236, 268], ["glycosylation", "TREATMENT", 280, 293], ["proteolytic processing", "TREATMENT", 298, 320], ["membrane transport", "TREATMENT", 322, 340], ["ER proteins", "TREATMENT", 355, 366], ["likely to be", "UNCERTAINTY", 14, 26]]], ["The latter includes proteins involved in the Golgi stacking, interconnections between stacks and the microtubule-dependent positioning of the organelle within the cell.", [["Golgi", "ANATOMY", 45, 50], ["microtubule", "ANATOMY", 101, 112], ["organelle", "ANATOMY", 142, 151], ["cell", "ANATOMY", 163, 167], ["Golgi", "CELLULAR_COMPONENT", 45, 50], ["stacks", "CELLULAR_COMPONENT", 86, 92], ["microtubule", "CELLULAR_COMPONENT", 101, 112], ["organelle", "CELLULAR_COMPONENT", 142, 151], ["cell", "CELL", 163, 167], ["microtubule", "PROTEIN", 101, 112], ["Golgi stacking", "OBSERVATION", 45, 59], ["microtubule", "OBSERVATION_MODIFIER", 101, 112], ["dependent", "OBSERVATION_MODIFIER", 113, 122], ["positioning", "OBSERVATION_MODIFIER", 123, 134], ["cell", "ANATOMY", 163, 167]]], ["It is not surprising that there are a large number of proteins associated with such diverse functions; these include membrane proteins with single transmembrane domains (both type I and type II membrane orientation), proteins with multiple transmembrane-spanning domains, peripheral membrane proteins and soluble resident Golgi proteins (Fig. 2) .", [["membrane", "ANATOMY", 117, 125], ["transmembrane", "ANATOMY", 147, 160], ["membrane", "ANATOMY", 194, 202], ["transmembrane", "ANATOMY", 240, 253], ["peripheral membrane", "ANATOMY", 272, 291], ["Golgi", "ANATOMY", 322, 327], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["type I", "GENE_OR_GENE_PRODUCT", 175, 181], ["type II", "GENE_OR_GENE_PRODUCT", 186, 193], ["membrane", "CELLULAR_COMPONENT", 194, 202], ["peripheral membrane", "CELLULAR_COMPONENT", 272, 291], ["Golgi", "CELLULAR_COMPONENT", 322, 327], ["membrane proteins", "PROTEIN", 117, 134], ["transmembrane domains", "PROTEIN", 147, 168], ["multiple transmembrane-spanning domains", "PROTEIN", 231, 270], ["peripheral membrane proteins", "PROTEIN", 272, 300], ["soluble resident Golgi proteins", "PROTEIN", 305, 336], ["a large number of proteins", "PROBLEM", 36, 62], ["such diverse functions", "PROBLEM", 79, 101], ["membrane proteins", "PROBLEM", 117, 134], ["single transmembrane domains", "PROBLEM", 140, 168], ["multiple transmembrane-spanning domains", "PROBLEM", 231, 270], ["peripheral membrane proteins", "TEST", 272, 300], ["not surprising", "UNCERTAINTY", 6, 20], ["large", "OBSERVATION_MODIFIER", 38, 43], ["number", "OBSERVATION_MODIFIER", 44, 50], ["proteins", "OBSERVATION", 54, 62], ["peripheral membrane", "ANATOMY", 272, 291]]], ["Although our understanding of the mechanims of localisation remain in the most cases rudimentary, in view of the diversity of Golgi proteins, one would expect a number of different mechanisms to be operating, as indeed appears to be the case.Resident Golgi proteinsBased on biochemical and functional considerations the resident proteins of the Golgi apparatus can be divided into at least seven groups (Table 1) .", [["Golgi", "ANATOMY", 126, 131], ["Golgi", "ANATOMY", 251, 256], ["Golgi apparatus", "ANATOMY", 345, 360], ["Golgi", "CELLULAR_COMPONENT", 126, 131], ["Golgi", "CELLULAR_COMPONENT", 251, 256], ["Golgi", "CELLULAR_COMPONENT", 345, 350], ["Golgi proteins", "PROTEIN", 126, 140], ["Resident Golgi proteins", "PROTEIN", 242, 265], ["resident proteins", "PROTEIN", 320, 337], ["the Golgi apparatus", "TREATMENT", 341, 360]]], ["Considerable work has focused on Golgi localisation signals of glycosyltransferases.", [["Golgi", "ANATOMY", 33, 38], ["Golgi", "CELLULAR_COMPONENT", 33, 38], ["glycosyltransferases", "PROTEIN", 63, 83]]], ["This is not surprising in view of the key role of the Golgi apparatus in the glycosylation of newly synthesised membrane and secreted proteins (Kornfeld and Kornfeld 1985; Gleeson 1988 ) and the estimated 100-200 different glycosyltransferase enzymes distributed throughout the Golgi stack.", [["Golgi apparatus", "ANATOMY", 54, 69], ["membrane", "ANATOMY", 112, 120], ["Golgi stack", "ANATOMY", 278, 289], ["Golgi apparatus", "CELLULAR_COMPONENT", 54, 69], ["membrane", "CELLULAR_COMPONENT", 112, 120], ["Golgi", "CELLULAR_COMPONENT", 278, 283], ["secreted proteins", "PROTEIN", 125, 142], ["glycosyltransferase enzymes", "PROTEIN", 223, 250], ["glycosyltransferase enzymes", "TEST", 223, 250], ["not surprising", "UNCERTAINTY", 8, 22], ["Golgi stack", "OBSERVATION", 278, 289]]], ["Although individual transferases constitute only a minor percentage of the proteins of the cisternae in which they reside, collectively, the glycosyltransferases of each Golgi cisterna may represent a very significant proportion, if not the bulk, of the resident membrane protein.Resident Golgi proteinsThe majority of known membrane proteins located in the Golgi stack are type II membrane proteins, with their amino-termini orientated in the cytoplasm and their carboxy-termini in the Golgi lumen.", [["cisternae", "ANATOMY", 91, 100], ["Golgi cisterna", "ANATOMY", 170, 184], ["membrane", "ANATOMY", 263, 271], ["Golgi", "ANATOMY", 289, 294], ["membrane", "ANATOMY", 325, 333], ["Golgi stack", "ANATOMY", 358, 369], ["membrane", "ANATOMY", 382, 390], ["cytoplasm", "ANATOMY", 444, 453], ["Golgi lumen", "ANATOMY", 487, 498], ["amino-termini", "CHEMICAL", 412, 425], ["amino", "CHEMICAL", 412, 417], ["carboxy", "CHEMICAL", 464, 471], ["cisternae", "CELLULAR_COMPONENT", 91, 100], ["Golgi", "CELLULAR_COMPONENT", 170, 175], ["cisterna", "MULTI-TISSUE_STRUCTURE", 176, 184], ["membrane", "CELLULAR_COMPONENT", 263, 271], ["Golgi", "CELLULAR_COMPONENT", 289, 294], ["membrane", "CELLULAR_COMPONENT", 325, 333], ["Golgi stack", "CELLULAR_COMPONENT", 358, 369], ["type II membrane", "CELLULAR_COMPONENT", 374, 390], ["amino-termini", "AMINO_ACID", 412, 425], ["cytoplasm", "ORGANISM_SUBSTANCE", 444, 453], ["Golgi lumen", "CELLULAR_COMPONENT", 487, 498], ["transferases", "PROTEIN", 20, 32], ["glycosyltransferases", "PROTEIN", 141, 161], ["resident membrane protein", "PROTEIN", 254, 279], ["Resident Golgi proteins", "PROTEIN", 280, 303], ["membrane proteins", "PROTEIN", 325, 342], ["type II membrane proteins", "PROTEIN", 374, 399], ["carboxy-termini", "PROTEIN", 464, 479], ["known membrane proteins", "PROBLEM", 319, 342], ["type II membrane proteins", "PROBLEM", 374, 399], ["their amino-termini", "TREATMENT", 406, 425], ["minor", "OBSERVATION_MODIFIER", 51, 56], ["percentage", "OBSERVATION_MODIFIER", 57, 67], ["proteins", "OBSERVATION", 75, 83], ["cisternae", "ANATOMY_MODIFIER", 91, 100], ["may represent", "UNCERTAINTY", 185, 198], ["membrane proteins", "OBSERVATION", 325, 342], ["Golgi stack", "OBSERVATION", 358, 369], ["type II", "OBSERVATION_MODIFIER", 374, 381], ["membrane proteins", "OBSERVATION", 382, 399], ["amino-termini", "OBSERVATION", 412, 425], ["cytoplasm", "OBSERVATION_MODIFIER", 444, 453], ["carboxy", "OBSERVATION_MODIFIER", 464, 471], ["termini", "OBSERVATION_MODIFIER", 472, 479], ["Golgi lumen", "OBSERVATION", 487, 498]]], ["However, there are some exceptions such as the yeast medial-Golgi Emp47 (Schr\u00f6der et al. 1995) , which is a type I membrane protein.", [["medial-Golgi", "ANATOMY", 53, 65], ["membrane", "ANATOMY", 115, 123], ["type I", "GENE_OR_GENE_PRODUCT", 108, 114], ["membrane", "CELLULAR_COMPONENT", 115, 123], ["Golgi Emp47", "PROTEIN", 60, 71], ["type I membrane protein", "PROTEIN", 108, 131], ["yeast", "SPECIES", 47, 52], ["yeast", "SPECIES", 47, 52], ["medial", "ANATOMY_MODIFIER", 53, 59]]], ["The localisation signals of the type II membrane proteins are complex and, in many cases, involve multiple regions of the protein.", [["type II membrane", "ANATOMY", 32, 48], ["type II membrane proteins", "GENE_OR_GENE_PRODUCT", 32, 57], ["type II membrane proteins", "PROTEIN", 32, 57], ["type II", "OBSERVATION_MODIFIER", 32, 39], ["membrane proteins", "OBSERVATION", 40, 57], ["complex", "OBSERVATION_MODIFIER", 62, 69], ["multiple", "OBSERVATION_MODIFIER", 98, 106]]], ["The dominance of the type II membrane proteins in the Golgi stack contrasts with many of the membrane proteins that reside in the TGN, which have the opposite orientation, namely type I.Resident Golgi proteinsIn the past few years it has become apparent that there is a distinct set of resident Golgi proteins in the TGN of mammalian cells, and the late Golgi of yeast, that have features associated with their localisation which are distinct from Golgi glycosyltransfeases (Luzio and Banting 1993; Stanley and Howell 1993; Wilsbach and Payne 1993) .", [["type II membrane", "ANATOMY", 21, 37], ["Golgi stack", "ANATOMY", 54, 65], ["membrane", "ANATOMY", 93, 101], ["TGN", "ANATOMY", 130, 133], ["Golgi", "ANATOMY", 295, 300], ["TGN", "ANATOMY", 317, 320], ["mammalian cells", "ANATOMY", 324, 339], ["late Golgi", "ANATOMY", 349, 359], ["Golgi", "ANATOMY", 448, 453], ["type II membrane proteins", "GENE_OR_GENE_PRODUCT", 21, 46], ["Golgi", "CELLULAR_COMPONENT", 54, 59], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["TGN", "GENE_OR_GENE_PRODUCT", 130, 133], ["type I.Resident Golgi", "GENE_OR_GENE_PRODUCT", 179, 200], ["Golgi", "CELLULAR_COMPONENT", 295, 300], ["TGN", "CELLULAR_COMPONENT", 317, 320], ["mammalian cells", "CELL", 324, 339], ["late Golgi", "CELLULAR_COMPONENT", 349, 359], ["Golgi", "CELLULAR_COMPONENT", 448, 453], ["type II membrane proteins", "PROTEIN", 21, 46], ["membrane proteins", "PROTEIN", 93, 110], ["TGN", "PROTEIN", 130, 133], ["type I.Resident Golgi proteins", "PROTEIN", 179, 209], ["resident Golgi proteins", "PROTEIN", 286, 309], ["TGN", "PROTEIN", 317, 320], ["mammalian cells", "CELL_TYPE", 324, 339], ["yeast", "SPECIES", 363, 368], ["yeast", "SPECIES", 363, 368], ["the type II membrane proteins", "PROBLEM", 17, 46], ["the membrane proteins", "PROBLEM", 89, 110], ["mammalian cells", "PROBLEM", 324, 339], ["the late Golgi of yeast", "PROBLEM", 345, 368], ["dominance", "OBSERVATION_MODIFIER", 4, 13], ["type II", "OBSERVATION_MODIFIER", 21, 28], ["membrane proteins", "OBSERVATION", 29, 46], ["Golgi stack", "OBSERVATION", 54, 65], ["membrane proteins", "OBSERVATION", 93, 110], ["mammalian cells", "OBSERVATION", 324, 339]]], ["A characteristic of these TGN proteins is their ability continuously to recycle between the TGN and post-TGN compartments.Resident Golgi proteinsThere are a number of multimembrane-spanning proteins which are localised to the Golgi, including viral glycoproteins, retrieval receptors, nucleotide-sugar transporters and the recently described copper translocating P-type ATPase (Petris et al. 1996) .", [["TGN", "ANATOMY", 26, 29], ["TGN", "ANATOMY", 92, 95], ["post-TGN compartments", "ANATOMY", 100, 121], ["Golgi", "ANATOMY", 131, 136], ["Golgi", "ANATOMY", 226, 231], ["nucleotide", "CHEMICAL", 285, 295], ["copper", "CHEMICAL", 342, 348], ["nucleotide", "CHEMICAL", 285, 295], ["sugar", "CHEMICAL", 296, 301], ["copper", "CHEMICAL", 342, 348], ["TGN", "GENE_OR_GENE_PRODUCT", 26, 29], ["TGN", "CELLULAR_COMPONENT", 92, 95], ["TGN compartments", "CELLULAR_COMPONENT", 105, 121], ["Golgi", "CELLULAR_COMPONENT", 131, 136], ["Golgi", "CELLULAR_COMPONENT", 226, 231], ["copper", "SIMPLE_CHEMICAL", 342, 348], ["ATPase", "GENE_OR_GENE_PRODUCT", 370, 376], ["TGN proteins", "PROTEIN", 26, 38], ["TGN", "PROTEIN", 92, 95], ["Resident Golgi proteins", "PROTEIN", 122, 145], ["multimembrane-spanning proteins", "PROTEIN", 167, 198], ["viral glycoproteins", "PROTEIN", 243, 262], ["retrieval receptors", "PROTEIN", 264, 283], ["nucleotide-sugar transporters", "PROTEIN", 285, 314], ["copper translocating P-type ATPase", "PROTEIN", 342, 376], ["these TGN proteins", "PROBLEM", 20, 38], ["multimembrane-spanning proteins", "PROBLEM", 167, 198], ["viral glycoproteins", "TREATMENT", 243, 262], ["retrieval receptors", "TREATMENT", 264, 283], ["nucleotide-sugar transporters", "TREATMENT", 285, 314], ["TGN proteins", "OBSERVATION", 26, 38], ["number", "OBSERVATION_MODIFIER", 157, 163], ["Golgi", "ANATOMY_MODIFIER", 226, 231], ["viral glycoproteins", "OBSERVATION", 243, 262]]], ["A number of peripheral membrane proteins, found on the cytoplasmic surface of Golgi membranes, have been identified, including those considered to be important in the organisation of Golgi membranes and a number implicated in membrane transport.", [["peripheral membrane", "ANATOMY", 12, 31], ["cytoplasmic surface", "ANATOMY", 55, 74], ["Golgi membranes", "ANATOMY", 78, 93], ["Golgi membranes", "ANATOMY", 183, 198], ["membrane", "ANATOMY", 226, 234], ["peripheral membrane", "MULTI-TISSUE_STRUCTURE", 12, 31], ["cytoplasmic surface", "CELLULAR_COMPONENT", 55, 74], ["Golgi membranes", "CELLULAR_COMPONENT", 78, 93], ["Golgi membranes", "CELLULAR_COMPONENT", 183, 198], ["membrane", "CELLULAR_COMPONENT", 226, 234], ["peripheral membrane proteins", "PROTEIN", 12, 40], ["peripheral membrane proteins", "PROBLEM", 12, 40], ["peripheral", "ANATOMY_MODIFIER", 12, 22], ["membrane proteins", "OBSERVATION", 23, 40], ["Golgi membranes", "OBSERVATION", 78, 93], ["Golgi membranes", "OBSERVATION", 183, 198]]], ["Finally, the first soluble protein localised to the Golgi lumen was described in 1996 (Scherer et al. 1996) , raising questions on the retention mechanism of yet another class of resident Golgi protein.Glycosylation machineryNumerous mammalian and yeast Golgi glycosyltransferases, and some processing glycosidases, have been cloned and sequenced (Schachter 1991; Shaper and Shaper 1992 ; van den Eijnden and Joziasse 1993; Kleene and Berger 1993; Moreman et al. 1994; Field and Wainwright 1995) .", [["Golgi lumen", "ANATOMY", 52, 63], ["Golgi", "ANATOMY", 188, 193], ["Golgi", "ANATOMY", 254, 259], ["Golgi lumen", "CELLULAR_COMPONENT", 52, 63], ["Golgi", "CELLULAR_COMPONENT", 188, 193], ["yeast Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 248, 280], ["soluble protein", "PROTEIN", 19, 34], ["resident Golgi protein", "PROTEIN", 179, 201], ["mammalian and yeast Golgi glycosyltransferases", "PROTEIN", 234, 280], ["glycosidases", "PROTEIN", 302, 314], ["yeast", "SPECIES", 248, 253], ["yeast", "SPECIES", 248, 253], ["the first soluble protein", "TREATMENT", 9, 34], ["Glycosylation machinery", "TREATMENT", 202, 225], ["yeast Golgi glycosyltransferases", "TREATMENT", 248, 280], ["some processing glycosidases", "PROBLEM", 286, 314], ["Golgi lumen", "OBSERVATION", 52, 63], ["yeast Golgi glycosyltransferases", "OBSERVATION", 248, 280]]], ["All are type II membrane proteins.", [["membrane", "ANATOMY", 16, 24], ["type II membrane proteins", "GENE_OR_GENE_PRODUCT", 8, 33], ["type II membrane proteins", "PROTEIN", 8, 33], ["type II membrane proteins", "PROBLEM", 8, 33], ["type II", "OBSERVATION_MODIFIER", 8, 15], ["membrane proteins", "OBSERVATION", 16, 33]]], ["Comparison of the amino acid sequences between these enzymes has revealed very little sequence similarity.", [["amino acid", "CHEMICAL", 18, 28], ["amino acid", "CHEMICAL", 18, 28], ["amino acid", "AMINO_ACID", 18, 28], ["amino acid sequences", "PROTEIN", 18, 38], ["enzymes", "PROTEIN", 53, 60], ["the amino acid sequences", "TEST", 14, 38], ["these enzymes", "TEST", 47, 60]]], ["This is dramatically illustrated by a lack of obvious amino acid similarity between the sequences of four different Glc-NAc transferases involved in the synthesis of the outer antennae of complex N-glycans, namely GlcNAc-TI (Kumar et al. 1990; Sarkar et al. 1991) , GlcNAc-TII (D'Agostaro et al. 1995) , GlcNAc-TIII (Nishikawa et al. 1992 ) and GlcNAc-TV (Shoreibah et al. 1993 ).", [["outer antennae", "ANATOMY", 170, 184], ["amino acid", "CHEMICAL", 54, 64], ["Glc", "CHEMICAL", 116, 119], ["amino acid", "CHEMICAL", 54, 64], ["Glc", "CHEMICAL", 116, 119], ["N", "CHEMICAL", 196, 197], ["GlcNAc", "CHEMICAL", 214, 220], ["GlcNAc", "CHEMICAL", 266, 272], ["GlcNAc", "CHEMICAL", 304, 310], ["GlcNAc", "CHEMICAL", 345, 351], ["amino acid", "AMINO_ACID", 54, 64], ["Glc-NAc transferases", "GENE_OR_GENE_PRODUCT", 116, 136], ["GlcNAc-TI", "SIMPLE_CHEMICAL", 214, 223], ["GlcNAc-TII", "SIMPLE_CHEMICAL", 266, 276], ["GlcNAc-TIII", "GENE_OR_GENE_PRODUCT", 304, 315], ["GlcNAc-TV", "GENE_OR_GENE_PRODUCT", 345, 354], ["Glc-NAc transferases", "PROTEIN", 116, 136], ["obvious amino acid similarity", "PROBLEM", 46, 75], ["the sequences", "TEST", 84, 97], ["Glc", "TEST", 116, 119], ["NAc transferases", "TREATMENT", 120, 136], ["GlcNAc", "TEST", 266, 272], ["GlcNAc", "TEST", 304, 310], ["GlcNAc", "TEST", 345, 351], ["dramatically", "OBSERVATION_MODIFIER", 8, 20]]], ["There is, however, an obvious similarity in the domain structure of all Golgi glycosyltransferases.", [["Golgi", "ANATOMY", 72, 77], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 72, 98], ["Golgi glycosyltransferases", "PROTEIN", 72, 98], ["obvious", "OBSERVATION_MODIFIER", 22, 29], ["similarity", "OBSERVATION", 30, 40], ["all", "OBSERVATION_MODIFIER", 68, 71], ["Golgi glycosyltransferases", "OBSERVATION", 72, 98]]], ["They have a short aminoterminal cytoplasmic domain (many have less than ten amino acids), a single hydrophobic membrane-spanning domain (16-25 amino acids), which also serves as a noncleavable signal sequence, and a large carboxylterminal catalytic domain situated in the lumen of the Golgi appa- Fig. 2 The different classes of resident Golgi proteins.", [["cytoplasmic", "ANATOMY", 32, 43], ["membrane", "ANATOMY", 111, 119], ["lumen", "ANATOMY", 272, 277], ["Golgi", "ANATOMY", 285, 290], ["Golgi", "ANATOMY", 338, 343], ["amino acids", "CHEMICAL", 76, 87], ["amino acids", "CHEMICAL", 143, 154], ["amino acids", "CHEMICAL", 76, 87], ["amino acids", "CHEMICAL", 143, 154], ["cytoplasmic", "ORGANISM_SUBSTANCE", 32, 43], ["amino acids", "AMINO_ACID", 76, 87], ["amino acids", "AMINO_ACID", 143, 154], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 272, 277], ["Golgi", "CELLULAR_COMPONENT", 285, 290], ["Golgi", "CELLULAR_COMPONENT", 338, 343], ["aminoterminal cytoplasmic domain", "PROTEIN", 18, 50], ["hydrophobic membrane-spanning domain", "PROTEIN", 99, 135], ["noncleavable signal sequence", "PROTEIN", 180, 208], ["carboxylterminal catalytic domain", "PROTEIN", 222, 255], ["Golgi appa", "PROTEIN", 285, 295], ["resident Golgi proteins", "PROTEIN", 329, 352], ["a short aminoterminal cytoplasmic domain", "PROBLEM", 10, 50], ["amino acids", "TEST", 76, 87], ["a single hydrophobic membrane", "TEST", 90, 119], ["amino acids", "TEST", 143, 154], ["a noncleavable signal sequence", "PROBLEM", 178, 208], ["a large carboxylterminal catalytic domain", "PROBLEM", 214, 255], ["large", "OBSERVATION_MODIFIER", 216, 221], ["carboxylterminal", "OBSERVATION", 222, 238], ["catalytic domain", "OBSERVATION", 239, 255], ["lumen", "ANATOMY_MODIFIER", 272, 277], ["Golgi proteins", "OBSERVATION", 338, 352]]], ["Resident Golgi proteins include type I and type II membrane proteins, multimembrane-spanning proteins, peripheral membrane proteins and soluble lumenal proteins& / f i g . c :Glycosylation machineryratus.", [["Golgi", "ANATOMY", 9, 14], ["peripheral membrane", "ANATOMY", 103, 122], ["lumenal", "ANATOMY", 144, 151], ["Golgi", "CELLULAR_COMPONENT", 9, 14], ["type I", "GENE_OR_GENE_PRODUCT", 32, 38], ["type II membrane proteins", "GENE_OR_GENE_PRODUCT", 43, 68], ["multimembrane-spanning proteins", "GENE_OR_GENE_PRODUCT", 70, 101], ["peripheral membrane", "CELLULAR_COMPONENT", 103, 122], ["Resident Golgi proteins", "PROTEIN", 0, 23], ["type I and type II membrane proteins", "PROTEIN", 32, 68], ["multimembrane-spanning proteins", "PROTEIN", 70, 101], ["peripheral membrane proteins", "PROTEIN", 103, 131], ["soluble lumenal proteins& / f i g", "PROTEIN", 136, 169], ["Golgi proteins", "TEST", 9, 23], ["type I and type II membrane proteins", "PROBLEM", 32, 68], ["multimembrane", "TEST", 70, 83], ["peripheral membrane proteins", "TEST", 103, 131], ["Glycosylation machineryratus", "TREATMENT", 175, 203], ["peripheral membrane", "ANATOMY", 103, 122]]], ["The catalytic domain is linked to the transmembrane domain by a loosely defined \"stem\" region which may play a role in positioning the catalytic domain away from the lipid bilayer, facilitating access to the oligosaccharide substrates.", [["transmembrane", "ANATOMY", 38, 51], ["lipid bilayer", "ANATOMY", 166, 179], ["transmembrane", "CELLULAR_COMPONENT", 38, 51], ["lipid bilayer", "CELLULAR_COMPONENT", 166, 179], ["catalytic domain", "PROTEIN", 4, 20], ["transmembrane domain", "PROTEIN", 38, 58], ["stem\" region", "PROTEIN", 81, 93], ["catalytic domain", "PROTEIN", 135, 151], ["a loosely defined \"stem\" region", "PROBLEM", 62, 93], ["the lipid bilayer", "TREATMENT", 162, 179], ["the oligosaccharide substrates", "TREATMENT", 204, 234], ["loosely", "OBSERVATION_MODIFIER", 64, 71], ["stem\"", "OBSERVATION", 81, 86]]], ["The lack of sequence homology between the different glycosyltransferases suggested from the outset that the Golgi localisation signals were unlikely to be linear amino acid sequence but rather involve structural features associated with conformation.Glycosylation machineryOther components associated with glycosylation machinery include nucleotide sugar transporters, to transfer the nucleotide-sugars (substrates for the glycosyltransferases) from the cytosol to the Golgi lumen, and nucleoside diphosphatases, which are required to convert the nucleoside diphosphates of the reaction products to nucleotide monophosphates prior to removal from the Golgi lumen.", [["Golgi", "ANATOMY", 108, 113], ["cytosol", "ANATOMY", 454, 461], ["Golgi lumen", "ANATOMY", 469, 480], ["Golgi lumen", "ANATOMY", 651, 662], ["amino acid", "CHEMICAL", 162, 172], ["nucleotide", "CHEMICAL", 338, 348], ["nucleotide", "CHEMICAL", 385, 395], ["nucleoside", "CHEMICAL", 486, 496], ["nucleoside diphosphates", "CHEMICAL", 547, 570], ["nucleotide monophosphates", "CHEMICAL", 599, 624], ["amino acid", "CHEMICAL", 162, 172], ["nucleotide", "CHEMICAL", 338, 348], ["sugar", "CHEMICAL", 349, 354], ["nucleotide", "CHEMICAL", 385, 395], ["sugars", "CHEMICAL", 396, 402], ["nucleoside", "CHEMICAL", 486, 496], ["nucleoside diphosphates", "CHEMICAL", 547, 570], ["nucleotide monophosphates", "CHEMICAL", 599, 624], ["Golgi", "CELLULAR_COMPONENT", 108, 113], ["amino acid", "AMINO_ACID", 162, 172], ["cytosol", "CELLULAR_COMPONENT", 454, 461], ["Golgi lumen", "CELLULAR_COMPONENT", 469, 480], ["nucleoside diphosphatases", "SIMPLE_CHEMICAL", 486, 511], ["nucleoside diphosphates", "SIMPLE_CHEMICAL", 547, 570], ["nucleotide monophosphates", "SIMPLE_CHEMICAL", 599, 624], ["Golgi lumen", "CELLULAR_COMPONENT", 651, 662], ["glycosyltransferases", "PROTEIN", 52, 72], ["nucleotide sugar transporters", "PROTEIN", 338, 367], ["glycosyltransferases", "PROTEIN", 423, 443], ["nucleoside diphosphatases", "PROTEIN", 486, 511], ["the different glycosyltransferases", "TEST", 38, 72], ["linear amino acid sequence", "TEST", 155, 181], ["Glycosylation machineryOther components", "TREATMENT", 250, 289], ["glycosylation machinery", "TREATMENT", 306, 329], ["nucleotide sugar transporters", "TREATMENT", 338, 367], ["the glycosyltransferases", "TREATMENT", 419, 443], ["nucleoside diphosphatases", "TREATMENT", 486, 511], ["the nucleoside diphosphates", "TREATMENT", 543, 570], ["the reaction products", "TREATMENT", 574, 595], ["nucleotide monophosphates", "TREATMENT", 599, 624], ["removal", "TREATMENT", 634, 641], ["the Golgi lumen", "TREATMENT", 647, 662], ["Golgi lumen", "ANATOMY", 469, 480], ["Golgi lumen", "OBSERVATION", 651, 662]]], ["The first Golgi UDP-GlcNAc transporter was recently cloned (Abeijon et al. 1996) and the predicted 328-amino acid protein is a multimembrane-spanning protein with five to eight membrane-spanning domains.", [["Golgi", "ANATOMY", 10, 15], ["membrane", "ANATOMY", 177, 185], ["UDP", "CHEMICAL", 16, 19], ["amino acid", "CHEMICAL", 103, 113], ["UDP", "CHEMICAL", 16, 19], ["GlcNAc", "CHEMICAL", 20, 26], ["amino acid", "CHEMICAL", 103, 113], ["Golgi", "CELLULAR_COMPONENT", 10, 15], ["UDP-GlcNAc", "GENE_OR_GENE_PRODUCT", 16, 26], ["amino acid", "AMINO_ACID", 103, 113], ["Golgi UDP-GlcNAc transporter", "PROTEIN", 10, 38], ["328-amino acid protein", "PROTEIN", 99, 121], ["multimembrane-spanning protein", "PROTEIN", 127, 157], ["membrane-spanning domains", "PROTEIN", 177, 202], ["amino acid protein", "TEST", 103, 121], ["a multimembrane", "TEST", 125, 140]]], ["Knowledge of the sequence of this transporter now opens the way for the Golgi localisation of this protein to be explored.Golgi retention sequences of glycosyltransferasesThere has been considerable effort over the past 7 years directed towards the identification of the targeting signals responsible for the localisation of mammalian gly-cosyltransferases.", [["Golgi", "ANATOMY", 72, 77], ["Golgi", "ANATOMY", 122, 127], ["Golgi", "CELLULAR_COMPONENT", 72, 77], ["Golgi", "CELLULAR_COMPONENT", 122, 127], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 151, 171], ["gly-cosyltransferases", "GENE_OR_GENE_PRODUCT", 335, 356], ["glycosyltransferases", "PROTEIN", 151, 171], ["mammalian gly-cosyltransferases", "PROTEIN", 325, 356], ["this transporter", "TREATMENT", 29, 45], ["this protein", "TREATMENT", 94, 106], ["glycosyltransferases", "TREATMENT", 151, 171], ["retention", "OBSERVATION", 128, 137], ["considerable", "OBSERVATION_MODIFIER", 186, 198], ["effort", "OBSERVATION_MODIFIER", 199, 205]]], ["Three mammalian glycosyltransferases have been examined in some detail, namely \u03b12,6ST, \u03b21,4GalT and GlcNAc-TI; these enzymes are residents predominantly of the TGN (Roth et al. 1985; Taatjes et al. 1988 ), TGN/trans-Golgi (Roth and Berger 1982; Suganuma et al. 1991; Nilsson et al. 1993a ) and medial-Golgi (Dunphy et al. 1985; Burke et al. 1992; Nilsson et al. 1993a ), respectively.Golgi retention sequences of glycosyltransferasesThe expression of intact glycosyltransferases in transfected mammalian cells results in very efficient Golgi localisation (Munro 1991; Nilsson et al. 1991; Aoki et al. 1992; Burke et al. 1992; Colley et al. 1992; Teasdale et al. 1992) .", [["TGN", "ANATOMY", 160, 163], ["medial-Golgi", "ANATOMY", 294, 306], ["Golgi", "ANATOMY", 384, 389], ["mammalian cells", "ANATOMY", 494, 509], ["Golgi", "ANATOMY", 536, 541], ["GlcNAc", "CHEMICAL", 100, 106], ["\u03b12,6ST", "SIMPLE_CHEMICAL", 79, 85], ["\u03b21,4GalT", "SIMPLE_CHEMICAL", 87, 95], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 100, 109], ["TGN", "CELLULAR_COMPONENT", 160, 163], ["TGN", "CELLULAR_COMPONENT", 206, 209], ["Golgi", "CELLULAR_COMPONENT", 216, 221], ["Golgi", "ORGANISM_SUBSTANCE", 301, 306], ["Golgi", "CELLULAR_COMPONENT", 384, 389], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 413, 433], ["mammalian cells", "CELL", 494, 509], ["Golgi", "CELLULAR_COMPONENT", 536, 541], ["mammalian glycosyltransferases", "PROTEIN", 6, 36], ["\u03b12,6ST", "PROTEIN", 79, 85], ["TI", "PROTEIN", 107, 109], ["enzymes", "PROTEIN", 117, 124], ["TGN", "PROTEIN", 160, 163], ["glycosyltransferases", "PROTEIN", 413, 433], ["intact glycosyltransferases", "PROTEIN", 451, 478], ["transfected mammalian cells", "CELL_LINE", 482, 509], ["Three mammalian glycosyltransferases", "TREATMENT", 0, 36], ["these enzymes", "TEST", 111, 124], ["glycosyltransferases", "TREATMENT", 413, 433], ["intact glycosyltransferases", "TREATMENT", 451, 478], ["medial", "ANATOMY_MODIFIER", 294, 300], ["retention", "OBSERVATION", 390, 399]]], ["This finding implies that the mechanism to retain glycosyltransferases is very difficult to saturate.", [["glycosyltransferases", "PROTEIN", 50, 70]]], ["The strategy employed to identify putative Golgi retention signal(s) has involved the generation of hybrid or chimeric molecules containing limited sequences derived from Golgi glycosyltransferases fused with a reporter molecule.", [["Golgi", "ANATOMY", 43, 48], ["Golgi", "ANATOMY", 171, 176], ["Golgi", "CELLULAR_COMPONENT", 43, 48], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 171, 197], ["chimeric molecules", "PROTEIN", 110, 128], ["Golgi glycosyltransferases", "PROTEIN", 171, 197], ["reporter molecule", "PROTEIN", 211, 228], ["hybrid or chimeric molecules", "PROBLEM", 100, 128], ["Golgi glycosyltransferases", "TREATMENT", 171, 197]]], ["Analysis of the intracellular location of these hybrid molecules in transfected cells showed the ability of the fusion protein to be retained in the Golgi apparatus.", [["intracellular", "ANATOMY", 16, 29], ["cells", "ANATOMY", 80, 85], ["Golgi apparatus", "ANATOMY", 149, 164], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 29], ["cells", "CELL", 80, 85], ["Golgi apparatus", "CELLULAR_COMPONENT", 149, 164], ["transfected cells", "CELL_LINE", 68, 85], ["fusion protein", "PROTEIN", 112, 126], ["these hybrid molecules in transfected cells", "PROBLEM", 42, 85], ["the fusion protein", "PROBLEM", 108, 126], ["hybrid molecules", "OBSERVATION", 48, 64], ["transfected cells", "OBSERVATION", 68, 85], ["fusion", "OBSERVATION", 112, 118], ["Golgi apparatus", "OBSERVATION", 149, 164]]], ["In some but not all cases, putative retention sequences have been replaced in the full-length glycosyltransferases to determine the ability to disrupt Golgi retention.", [["Golgi", "ANATOMY", 151, 156], ["Golgi", "CELLULAR_COMPONENT", 151, 156], ["full-length glycosyltransferases", "PROTEIN", 82, 114], ["putative retention sequences", "TEST", 27, 55], ["the full-length glycosyltransferases", "TREATMENT", 78, 114], ["Golgi retention", "PROBLEM", 151, 166], ["Golgi retention", "OBSERVATION", 151, 166]]], ["Disruption of the Golgi retention signal is indicated by the appearance of the glycosyltransferase mutants on the cell surface.Golgi retention sequences of glycosyltransferasesIn all cases so far examined, the membrane-spanning domains of the mammalian Golgi glycosyltransferases have been shown to direct, at least partial, localisation of hybrid molecules to the Golgi apparatus (Munro 1991; 521 Nilsson et al. 1991; Aoki et al. 1992; Russo et al. 1992; Tang et al. 1992; Teasdale et al. 1992; Wong et al. 1992; Burke et al. 1994) .", [["Golgi", "ANATOMY", 18, 23], ["cell surface", "ANATOMY", 114, 126], ["Golgi", "ANATOMY", 127, 132], ["membrane", "ANATOMY", 210, 218], ["Golgi", "ANATOMY", 253, 258], ["Golgi apparatus", "ANATOMY", 365, 380], ["Golgi", "CELLULAR_COMPONENT", 18, 23], ["glycosyltransferase", "GENE_OR_GENE_PRODUCT", 79, 98], ["cell surface", "CELLULAR_COMPONENT", 114, 126], ["Golgi", "CELLULAR_COMPONENT", 127, 132], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 156, 176], ["membrane", "CELLULAR_COMPONENT", 210, 218], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 253, 279], ["Golgi apparatus", "CELLULAR_COMPONENT", 365, 380], ["glycosyltransferase mutants", "PROTEIN", 79, 106], ["glycosyltransferases", "PROTEIN", 156, 176], ["membrane-spanning domains", "PROTEIN", 210, 235], ["mammalian Golgi glycosyltransferases", "PROTEIN", 243, 279], ["hybrid molecules", "PROTEIN", 341, 357], ["Disruption of the Golgi retention signal", "PROBLEM", 0, 40], ["the glycosyltransferase mutants", "PROBLEM", 75, 106], ["glycosyltransferases", "TREATMENT", 156, 176], ["the mammalian Golgi glycosyltransferases", "TREATMENT", 239, 279], ["Golgi retention", "OBSERVATION", 18, 33], ["glycosyltransferase mutants", "OBSERVATION", 79, 106], ["cell", "OBSERVATION_MODIFIER", 114, 118], ["surface", "OBSERVATION_MODIFIER", 119, 126], ["retention", "OBSERVATION", 133, 142]]], ["Moreover, the transmembrane domain of \u03b21,4GalT and GlcNAc-TI can specifically localise hybrid proteins to the trans and medial cisternae, respectively (Nilsson et al. 1991; Burke et al. 1994) .", [["transmembrane", "ANATOMY", 14, 27], ["medial cisternae", "ANATOMY", 120, 136], ["GlcNAc", "CHEMICAL", 51, 57], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 38, 46], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 51, 60], ["medial cisternae", "MULTI-TISSUE_STRUCTURE", 120, 136], ["transmembrane domain", "PROTEIN", 14, 34], ["\u03b21,4GalT", "PROTEIN", 38, 46], ["GlcNAc", "PROTEIN", 51, 57], ["TI", "PROTEIN", 58, 60], ["hybrid proteins", "PROTEIN", 87, 102], ["the transmembrane domain", "TEST", 10, 34], ["GlcNAc-TI", "TREATMENT", 51, 60], ["medial", "ANATOMY_MODIFIER", 120, 126], ["cisternae", "ANATOMY_MODIFIER", 127, 136]]], ["More recently, a number of yeast glycosyltransferases have also been examined which encompass enzymes considered to be localised to the yeast equivalent of either the cis-, medial-or trans-Golgi.", [["Golgi", "ANATOMY", 189, 194], ["yeast glycosyltransferases", "GENE_OR_GENE_PRODUCT", 27, 53], ["Golgi", "CELLULAR_COMPONENT", 189, 194], ["yeast glycosyltransferases", "PROTEIN", 27, 53], ["enzymes", "PROTEIN", 94, 101], ["cis-, medial-or trans-Golgi", "PROTEIN", 167, 194], ["yeast", "SPECIES", 27, 32], ["yeast", "SPECIES", 136, 141], ["yeast", "SPECIES", 27, 32], ["yeast", "SPECIES", 136, 141], ["yeast glycosyltransferases", "PROBLEM", 27, 53], ["enzymes", "TEST", 94, 101], ["yeast glycosyltransferases", "OBSERVATION", 27, 53], ["yeast equivalent", "OBSERVATION", 136, 152], ["medial", "OBSERVATION_MODIFIER", 173, 179]]], ["These include the initiating \u03b11,6-mannosyltransferase (Och1p) (early-Golgi) (Harris and Waters 1996) , \u03b11,2-mannosyltransferase (Mnt1p) (medial-Golgi) (Lussier et al. 1995) , and terminal \u03b11,3-mannosyltransferase (Mnn1p) (late-Golgi) (Graham and Krasnov 1995) .", [["medial-Golgi", "ANATOMY", 137, 149], ["\u03b11,6-mannosyltransferase", "GENE_OR_GENE_PRODUCT", 29, 53], ["Och1p", "GENE_OR_GENE_PRODUCT", 55, 60], ["Golgi", "CELLULAR_COMPONENT", 69, 74], ["\u03b11,2-mannosyltransferase", "GENE_OR_GENE_PRODUCT", 103, 127], ["Mnt1p", "GENE_OR_GENE_PRODUCT", 129, 134], ["\u03b11,3-mannosyltransferase", "GENE_OR_GENE_PRODUCT", 188, 212], ["Mnn1p", "GENE_OR_GENE_PRODUCT", 214, 219], ["\u03b11,6-mannosyltransferase", "PROTEIN", 29, 53], ["Och1p", "PROTEIN", 55, 60], ["\u03b11,2-mannosyltransferase", "PROTEIN", 103, 127], ["Mnt1p", "PROTEIN", 129, 134], ["Golgi", "PROTEIN", 144, 149], ["terminal \u03b11,3-mannosyltransferase", "PROTEIN", 179, 212], ["Mnn1p", "PROTEIN", 214, 219], ["terminal \u03b11,3-mannosyltransferase (Mnn1p)", "TREATMENT", 179, 220]]], ["The transmembrane domains of each of these three glycosyltransferases will also localise (at least partially) heterologous proteins to the yeast Golgi (Chapman and Munro 1994a; Graham and Krasnov 1995; Lussier et al. 1995) .", [["transmembrane", "ANATOMY", 4, 17], ["Golgi", "ANATOMY", 145, 150], ["Golgi", "CELLULAR_COMPONENT", 145, 150], ["transmembrane domains", "PROTEIN", 4, 25], ["glycosyltransferases", "PROTEIN", 49, 69], ["heterologous proteins", "PROTEIN", 110, 131], ["yeast", "SPECIES", 139, 144], ["yeast", "SPECIES", 139, 144]]], ["This observation, together with the finding that the transmembrane domain of the mammalian \u03b12,6ST can act as a Golgi retention signal in yeast (Schwientek et al. 1995) , suggests there is a transmembrane domain-mediated mechanism involved in the retention of Golgi glycosyltransferases in both mammalian cells and yeast.Golgi retention sequences of glycosyltransferasesAlthough the transmembrane domain is clearly relevant, numerous other studies have revealed that the situation is far more complex than at first appreciated.", [["transmembrane", "ANATOMY", 53, 66], ["Golgi", "ANATOMY", 111, 116], ["transmembrane", "ANATOMY", 190, 203], ["Golgi", "ANATOMY", 259, 264], ["cells", "ANATOMY", 304, 309], ["Golgi", "ANATOMY", 320, 325], ["transmembrane", "ANATOMY", 382, 395], ["transmembrane", "CELLULAR_COMPONENT", 53, 66], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 91, 97], ["Golgi", "CELLULAR_COMPONENT", 111, 116], ["Golgi", "CELLULAR_COMPONENT", 259, 264], ["cells", "CELL", 304, 309], ["yeast", "CELL", 314, 319], ["Golgi", "CELLULAR_COMPONENT", 320, 325], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 349, 369], ["transmembrane", "CELLULAR_COMPONENT", 382, 395], ["transmembrane domain", "PROTEIN", 53, 73], ["mammalian \u03b12,6ST", "PROTEIN", 81, 97], ["transmembrane domain", "PROTEIN", 190, 210], ["Golgi glycosyltransferases", "PROTEIN", 259, 285], ["mammalian cells", "CELL_TYPE", 294, 309], ["glycosyltransferases", "PROTEIN", 349, 369], ["transmembrane domain", "PROTEIN", 382, 402], ["yeast", "SPECIES", 137, 142], ["yeast", "SPECIES", 314, 319], ["yeast", "SPECIES", 137, 142], ["yeast", "SPECIES", 314, 319], ["This observation", "TEST", 0, 16], ["a Golgi retention signal in yeast", "PROBLEM", 109, 142], ["a transmembrane domain-mediated mechanism", "PROBLEM", 188, 229], ["Golgi glycosyltransferases", "TREATMENT", 259, 285], ["yeast", "PROBLEM", 314, 319], ["glycosyltransferases", "TREATMENT", 349, 369], ["numerous other studies", "TEST", 424, 446], ["Golgi retention", "OBSERVATION", 111, 126], ["Golgi glycosyltransferases", "OBSERVATION", 259, 285], ["mammalian cells", "OBSERVATION", 294, 309], ["retention", "OBSERVATION", 326, 335], ["more complex", "OBSERVATION_MODIFIER", 487, 499]]], ["A large number of constructs of the three mammalian glycosyltransferases have now been examined.", [["mammalian glycosyltransferases", "PROTEIN", 42, 72], ["the three mammalian glycosyltransferases", "TREATMENT", 32, 72], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["However, the results of a number of these studies appear contradictory.", [["these studies", "TEST", 36, 49]]], ["Comparison of the results of the different studies is not straightforward as there are a number of factors which may account for the apparent lack of consensus.", [["the different studies", "TEST", 29, 50], ["may account for", "UNCERTAINTY", 113, 128]]], ["Differences in results between the different glycosyltransferases may reflect compartment-specific differences; at this stage there is no evidence that glycosyltransferases localised to different compartments are retained by the same mechanism.", [["compartments", "ANATOMY", 196, 208], ["glycosyltransferases", "PROTEIN", 152, 172], ["glycosyltransferases", "TREATMENT", 152, 172], ["may reflect", "UNCERTAINTY", 66, 77], ["compartment", "OBSERVATION_MODIFIER", 78, 89], ["no evidence", "UNCERTAINTY", 135, 146]]], ["The lack of agreement between studies on the same glycosyltransferases may be due to: (1) cell type-dependent differences; (2) differences in levels of expression of proteins resulting in differences in intracellular distribution; (3) differences in the precise region of the glycosyltransferase examined, together with the use of different reporter proteins, which may dramatically affect conformation of the segment under study; (4) the use of techniques to monitor localisation which differ widely in sensitivity, especially assessment of cell surface expression; and (5) the presence of more than one region of the glycosyltransferase which can act independently to retain hybrid molecules to the Golgi.", [["cell", "ANATOMY", 90, 94], ["intracellular", "ANATOMY", 203, 216], ["cell surface", "ANATOMY", 542, 554], ["Golgi", "ANATOMY", 701, 706], ["cell", "CELL", 90, 94], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 203, 216], ["cell surface", "CELLULAR_COMPONENT", 542, 554], ["glycosyltransferase", "GENE_OR_GENE_PRODUCT", 619, 638], ["Golgi", "CELLULAR_COMPONENT", 701, 706], ["glycosyltransferase", "PROTEIN", 276, 295], ["reporter proteins", "PROTEIN", 341, 358], ["glycosyltransferase", "PROTEIN", 619, 638], ["hybrid molecules", "PROTEIN", 677, 693], ["(1) cell type-dependent differences", "PROBLEM", 86, 121], ["expression of proteins", "PROBLEM", 152, 174], ["different reporter proteins", "TEST", 331, 358], ["the segment under study", "TEST", 406, 429], ["localisation", "TEST", 468, 480], ["cell surface expression", "PROBLEM", 542, 565], ["the glycosyltransferase", "TREATMENT", 615, 638], ["dependent", "OBSERVATION_MODIFIER", 100, 109], ["intracellular distribution", "OBSERVATION", 203, 229], ["cell surface expression", "OBSERVATION", 542, 565]]], ["For a more detailed comparison of the constructs and discussion of the experimental variables see reviews by Gleeson et al. (1994) and Colley (1997) .Golgi retention sequences of glycosyltransferasesA number of investigators have shown that the \u03b12,6ST transmembrane domain and flanking sequences are alone sufficient to localise reporter molecules to the Golgi in certain cell types (Munro 1991; Dahdal and Colley 1993; Tang et al. 1995) .", [["Golgi", "ANATOMY", 150, 155], ["Golgi", "ANATOMY", 355, 360], ["cell", "ANATOMY", 372, 376], ["Golgi", "CELLULAR_COMPONENT", 150, 155], ["Golgi", "CELLULAR_COMPONENT", 355, 360], ["cell", "CELL", 372, 376], ["\u03b12,6ST transmembrane domain", "PROTEIN", 245, 272], ["flanking sequences", "DNA", 277, 295], ["reporter molecules", "PROTEIN", 329, 347], ["the \u03b12,6ST transmembrane domain and flanking sequences", "PROBLEM", 241, 295], ["retention", "OBSERVATION", 156, 165]]], ["However, it is very clear that Golgi retention does not depend on specific sequences within the transmembrane domain as considerable alterations can be made to the \u03b12,6ST transmembrane domain without abolishing Golgi retention.", [["Golgi", "ANATOMY", 31, 36], ["transmembrane", "ANATOMY", 96, 109], ["Golgi", "ANATOMY", 211, 216], ["Golgi", "CELLULAR_COMPONENT", 31, 36], ["transmembrane", "CELLULAR_COMPONENT", 96, 109], ["Golgi", "CELLULAR_COMPONENT", 211, 216], ["transmembrane domain", "PROTEIN", 96, 116], ["\u03b12,6ST transmembrane domain", "PROTEIN", 164, 191], ["Golgi retention", "PROBLEM", 31, 46], ["the transmembrane domain", "TEST", 92, 116], ["Golgi retention", "PROBLEM", 211, 226], ["Golgi retention", "OBSERVATION", 31, 46], ["Golgi retention", "OBSERVATION", 211, 226]]], ["For example, sequential replacement of four or five amino acid blocks of the transmembrane domain had no effect on Golgi localisation of full-length \u03b12,6ST or an \u03b12,6ST hybrid molecule (Colley et al. 1992; Dahdal and Colley 1993) .", [["transmembrane", "ANATOMY", 77, 90], ["Golgi", "ANATOMY", 115, 120], ["amino acid", "CHEMICAL", 52, 62], ["amino acid", "CHEMICAL", 52, 62], ["amino acid", "AMINO_ACID", 52, 62], ["Golgi", "CELLULAR_COMPONENT", 115, 120], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 149, 155], ["transmembrane domain", "PROTEIN", 77, 97], ["\u03b12,6ST", "PROTEIN", 149, 155], ["sequential replacement", "TREATMENT", 13, 35], ["five amino acid blocks", "TREATMENT", 47, 69], ["the transmembrane domain", "TEST", 73, 97], ["an \u03b12,6ST hybrid molecule", "PROBLEM", 159, 184], ["no", "UNCERTAINTY", 102, 104]]], ["Strikingly, the transmembrane domain of an \u03b12,6ST hybrid protein (containing the cytoplasmic tail and partial stem of \u03b12,6ST) can be totally replaced by a polyleucine sequence of similar length without adversely affecting Golgi retention (Munro 1991) .", [["transmembrane", "ANATOMY", 16, 29], ["cytoplasmic tail", "ANATOMY", 81, 97], ["Golgi", "ANATOMY", 222, 227], ["polyleucine", "CHEMICAL", 155, 166], ["transmembrane", "CELLULAR_COMPONENT", 16, 29], ["cytoplasmic", "ORGANISM_SUBSTANCE", 81, 92], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 118, 124], ["polyleucine", "SIMPLE_CHEMICAL", 155, 166], ["Golgi", "CELLULAR_COMPONENT", 222, 227], ["transmembrane domain", "PROTEIN", 16, 36], ["\u03b12,6ST hybrid protein", "PROTEIN", 43, 64], ["cytoplasmic tail", "PROTEIN", 81, 97], ["\u03b12,6ST", "PROTEIN", 118, 124], ["polyleucine sequence", "PROTEIN", 155, 175], ["the transmembrane domain", "TEST", 12, 36], ["an \u03b12,6ST hybrid protein", "PROBLEM", 40, 64], ["a polyleucine sequence", "TEST", 153, 175], ["tail", "OBSERVATION_MODIFIER", 93, 97], ["partial stem", "OBSERVATION", 102, 114], ["Golgi retention", "OBSERVATION", 222, 237]]], ["Further, Munro (1991) has shown that the length of the hydrophobic transmembrane domain is the critical feature in maintaining efficient Golgi localisation of \u03b12,6ST hybrid molecules as increasing the length of the transmembrane domain to 23 leucine residues resulted in increased expression at the cell surface.", [["Golgi", "ANATOMY", 137, 142], ["transmembrane", "ANATOMY", 215, 228], ["cell surface", "ANATOMY", 299, 311], ["leucine", "CHEMICAL", 242, 249], ["leucine", "CHEMICAL", 242, 249], ["Golgi", "CELLULAR_COMPONENT", 137, 142], ["transmembrane", "CELLULAR_COMPONENT", 215, 228], ["leucine", "AMINO_ACID", 242, 249], ["cell surface", "CELLULAR_COMPONENT", 299, 311], ["hydrophobic transmembrane domain", "PROTEIN", 55, 87], ["\u03b12,6ST hybrid molecules", "PROTEIN", 159, 182], ["transmembrane domain", "PROTEIN", 215, 235], ["the hydrophobic transmembrane domain", "PROBLEM", 51, 87], ["2,6ST hybrid molecules", "PROBLEM", 160, 182], ["the transmembrane domain", "TEST", 211, 235], ["23 leucine residues", "PROBLEM", 239, 258], ["increased expression at the cell surface", "PROBLEM", 271, 311], ["Golgi localisation", "OBSERVATION", 137, 155], ["increased", "OBSERVATION_MODIFIER", 271, 280], ["expression", "OBSERVATION", 281, 291], ["cell surface", "OBSERVATION", 299, 311]]], ["The precise relationship between the hydrophobic transmembrane domain and the flanking charged residues appears to be important in retaining \u03b12,6ST to the TGN (Munro 1991 (Munro , 1995 Dahdal and Colley 1993) .", [["transmembrane", "ANATOMY", 49, 62], ["TGN", "ANATOMY", 155, 158], ["TGN", "CELLULAR_COMPONENT", 155, 158], ["hydrophobic transmembrane domain", "PROTEIN", 37, 69], ["\u03b12,6ST", "PROTEIN", 141, 147], ["the hydrophobic transmembrane domain", "TREATMENT", 33, 69], ["the flanking charged residues", "PROBLEM", 74, 103], ["flanking", "OBSERVATION", 78, 86], ["charged residues", "OBSERVATION", 87, 103], ["appears to be", "UNCERTAINTY", 104, 117]]], ["This conclusion is further strengthened by the observation that simply exchanging the transmembrane domains of two cell surface proteins resulted in hybrid proteins which were retarded in transport through the Golgi (Low et al. 1994) , indicating that the precise arrangment of the transmembrane domain and flanking sequences may influence exit from the Golgi.Golgi retention sequences of glycosyltransferasesNonetheless, it is also clear that other regions in addition to the transmembrane domain of \u03b12,6ST play a role in Golgi localisation, in particular the stem region.", [["transmembrane", "ANATOMY", 86, 99], ["cell surface", "ANATOMY", 115, 127], ["Golgi", "ANATOMY", 210, 215], ["transmembrane", "ANATOMY", 282, 295], ["Golgi", "ANATOMY", 354, 359], ["Golgi", "ANATOMY", 360, 365], ["transmembrane", "ANATOMY", 477, 490], ["Golgi", "ANATOMY", 523, 528], ["stem region", "ANATOMY", 561, 572], ["transmembrane", "CELLULAR_COMPONENT", 86, 99], ["cell surface", "CELLULAR_COMPONENT", 115, 127], ["Golgi", "CELLULAR_COMPONENT", 210, 215], ["transmembrane", "CELLULAR_COMPONENT", 282, 295], ["Golgi", "CELLULAR_COMPONENT", 354, 359], ["Golgi", "CELLULAR_COMPONENT", 360, 365], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 389, 409], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 501, 507], ["Golgi", "CELLULAR_COMPONENT", 523, 528], ["transmembrane domains", "PROTEIN", 86, 107], ["cell surface proteins", "PROTEIN", 115, 136], ["hybrid proteins", "PROTEIN", 149, 164], ["transmembrane domain", "PROTEIN", 282, 302], ["flanking sequences", "DNA", 307, 325], ["glycosyltransferases", "PROTEIN", 389, 409], ["transmembrane domain", "PROTEIN", 477, 497], ["\u03b12,6ST", "PROTEIN", 501, 507], ["the transmembrane domains", "TEST", 82, 107], ["two cell surface proteins", "PROBLEM", 111, 136], ["hybrid proteins", "PROBLEM", 149, 164], ["the transmembrane domain and flanking sequences", "TEST", 278, 325], ["glycosyltransferases", "TREATMENT", 389, 409], ["the transmembrane domain", "TEST", 473, 497], ["Golgi localisation", "TEST", 523, 541], ["hybrid proteins", "OBSERVATION", 149, 164], ["retention", "OBSERVATION", 366, 375], ["clear", "OBSERVATION", 433, 438], ["Golgi localisation", "OBSERVATION", 523, 541], ["stem", "ANATOMY", 561, 565], ["region", "ANATOMY_MODIFIER", 566, 572]]], ["Firstly, the stem sequences of \u03b12,6ST improve the Golgi localisation of hybrid molecules (Tang et al. 1995) .", [["Golgi", "ANATOMY", 50, 55], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 31, 37], ["Golgi", "CELLULAR_COMPONENT", 50, 55], ["stem sequences", "DNA", 13, 27], ["\u03b12,6ST", "DNA", 31, 37], ["hybrid molecules", "PROTEIN", 72, 88], ["the stem sequences", "TEST", 9, 27], ["hybrid molecules", "OBSERVATION", 72, 88]]], ["Secondly, Dahdal and Colley (1993) replaced the 17-amino acid transmembrane domain of native \u03b12,6ST with the long 29-amino acid transmembrane domain from influenza neuraminidase without any apparent disruption of the retention signal, indicating that luminal sequences of \u03b12,6ST can override the length resistrictions of the transmembrane domain.", [["luminal", "ANATOMY", 251, 258], ["transmembrane", "ANATOMY", 325, 338], ["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 117, 127], ["luminal", "CHEMICAL", 251, 258], ["17-amino acid", "CHEMICAL", 48, 61], ["amino acid", "CHEMICAL", 117, 127], ["amino acid", "AMINO_ACID", 51, 61], ["amino acid", "AMINO_ACID", 117, 127], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 272, 278], ["transmembrane", "CELLULAR_COMPONENT", 325, 338], ["17-amino acid transmembrane domain", "PROTEIN", 48, 82], ["native \u03b12,6ST", "PROTEIN", 86, 99], ["long 29-amino acid transmembrane domain", "PROTEIN", 109, 148], ["influenza neuraminidase", "PROTEIN", 154, 177], ["\u03b12,6ST", "DNA", 272, 278], ["transmembrane domain", "PROTEIN", 325, 345], ["amino acid transmembrane domain", "TEST", 51, 82], ["the long 29-amino acid transmembrane domain", "PROBLEM", 105, 148], ["influenza neuraminidase", "PROBLEM", 154, 177], ["the retention signal", "PROBLEM", 213, 233], ["luminal sequences", "TEST", 251, 268], ["influenza neuraminidase", "OBSERVATION", 154, 177], ["retention signal", "OBSERVATION", 217, 233], ["luminal", "ANATOMY_MODIFIER", 251, 258], ["length", "OBSERVATION_MODIFIER", 296, 302]]], ["Thirdly, the stem region was demonstrated to be responsible for the transient retention of a soluble form of \u03b12,6ST (Colley et al. 1992) .Golgi retention sequences of glycosyltransferasesA number of studies have demonstrated that the localisation of \u03b21,4GalT to the trans-Golgi is predominantly dependent on the transmembrane domain (Nilsson et al. 1991; Aoki et al. 1992; Russo et al. 1992; Teasdale et al. 1992 Teasdale et al. , 1994 Masibay et al. 1993) , although the cytoplasmic tail and the lumenal domain may play minor roles.", [["stem region", "ANATOMY", 13, 24], ["Golgi", "ANATOMY", 138, 143], ["transmembrane", "ANATOMY", 312, 325], ["cytoplasmic tail", "ANATOMY", 472, 488], ["lumenal", "ANATOMY", 497, 504], ["\u03b12,6ST", "SIMPLE_CHEMICAL", 109, 115], ["Golgi", "CELLULAR_COMPONENT", 138, 143], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 250, 258], ["Golgi", "CELLULAR_COMPONENT", 272, 277], ["transmembrane", "CELLULAR_COMPONENT", 312, 325], ["cytoplasmic", "ORGANISM_SUBSTANCE", 472, 483], ["tail", "MULTI-TISSUE_STRUCTURE", 484, 488], ["\u03b12,6ST", "PROTEIN", 109, 115], ["\u03b21,4GalT", "PROTEIN", 250, 258], ["trans-Golgi", "PROTEIN", 266, 277], ["transmembrane domain", "PROTEIN", 312, 332], ["cytoplasmic tail", "PROTEIN", 472, 488], ["lumenal domain", "PROTEIN", 497, 511], ["the transient retention", "PROBLEM", 64, 87], ["the localisation", "TEST", 230, 246], ["stem", "ANATOMY_MODIFIER", 13, 17], ["transient", "OBSERVATION_MODIFIER", 68, 77], ["retention", "OBSERVATION", 78, 87], ["retention", "OBSERVATION", 144, 153], ["predominantly", "OBSERVATION_MODIFIER", 281, 294], ["dependent", "OBSERVATION", 295, 304], ["lumenal", "ANATOMY_MODIFIER", 497, 504]]], ["As for \u03b12,6ST, alterations in the transmembrane domain have not identified a specific sequence that is required for Golgi localisation (Nilsson et al. 1991) .", [["transmembrane", "ANATOMY", 34, 47], ["Golgi", "ANATOMY", 116, 121], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 7, 13], ["transmembrane", "CELLULAR_COMPONENT", 34, 47], ["Golgi", "CELLULAR_COMPONENT", 116, 121], ["\u03b12,6ST", "PROTEIN", 7, 13], ["transmembrane domain", "PROTEIN", 34, 54], ["alterations in the transmembrane domain", "PROBLEM", 15, 54], ["a specific sequence", "TEST", 75, 94]]], ["There is some evidence from one study that uncharged polar amino acids of the transmembrane domain are important (Aoki et al. 1992) , although this remains inconclusive as contrasting results have been obtained from another group (Nilsson et al. 1991) .", [["transmembrane", "ANATOMY", 78, 91], ["amino acids", "CHEMICAL", 59, 70], ["amino acids", "CHEMICAL", 59, 70], ["amino acids", "AMINO_ACID", 59, 70], ["transmembrane domain", "PROTEIN", 78, 98], ["one study", "TEST", 28, 37]]], ["Previous studies in this laboratory have demonstrated that replacement of the 20amino acid transmembrane domain of \u03b21,4GalT with the longer 27-amino acid transmembrane domain of the transferrin receptor leads to a predominantly cell surface expression in transiently expressing COS cells, whereas stably expressing mouse L cells, where the level of expression is only 2-3 times that of endogenous \u03b21,4GalT, retain a significant proportion of the hybrid molecules specifically in the Golgi .", [["cell surface", "ANATOMY", 228, 240], ["COS cells", "ANATOMY", 278, 287], ["L cells", "ANATOMY", 321, 328], ["Golgi", "ANATOMY", 483, 488], ["20amino acid", "CHEMICAL", 78, 90], ["amino acid", "CHEMICAL", 143, 153], ["20amino acid", "CHEMICAL", 78, 90], ["amino acid", "CHEMICAL", 143, 153], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 115, 123], ["amino acid", "AMINO_ACID", 143, 153], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 182, 202], ["cell surface", "CELLULAR_COMPONENT", 228, 240], ["COS cells", "CELL", 278, 287], ["mouse", "ORGANISM", 315, 320], ["L cells", "CELL", 321, 328], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 397, 405], ["Golgi", "CELLULAR_COMPONENT", 483, 488], ["20amino acid transmembrane domain", "PROTEIN", 78, 111], ["\u03b21,4GalT", "PROTEIN", 115, 123], ["27-amino acid transmembrane domain", "PROTEIN", 140, 174], ["transferrin receptor", "PROTEIN", 182, 202], ["COS cells", "CELL_LINE", 278, 287], ["mouse L cells", "CELL_LINE", 315, 328], ["\u03b21,4GalT", "PROTEIN", 397, 405], ["hybrid molecules", "PROTEIN", 446, 462], ["mouse", "SPECIES", 315, 320], ["mouse", "SPECIES", 315, 320], ["Previous studies", "TEST", 0, 16], ["replacement", "TREATMENT", 59, 70], ["the 20amino acid transmembrane domain", "TEST", 74, 111], ["the longer 27-amino acid transmembrane domain", "PROBLEM", 129, 174], ["the transferrin receptor", "TREATMENT", 178, 202], ["transiently expressing COS cells", "PROBLEM", 255, 287], ["the hybrid molecules", "PROBLEM", 442, 462], ["replacement", "OBSERVATION", 59, 70], ["predominantly cell", "OBSERVATION", 214, 232], ["surface expression", "OBSERVATION", 233, 251], ["transiently expressing COS cells", "OBSERVATION", 255, 287], ["significant", "OBSERVATION_MODIFIER", 416, 427], ["hybrid molecules", "OBSERVATION", 446, 462]]], ["This result highlights the complications that can arise from differences in the level of expression, and cell type, in the intracellular distribution of a hybrid molecule.Golgi retention sequences of glycosyltransferasesFrom studies on the localisation of the medial-Golgi enzyme, GlcNAc-TI, it is evident that there are a number of regions which contribute to Golgi localisation.", [["cell", "ANATOMY", 105, 109], ["intracellular", "ANATOMY", 123, 136], ["Golgi", "ANATOMY", 171, 176], ["medial-Golgi", "ANATOMY", 260, 272], ["Golgi", "ANATOMY", 361, 366], ["GlcNAc", "CHEMICAL", 281, 287], ["cell type", "CELL", 105, 114], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 136], ["Golgi", "CELLULAR_COMPONENT", 171, 176], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 200, 220], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 281, 290], ["Golgi", "CELLULAR_COMPONENT", 361, 366], ["glycosyltransferases", "PROTEIN", 200, 220], ["medial-Golgi enzyme", "PROTEIN", 260, 279], ["GlcNAc", "PROTEIN", 281, 287], ["TI", "PROTEIN", 288, 290], ["the complications", "PROBLEM", 23, 40], ["a hybrid molecule", "PROBLEM", 153, 170], ["glycosyltransferases", "TREATMENT", 200, 220], ["complications", "OBSERVATION", 27, 40], ["cell type", "OBSERVATION", 105, 114], ["intracellular", "ANATOMY_MODIFIER", 123, 136], ["hybrid molecule", "OBSERVATION", 155, 170], ["retention", "OBSERVATION", 177, 186], ["medial", "ANATOMY_MODIFIER", 260, 266], ["Golgi localisation", "OBSERVATION", 361, 379]]], ["Subsequent to the demonstration that the transmembrane domain of GlcNAc-TI could localise heterologous proteins to the Golgi Tang et al. 1992) , further analysis showed that the luminal domain and short cytoplasmic tail were required for very efficient Golgi localisation .", [["transmembrane", "ANATOMY", 41, 54], ["Golgi", "ANATOMY", 119, 124], ["luminal domain", "ANATOMY", 178, 192], ["cytoplasmic tail", "ANATOMY", 203, 219], ["Golgi", "ANATOMY", 253, 258], ["luminal", "CHEMICAL", 178, 185], ["GlcNAc", "CHEMICAL", 65, 71], ["transmembrane", "CELLULAR_COMPONENT", 41, 54], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 65, 74], ["Golgi", "CELLULAR_COMPONENT", 119, 124], ["cytoplasmic tail", "CELLULAR_COMPONENT", 203, 219], ["Golgi", "CELLULAR_COMPONENT", 253, 258], ["transmembrane domain", "PROTEIN", 41, 61], ["GlcNAc", "PROTEIN", 65, 71], ["TI", "PROTEIN", 72, 74], ["heterologous proteins", "PROTEIN", 90, 111], ["luminal domain", "PROTEIN", 178, 192], ["cytoplasmic tail", "PROTEIN", 203, 219], ["GlcNAc-TI", "TREATMENT", 65, 74], ["further analysis", "TEST", 145, 161], ["the luminal domain and short cytoplasmic tail", "PROBLEM", 174, 219], ["luminal", "ANATOMY_MODIFIER", 178, 185], ["Golgi localisation", "OBSERVATION", 253, 271]]], ["The stem sequences of Glc-NAc-TI were shown by Tang et al. (1992) to contribute to the efficiency of Golgi localisation of GlcNAc-TI hybrid molecules and more recently by Warren and colleagues (Nilsson et al. 1996) independently to retain a heterologous molecule to the Golgi apparatus.", [["Golgi", "ANATOMY", 101, 106], ["Golgi apparatus", "ANATOMY", 270, 285], ["Glc", "CHEMICAL", 22, 25], ["Glc", "CHEMICAL", 22, 25], ["GlcNAc", "CHEMICAL", 123, 129], ["Glc-NAc-TI", "GENE_OR_GENE_PRODUCT", 22, 32], ["Golgi", "CELLULAR_COMPONENT", 101, 106], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 123, 129], ["Golgi apparatus", "CELLULAR_COMPONENT", 270, 285], ["GlcNAc-TI hybrid molecules", "PROTEIN", 123, 149], ["heterologous molecule", "PROTEIN", 241, 262], ["The stem sequences", "TEST", 0, 18], ["Glc", "TEST", 22, 25], ["GlcNAc-TI hybrid molecules", "PROBLEM", 123, 149]]], ["These data argue that the GlcNAc-TI stem region contains a localisation signal independent of the transmembrane domain.Golgi retention sequences of glycosyltransferasesThe potential of regions outside the transmembrane domain to assist in Golgi retention is also illustrated by recent studies on yeast Golgi glycosyltransferases.", [["transmembrane", "ANATOMY", 98, 111], ["Golgi", "ANATOMY", 119, 124], ["transmembrane", "ANATOMY", 205, 218], ["Golgi", "ANATOMY", 239, 244], ["Golgi", "ANATOMY", 302, 307], ["GlcNAc", "CHEMICAL", 26, 32], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 26, 32], ["transmembrane", "CELLULAR_COMPONENT", 98, 111], ["Golgi", "CELLULAR_COMPONENT", 119, 124], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 148, 168], ["transmembrane", "CELLULAR_COMPONENT", 205, 218], ["Golgi", "CELLULAR_COMPONENT", 239, 244], ["yeast Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 296, 328], ["GlcNAc", "PROTEIN", 26, 32], ["TI stem region", "PROTEIN", 33, 47], ["transmembrane domain", "PROTEIN", 98, 118], ["glycosyltransferases", "PROTEIN", 148, 168], ["transmembrane domain", "PROTEIN", 205, 225], ["yeast Golgi glycosyltransferases", "PROTEIN", 296, 328], ["yeast", "SPECIES", 296, 301], ["yeast", "SPECIES", 296, 301], ["the GlcNAc-TI stem region", "TREATMENT", 22, 47], ["glycosyltransferases", "TREATMENT", 148, 168], ["Golgi retention", "PROBLEM", 239, 254], ["recent studies", "TEST", 278, 292], ["yeast Golgi glycosyltransferases", "TREATMENT", 296, 328], ["TI stem", "ANATOMY_MODIFIER", 33, 40], ["localisation signal", "OBSERVATION", 59, 78], ["retention", "OBSERVATION", 125, 134], ["Golgi retention", "OBSERVATION", 239, 254]]], ["For example, no single domain of Mnt1p was able to confer efficient localisation of a reporter molecule to the yeast Golgi (Lussier et al. 1995) ; efficient localisation required the short cytoplasmic tail, the transmembrane domain and a segment of the lumenal stem region of Mnt1p, reinforcing the view that multiple signals may be required in some cases.", [["yeast Golgi", "ANATOMY", 111, 122], ["cytoplasmic tail", "ANATOMY", 189, 205], ["transmembrane", "ANATOMY", 211, 224], ["lumenal stem", "ANATOMY", 253, 265], ["Mnt1p", "GENE_OR_GENE_PRODUCT", 33, 38], ["Golgi", "CELLULAR_COMPONENT", 117, 122], ["cytoplasmic tail", "CELLULAR_COMPONENT", 189, 205], ["transmembrane", "CELLULAR_COMPONENT", 211, 224], ["lumenal stem region", "CELLULAR_COMPONENT", 253, 272], ["Mnt1p", "GENE_OR_GENE_PRODUCT", 276, 281], ["Mnt1p", "PROTEIN", 33, 38], ["reporter molecule", "PROTEIN", 86, 103], ["cytoplasmic tail", "PROTEIN", 189, 205], ["transmembrane domain", "PROTEIN", 211, 231], ["lumenal stem region", "PROTEIN", 253, 272], ["Mnt1p", "PROTEIN", 276, 281], ["yeast", "SPECIES", 111, 116], ["yeast", "SPECIES", 111, 116], ["single domain of Mnt1p", "PROBLEM", 16, 38], ["the short cytoplasmic tail", "PROBLEM", 179, 205], ["no", "UNCERTAINTY", 13, 15], ["segment", "ANATOMY_MODIFIER", 238, 245], ["lumenal stem", "ANATOMY", 253, 265]]], ["The ability of the lumenal domain to act independently of the transmembrane domain is also highlighted by the observation that the yeast Mnn1p lumenal domain is localised to the Golgi complex even when expressed as a soluble protein (Graham and Krasnov 1995) .Golgi retention sequences of glycosyltransferasesOverall, the data suggest that Golgi retention in many instances is not determined by a discrete and continuous sequence motif but, rather, localisation of Golgi glycosyltransferases could be mediated by disparate regions of the molecule.", [["lumenal", "ANATOMY", 19, 26], ["transmembrane", "ANATOMY", 62, 75], ["Golgi complex", "ANATOMY", 178, 191], ["Golgi", "ANATOMY", 260, 265], ["Golgi", "ANATOMY", 340, 345], ["Golgi", "ANATOMY", 465, 470], ["lumenal", "CELLULAR_COMPONENT", 19, 26], ["transmembrane", "CELLULAR_COMPONENT", 62, 75], ["Mnn1p", "GENE_OR_GENE_PRODUCT", 137, 142], ["Golgi", "CELLULAR_COMPONENT", 178, 183], ["Golgi", "CELLULAR_COMPONENT", 260, 265], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 289, 309], ["Golgi", "CELLULAR_COMPONENT", 340, 345], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 465, 491], ["lumenal domain", "PROTEIN", 19, 33], ["transmembrane domain", "PROTEIN", 62, 82], ["yeast Mnn1p lumenal domain", "PROTEIN", 131, 157], ["Golgi complex", "PROTEIN", 178, 191], ["soluble protein", "PROTEIN", 217, 232], ["glycosyltransferases", "PROTEIN", 289, 309], ["Golgi glycosyltransferases", "PROTEIN", 465, 491], ["yeast", "SPECIES", 131, 136], ["yeast", "SPECIES", 131, 136], ["the transmembrane domain", "TEST", 58, 82], ["the yeast Mnn1p lumenal domain", "PROBLEM", 127, 157], ["glycosyltransferases", "TREATMENT", 289, 309], ["the data", "TEST", 318, 326], ["Golgi retention", "PROBLEM", 340, 355], ["a discrete and continuous sequence motif", "TEST", 395, 435], ["Golgi glycosyltransferases", "PROBLEM", 465, 491], ["lumenal", "ANATOMY_MODIFIER", 19, 26], ["retention", "OBSERVATION", 266, 275], ["Golgi retention", "OBSERVATION", 340, 355], ["Golgi glycosyltransferases", "OBSERVATION", 465, 491]]], ["Hence, multiple signals involving cytoplasmic tail, transmembrane and lumenal domains may act together to mediate efficient Golgi localisation.", [["cytoplasmic tail", "ANATOMY", 34, 50], ["transmembrane", "ANATOMY", 52, 65], ["lumenal", "ANATOMY", 70, 77], ["Golgi", "ANATOMY", 124, 129], ["cytoplasmic tail", "CELLULAR_COMPONENT", 34, 50], ["transmembrane", "CELLULAR_COMPONENT", 52, 65], ["lumenal", "CELLULAR_COMPONENT", 70, 77], ["Golgi", "CELLULAR_COMPONENT", 124, 129], ["cytoplasmic tail, transmembrane and lumenal domains", "PROTEIN", 34, 85], ["cytoplasmic tail", "OBSERVATION", 34, 50], ["lumenal", "ANATOMY_MODIFIER", 70, 77]]], ["It is noteworthy that the localisation of Sed 5 (Banfield et al. 1994 ), a putative vesicle targeting molecule, and p63 (Schweizer et al. 1994) , both type II membrane proteins of the CGN, involves multiple domains of the molecule including the transmembrane domain.", [["vesicle", "ANATOMY", 84, 91], ["transmembrane", "ANATOMY", 245, 258], ["Sed 5", "ORGANISM", 42, 47], ["vesicle", "CELLULAR_COMPONENT", 84, 91], ["p63", "GENE_OR_GENE_PRODUCT", 116, 119], ["type II membrane proteins", "GENE_OR_GENE_PRODUCT", 151, 176], ["CGN", "GENE_OR_GENE_PRODUCT", 184, 187], ["transmembrane", "CELLULAR_COMPONENT", 245, 258], ["Sed 5", "PROTEIN", 42, 47], ["putative vesicle targeting molecule", "PROTEIN", 75, 110], ["p63", "PROTEIN", 116, 119], ["type II membrane proteins", "PROTEIN", 151, 176], ["CGN", "PROTEIN", 184, 187], ["transmembrane domain", "PROTEIN", 245, 265], ["CGN", "OBSERVATION", 184, 187]]], ["If multiple independent signals act together to mediate efficient Golgi localisation then it is possible that some of these signals may be associated with a saturable mechanism(s) and others, conversely, with a non-saturable mechanism(s) of localisation.", [["Golgi", "ANATOMY", 66, 71], ["Golgi", "CELLULAR_COMPONENT", 66, 71]]], ["For the reasons discussed above, in future it will be important to analyse individual signals using stable expression systems where the level of expression is carefully monitored.Mechanism of localisation of glycosyltransferasesAs mentioned earlier, overexpression of native glycosyltransferases does not result in saturation of the Golgi retention mechanism.", [["Golgi", "ANATOMY", 333, 338], ["Golgi", "CELLULAR_COMPONENT", 333, 338], ["glycosyltransferases", "PROTEIN", 208, 228], ["native glycosyltransferases", "PROTEIN", 268, 295], ["localisation of glycosyltransferases", "PROBLEM", 192, 228], ["overexpression of native glycosyltransferases", "PROBLEM", 250, 295], ["Golgi retention", "OBSERVATION", 333, 348]]], ["The identification of multiple signals involved in the Golgi retention of glycosyltransferases suggests that there could be more than one mechanism to account for this highly efficient process.", [["Golgi", "ANATOMY", 55, 60], ["Golgi", "CELLULAR_COMPONENT", 55, 60], ["glycosyltransferases", "PROTEIN", 74, 94], ["multiple signals", "PROBLEM", 22, 38], ["this highly efficient process", "PROBLEM", 163, 192], ["multiple", "OBSERVATION_MODIFIER", 22, 30], ["Golgi retention", "OBSERVATION", 55, 70]]], ["One or more of the Golgi retention mechanisms appear to be highly conserved as \u03b12,6ST hybrid molecules are retained in the Golgi apparatus of yeast (Schwientek et al. 1995) and the mammalian enzyme, GlcNAc-TI, appears to be correctly housed in the Golgi apparatus of plant cells (Gomez and Chrispeels 1994) .Mechanism of localisation of glycosyltransferasesThere are two major models which have been widely discussed to account for compartment-specific localisation of membrane-bound glycosyltransferases, one based on aggregation and the other on lipid-mediated sorting.", [["Golgi", "ANATOMY", 19, 24], ["Golgi apparatus", "ANATOMY", 123, 138], ["Golgi apparatus", "ANATOMY", 248, 263], ["cells", "ANATOMY", 273, 278], ["membrane", "ANATOMY", 469, 477], ["GlcNAc", "CHEMICAL", 199, 205], ["Golgi", "CELLULAR_COMPONENT", 19, 24], ["Golgi", "CELLULAR_COMPONENT", 123, 128], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 199, 208], ["Golgi", "CELLULAR_COMPONENT", 248, 253], ["plant cells", "CELL", 267, 278], ["membrane", "CELLULAR_COMPONENT", 469, 477], ["lipid", "SIMPLE_CHEMICAL", 548, 553], ["\u03b12,6ST hybrid molecules", "PROTEIN", 79, 102], ["mammalian enzyme", "PROTEIN", 181, 197], ["GlcNAc", "PROTEIN", 199, 205], ["TI", "PROTEIN", 206, 208], ["plant cells", "CELL_TYPE", 267, 278], ["glycosyltransferases", "PROTEIN", 337, 357], ["membrane-bound glycosyltransferases", "PROTEIN", 469, 504], ["yeast", "SPECIES", 142, 147], ["yeast", "SPECIES", 142, 147], ["the Golgi retention mechanisms", "PROBLEM", 15, 45], ["2,6ST hybrid molecules", "PROBLEM", 80, 102], ["the mammalian enzyme", "TEST", 177, 197], ["localisation of glycosyltransferases", "PROBLEM", 321, 357], ["membrane-bound glycosyltransferases", "TREATMENT", 469, 504], ["aggregation", "PROBLEM", 519, 530], ["Golgi retention", "OBSERVATION", 19, 34], ["appear to be", "UNCERTAINTY", 46, 58], ["plant cells", "OBSERVATION", 267, 278]]], ["Both models favour mechanisms in which Golgi glycosyltransferases are prevented from entry into forward moving transport vesicles and thereby are actively retained in one Golgi region.Mechanism of localisation of glycosyltransferasesThe aggregation model was first proposed by Machamer (1991) , who suggested that glycosyltransferases are induced to form aggregates as they reach the correct Golgi compartment.", [["Golgi", "ANATOMY", 39, 44], ["vesicles", "ANATOMY", 121, 129], ["Golgi region", "ANATOMY", 171, 183], ["Golgi compartment", "ANATOMY", 392, 409], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 39, 65], ["vesicles", "CELLULAR_COMPONENT", 121, 129], ["Golgi", "CELLULAR_COMPONENT", 171, 176], ["Golgi compartment", "CELLULAR_COMPONENT", 392, 409], ["Golgi glycosyltransferases", "PROTEIN", 39, 65], ["Golgi region", "PROTEIN", 171, 183], ["glycosyltransferases", "PROTEIN", 213, 233], ["glycosyltransferases", "PROTEIN", 314, 334], ["Golgi glycosyltransferases", "TREATMENT", 39, 65], ["localisation of glycosyltransferases", "PROBLEM", 197, 233], ["glycosyltransferases", "TREATMENT", 314, 334], ["Golgi compartment", "OBSERVATION", 392, 409]]], ["At the time, Machamer (1991) proposed that the interaction between the transmembrane domains of glycosyltransferase and lipid bilayers of Golgi membranes may be the driving force for oligomerisation.", [["transmembrane", "ANATOMY", 71, 84], ["Golgi membranes", "ANATOMY", 138, 153], ["transmembrane", "CELLULAR_COMPONENT", 71, 84], ["glycosyltransferase", "GENE_OR_GENE_PRODUCT", 96, 115], ["lipid bilayers", "CELLULAR_COMPONENT", 120, 134], ["Golgi membranes", "CELLULAR_COMPONENT", 138, 153], ["transmembrane domains", "PROTEIN", 71, 92], ["glycosyltransferase", "PROTEIN", 96, 115], ["glycosyltransferase and lipid bilayers of Golgi membranes", "TREATMENT", 96, 153], ["oligomerisation", "PROBLEM", 183, 198], ["Golgi membranes", "OBSERVATION", 138, 153]]], ["An extension of the aggregation model was put forward by Warren and colleagues (Nilsson et al. 1993b who suggested that different enzymes of a particular Golgi compartment interact with each other (\"kin recognition\") forming large hetero-oligomeric structures which are prevented from entering budding vesicles arising from the dilated rims of the cisternae.", [["Golgi compartment", "ANATOMY", 154, 171], ["hetero-oligomeric structures", "ANATOMY", 231, 259], ["budding vesicles", "ANATOMY", 294, 310], ["cisternae", "ANATOMY", 348, 357], ["Golgi compartment", "CELLULAR_COMPONENT", 154, 171], ["budding vesicles", "CELLULAR_COMPONENT", 294, 310], ["cisternae", "CELLULAR_COMPONENT", 348, 357], ["large hetero-oligomeric structures", "PROBLEM", 225, 259], ["aggregation", "OBSERVATION", 20, 31], ["large", "OBSERVATION_MODIFIER", 225, 230], ["hetero-oligomeric structures", "OBSERVATION", 231, 259], ["dilated", "OBSERVATION", 328, 335], ["rims", "ANATOMY_MODIFIER", 336, 340], ["cisternae", "ANATOMY_MODIFIER", 348, 357]]], ["It was further speculated that the kin oligomers could be anchored by interaction of their cytoplasmic tails with the Golgi matrix to increase the efficiency of retention .", [["cytoplasmic", "ANATOMY", 91, 102], ["Golgi matrix", "ANATOMY", 118, 130], ["cytoplasmic", "ORGANISM_SUBSTANCE", 91, 102], ["Golgi matrix", "CELLULAR_COMPONENT", 118, 130], ["cytoplasmic tails", "PROTEIN", 91, 108], ["the kin oligomers", "TREATMENT", 31, 48], ["the Golgi matrix", "TREATMENT", 114, 130], ["retention", "PROBLEM", 161, 170], ["efficiency", "OBSERVATION_MODIFIER", 147, 157], ["retention", "OBSERVATION", 161, 170]]], ["The main support for kin recognition comes from the elegant experiments of Nilsson et al. (1994) who showed that the addition of an ER retention motif to the GlcNAc-TI cytoplasmic tail not only causes GlcNAc-TI to localise to the ER but also partially retains another medial-Golgi enzyme, namely \u03b1-mannosidase II (Mann-II), within the ER.", [["cytoplasmic", "ANATOMY", 168, 179], ["ER", "ANATOMY", 230, 232], ["medial-Golgi", "ANATOMY", 268, 280], ["ER", "ANATOMY", 335, 337], ["Mann-II", "CHEMICAL", 314, 321], ["GlcNAc", "CHEMICAL", 158, 164], ["GlcNAc", "CHEMICAL", 201, 207], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 158, 164], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 201, 210], ["ER", "GENE_OR_GENE_PRODUCT", 230, 232], ["Golgi", "CELLULAR_COMPONENT", 275, 280], ["\u03b1-mannosidase II", "GENE_OR_GENE_PRODUCT", 296, 312], ["Mann-II", "GENE_OR_GENE_PRODUCT", 314, 321], ["ER", "GENE_OR_GENE_PRODUCT", 335, 337], ["ER retention motif", "PROTEIN", 132, 150], ["GlcNAc-TI cytoplasmic tail", "PROTEIN", 158, 184], ["TI", "PROTEIN", 208, 210], ["ER", "PROTEIN", 230, 232], ["medial-Golgi enzyme", "PROTEIN", 268, 287], ["\u03b1-mannosidase II", "PROTEIN", 296, 312], ["Mann-II", "PROTEIN", 314, 321], ["ER", "PROTEIN", 335, 337], ["an ER retention motif", "PROBLEM", 129, 150], ["the GlcNAc-TI cytoplasmic tail", "TREATMENT", 154, 184]]], ["In contrast, the trans-Golgi enzyme, \u03b21,4GalT, was not relocated to the ER in these experiments.", [["ER", "ANATOMY", 72, 74], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 37, 45], ["ER", "GENE_OR_GENE_PRODUCT", 72, 74], ["trans-Golgi enzyme", "PROTEIN", 17, 35], ["\u03b21,4GalT", "PROTEIN", 37, 45], ["ER", "PROTEIN", 72, 74], ["the trans-Golgi enzyme", "TEST", 13, 35]]], ["If interactions between different glycosyltransferases are relevant to Golgi retention the question then arises as to why they are observed in the ER.", [["Golgi", "ANATOMY", 71, 76], ["ER", "ANATOMY", 147, 149], ["Golgi", "CELLULAR_COMPONENT", 71, 76], ["ER", "GENE_OR_GENE_PRODUCT", 147, 149], ["ER", "PROTEIN", 147, 149], ["different glycosyltransferases", "TREATMENT", 24, 54]]], ["One possibility is that oligomerisation is a concentration-depen-dent process, and the increase in concentration of \"tagged\" GlcNAc-TI in the ER allows for productive interactions which would normally only take place in the Golgi environment.", [["ER", "ANATOMY", 142, 144], ["Golgi", "ANATOMY", 224, 229], ["GlcNAc", "CHEMICAL", 125, 131], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 125, 134], ["ER", "GENE_OR_GENE_PRODUCT", 142, 144], ["Golgi", "CELLULAR_COMPONENT", 224, 229], ["TI", "PROTEIN", 132, 134], ["ER", "PROTEIN", 142, 144], ["productive interactions", "PROBLEM", 156, 179], ["oligomerisation", "OBSERVATION", 24, 39], ["increase", "OBSERVATION_MODIFIER", 87, 95]]], ["Support for the presence of kin oligomers within medial-Golgi membranes is suggested by the obervation that GlcNAc-TII, another medial-Golgi enzyme, co-immunoprecipitates with GlcNAc-TI (A. Opat, H. Putalakath and P. Gleeson, unpublished observations) .Mechanism of localisation of glycosyltransferasesWhat is the basis of kin recognition?", [["medial-Golgi membranes", "ANATOMY", 49, 71], ["medial-Golgi", "ANATOMY", 128, 140], ["GlcNAc", "CHEMICAL", 108, 114], ["GlcNAc", "CHEMICAL", 176, 182], ["Golgi membranes", "CELLULAR_COMPONENT", 56, 71], ["GlcNAc-TII", "GENE_OR_GENE_PRODUCT", 108, 118], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 176, 185], ["GlcNAc", "PROTEIN", 108, 114], ["TII", "PROTEIN", 115, 118], ["medial-Golgi enzyme", "PROTEIN", 128, 147], ["glycosyltransferases", "PROTEIN", 282, 302], ["kin oligomers", "PROBLEM", 28, 41], ["GlcNAc", "TEST", 108, 114], ["Golgi enzyme", "TEST", 135, 147], ["GlcNAc", "TEST", 176, 182], ["localisation of glycosyltransferases", "PROBLEM", 266, 302], ["medial", "ANATOMY_MODIFIER", 49, 55], ["Golgi membranes", "OBSERVATION", 56, 71]]], ["Using the kin recognition assay of Warren , Munro (1995) demonstrated that the the lumenal domain of Glc-NAc-TI, and not the transmembrane domain, was responsible for interaction with MannII.", [["lumenal", "ANATOMY", 83, 90], ["transmembrane", "ANATOMY", 125, 138], ["Glc", "CHEMICAL", 101, 104], ["Glc", "CHEMICAL", 101, 104], ["Glc-NAc-TI", "GENE_OR_GENE_PRODUCT", 101, 111], ["MannII", "GENE_OR_GENE_PRODUCT", 184, 190], ["lumenal domain", "PROTEIN", 83, 97], ["Glc", "PROTEIN", 101, 104], ["NAc", "PROTEIN", 105, 108], ["TI", "PROTEIN", 109, 111], ["transmembrane domain", "PROTEIN", 125, 145], ["MannII", "PROTEIN", 184, 190], ["Glc", "TEST", 101, 104], ["the transmembrane domain", "PROBLEM", 121, 145], ["MannII", "TREATMENT", 184, 190], ["lumenal", "ANATOMY_MODIFIER", 83, 90]]], ["Nilsson et al. (1996) have confirmed and extended this finding and demonstrated that residues 73-103 of the luminal stem region of GlcNAc-TI are important for kin recognition.", [["luminal stem", "ANATOMY", 108, 120], ["luminal", "CHEMICAL", 108, 115], ["GlcNAc", "CHEMICAL", 131, 137], ["luminal stem", "TISSUE", 108, 120], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 131, 140], ["GlcNAc", "PROTEIN", 131, 137], ["luminal stem", "ANATOMY", 108, 120]]], ["Mutation of charged residues of this stem region resulted in a dramatic decrease in kin recognition (Nilsson et al. 1996) .", [["stem region", "ANATOMY", 37, 48], ["Mutation of charged residues of this stem region", "PROBLEM", 0, 48], ["a dramatic decrease in kin recognition", "PROBLEM", 61, 99], ["charged residues", "OBSERVATION", 12, 28], ["stem", "ANATOMY_MODIFIER", 37, 41], ["dramatic", "OBSERVATION_MODIFIER", 63, 71], ["decrease", "OBSERVATION_MODIFIER", 72, 80]]], ["Furthermore, comparison of the distribution of charged residues in the stem regions of GlcNAc-TI and MannII indicates the potential for charged pairing between these two enzymes that could account for the observed protein oligomerisation.Mechanism of localisation of glycosyltransferasesIn addition to the studies described above involving medial-Golgi enzymes, there is also evidence that \u03b21,4GalT may also form small oligomers Yamaguchi and Fukuda 1995) , although kin recognition has not been detected for late-Golgi enzymes (Munro 1995) .", [["stem regions", "ANATOMY", 71, 83], ["medial-Golgi", "ANATOMY", 340, 352], ["GlcNAc", "CHEMICAL", 87, 93], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 87, 96], ["MannII", "AMINO_ACID", 101, 107], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 390, 398], ["stem regions", "PROTEIN", 71, 83], ["GlcNAc", "PROTEIN", 87, 93], ["TI", "PROTEIN", 94, 96], ["MannII", "PROTEIN", 101, 107], ["enzymes", "PROTEIN", 170, 177], ["glycosyltransferases", "PROTEIN", 267, 287], ["medial-Golgi enzymes", "PROTEIN", 340, 360], ["\u03b21,4GalT", "PROTEIN", 390, 398], ["late-Golgi enzymes", "PROTEIN", 509, 527], ["charged residues", "PROBLEM", 47, 63], ["GlcNAc-TI and MannII", "PROBLEM", 87, 107], ["these two enzymes", "TEST", 160, 177], ["the observed protein oligomerisation", "PROBLEM", 201, 237], ["localisation of glycosyltransferases", "PROBLEM", 251, 287], ["the studies", "TEST", 302, 313], ["medial-Golgi enzymes", "TEST", 340, 360], ["charged residues", "OBSERVATION", 47, 63], ["stem", "ANATOMY_MODIFIER", 71, 75], ["GlcNAc", "ANATOMY_MODIFIER", 87, 93], ["protein oligomerisation", "OBSERVATION", 214, 237], ["small", "OBSERVATION_MODIFIER", 413, 418]]], ["A fundamental issue is whether the formation of homo-or hetero-oligomers is intimately linked with Golgi localisation.", [["Golgi", "ANATOMY", 99, 104], ["Golgi", "CELLULAR_COMPONENT", 99, 104], ["homo-or hetero-oligomers", "PROTEIN", 48, 72], ["homo-or hetero-oligomers", "PROBLEM", 48, 72]]], ["Although hetero-oligomerisation is a highly attractive proposition from the viewpoint of the coordination of the glycosylation process, there is no direct evidence at this stage that such interactions are indeed revelant to the Golgi retention of glycosyltransferases.", [["Golgi", "ANATOMY", 228, 233], ["Golgi", "CELLULAR_COMPONENT", 228, 233], ["glycosyltransferases", "PROTEIN", 247, 267], ["no direct evidence", "UNCERTAINTY", 145, 163], ["Golgi retention", "OBSERVATION", 228, 243]]], ["However, the finding that aggregation of avian coronavirus M protein correlates with Golgi retention (Weisz et al. 1993 ) and that the retention of p63 to the intermediate compartment depends on the formation of detergent insoluble homo-oligomers (Schweizer et al. 1994) , indicates that oligomerisation may be a general mechanism that specifies location of proteins to different compartments.Mechanism of localisation of glycosyltransferasesThe lipid-mediated sorting model, proposed by Bretscher and Munro (1993) , is based on two observations, namely that the length of the transmembrane domains of Golgi proteins are generally shorter than those of the plasma membrane and that a cholesterol concentration gradient throughout the secretory pathway would result in a lipid bilayer with increasing thickness across the Golgi.", [["Golgi", "ANATOMY", 85, 90], ["intermediate compartment", "ANATOMY", 159, 183], ["transmembrane", "ANATOMY", 577, 590], ["Golgi", "ANATOMY", 602, 607], ["plasma membrane", "ANATOMY", 657, 672], ["lipid bilayer", "ANATOMY", 770, 783], ["Golgi", "ANATOMY", 821, 826], ["cholesterol", "CHEMICAL", 684, 695], ["cholesterol", "CHEMICAL", 684, 695], ["avian coronavirus M", "ORGANISM", 41, 60], ["Golgi", "CELLULAR_COMPONENT", 85, 90], ["p63", "GENE_OR_GENE_PRODUCT", 148, 151], ["lipid", "SIMPLE_CHEMICAL", 446, 451], ["transmembrane", "CELLULAR_COMPONENT", 577, 590], ["Golgi", "CELLULAR_COMPONENT", 602, 607], ["plasma membrane", "CELLULAR_COMPONENT", 657, 672], ["cholesterol", "SIMPLE_CHEMICAL", 684, 695], ["lipid bilayer", "CELLULAR_COMPONENT", 770, 783], ["Golgi", "CELLULAR_COMPONENT", 821, 826], ["avian coronavirus M protein", "PROTEIN", 41, 68], ["p63", "PROTEIN", 148, 151], ["glycosyltransferases", "PROTEIN", 422, 442], ["transmembrane domains", "PROTEIN", 577, 598], ["Golgi proteins", "PROTEIN", 602, 616], ["avian coronavirus", "SPECIES", 41, 58], ["avian coronavirus M protein", "TEST", 41, 68], ["Golgi retention", "PROBLEM", 85, 100], ["the retention of p63", "PROBLEM", 131, 151], ["localisation of glycosyltransferases", "PROBLEM", 406, 442], ["Golgi proteins", "PROBLEM", 602, 616], ["a cholesterol concentration gradient", "TEST", 682, 718], ["a lipid bilayer", "PROBLEM", 768, 783], ["Golgi retention", "OBSERVATION", 85, 100], ["Golgi proteins", "OBSERVATION", 602, 616], ["increasing", "OBSERVATION_MODIFIER", 789, 799], ["thickness", "OBSERVATION_MODIFIER", 800, 809], ["Golgi", "ANATOMY_MODIFIER", 821, 826]]], ["Thus, this model proposes that Golgi-resident proteins segregate into different lipid microdomains from the non-resident proteins as a result of differences in the length of their transmembrane segments (Bretscher and Munro 1993) .", [["lipid microdomains", "ANATOMY", 80, 98], ["transmembrane", "ANATOMY", 180, 193], ["Golgi-resident proteins", "GENE_OR_GENE_PRODUCT", 31, 54], ["lipid microdomains", "CELLULAR_COMPONENT", 80, 98], ["Golgi-resident proteins", "PROTEIN", 31, 54], ["non-resident proteins", "PROTEIN", 108, 129], ["transmembrane segments", "PROTEIN", 180, 202], ["the non-resident proteins", "PROBLEM", 104, 129]]], ["Experimental evidence for this model comes from the finding that the length of the transmembrane domain of \u03b12,6ST in important in retention (Munro 1991) .", [["transmembrane", "ANATOMY", 83, 96], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 107, 113], ["transmembrane domain", "PROTEIN", 83, 103], ["\u03b12,6ST", "PROTEIN", 107, 113], ["the transmembrane domain", "TEST", 79, 103]]], ["A difficulty with this model is that a number of Golgi glycosyltransferases, for example GlcNAc-TI, have transmembrane domains of similar length to cell surface proteins, and that regions other than the transmembrane domain can act as independent retention signals in a number of cases.Mechanism of localisation of glycosyltransferasesThe two models described above are not mutually exclusive and both mechanisms may contribute to different extents, depending on the protein and the targeted compartment (Munro 1995) .", [["Golgi", "ANATOMY", 49, 54], ["cell surface", "ANATOMY", 148, 160], ["transmembrane", "ANATOMY", 203, 216], ["GlcNAc", "CHEMICAL", 89, 95], ["Golgi", "CELLULAR_COMPONENT", 49, 54], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 89, 98], ["cell surface", "CELLULAR_COMPONENT", 148, 160], ["transmembrane", "CELLULAR_COMPONENT", 203, 216], ["Golgi glycosyltransferases", "PROTEIN", 49, 75], ["GlcNAc", "PROTEIN", 89, 95], ["TI", "PROTEIN", 96, 98], ["transmembrane domains", "PROTEIN", 105, 126], ["cell surface proteins", "PROTEIN", 148, 169], ["transmembrane domain", "PROTEIN", 203, 223], ["glycosyltransferases", "PROTEIN", 315, 335], ["Golgi glycosyltransferases", "TREATMENT", 49, 75], ["transmembrane domains", "PROBLEM", 105, 126], ["cell surface proteins", "TEST", 148, 169], ["the transmembrane domain", "PROBLEM", 199, 223], ["localisation of glycosyltransferases", "PROBLEM", 299, 335], ["the protein", "TEST", 463, 474]]], ["Nonetheless, it is now becoming very clear that these two models cannot fully explain the basis for Golgi localisation of glycosyltransferases.", [["Golgi", "ANATOMY", 100, 105], ["Golgi", "CELLULAR_COMPONENT", 100, 105], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 122, 142], ["glycosyltransferases", "PROTEIN", 122, 142], ["Golgi localisation of glycosyltransferases", "PROBLEM", 100, 142], ["clear", "OBSERVATION", 37, 42]]], ["Lippincott-Schwartz and colleagues (Cole et al. 1996) have measured the diffusional mobility of \u03b21,4GalT and MannII, tagged with a green fluorescent protein in mammalian cells, and have shown that the green fluorescent chimeric proteins could diffuse rapidly and freely in Golgi membranes, indicating that Golgi targeting and retention does not depend on protein immobilisation.", [["cells", "ANATOMY", 170, 175], ["Golgi membranes", "ANATOMY", 273, 288], ["Golgi", "ANATOMY", 306, 311], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 96, 104], ["MannII", "GENE_OR_GENE_PRODUCT", 109, 115], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 131, 156], ["mammalian cells", "CELL", 160, 175], ["Golgi membranes", "CELLULAR_COMPONENT", 273, 288], ["Golgi", "CELLULAR_COMPONENT", 306, 311], ["\u03b21,4GalT", "PROTEIN", 96, 104], ["MannII", "PROTEIN", 109, 115], ["green fluorescent protein", "PROTEIN", 131, 156], ["mammalian cells", "CELL_TYPE", 160, 175], ["green fluorescent chimeric proteins", "PROTEIN", 201, 236], ["the diffusional mobility", "TEST", 68, 92], ["a green fluorescent protein in mammalian cells", "PROBLEM", 129, 175], ["the green fluorescent chimeric proteins", "TEST", 197, 236], ["protein immobilisation", "TREATMENT", 355, 377], ["mammalian cells", "OBSERVATION", 160, 175], ["diffuse", "OBSERVATION_MODIFIER", 243, 250], ["Golgi membranes", "OBSERVATION", 273, 288]]], ["If these findings are extended to other glycosyltransferases then models involving retention via mechanisms invoking protein immobilisation within Golgi membranes would seem unlikely.Mechanism of localisation of glycosyltransferasesAnother possibility is that recycling may contribute to localisation.", [["Golgi membranes", "ANATOMY", 147, 162], ["Golgi membranes", "CELLULAR_COMPONENT", 147, 162], ["glycosyltransferases", "PROTEIN", 212, 232], ["retention via mechanisms", "PROBLEM", 83, 107], ["protein immobilisation", "PROBLEM", 117, 139], ["localisation of glycosyltransferases", "PROBLEM", 196, 232], ["protein immobilisation", "OBSERVATION", 117, 139], ["Golgi membranes", "OBSERVATION", 147, 162], ["seem unlikely", "UNCERTAINTY", 169, 182], ["may contribute to", "UNCERTAINTY", 270, 287]]], ["Although recycling of \u03b12,6ST and \u03b21,4GalT from post-Golgi membranes is unlikely Chapman and Munro 1994b; Teasdale et al. 1994) , there is some support for the possibility of intra-Golgi recycling.", [["Golgi membranes", "ANATOMY", 52, 67], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 22, 28], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 33, 41], ["Golgi membranes", "CELLULAR_COMPONENT", 52, 67], ["intra-Golgi", "SIMPLE_CHEMICAL", 174, 185], ["\u03b12,6ST", "PROTEIN", 22, 28], ["\u03b21,4GalT", "PROTEIN", 33, 41], ["intra-Golgi recycling", "PROBLEM", 174, 195]]], ["For example, the localisation of the cis-Golgi yeast mannosyltransferase, Och1p, appears to involve retrieval from a more distal Golgi compartment (Harris and Waters 1996) , rather than active retention in the cis-Golgi.", [["Golgi compartment", "ANATOMY", 129, 146], ["cis-Golgi", "ANATOMY", 210, 219], ["cis-Golgi", "CELLULAR_COMPONENT", 37, 46], ["mannosyltransferase", "GENE_OR_GENE_PRODUCT", 53, 72], ["Och1p", "GENE_OR_GENE_PRODUCT", 74, 79], ["Golgi compartment", "CELLULAR_COMPONENT", 129, 146], ["cis-Golgi", "CELLULAR_COMPONENT", 210, 219], ["cis-Golgi yeast mannosyltransferase", "PROTEIN", 37, 72], ["Och1p", "PROTEIN", 74, 79], ["cis-Golgi", "PROTEIN", 210, 219], ["yeast", "SPECIES", 47, 52], ["active retention in the cis-Golgi", "PROBLEM", 186, 219], ["cis-Golgi yeast mannosyltransferase", "OBSERVATION", 37, 72], ["appears to involve", "UNCERTAINTY", 81, 99], ["distal", "ANATOMY_MODIFIER", 122, 128], ["Golgi", "ANATOMY_MODIFIER", 129, 134], ["compartment", "ANATOMY_MODIFIER", 135, 146], ["active", "OBSERVATION_MODIFIER", 186, 192], ["retention", "OBSERVATION", 193, 202]]], ["In addition, there is also evidence that Glc-NAc-TI may recycle between the cis-and medial-Golgi cisternae in a mutant CHO cell line (Hoe et al. 1995) .", [["medial-Golgi cisternae", "ANATOMY", 84, 106], ["CHO cell line", "ANATOMY", 119, 132], ["Glc", "CHEMICAL", 41, 44], ["Glc", "CHEMICAL", 41, 44], ["Glc-NAc-TI", "GENE_OR_GENE_PRODUCT", 41, 51], ["Golgi cisternae", "CELLULAR_COMPONENT", 91, 106], ["CHO cell line", "CELL", 119, 132], ["Hoe et al. 1995", "CELL", 134, 149], ["mutant CHO cell line", "CELL_LINE", 112, 132], ["Glc", "TEST", 41, 44], ["a mutant CHO cell line", "TREATMENT", 110, 132], ["medial", "ANATOMY_MODIFIER", 84, 90], ["Golgi cisternae", "OBSERVATION", 91, 106], ["CHO cell line", "OBSERVATION", 119, 132]]], ["The sialylation of the medial-Golgi membrane protein, MG160, has been suggested to result from retrograde transport from the TGN to the medial-Golgi (Johnson et al. 1994 ).", [["medial-Golgi membrane", "ANATOMY", 23, 44], ["TGN", "ANATOMY", 125, 128], ["medial-Golgi", "ANATOMY", 136, 148], ["Golgi membrane", "CELLULAR_COMPONENT", 30, 44], ["MG160", "GENE_OR_GENE_PRODUCT", 54, 59], ["TGN", "CELLULAR_COMPONENT", 125, 128], ["Golgi", "CELLULAR_COMPONENT", 143, 148], ["medial-Golgi membrane protein", "PROTEIN", 23, 52], ["MG160", "PROTEIN", 54, 59], ["TGN", "PROTEIN", 125, 128], ["medial", "ANATOMY_MODIFIER", 23, 29], ["Golgi", "ANATOMY_MODIFIER", 30, 35], ["membrane protein", "OBSERVATION", 36, 52], ["medial", "ANATOMY_MODIFIER", 136, 142]]], ["More information on intra-Golgi recycling and the potential of retrieval in the localisation of other glycosyltransferases needs to be more fully explored.Mechanism of localisation of glycosyltransferasesOverall, the specific localisation of Golgi glycosyltransferases is clearly complex.", [["Golgi", "ANATOMY", 242, 247], ["Golgi", "CELLULAR_COMPONENT", 242, 247], ["glycosyltransferases", "PROTEIN", 102, 122], ["glycosyltransferases", "PROTEIN", 184, 204], ["Golgi glycosyltransferases", "PROTEIN", 242, 268], ["intra-Golgi recycling", "TREATMENT", 20, 41], ["retrieval", "TREATMENT", 63, 72], ["other glycosyltransferases", "TREATMENT", 96, 122], ["localisation of glycosyltransferases", "PROBLEM", 168, 204], ["Golgi glycosyltransferases", "OBSERVATION", 242, 268]]], ["Aggregation, lipid bilayer mediated sorting and intra-Golgi retrieval may all act to play a role in retention.", [["lipid bilayer", "ANATOMY", 13, 26], ["Aggregation", "PROBLEM", 0, 11], ["lipid bilayer mediated sorting", "TREATMENT", 13, 43], ["intra-Golgi retrieval", "TREATMENT", 48, 69]]], ["A limiting factor in our understanding of Golgi retention is the lack of information about the behaviour of glycosyltransferases in Golgi membranes.", [["Golgi", "ANATOMY", 42, 47], ["Golgi membranes", "ANATOMY", 132, 147], ["Golgi", "CELLULAR_COMPONENT", 42, 47], ["glycosyltransferases", "GENE_OR_GENE_PRODUCT", 108, 128], ["Golgi membranes", "CELLULAR_COMPONENT", 132, 147], ["glycosyltransferases", "PROTEIN", 108, 128], ["Golgi retention", "PROBLEM", 42, 57], ["glycosyltransferases in Golgi membranes", "PROBLEM", 108, 147], ["Golgi retention", "OBSERVATION", 42, 57], ["Golgi membranes", "OBSERVATION", 132, 147]]], ["The localisation of a particular glycosyltransferase is a reflection of its steady-state distribution.", [["glycosyltransferase", "PROTEIN", 33, 52], ["a particular glycosyltransferase", "PROBLEM", 20, 52], ["steady", "OBSERVATION_MODIFIER", 76, 82]]], ["In turn, the steady-state distribution of a glycosyltransferase in the Golgi may well be a combination of a number of factors, including the degree of aggregation, coupled with the rate of forward transport (either by vesicular transport or through connecting tubules), together with the efficiency of retrograde transport.Mechanism of localisation of glycosyltransferasesCollectively, these processes may also be fundamental for the structural maintenance of Golgi membranes.", [["Golgi", "ANATOMY", 71, 76], ["vesicular", "ANATOMY", 218, 227], ["tubules", "ANATOMY", 260, 267], ["Golgi membranes", "ANATOMY", 460, 475], ["glycosyltransferase", "GENE_OR_GENE_PRODUCT", 44, 63], ["Golgi", "CELLULAR_COMPONENT", 71, 76], ["vesicular", "MULTI-TISSUE_STRUCTURE", 218, 227], ["tubules", "TISSUE", 260, 267], ["Golgi membranes", "CELLULAR_COMPONENT", 460, 475], ["glycosyltransferase", "PROTEIN", 44, 63], ["glycosyltransferases", "PROTEIN", 352, 372], ["a glycosyltransferase", "PROBLEM", 42, 63], ["aggregation", "PROBLEM", 151, 162], ["localisation of glycosyltransferases", "PROBLEM", 336, 372], ["aggregation", "OBSERVATION", 151, 162], ["may also be", "UNCERTAINTY", 402, 413], ["Golgi membranes", "OBSERVATION", 460, 475]]], ["Modifications of the transmembrane domain of GlcNAc-TI resulted in the loss of stack structure and an abundance of tubulo-vesicular clusters which contained the mutant GlcNAc-TI molecules (Nilsson et al. 1996) .", [["transmembrane", "ANATOMY", 21, 34], ["GlcNAc", "CHEMICAL", 45, 51], ["GlcNAc", "CHEMICAL", 168, 174], ["transmembrane", "CELLULAR_COMPONENT", 21, 34], ["GlcNAc-TI", "GENE_OR_GENE_PRODUCT", 45, 54], ["transmembrane domain", "PROTEIN", 21, 41], ["GlcNAc", "PROTEIN", 45, 51], ["TI", "PROTEIN", 52, 54], ["mutant GlcNAc-TI molecules", "PROTEIN", 161, 187], ["GlcNAc-TI", "TREATMENT", 45, 54], ["the loss of stack structure", "PROBLEM", 67, 94], ["tubulo-vesicular clusters", "PROBLEM", 115, 140], ["loss", "OBSERVATION_MODIFIER", 71, 75], ["abundance", "OBSERVATION_MODIFIER", 102, 111], ["tubulo", "OBSERVATION_MODIFIER", 115, 121], ["vesicular clusters", "OBSERVATION", 122, 140]]], ["In another study, these investigators noted that relocation of medial-Golgi enzymes to the ER perturbed the structure of the stack .", [["medial-Golgi", "ANATOMY", 63, 75], ["ER", "ANATOMY", 91, 93], ["ER", "GENE_OR_GENE_PRODUCT", 91, 93], ["medial-Golgi enzymes", "PROTEIN", 63, 83], ["ER", "PROTEIN", 91, 93], ["another study", "TEST", 3, 16], ["medial", "ANATOMY_MODIFIER", 63, 69]]], ["Also noteworthy is the finding that a number of yeast mutants, which fail to retain Mnt1p hybrid molecules to the Golgi, appear to have defects associated with the organisation of the Golgi (Chapman and Munro 1994a) .", [["Golgi", "ANATOMY", 114, 119], ["Golgi", "ANATOMY", 184, 189], ["Mnt1p hybrid molecules", "GENE_OR_GENE_PRODUCT", 84, 106], ["Golgi", "CELLULAR_COMPONENT", 114, 119], ["Golgi", "CELLULAR_COMPONENT", 184, 189], ["Mnt1p hybrid molecules", "PROTEIN", 84, 106], ["yeast", "SPECIES", 48, 53], ["yeast", "SPECIES", 48, 53], ["yeast mutants", "PROBLEM", 48, 61], ["defects", "PROBLEM", 136, 143], ["yeast mutants", "OBSERVATION", 48, 61], ["defects", "OBSERVATION", 136, 143]]], ["As proteins can play a major role in defining the structure of an organelle, as demonstrated by the de novo formation of caveolae in lymphocytes by the expression of the protein caveolin (Fra et al. 1995) , it is conceivable that glycosyltransferases may contribute significantly to the formation of the typical cisternae structure of Golgi membranes.", [["organelle", "ANATOMY", 66, 75], ["caveolae", "ANATOMY", 121, 129], ["lymphocytes", "ANATOMY", 133, 144], ["cisternae structure", "ANATOMY", 312, 331], ["Golgi membranes", "ANATOMY", 335, 350], ["organelle", "CELLULAR_COMPONENT", 66, 75], ["caveolae", "CELLULAR_COMPONENT", 121, 129], ["lymphocytes", "CELL", 133, 144], ["caveolin", "GENE_OR_GENE_PRODUCT", 178, 186], ["cisternae", "CELLULAR_COMPONENT", 312, 321], ["Golgi membranes", "CELLULAR_COMPONENT", 335, 350], ["lymphocytes", "CELL_TYPE", 133, 144], ["protein caveolin", "PROTEIN", 170, 186], ["glycosyltransferases", "PROTEIN", 230, 250], ["caveolae in lymphocytes", "TREATMENT", 121, 144], ["glycosyltransferases", "PROBLEM", 230, 250], ["typical", "OBSERVATION_MODIFIER", 304, 311], ["cisternae structure", "OBSERVATION", 312, 331], ["Golgi membranes", "OBSERVATION", 335, 350]]], ["Thus, understanding retention of Golgi glycosyltransferases may well be intimately linked to understanding the biogenesis of Golgi membranes.Golgi-localised viral proteinsA number of viruses from the coronavirus, bunyavirus and togavirus families acquire their envelopes by budding into Golgi membranes (Pettersson 1991; Griffiths and Rottier 1992; Hobman 1993) .", [["Golgi", "ANATOMY", 33, 38], ["Golgi membranes", "ANATOMY", 125, 140], ["Golgi membranes", "ANATOMY", 287, 302], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 33, 59], ["Golgi membranes", "CELLULAR_COMPONENT", 125, 140], ["coronavirus", "ORGANISM", 200, 211], ["bunyavirus", "GENE_OR_GENE_PRODUCT", 213, 223], ["togavirus", "GENE_OR_GENE_PRODUCT", 228, 237], ["Golgi membranes", "CELLULAR_COMPONENT", 287, 302], ["Golgi glycosyltransferases", "PROTEIN", 33, 59], ["Golgi-localised viral proteins", "PROTEIN", 141, 171], ["coronavirus", "SPECIES", 200, 211], ["Golgi glycosyltransferases", "TREATMENT", 33, 59], ["Golgi-localised viral proteins", "PROBLEM", 141, 171], ["viruses", "PROBLEM", 183, 190], ["the coronavirus", "PROBLEM", 196, 211], ["bunyavirus", "PROBLEM", 213, 223], ["Golgi membranes", "OBSERVATION", 125, 140], ["viral proteins", "OBSERVATION", 157, 171], ["Golgi membranes", "OBSERVATION", 287, 302]]], ["Viral budding from the Golgi apparatus is determined by the targeting of one or more viral glycoproteins to the Golgi membranes.", [["Golgi apparatus", "ANATOMY", 23, 38], ["Golgi membranes", "ANATOMY", 112, 127], ["Golgi", "CELLULAR_COMPONENT", 23, 28], ["Golgi membranes", "CELLULAR_COMPONENT", 112, 127], ["viral glycoproteins", "PROTEIN", 85, 104], ["Viral budding", "PROBLEM", 0, 13], ["the Golgi apparatus", "TEST", 19, 38], ["Golgi apparatus", "OBSERVATION", 23, 38], ["Golgi membranes", "OBSERVATION", 112, 127]]], ["Various viral proteins have been shown to be independently targeted to the Golgi apparatus, including the M (membrane) proteins of an avian coronavirus (Machamer et al. 1990 ) and a related murine coronavirus (Armstrong et al. 1987; Krijnse Locker et al. 1992) , the E2 spike glycoprotein of rubella virus ) and the G1 glycoproteins of Punta Tora virus (Chen et al. 1991 ) and of Uukuniemi virus (Melin et al. 1995) .", [["Golgi apparatus", "ANATOMY", 75, 90], ["avian coronavirus", "DISEASE", 134, 151], ["murine coronavirus", "DISEASE", 190, 208], ["E2", "CHEMICAL", 267, 269], ["Golgi apparatus", "CELLULAR_COMPONENT", 75, 90], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["avian coronavirus", "ORGANISM", 134, 151], ["murine", "ORGANISM", 190, 196], ["coronavirus", "ORGANISM", 197, 208], ["E2 spike glycoprotein", "GENE_OR_GENE_PRODUCT", 267, 288], ["rubella virus", "ORGANISM", 292, 305], ["Punta Tora virus", "ORGANISM", 336, 352], ["Uukuniemi virus", "ORGANISM", 380, 395], ["viral proteins", "PROTEIN", 8, 22], ["M (membrane) proteins", "PROTEIN", 106, 127], ["E2 spike glycoprotein", "PROTEIN", 267, 288], ["G1 glycoproteins", "PROTEIN", 316, 332], ["avian coronavirus", "SPECIES", 134, 151], ["murine", "SPECIES", 190, 196], ["coronavirus", "SPECIES", 197, 208], ["rubella virus", "SPECIES", 292, 305], ["Punta Tora virus", "SPECIES", 336, 352], ["Uukuniemi virus", "SPECIES", 380, 395], ["murine coronavirus", "SPECIES", 190, 208], ["rubella virus", "SPECIES", 292, 305], ["Punta Tora virus", "SPECIES", 336, 352], ["Uukuniemi virus", "SPECIES", 380, 395], ["Various viral proteins", "TEST", 0, 22], ["an avian coronavirus", "PROBLEM", 131, 151], ["a related murine coronavirus", "PROBLEM", 180, 208], ["rubella virus", "PROBLEM", 292, 305], ["Punta Tora virus", "PROBLEM", 336, 352], ["Uukuniemi virus", "PROBLEM", 380, 395], ["viral proteins", "OBSERVATION", 8, 22], ["murine coronavirus", "OBSERVATION", 190, 208]]], ["Viral proteins targeted to the Golgi include both type I membrane and multimembrane-spanning proteins ( Table 1) .", [["Golgi", "ANATOMY", 31, 36], ["membrane", "ANATOMY", 57, 65], ["Golgi", "CELLULAR_COMPONENT", 31, 36], ["type I", "GENE_OR_GENE_PRODUCT", 50, 56], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["Table 1", "GENE_OR_GENE_PRODUCT", 104, 111], ["Viral proteins", "PROTEIN", 0, 14], ["type I membrane and multimembrane-spanning proteins", "PROTEIN", 50, 101], ["Table 1", "PROTEIN", 104, 111], ["Viral proteins", "TEST", 0, 14]]], ["Some of these viral proteins have been shown to be targeted to different Golgi compartments.", [["Golgi compartments", "ANATOMY", 73, 91], ["Golgi compartments", "CELLULAR_COMPONENT", 73, 91], ["viral proteins", "PROTEIN", 14, 28], ["these viral proteins", "TEST", 8, 28], ["viral", "OBSERVATION", 14, 19], ["Golgi compartments", "OBSERVATION", 73, 91]]], ["For example, the M protein of the avian coronovirus, IBV, has been shown to be localised specifically to the cis- Golgi cisternae (Machamer et al. 1990 ), whereas the M protein of the coronavirus mouse hepatitis virus (MHV) is targeted to the TGN when expressed from cDNA (Krijnse Locker et al. 1992) .", [["Golgi cisternae", "ANATOMY", 114, 129], ["TGN", "ANATOMY", 243, 246], ["hepatitis", "DISEASE", 202, 211], ["avian coronovirus", "ORGANISM", 34, 51], ["IBV", "ORGANISM", 53, 56], ["Golgi cisternae", "CELLULAR_COMPONENT", 114, 129], ["coronavirus", "ORGANISM", 184, 195], ["mouse hepatitis virus", "ORGANISM", 196, 217], ["MHV", "ORGANISM", 219, 222], ["TGN", "GENE_OR_GENE_PRODUCT", 243, 246], ["M protein", "PROTEIN", 17, 26], ["M protein", "PROTEIN", 167, 176], ["TGN", "PROTEIN", 243, 246], ["cDNA", "DNA", 267, 271], ["avian coronovirus", "SPECIES", 34, 51], ["coronavirus", "SPECIES", 184, 195], ["mouse", "SPECIES", 196, 201], ["hepatitis virus", "SPECIES", 202, 217], ["IBV", "SPECIES", 53, 56], ["mouse hepatitis virus", "SPECIES", 196, 217], ["MHV", "SPECIES", 219, 222], ["the M protein", "TEST", 13, 26], ["the avian coronovirus", "PROBLEM", 30, 51], ["IBV", "PROBLEM", 53, 56], ["the M protein", "TEST", 163, 176], ["the coronavirus mouse hepatitis virus", "PROBLEM", 180, 217], ["coronavirus mouse", "OBSERVATION", 184, 201], ["hepatitis virus", "OBSERVATION", 202, 217]]], ["As a consequence of the specific localisation of these viral glycoproteins they are very useful tools to study retention of resident Golgi proteins.Golgi-localised viral proteinsAs for Golgi glycosyltransferases, transmembrane domains of a number of Golgi-localised viral proteins have been shown to play a crucial role in localisation (Swift and Machamer 1991; Krijnse Locker et al. 1994b; Matsuoka et al. 1994; Hobman et al. 1995 ) ; in some cases the cytoplasmic tail is also essential for efficient Golgi retention (Krijnse Locker et al. 1994b; Matsuoka et al. 1994) .Golgi-localised viral proteinsThe M proteins of coronaviruses contain three membrane-spanning domains, a short glycosylated amino-terminal domain and a carboxy-terminal cytoplasmic tail.Golgi-localised viral proteinsThe first of the three membrane-spanning domains of the M protein of IBV is required to retain this protein in the Golgi (Machamer and Rose, 1987) .", [["Golgi", "ANATOMY", 133, 138], ["Golgi", "ANATOMY", 185, 190], ["transmembrane", "ANATOMY", 213, 226], ["cytoplasmic tail", "ANATOMY", 454, 470], ["Golgi", "ANATOMY", 503, 508], ["Golgi", "ANATOMY", 572, 577], ["membrane", "ANATOMY", 648, 656], ["cytoplasmic", "ANATOMY", 741, 752], ["membrane", "ANATOMY", 811, 819], ["Golgi", "ANATOMY", 903, 908], ["amino-terminal", "CHEMICAL", 696, 710], ["amino", "CHEMICAL", 696, 701], ["carboxy", "CHEMICAL", 724, 731], ["Golgi", "CELLULAR_COMPONENT", 133, 138], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 185, 211], ["transmembrane", "CELLULAR_COMPONENT", 213, 226], ["Golgi-", "GENE_OR_GENE_PRODUCT", 250, 256], ["cytoplasmic", "ORGANISM_SUBSTANCE", 454, 465], ["Golgi", "CELLULAR_COMPONENT", 503, 508], ["Golgi", "CELLULAR_COMPONENT", 572, 577], ["coronaviruses", "ORGANISM", 620, 633], ["cytoplasmic", "ORGANISM_SUBSTANCE", 741, 752], ["membrane", "CELLULAR_COMPONENT", 811, 819], ["IBV", "ORGANISM", 857, 860], ["Golgi", "CELLULAR_COMPONENT", 903, 908], ["viral glycoproteins", "PROTEIN", 55, 74], ["resident Golgi proteins", "PROTEIN", 124, 147], ["Golgi-localised viral proteins", "PROTEIN", 148, 178], ["Golgi glycosyltransferases", "PROTEIN", 185, 211], ["transmembrane domains", "PROTEIN", 213, 234], ["Golgi-localised viral proteins", "PROTEIN", 250, 280], ["cytoplasmic tail", "PROTEIN", 454, 470], ["Golgi-localised viral proteins", "PROTEIN", 572, 602], ["M proteins", "PROTEIN", 606, 616], ["membrane-spanning domains", "PROTEIN", 648, 673], ["short glycosylated amino-terminal domain", "PROTEIN", 677, 717], ["carboxy-terminal cytoplasmic tail", "PROTEIN", 724, 757], ["Golgi-localised viral proteins", "PROTEIN", 758, 788], ["membrane-spanning domains", "PROTEIN", 811, 836], ["M protein", "PROTEIN", 844, 853], ["IBV", "SPECIES", 857, 860], ["these viral glycoproteins", "PROBLEM", 49, 74], ["Golgi-localised viral proteins", "PROBLEM", 148, 178], ["Golgi glycosyltransferases", "TREATMENT", 185, 211], ["Golgi-localised viral proteins", "PROBLEM", 250, 280], ["efficient Golgi retention", "PROBLEM", 493, 518], ["Golgi", "TEST", 572, 577], ["localised viral proteins", "PROBLEM", 578, 602], ["The M proteins", "TEST", 602, 616], ["coronaviruses", "PROBLEM", 620, 633], ["a short glycosylated amino-terminal domain", "PROBLEM", 675, 717], ["Golgi-localised viral proteins", "PROBLEM", 758, 788], ["the M protein of IBV", "TREATMENT", 840, 860], ["viral proteins", "OBSERVATION", 164, 178], ["cytoplasmic tail", "OBSERVATION", 454, 470], ["viral proteins", "OBSERVATION", 588, 602], ["coronaviruses", "OBSERVATION", 620, 633], ["three membrane", "OBSERVATION", 642, 656], ["terminal", "OBSERVATION_MODIFIER", 732, 740], ["cytoplasmic tail", "OBSERVATION", 741, 757], ["viral proteins", "OBSERVATION", 774, 788]]], ["Furthermore, this membrane-spanning domain is sufficient to confer Golgi localisation upon a plasma membrane-localised protein (Swift and Machamer 1991) .", [["membrane", "ANATOMY", 18, 26], ["Golgi", "ANATOMY", 67, 72], ["plasma membrane", "ANATOMY", 93, 108], ["membrane", "CELLULAR_COMPONENT", 18, 26], ["Golgi", "CELLULAR_COMPONENT", 67, 72], ["plasma membrane", "CELLULAR_COMPONENT", 93, 108], ["membrane-spanning domain", "PROTEIN", 18, 42], ["plasma membrane-localised protein", "PROTEIN", 93, 126], ["a plasma membrane", "TEST", 91, 108]]], ["In contrast to the findings for the M protein of IBV, Krijnse Locker et al. (1994b) demonstrated that two signals are required for the Golgi localisation of MHV M protein, namely one contained within a transmembrane domain and one within the cytoplasmic tail.", [["Golgi", "ANATOMY", 135, 140], ["transmembrane", "ANATOMY", 202, 215], ["cytoplasmic tail", "ANATOMY", 242, 258], ["IBV", "ORGANISM", 49, 52], ["Golgi", "CELLULAR_COMPONENT", 135, 140], ["MHV M protein", "GENE_OR_GENE_PRODUCT", 157, 170], ["cytoplasmic tail", "CELLULAR_COMPONENT", 242, 258], ["M protein", "PROTEIN", 36, 45], ["MHV M protein", "PROTEIN", 157, 170], ["transmembrane domain", "PROTEIN", 202, 222], ["cytoplasmic tail", "PROTEIN", 242, 258], ["IBV", "SPECIES", 49, 52], ["the M protein", "TEST", 32, 45], ["MHV M protein", "TEST", 157, 170], ["a transmembrane domain", "TEST", 200, 222], ["MHV", "OBSERVATION", 157, 160], ["transmembrane domain", "OBSERVATION", 202, 222], ["cytoplasmic tail", "OBSERVATION", 242, 258]]], ["As the MHV M protein is targeted to the TGN, and the IBV M protein to the cis-Golgi, the different locations of these coronovirus M proteins may account for the difference in targeting signals.Golgi-localised viral proteinsExtensive mutagenesis has identified features of the transmembrane domain of IBV M protein that may be important for localisation.", [["TGN", "ANATOMY", 40, 43], ["Golgi", "ANATOMY", 78, 83], ["transmembrane", "ANATOMY", 276, 289], ["MHV M", "GENE_OR_GENE_PRODUCT", 7, 12], ["TGN", "GENE_OR_GENE_PRODUCT", 40, 43], ["IBV M protein", "GENE_OR_GENE_PRODUCT", 53, 66], ["Golgi", "CELLULAR_COMPONENT", 78, 83], ["coronovirus M", "GENE_OR_GENE_PRODUCT", 118, 131], ["transmembrane", "CELLULAR_COMPONENT", 276, 289], ["IBV M protein", "GENE_OR_GENE_PRODUCT", 300, 313], ["MHV M protein", "PROTEIN", 7, 20], ["TGN", "PROTEIN", 40, 43], ["IBV M protein", "PROTEIN", 53, 66], ["coronovirus M proteins", "PROTEIN", 118, 140], ["Golgi-localised viral proteins", "PROTEIN", 193, 223], ["transmembrane domain", "PROTEIN", 276, 296], ["IBV M protein", "PROTEIN", 300, 313], ["MHV", "SPECIES", 7, 10], ["IBV", "SPECIES", 53, 56], ["IBV", "SPECIES", 300, 303], ["the MHV M protein", "TEST", 3, 20], ["the IBV M protein", "TEST", 49, 66], ["these coronovirus M proteins", "PROBLEM", 112, 140], ["the difference in targeting signals", "PROBLEM", 157, 192], ["Golgi-localised viral proteins", "PROBLEM", 193, 223], ["IBV M protein", "TREATMENT", 300, 313], ["may account for", "UNCERTAINTY", 141, 156], ["Extensive mutagenesis", "OBSERVATION", 223, 244]]], ["Four polar residues in the first IBV M transmembrane domain are critical for Golgi retention of a reporter molecule ).", [["Golgi", "ANATOMY", 77, 82], ["Golgi", "CELLULAR_COMPONENT", 77, 82], ["IBV M transmembrane domain", "PROTEIN", 33, 59], ["reporter molecule", "PROTEIN", 98, 115], ["Four polar residues", "TREATMENT", 0, 19], ["polar residues", "OBSERVATION", 5, 19], ["Golgi retention", "OBSERVATION", 77, 92]]], ["These four polar residues are predicted to form an uncharged polar face along one side of an \u03b1-helix.", [["\u03b1-helix", "SIMPLE_CHEMICAL", 93, 100], ["\u03b1-helix", "PROTEIN", 93, 100], ["polar residues", "OBSERVATION", 11, 25], ["uncharged", "OBSERVATION_MODIFIER", 51, 60], ["polar", "OBSERVATION_MODIFIER", 61, 66]]], ["Likewise, alterations to the predicted polar face of the transmembrane domain \u03b1-helix of Punta Toro virus G1 glycoprotein also perturbed Golgi localisation and resulted in partial expression of this protein on the cell surface (Matsuoka et al. 1996) .", [["transmembrane", "ANATOMY", 57, 70], ["Golgi", "ANATOMY", 137, 142], ["cell surface", "ANATOMY", 214, 226], ["transmembrane", "CELLULAR_COMPONENT", 57, 70], ["Punta Toro virus", "ORGANISM", 89, 105], ["G1 glycoprotein", "GENE_OR_GENE_PRODUCT", 106, 121], ["Golgi", "CELLULAR_COMPONENT", 137, 142], ["cell surface", "CELLULAR_COMPONENT", 214, 226], ["transmembrane domain \u03b1-helix", "PROTEIN", 57, 85], ["Punta Toro virus G1 glycoprotein", "PROTEIN", 89, 121], ["Punta Toro virus", "SPECIES", 89, 105], ["Punta Toro virus", "SPECIES", 89, 105], ["the transmembrane domain \u03b1-helix", "TEST", 53, 85], ["partial expression", "OBSERVATION", 172, 190]]], ["The uncharged polar face of the \u03b1-helix may promote protein-protein interactions and thereby mediate oligomer formation.Golgi-localised viral proteinsThere is evidence that aggregation may be important in Golgi retention of coronavirus M proteins.", [["Golgi", "ANATOMY", 120, 125], ["Golgi", "ANATOMY", 205, 210], ["\u03b1-helix", "SIMPLE_CHEMICAL", 32, 39], ["Golgi", "CELLULAR_COMPONENT", 120, 125], ["Golgi", "CELLULAR_COMPONENT", 205, 210], ["coronavirus M proteins", "GENE_OR_GENE_PRODUCT", 224, 246], ["\u03b1-helix", "PROTEIN", 32, 39], ["Golgi-localised viral proteins", "PROTEIN", 120, 150], ["coronavirus M proteins", "PROTEIN", 224, 246], ["protein-protein interactions", "TREATMENT", 52, 80], ["Golgi-localised viral proteins", "PROBLEM", 120, 150], ["aggregation", "PROBLEM", 173, 184], ["coronavirus M proteins", "PROBLEM", 224, 246], ["uncharged", "OBSERVATION_MODIFIER", 4, 13], ["polar", "OBSERVATION_MODIFIER", 14, 19], ["oligomer formation", "OBSERVATION", 101, 119], ["viral proteins", "OBSERVATION", 136, 150], ["aggregation", "OBSERVATION", 173, 184], ["may be important", "UNCERTAINTY", 185, 201], ["Golgi retention", "OBSERVATION", 205, 220]]], ["For instance, aggregation has been shown to correlate with retention of an IBV M hybrid protein in the Golgi apparatus (Weisz et al. 1993) .", [["Golgi apparatus", "ANATOMY", 103, 118], ["Golgi", "CELLULAR_COMPONENT", 103, 108], ["IBV M hybrid protein", "PROTEIN", 75, 95], ["IBV", "SPECIES", 75, 78], ["aggregation", "PROBLEM", 14, 25], ["an IBV M hybrid protein", "PROBLEM", 72, 95]]], ["These investigators demonstrated that the appearance of SDS-resistant aggregates of an M hybrid protein correlated with Golgi localisation, whereas mislocalised transmembrane domain mutants do not oligomerise.", [["Golgi", "ANATOMY", 120, 125], ["SDS", "CHEMICAL", 56, 59], ["Golgi", "CELLULAR_COMPONENT", 120, 125], ["M hybrid protein", "PROTEIN", 87, 103], ["mislocalised transmembrane domain mutants", "PROTEIN", 148, 189], ["SDS", "PROBLEM", 56, 59], ["resistant aggregates", "PROBLEM", 60, 80], ["an M hybrid protein", "PROBLEM", 84, 103], ["Golgi localisation", "TEST", 120, 138], ["mislocalised transmembrane domain mutants", "PROBLEM", 148, 189]]], ["However, SDS-resistant oligomers of the intact M protein were not detected in this study (Weisz et al. 1993) , thus the relationship between aggregate formation of the M hybrid molecule and Golgi retention of the native M protein remains unclear.", [["Golgi", "ANATOMY", 190, 195], ["SDS", "CHEMICAL", 9, 12], ["M hybrid molecule", "GENE_OR_GENE_PRODUCT", 168, 185], ["Golgi", "CELLULAR_COMPONENT", 190, 195], ["M protein", "PROTEIN", 47, 56], ["M hybrid molecule", "PROTEIN", 168, 185], ["native M protein", "PROTEIN", 213, 229], ["SDS", "TEST", 9, 12], ["the intact M protein", "TEST", 36, 56], ["this study", "TEST", 78, 88], ["the M hybrid molecule", "PROBLEM", 164, 185], ["Golgi retention", "PROBLEM", 190, 205], ["resistant", "OBSERVATION_MODIFIER", 13, 22], ["oligomers", "OBSERVATION", 23, 32], ["intact M protein", "OBSERVATION_MODIFIER", 40, 56], ["Golgi retention", "OBSERVATION", 190, 205]]], ["On the other hand, Krijnse Locker et al. (1995) have demonstrated that newly synthesised MHV M protein in the ER or intermediate compartment exists essentially as a monomer, however, MHV M protein formed large detergent-insoluble complexes following arrival in the Golgi apparatus.", [["ER", "ANATOMY", 110, 112], ["intermediate compartment", "ANATOMY", 116, 140], ["Golgi apparatus", "ANATOMY", 265, 280], ["MHV M", "GENE_OR_GENE_PRODUCT", 89, 94], ["ER", "GENE_OR_GENE_PRODUCT", 110, 112], ["MHV M", "GENE_OR_GENE_PRODUCT", 183, 188], ["Golgi apparatus", "CELLULAR_COMPONENT", 265, 280], ["MHV M protein", "PROTEIN", 89, 102], ["ER", "PROTEIN", 110, 112], ["MHV M protein", "PROTEIN", 183, 196], ["detergent-insoluble complexes", "PROTEIN", 210, 239], ["MHV", "SPECIES", 89, 92], ["MHV", "SPECIES", 183, 186], ["newly synthesised MHV M protein", "TEST", 71, 102], ["MHV M protein", "TEST", 183, 196], ["large detergent-insoluble complexes", "PROBLEM", 204, 239], ["MHV", "OBSERVATION", 89, 92], ["large", "OBSERVATION_MODIFIER", 204, 209]]], ["The behaviour of mutant proteins suggested that the self-association of MHV M protein may be mediated by the transmembrane domain, whereas the cytoplasmic tail, which is also required for Golgi localisation, could be required to interact with components of the TGN to immobilise the oligomers.", [["transmembrane", "ANATOMY", 109, 122], ["cytoplasmic tail", "ANATOMY", 143, 159], ["Golgi", "ANATOMY", 188, 193], ["TGN", "ANATOMY", 261, 264], ["MHV M", "GENE_OR_GENE_PRODUCT", 72, 77], ["transmembrane", "CELLULAR_COMPONENT", 109, 122], ["cytoplasmic tail", "CELLULAR_COMPONENT", 143, 159], ["Golgi", "CELLULAR_COMPONENT", 188, 193], ["TGN", "GENE_OR_GENE_PRODUCT", 261, 264], ["mutant proteins", "PROTEIN", 17, 32], ["MHV M protein", "PROTEIN", 72, 85], ["transmembrane domain", "PROTEIN", 109, 129], ["cytoplasmic tail", "PROTEIN", 143, 159], ["TGN", "PROTEIN", 261, 264], ["mutant proteins", "PROBLEM", 17, 32], ["MHV M protein", "TREATMENT", 72, 85], ["the transmembrane domain", "TEST", 105, 129], ["cytoplasmic tail", "OBSERVATION", 143, 159]]], ["These results not only reinforce the potential importance of aggregation in the localisation of Golgi membrane proteins but also highlight the possibility that multiple retention mechanisms are operating.Golgi-localised viral proteinsRecycling membrane proteins of the TGN In contrast to the complex retention signals of Golgi glycosyltransferases, the retention signals of a class of membrane proteins in the TGN are becoming well defined.", [["Golgi membrane", "ANATOMY", 96, 110], ["membrane", "ANATOMY", 244, 252], ["TGN", "ANATOMY", 269, 272], ["Golgi", "ANATOMY", 321, 326], ["membrane", "ANATOMY", 385, 393], ["TGN", "ANATOMY", 410, 413], ["Golgi membrane", "CELLULAR_COMPONENT", 96, 110], ["TGN", "CELLULAR_COMPONENT", 269, 272], ["Golgi glycosyltransferases", "GENE_OR_GENE_PRODUCT", 321, 347], ["membrane", "CELLULAR_COMPONENT", 385, 393], ["TGN", "GENE_OR_GENE_PRODUCT", 410, 413], ["Golgi membrane proteins", "PROTEIN", 96, 119], ["Golgi-localised viral proteins", "PROTEIN", 204, 234], ["Recycling membrane proteins", "PROTEIN", 234, 261], ["TGN", "PROTEIN", 269, 272], ["Golgi glycosyltransferases", "PROTEIN", 321, 347], ["membrane proteins", "PROTEIN", 385, 402], ["TGN", "PROTEIN", 410, 413], ["aggregation", "PROBLEM", 61, 72], ["Golgi membrane proteins", "TREATMENT", 96, 119], ["multiple retention mechanisms", "PROBLEM", 160, 189], ["Golgi-localised viral proteins", "PROBLEM", 204, 234], ["aggregation", "OBSERVATION", 61, 72], ["multiple", "OBSERVATION_MODIFIER", 160, 168], ["retention", "OBSERVATION", 169, 178], ["viral proteins", "OBSERVATION", 220, 234], ["complex", "OBSERVATION_MODIFIER", 292, 299], ["retention", "OBSERVATION", 300, 309], ["Golgi glycosyltransferases", "OBSERVATION", 321, 347], ["retention", "OBSERVATION_MODIFIER", 353, 362], ["membrane proteins", "OBSERVATION", 385, 402], ["TGN", "OBSERVATION_MODIFIER", 410, 413]]], ["This group includes mammalian TGN proteins as well as membrane proteins in the late Golgi of yeast, considered to be functionally equivalent to the TGN of animal cells (Wilsbach and Payne 1993) .", [["TGN", "ANATOMY", 30, 33], ["membrane", "ANATOMY", 54, 62], ["late Golgi", "ANATOMY", 79, 89], ["TGN", "ANATOMY", 148, 151], ["cells", "ANATOMY", 162, 167], ["TGN", "GENE_OR_GENE_PRODUCT", 30, 33], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["late Golgi", "CELLULAR_COMPONENT", 79, 89], ["TGN", "CELLULAR_COMPONENT", 148, 151], ["cells", "CELL", 162, 167], ["mammalian TGN proteins", "PROTEIN", 20, 42], ["membrane proteins", "PROTEIN", 54, 71], ["animal cells", "CELL_TYPE", 155, 167], ["yeast", "SPECIES", 93, 98], ["yeast", "SPECIES", 93, 98], ["mammalian TGN proteins", "TREATMENT", 20, 42], ["membrane proteins", "TEST", 54, 71], ["TGN proteins", "OBSERVATION", 30, 42], ["animal cells", "OBSERVATION", 155, 167]]], ["This group of TGN proteins shares the following characteristics: (1) ability to recycle from post-Golgi compartments; (2) retention signals located within their cytoplasmic tails; (3) a TGN localisation which can be saturated; and (4) in many cases, a type I membrane orientation.Golgi-localised viral proteinsThis group includes the mammalian proteins TGN38 (and the isoform TGN41) (Stanley and Howell 1993) , furin (Molloy et al. 1994) , Menkes P-type ATPase (Petris et al. 1996) and varicella-zoster virus glycoprotein I (gpI) (Alconada et al. 1996; Zhu et al. 1996) , as well as the yeast proteolytic enzymes Kex1p, Kex2p and dipeptidylaminopeptidase A (DPAP A) (Nothwehr and Stevens 1994) .", [["TGN", "ANATOMY", 14, 17], ["Golgi compartments", "ANATOMY", 98, 116], ["cytoplasmic", "ANATOMY", 161, 172], ["TGN", "ANATOMY", 186, 189], ["membrane", "ANATOMY", 259, 267], ["Golgi", "ANATOMY", 280, 285], ["varicella-zoster", "DISEASE", 486, 502], ["TGN", "GENE_OR_GENE_PRODUCT", 14, 17], ["cytoplasmic", "ORGANISM_SUBSTANCE", 161, 172], ["TGN", "CELLULAR_COMPONENT", 186, 189], ["membrane", "CELLULAR_COMPONENT", 259, 267], ["Golgi", "CELLULAR_COMPONENT", 280, 285], ["TGN38", "GENE_OR_GENE_PRODUCT", 353, 358], ["TGN41", "GENE_OR_GENE_PRODUCT", 376, 381], ["furin", "GENE_OR_GENE_PRODUCT", 411, 416], ["varicella-zoster virus glycoprotein I", "ORGANISM", 486, 523], ["Kex1p", "GENE_OR_GENE_PRODUCT", 613, 618], ["Kex2p", "GENE_OR_GENE_PRODUCT", 620, 625], ["dipeptidylaminopeptidase A", "GENE_OR_GENE_PRODUCT", 630, 656], ["DPAP A", "GENE_OR_GENE_PRODUCT", 658, 664], ["TGN proteins", "PROTEIN", 14, 26], ["cytoplasmic tails", "PROTEIN", 161, 178], ["TGN", "PROTEIN", 186, 189], ["Golgi-localised viral proteins", "PROTEIN", 280, 310], ["mammalian proteins", "PROTEIN", 334, 352], ["TGN38", "PROTEIN", 353, 358], ["isoform TGN41", "PROTEIN", 368, 381], ["ATPase", "PROTEIN", 454, 460], ["glycoprotein I", "PROTEIN", 509, 523], ["gpI", "PROTEIN", 525, 528], ["yeast proteolytic enzymes", "PROTEIN", 587, 612], ["Kex1p", "PROTEIN", 613, 618], ["Kex2p", "PROTEIN", 620, 625], ["dipeptidylaminopeptidase A", "PROTEIN", 630, 656], ["DPAP A", "PROTEIN", 658, 664], ["varicella-zoster virus", "SPECIES", 486, 508], ["yeast", "SPECIES", 587, 592], ["varicella-zoster virus", "SPECIES", 486, 508], ["yeast", "SPECIES", 587, 592], ["retention signals", "PROBLEM", 122, 139], ["a TGN localisation", "TEST", 184, 202], ["Golgi-localised viral proteins", "PROBLEM", 280, 310], ["the mammalian proteins", "TEST", 330, 352], ["furin", "TEST", 411, 416], ["Menkes P", "TEST", 440, 448], ["Petris et al.", "TEST", 462, 475], ["varicella", "PROBLEM", 486, 495], ["the yeast proteolytic enzymes", "TEST", 583, 612], ["cytoplasmic tails", "OBSERVATION", 161, 178], ["viral proteins", "OBSERVATION", 296, 310], ["varicella", "ANATOMY", 486, 495], ["zoster", "OBSERVATION", 496, 502]]], ["In contrast to the Golgi glycosyltransferases, TGN38, furin, gpI, Kex1p and Kex2p are type I membrane proteins, however, membrane orientation is not an absolute characteristic of the group as DPAP A is a type II membrane protein and Menkes P-type ATPase is a multimembrane-spanning protein.", [["Golgi", "ANATOMY", 19, 24], ["membrane", "ANATOMY", 93, 101], ["membrane", "ANATOMY", 121, 129], ["Golgi", "CELLULAR_COMPONENT", 19, 24], ["TGN38", "GENE_OR_GENE_PRODUCT", 47, 52], ["furin", "GENE_OR_GENE_PRODUCT", 54, 59], ["gpI", "GENE_OR_GENE_PRODUCT", 61, 64], ["Kex1p", "GENE_OR_GENE_PRODUCT", 66, 71], ["Kex2p", "GENE_OR_GENE_PRODUCT", 76, 81], ["type I membrane proteins", "GENE_OR_GENE_PRODUCT", 86, 110], ["membrane", "CELLULAR_COMPONENT", 121, 129], ["DPAP A", "GENE_OR_GENE_PRODUCT", 192, 198], ["type II", "GENE_OR_GENE_PRODUCT", 204, 211], ["membrane", "CELLULAR_COMPONENT", 212, 220], ["Menkes P-type ATPase", "GENE_OR_GENE_PRODUCT", 233, 253], ["Golgi glycosyltransferases", "PROTEIN", 19, 45], ["TGN38", "PROTEIN", 47, 52], ["furin", "PROTEIN", 54, 59], ["gpI", "PROTEIN", 61, 64], ["Kex1p", "PROTEIN", 66, 71], ["Kex2p", "PROTEIN", 76, 81], ["type I membrane proteins", "PROTEIN", 86, 110], ["DPAP A", "PROTEIN", 192, 198], ["type II membrane protein", "PROTEIN", 204, 228], ["Menkes P-type ATPase", "PROTEIN", 233, 253], ["multimembrane-spanning protein", "PROTEIN", 259, 289], ["the Golgi glycosyltransferases", "TEST", 15, 45], ["TGN38", "TEST", 47, 52], ["furin", "TEST", 54, 59], ["gpI", "TEST", 61, 64], ["Kex1p", "TEST", 66, 71], ["type I membrane proteins", "PROBLEM", 86, 110], ["Menkes P", "TEST", 233, 241]]], ["The mannose-6-phosphate receptors share some of the properties of this Golgi resident group, however, as the bulk of these receptors appears to be found in an endosome compartment and not the TGN, these receptors will not be included in this discussion (Kornfeld 1992) .Golgi-localised viral proteinsThe functions of these mammalian TGN molecules are diverse.", [["Golgi", "ANATOMY", 71, 76], ["endosome compartment", "ANATOMY", 159, 179], ["TGN", "ANATOMY", 192, 195], ["TGN molecules", "ANATOMY", 333, 346], ["mannose-6-phosphate", "CHEMICAL", 4, 23], ["mannose-6-phosphate", "CHEMICAL", 4, 23], ["mannose-6-phosphate receptors", "GENE_OR_GENE_PRODUCT", 4, 33], ["Golgi", "CELLULAR_COMPONENT", 71, 76], ["endosome compartment", "CELLULAR_COMPONENT", 159, 179], ["TGN", "CELLULAR_COMPONENT", 192, 195], ["TGN", "GENE_OR_GENE_PRODUCT", 333, 336], ["mannose-6-phosphate receptors", "PROTEIN", 4, 33], ["TGN", "PROTEIN", 192, 195], ["Golgi-localised viral proteins", "PROTEIN", 270, 300], ["mammalian TGN molecules", "PROTEIN", 323, 346], ["The mannose-6-phosphate receptors", "TREATMENT", 0, 33], ["Golgi-localised viral proteins", "PROBLEM", 270, 300], ["viral proteins", "OBSERVATION", 286, 300], ["TGN molecules", "OBSERVATION", 333, 346], ["diverse", "OBSERVATION_MODIFIER", 351, 358]]], ["Furin belongs to a family of subtilisin-related mammalian endoproteases (Barr et al. 1991) , TGN38 may be involved in the formation of exocytic vesicles from the TGN (Luzio et al. 1990; Reaves et al. 1992; Jones et al. 1993; Stanley and Howell 1993) and Menkes P-type ATPase is a copper translocating pump involved in copper efflux (Camakaris et al. 1995) .", [["exocytic vesicles", "ANATOMY", 135, 152], ["TGN", "ANATOMY", 162, 165], ["Furin", "CHEMICAL", 0, 5], ["copper", "CHEMICAL", 280, 286], ["copper", "CHEMICAL", 318, 324], ["copper", "CHEMICAL", 280, 286], ["copper", "CHEMICAL", 318, 324], ["Furin", "GENE_OR_GENE_PRODUCT", 0, 5], ["subtilisin", "GENE_OR_GENE_PRODUCT", 29, 39], ["TGN38", "GENE_OR_GENE_PRODUCT", 93, 98], ["exocytic vesicles", "CELLULAR_COMPONENT", 135, 152], ["TGN", "CELLULAR_COMPONENT", 162, 165], ["ATPase", "GENE_OR_GENE_PRODUCT", 268, 274], ["copper", "SIMPLE_CHEMICAL", 318, 324], ["Furin", "PROTEIN", 0, 5], ["subtilisin", "PROTEIN", 29, 39], ["TGN38", "PROTEIN", 93, 98], ["TGN", "PROTEIN", 162, 165], ["Menkes P-type ATPase", "PROTEIN", 254, 274], ["exocytic vesicles", "PROBLEM", 135, 152], ["a copper translocating pump", "TREATMENT", 278, 305], ["exocytic vesicles", "OBSERVATION", 135, 152]]], ["At steady state these proteins are found predominantly in the TGN.", [["TGN", "ANATOMY", 62, 65], ["TGN", "CELLULAR_COMPONENT", 62, 65], ["TGN", "PROTEIN", 62, 65], ["predominantly", "OBSERVATION_MODIFIER", 41, 54]]], ["However, overexpression of furin (Takahashi et al. 1995) , TGN38 (Reaves and Banting 1994) and gpI (Alconada et al. 1996) results in detection of the proteins at the cell surface, indicating that the mechanism of TGN localisation can be saturated.", [["cell surface", "ANATOMY", 166, 178], ["TGN", "ANATOMY", 213, 216], ["furin", "GENE_OR_GENE_PRODUCT", 27, 32], ["cell surface", "CELLULAR_COMPONENT", 166, 178], ["TGN", "GENE_OR_GENE_PRODUCT", 213, 216], ["furin", "PROTEIN", 27, 32], ["TGN", "PROTEIN", 213, 216], ["gpI", "TEST", 95, 98], ["the proteins", "PROBLEM", 146, 158], ["TGN localisation", "PROBLEM", 213, 229]]], ["Furthermore, numerous studies have shown that all these proteins continuously recycle between the TGN, endosomes and the cell surface.", [["TGN", "ANATOMY", 98, 101], ["endosomes", "ANATOMY", 103, 112], ["cell surface", "ANATOMY", 121, 133], ["TGN", "CELLULAR_COMPONENT", 98, 101], ["endosomes", "CELLULAR_COMPONENT", 103, 112], ["cell surface", "CELLULAR_COMPONENT", 121, 133], ["TGN", "PROTEIN", 98, 101], ["numerous studies", "TEST", 13, 29], ["cell", "OBSERVATION_MODIFIER", 121, 125], ["surface", "OBSERVATION_MODIFIER", 126, 133]]], ["For example, antibody uptake experiments and the use of drugs which inhibit endosomal recycling, such as chloroquine or bafilomycin A1, have shown that furin (Chapman and Munro 1994b; Molloy et al. 1994) , TGN38 (Ladinsky and Howell 1992; Bos et al. 1993; Reaves et al. 1993) , gpI (Alconada et al. 1996) and Menkes P-type ATPase (Petris et al. 1996) are internalised from the cell surface and returned to the TGN via endosomes.", [["endosomal", "ANATOMY", 76, 85], ["cell surface", "ANATOMY", 377, 389], ["TGN", "ANATOMY", 410, 413], ["endosomes", "ANATOMY", 418, 427], ["chloroquine", "CHEMICAL", 105, 116], ["bafilomycin", "CHEMICAL", 120, 131], ["chloroquine", "CHEMICAL", 105, 116], ["bafilomycin A1", "CHEMICAL", 120, 134], ["endosomal", "CELLULAR_COMPONENT", 76, 85], ["chloroquine", "SIMPLE_CHEMICAL", 105, 116], ["bafilomycin A1", "SIMPLE_CHEMICAL", 120, 134], ["furin", "GENE_OR_GENE_PRODUCT", 152, 157], ["cell surface", "CELLULAR_COMPONENT", 377, 389], ["TGN", "CELLULAR_COMPONENT", 410, 413], ["endosomes", "CELLULAR_COMPONENT", 418, 427], ["Menkes P-type ATPase", "PROTEIN", 309, 329], ["TGN", "PROTEIN", 410, 413], ["antibody uptake experiments", "PROBLEM", 13, 40], ["drugs", "TREATMENT", 56, 61], ["endosomal recycling", "TREATMENT", 76, 95], ["chloroquine", "TREATMENT", 105, 116], ["bafilomycin A1", "TREATMENT", 120, 134], ["gpI", "TEST", 278, 281], ["Menkes P", "TEST", 309, 317]]], ["On the other hand, the pathway that these TGN residents follow on the way to the cell surface is not so well characterised; it may involve transit through an en-dosome and/or direct transport to the cell surface (see Takahashi et al. 1995) .Golgi-localised viral proteinsThe recycling of these proteins is likely to be linked to their function, however, at this stage the biological relevance of the intracellular trafficking of TGN38 and furin is unclear.", [["TGN", "ANATOMY", 42, 45], ["cell surface", "ANATOMY", 81, 93], ["cell surface", "ANATOMY", 199, 211], ["Golgi", "ANATOMY", 241, 246], ["intracellular", "ANATOMY", 400, 413], ["TGN", "GENE_OR_GENE_PRODUCT", 42, 45], ["cell surface", "CELLULAR_COMPONENT", 81, 93], ["cell surface", "CELLULAR_COMPONENT", 199, 211], ["Golgi", "CELLULAR_COMPONENT", 241, 246], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 400, 413], ["TGN38", "GENE_OR_GENE_PRODUCT", 429, 434], ["furin", "GENE_OR_GENE_PRODUCT", 439, 444], ["Golgi-localised viral proteins", "PROTEIN", 241, 271], ["TGN38", "PROTEIN", 429, 434], ["furin", "PROTEIN", 439, 444], ["Golgi", "TEST", 241, 246], ["localised viral proteins", "PROBLEM", 247, 271], ["the intracellular trafficking of TGN38", "PROBLEM", 396, 434], ["viral proteins", "OBSERVATION", 257, 271]]], ["The recycling of Menkes protein appears to be intimately associated with its function in copper efflux; when cells are subjected to elevated copper levels the intracellular distribution of the protein is dramatically altered, with a decrease in the TGN pool and an increase in the pool at the cell surface (Petris et al. 1996) .", [["cells", "ANATOMY", 109, 114], ["intracellular", "ANATOMY", 159, 172], ["TGN", "ANATOMY", 249, 252], ["cell surface", "ANATOMY", 293, 305], ["copper", "CHEMICAL", 89, 95], ["copper", "CHEMICAL", 141, 147], ["copper", "CHEMICAL", 89, 95], ["copper", "CHEMICAL", 141, 147], ["Menkes protein", "GENE_OR_GENE_PRODUCT", 17, 31], ["copper", "SIMPLE_CHEMICAL", 89, 95], ["cells", "CELL", 109, 114], ["copper", "SIMPLE_CHEMICAL", 141, 147], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 159, 172], ["TGN", "GENE_OR_GENE_PRODUCT", 249, 252], ["cell surface", "CELLULAR_COMPONENT", 293, 305], ["Menkes protein", "PROTEIN", 17, 31], ["Menkes protein", "PROBLEM", 17, 31], ["copper efflux", "PROBLEM", 89, 102], ["elevated copper levels", "PROBLEM", 132, 154], ["dramatically altered", "PROBLEM", 204, 224], ["a decrease in the TGN pool", "PROBLEM", 231, 257], ["copper efflux", "OBSERVATION", 89, 102], ["intracellular", "OBSERVATION_MODIFIER", 159, 172], ["distribution", "OBSERVATION_MODIFIER", 173, 185], ["dramatically", "OBSERVATION_MODIFIER", 204, 216], ["altered", "OBSERVATION_MODIFIER", 217, 224], ["decrease", "OBSERVATION_MODIFIER", 233, 241], ["TGN pool", "OBSERVATION", 249, 257], ["increase", "OBSERVATION_MODIFIER", 265, 273]]], ["The increased trafficking of the Menkes protein to the cell surface is associated with the removal of intracellular copper.Golgi-localised viral proteinsAlthough these Golgi proteins continuously recycle between the TGN and the plasma membrane, there clearly has to be a mechanism for retaining the bulk of these molecules in the TGN.", [["cell surface", "ANATOMY", 55, 67], ["intracellular", "ANATOMY", 102, 115], ["Golgi", "ANATOMY", 168, 173], ["TGN", "ANATOMY", 216, 219], ["plasma membrane", "ANATOMY", 228, 243], ["TGN", "ANATOMY", 330, 333], ["copper", "CHEMICAL", 116, 122], ["copper", "CHEMICAL", 116, 122], ["cell surface", "CELLULAR_COMPONENT", 55, 67], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 115], ["copper", "SIMPLE_CHEMICAL", 116, 122], ["Golgi", "CELLULAR_COMPONENT", 168, 173], ["TGN", "CELLULAR_COMPONENT", 216, 219], ["plasma membrane", "CELLULAR_COMPONENT", 228, 243], ["TGN", "CELLULAR_COMPONENT", 330, 333], ["Menkes protein", "PROTEIN", 33, 47], ["Golgi-localised viral proteins", "PROTEIN", 123, 153], ["Golgi proteins", "PROTEIN", 168, 182], ["TGN", "PROTEIN", 216, 219], ["TGN", "PROTEIN", 330, 333], ["The increased trafficking of the Menkes protein", "PROBLEM", 0, 47], ["intracellular copper", "PROBLEM", 102, 122], ["Golgi-localised viral proteins", "PROBLEM", 123, 153], ["these Golgi proteins", "TEST", 162, 182], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["trafficking", "OBSERVATION_MODIFIER", 14, 25], ["cell surface", "OBSERVATION", 55, 67], ["removal", "OBSERVATION", 91, 98], ["intracellular copper", "OBSERVATION", 102, 122], ["viral proteins", "OBSERVATION", 139, 153], ["plasma membrane", "OBSERVATION", 228, 243]]], ["Presumably exit from the TGN is the rate limiting step in recycling.", [["TGN", "ANATOMY", 25, 28], ["TGN", "CELLULAR_COMPONENT", 25, 28], ["TGN", "PROTEIN", 25, 28]]], ["The cytoplasmic domains of TGN 38 (Bos et al. 1993; Humphrey et al. 1993; Wong and Hong 1993) , furin (Chapman and Munro 1994b; Molloy et al. 1994 ) and gpI (Alconada et al. 1996; Zhu et al. 1996) have been shown to mediate TGN localisation and internalisation from the plasma membrane.", [["cytoplasmic", "ANATOMY", 4, 15], ["TGN", "ANATOMY", 224, 227], ["plasma membrane", "ANATOMY", 270, 285], ["cytoplasmic", "ORGANISM_SUBSTANCE", 4, 15], ["TGN", "GENE_OR_GENE_PRODUCT", 27, 30], ["furin", "GENE_OR_GENE_PRODUCT", 96, 101], ["TGN", "GENE_OR_GENE_PRODUCT", 224, 227], ["plasma membrane", "CELLULAR_COMPONENT", 270, 285], ["cytoplasmic domains", "PROTEIN", 4, 23], ["TGN 38", "PROTEIN", 27, 33], ["TGN", "PROTEIN", 224, 227], ["The cytoplasmic domains of TGN", "TEST", 0, 30]]], ["A tyrosine-based tetrapeptide motif, YXXZ (Y is tyrosine, X is any amino acid and Z is a hydrophobic residue), in the cytoplasmic tails of TGN38 (Bos et al. 1993; Humphrey et al. 1993; Wong and Hong 1993) , furin (Jones et al. 1995; Schafer et al. 1995; Takahashi et al. 1995; Voorhees et al. 1995) , and gpI (Alconada et al. 1996) has been shown to be important in their localisation.", [["cytoplasmic", "ANATOMY", 118, 129], ["tyrosine", "CHEMICAL", 2, 10], ["tyrosine", "CHEMICAL", 48, 56], ["amino acid", "CHEMICAL", 67, 77], ["tyrosine", "CHEMICAL", 2, 10], ["tetrapeptide", "CHEMICAL", 17, 29], ["tyrosine", "CHEMICAL", 48, 56], ["amino acid", "CHEMICAL", 67, 77], ["tyrosine", "AMINO_ACID", 2, 10], ["tyrosine", "AMINO_ACID", 48, 56], ["amino acid", "AMINO_ACID", 67, 77], ["cytoplasmic", "ORGANISM_SUBSTANCE", 118, 129], ["TGN38", "GENE_OR_GENE_PRODUCT", 139, 144], ["furin", "GENE_OR_GENE_PRODUCT", 207, 212], ["YXXZ (Y is tyrosine, X", "PROTEIN", 37, 59], ["Z", "PROTEIN", 82, 83], ["cytoplasmic tails", "PROTEIN", 118, 135], ["TGN38", "PROTEIN", 139, 144], ["A tyrosine-based tetrapeptide motif, YXXZ (Y is tyrosine", "TREATMENT", 0, 56], ["any amino acid", "TREATMENT", 63, 77], ["a hydrophobic residue", "PROBLEM", 87, 108]]], ["YXXZ-type signals are capable of mediating rapid internalisation at the plasma membrane through coated pits into endosomes (Trowbridge et al. 1993) .", [["plasma membrane", "ANATOMY", 72, 87], ["endosomes", "ANATOMY", 113, 122], ["YXXZ", "GENE_OR_GENE_PRODUCT", 0, 4], ["plasma membrane", "CELLULAR_COMPONENT", 72, 87], ["endosomes", "CELLULAR_COMPONENT", 113, 122], ["YXXZ", "PROTEIN", 0, 4], ["rapid", "OBSERVATION_MODIFIER", 43, 48], ["internalisation", "OBSERVATION", 49, 64]]], ["In addition to the YXXZ signal a second, novel, signal involving a cluster of acidic amino acids has been identified in the cytoplasmic domain of furin (Schafer et al. 1995; Voorhees et al. 1995) and gpI (Alconada et al. 1996; Zhu et al. 1996) .", [["cytoplasmic", "ANATOMY", 124, 135], ["amino acids", "CHEMICAL", 85, 96], ["amino acids", "CHEMICAL", 85, 96], ["YXXZ", "GENE_OR_GENE_PRODUCT", 19, 23], ["amino acids", "AMINO_ACID", 85, 96], ["cytoplasmic", "ORGANISM_SUBSTANCE", 124, 135], ["furin", "GENE_OR_GENE_PRODUCT", 146, 151], ["YXXZ", "PROTEIN", 19, 23], ["acidic amino acids", "PROTEIN", 78, 96], ["cytoplasmic domain", "PROTEIN", 124, 142], ["furin", "PROTEIN", 146, 151], ["a cluster of acidic amino acids", "PROBLEM", 65, 96], ["acidic amino acids", "OBSERVATION", 78, 96]]], ["This latter signal may also control endocytosis and recycling back to the TGN (Voorhees et al. 1995; Alconada et al. 1996) and, in the case of furin, has also been reported to act as the dominant signal for TGN localisation (Schafer et al. 1995; Voorhees et al. 1995) .", [["TGN", "ANATOMY", 74, 77], ["TGN", "ANATOMY", 207, 210], ["TGN", "CELLULAR_COMPONENT", 74, 77], ["furin", "GENE_OR_GENE_PRODUCT", 143, 148], ["TGN", "GENE_OR_GENE_PRODUCT", 207, 210], ["furin", "PROTEIN", 143, 148]]], ["The acidic cluster of both furin (Jones et al. 1995; Takahashi et al. 1995) and gpI (Alconada et al. 1996) includes potential casein kinase II phosphorylation sites.", [["furin", "GENE_OR_GENE_PRODUCT", 27, 32], ["casein kinase II", "GENE_OR_GENE_PRODUCT", 126, 142], ["furin", "PROTEIN", 27, 32], ["casein kinase II phosphorylation sites", "PROTEIN", 126, 164], ["potential casein kinase II phosphorylation sites", "TREATMENT", 116, 164], ["acidic", "OBSERVATION_MODIFIER", 4, 10], ["cluster", "OBSERVATION_MODIFIER", 11, 18]]], ["In furin these sites have been demonstrated to be phoshorylated in vitro by casein kinase II (Jones et al. 1995; Takahashi et al. 1995) and in vivo (Jones et al. 1995) .", [["furin", "GENE_OR_GENE_PRODUCT", 3, 8], ["casein kinase II", "GENE_OR_GENE_PRODUCT", 76, 92], ["furin", "PROTEIN", 3, 8], ["casein kinase II", "PROTEIN", 76, 92]]], ["Mutation of the potential phosphorylation sites in gpI (Alconada et al. 1996) and furin (Takahashi et al. 1995) results in a dramatic alteration of the intracellular distribution of the protein.", [["intracellular", "ANATOMY", 152, 165], ["furin", "GENE_OR_GENE_PRODUCT", 82, 87], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 152, 165], ["phosphorylation sites", "PROTEIN", 26, 47], ["Mutation of the potential phosphorylation sites", "PROBLEM", 0, 47], ["intracellular distribution", "OBSERVATION", 152, 178]]], ["Hence, the intracellular trafficking of furin and gpI may be modulated by the phosphorylation state.Golgi-localised viral proteinsThere are a number of differences in the nature of the targeting signals of furin and TGN38.", [["intracellular", "ANATOMY", 11, 24], ["Golgi", "ANATOMY", 100, 105], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 24], ["furin", "GENE_OR_GENE_PRODUCT", 40, 45], ["gpI", "GENE_OR_GENE_PRODUCT", 50, 53], ["Golgi", "CELLULAR_COMPONENT", 100, 105], ["furin", "GENE_OR_GENE_PRODUCT", 206, 211], ["TGN38", "GENE_OR_GENE_PRODUCT", 216, 221], ["furin", "PROTEIN", 40, 45], ["gpI", "PROTEIN", 50, 53], ["Golgi-localised viral proteins", "PROTEIN", 100, 130], ["furin", "PROTEIN", 206, 211], ["TGN38", "PROTEIN", 216, 221], ["furin and gpI", "TREATMENT", 40, 53], ["Golgi-localised viral proteins", "PROBLEM", 100, 130], ["viral proteins", "OBSERVATION", 116, 130], ["number", "OBSERVATION_MODIFIER", 142, 148]]], ["Firstly, in constrast to furin, TGN38 lacks an acidic cluster signal.", [["TGN38", "CHEMICAL", 32, 37], ["furin", "GENE_OR_GENE_PRODUCT", 25, 30], ["TGN38", "GENE_OR_GENE_PRODUCT", 32, 37], ["furin", "PROTEIN", 25, 30], ["TGN38", "PROTEIN", 32, 37], ["an acidic cluster signal", "PROBLEM", 44, 68]]], ["However, the tyrosine-based motif of TGN38 (SDYQRL) ap-pears capable of not only mediating the internalisation of TGN38 from the cell surface but also the trafficking of internalised TGN38 to the TGN.", [["cell surface", "ANATOMY", 129, 141], ["TGN", "ANATOMY", 196, 199], ["tyrosine", "CHEMICAL", 13, 21], ["tyrosine", "CHEMICAL", 13, 21], ["tyrosine", "AMINO_ACID", 13, 21], ["TGN38", "GENE_OR_GENE_PRODUCT", 37, 42], ["TGN38", "GENE_OR_GENE_PRODUCT", 114, 119], ["cell surface", "CELLULAR_COMPONENT", 129, 141], ["TGN38", "GENE_OR_GENE_PRODUCT", 183, 188], ["TGN", "CELLULAR_COMPONENT", 196, 199], ["tyrosine-based motif", "PROTEIN", 13, 33], ["TGN38 (SDYQRL) ap", "PROTEIN", 37, 54], ["TGN38", "PROTEIN", 114, 119], ["TGN38", "PROTEIN", 183, 188], ["TGN", "PROTEIN", 196, 199], ["the tyrosine", "TREATMENT", 9, 21]]], ["For example, mutation of the YQRL sequence to YQDL abrogated TGN localistion of TGN 38 but did not affect internalisation (Humphrey et al. 1993) .", [["TGN", "ANATOMY", 61, 64], ["YQRL", "GENE_OR_GENE_PRODUCT", 29, 33], ["YQDL", "GENE_OR_GENE_PRODUCT", 46, 50], ["TGN", "GENE_OR_GENE_PRODUCT", 61, 64], ["TGN", "GENE_OR_GENE_PRODUCT", 80, 83], ["YQRL sequence", "DNA", 29, 42], ["YQDL", "DNA", 46, 50], ["TGN", "PROTEIN", 61, 64], ["TGN 38", "PROTEIN", 80, 86], ["mutation of the YQRL sequence", "PROBLEM", 13, 42], ["TGN localistion of TGN", "TEST", 61, 83]]], ["Thus, the precise context of the YXXZ motif may provide specificity for intracellular targeting to the TGN (Marks et al. 1997 ).", [["intracellular", "ANATOMY", 72, 85], ["TGN", "ANATOMY", 103, 106], ["YXXZ", "GENE_OR_GENE_PRODUCT", 33, 37], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["TGN", "CELLULAR_COMPONENT", 103, 106], ["YXXZ motif", "DNA", 33, 43], ["the YXXZ motif", "TREATMENT", 29, 43]]], ["In addition, the transmembrane domain of TGN38 appears to also contribute to TGN localisation (Ponnambalam et al. 1994) , whereas this is not the case for furin (Schafer et al. 1995) .", [["transmembrane", "ANATOMY", 17, 30], ["TGN", "ANATOMY", 77, 80], ["transmembrane", "CELLULAR_COMPONENT", 17, 30], ["TGN38", "GENE_OR_GENE_PRODUCT", 41, 46], ["TGN", "GENE_OR_GENE_PRODUCT", 77, 80], ["furin", "GENE_OR_GENE_PRODUCT", 155, 160], ["transmembrane domain", "PROTEIN", 17, 37], ["TGN38", "PROTEIN", 41, 46], ["TGN", "PROTEIN", 77, 80], ["furin", "PROTEIN", 155, 160], ["the transmembrane domain of TGN38", "PROBLEM", 13, 46], ["TGN localisation", "PROBLEM", 77, 93]]], ["Similar trafficking pathways of furin and TGN38 may therefore be mediated by different sets of signals.", [["furin", "GENE_OR_GENE_PRODUCT", 32, 37], ["TGN38", "GENE_OR_GENE_PRODUCT", 42, 47], ["furin", "PROTEIN", 32, 37], ["TGN38", "PROTEIN", 42, 47]]], ["The cytoplasmic domain of Menkes P-type ATPase contains a number of potential signals, including multiple tyrosine-based motifs, dileucine motifs and an acidic cluster, however, the relative importance of each in localisation and trafficking of this protein is not known (Petris et al. 1996) .Golgi-localised viral proteinsThe yeast proteins DPAP A, Kex2p and Kex1p are all integral membrane proteins with cytoplasmic tails of about 100 amino acids.", [["cytoplasmic", "ANATOMY", 4, 15], ["Golgi", "ANATOMY", 293, 298], ["membrane", "ANATOMY", 383, 391], ["cytoplasmic", "ANATOMY", 406, 417], ["tyrosine", "CHEMICAL", 106, 114], ["amino acids", "CHEMICAL", 437, 448], ["tyrosine", "CHEMICAL", 106, 114], ["dileucine", "CHEMICAL", 129, 138], ["amino acids", "CHEMICAL", 437, 448], ["cytoplasmic", "ORGANISM_SUBSTANCE", 4, 15], ["Menkes P-type ATPase", "GENE_OR_GENE_PRODUCT", 26, 46], ["Golgi", "CELLULAR_COMPONENT", 293, 298], ["DPAP A", "GENE_OR_GENE_PRODUCT", 342, 348], ["Kex2p", "GENE_OR_GENE_PRODUCT", 350, 355], ["Kex1p", "GENE_OR_GENE_PRODUCT", 360, 365], ["membrane", "CELLULAR_COMPONENT", 383, 391], ["cytoplasmic", "ORGANISM_SUBSTANCE", 406, 417], ["amino acids", "AMINO_ACID", 437, 448], ["cytoplasmic domain", "PROTEIN", 4, 22], ["Menkes P-type ATPase", "PROTEIN", 26, 46], ["tyrosine-based motifs", "PROTEIN", 106, 127], ["dileucine motifs", "PROTEIN", 129, 145], ["acidic cluster", "PROTEIN", 153, 167], ["Golgi-localised viral proteins", "PROTEIN", 293, 323], ["yeast proteins", "PROTEIN", 327, 341], ["DPAP A", "PROTEIN", 342, 348], ["Kex2p", "PROTEIN", 350, 355], ["Kex1p", "PROTEIN", 360, 365], ["integral membrane proteins", "PROTEIN", 374, 400], ["cytoplasmic tails", "PROTEIN", 406, 423], ["yeast", "SPECIES", 327, 332], ["yeast", "SPECIES", 327, 332], ["multiple tyrosine-based motifs", "TREATMENT", 97, 127], ["dileucine motifs", "TREATMENT", 129, 145], ["an acidic cluster", "PROBLEM", 150, 167], ["Golgi", "TEST", 293, 298], ["localised viral proteins", "PROBLEM", 299, 323], ["The yeast proteins", "TEST", 323, 341], ["cytoplasmic tails", "TEST", 406, 423], ["amino acids", "TREATMENT", 437, 448], ["viral proteins", "OBSERVATION", 309, 323], ["yeast proteins DPAP", "OBSERVATION", 327, 346], ["cytoplasmic tails", "OBSERVATION", 406, 423]]], ["These cytoplasmic tails are required for retention of these enzymes in the late Golgi since deletions in the tail reduce the efficiency of retention (Cooper and Bussey 1992; Wilcox et al. 1992; Nothwehr et al. 1993) .", [["cytoplasmic", "ANATOMY", 6, 17], ["Golgi", "ANATOMY", 80, 85], ["tail", "ANATOMY", 109, 113], ["cytoplasmic", "ORGANISM_SUBSTANCE", 6, 17], ["late Golgi", "CELLULAR_COMPONENT", 75, 85], ["tail", "ORGANISM_SUBDIVISION", 109, 113], ["cytoplasmic tails", "PROTEIN", 6, 23], ["enzymes", "PROTEIN", 60, 67], ["These cytoplasmic tails", "PROBLEM", 0, 23], ["these enzymes", "TEST", 54, 67], ["cytoplasmic tails", "OBSERVATION", 6, 23], ["tail", "ANATOMY", 109, 113], ["efficiency", "OBSERVATION_MODIFIER", 125, 135]]], ["Aromatic-based Golgi localisation signals have been identified within the cytoplasmic tails of Kex2p and DPAP A which are very similar to the general motif for clustering into clathrin-coated pits of animal cells (Wilcox et al. 1992; Nothwehr et al. 1993) .", [["Golgi", "ANATOMY", 15, 20], ["cytoplasmic", "ANATOMY", 74, 85], ["cells", "ANATOMY", 207, 212], ["Golgi", "CELLULAR_COMPONENT", 15, 20], ["cytoplasmic", "ORGANISM_SUBSTANCE", 74, 85], ["Kex2p", "GENE_OR_GENE_PRODUCT", 95, 100], ["DPAP A", "GENE_OR_GENE_PRODUCT", 105, 111], ["clathrin", "GENE_OR_GENE_PRODUCT", 176, 184], ["cells", "CELL", 207, 212], ["cytoplasmic tails", "PROTEIN", 74, 91], ["Kex2p", "PROTEIN", 95, 100], ["DPAP A", "PROTEIN", 105, 111], ["clathrin", "PROTEIN", 176, 184], ["animal cells", "CELL_TYPE", 200, 212], ["Aromatic-based Golgi localisation signals", "PROBLEM", 0, 41], ["Golgi localisation", "OBSERVATION", 15, 33], ["cytoplasmic tails", "OBSERVATION", 74, 91], ["animal cells", "OBSERVATION", 200, 212]]], ["Deletion of the Golgi retention signal, or overexpression of these proteins, results in mislocalisation to the vacuolar compartment.", [["Golgi", "ANATOMY", 16, 21], ["vacuolar compartment", "ANATOMY", 111, 131], ["Golgi", "CELLULAR_COMPONENT", 16, 21], ["vacuolar compartment", "CELLULAR_COMPONENT", 111, 131], ["Deletion of the Golgi retention signal", "PROBLEM", 0, 38], ["overexpression of these proteins", "PROBLEM", 43, 75], ["Golgi retention", "OBSERVATION", 16, 31], ["vacuolar compartment", "OBSERVATION", 111, 131]]], ["This initially surprising finding leads to the conclusion that the default destination for membrane proteins in the yeast secretory pathway is the vacuolar compartment and not the plasma membrane.Golgi-localised viral proteinsStudies on the yeast class E vacuolar protein sorting (vps) mutants suggest that DPAP A may leak from the late Golgi and is transported, via the default pathway, to a post-Golgi/pre-vacuolar compartment (Nothwehr and Stevens 1994) .", [["membrane", "ANATOMY", 91, 99], ["vacuolar compartment", "ANATOMY", 147, 167], ["plasma membrane", "ANATOMY", 180, 195], ["late Golgi", "ANATOMY", 332, 342], ["Golgi", "ANATOMY", 398, 403], ["pre-vacuolar compartment", "ANATOMY", 404, 428], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["vacuolar compartment", "CELLULAR_COMPONENT", 147, 167], ["plasma membrane", "CELLULAR_COMPONENT", 180, 195], ["yeast class E vacuolar protein sorting (vps)", "GENE_OR_GENE_PRODUCT", 241, 285], ["DPAP A", "GENE_OR_GENE_PRODUCT", 307, 313], ["late Golgi", "CELLULAR_COMPONENT", 332, 342], ["Golgi", "CELLULAR_COMPONENT", 398, 403], ["membrane proteins", "PROTEIN", 91, 108], ["Golgi-localised viral proteins", "PROTEIN", 196, 226], ["yeast class E vacuolar protein sorting (vps) mutants", "PROTEIN", 241, 293], ["DPAP A", "PROTEIN", 307, 313], ["yeast", "SPECIES", 116, 121], ["yeast", "SPECIES", 241, 246], ["yeast", "SPECIES", 116, 121], ["yeast", "SPECIES", 241, 246], ["membrane proteins", "PROBLEM", 91, 108], ["Golgi-localised viral proteinsStudies", "TEST", 196, 233], ["yeast", "OBSERVATION", 116, 121], ["secretory pathway", "OBSERVATION", 122, 139], ["vacuolar compartment", "OBSERVATION", 147, 167], ["plasma membrane", "OBSERVATION", 180, 195], ["leak", "OBSERVATION", 318, 322]]], ["The aromatic-based motif in the cytoplasmic domain of these escaped DPAP A molecules then mediates retrieval back to the late Golgi; in the absence of the cytoplasmic tail Golgi localisation signals, these membrane proteins would continue to be transported along this default pathway to vacuoles.", [["cytoplasmic", "ANATOMY", 32, 43], ["Golgi", "ANATOMY", 126, 131], ["cytoplasmic", "ANATOMY", 155, 166], ["Golgi", "ANATOMY", 172, 177], ["membrane", "ANATOMY", 206, 214], ["vacuoles", "ANATOMY", 287, 295], ["cytoplasmic", "ORGANISM_SUBSTANCE", 32, 43], ["DPAP A", "GENE_OR_GENE_PRODUCT", 68, 74], ["Golgi", "CELLULAR_COMPONENT", 126, 131], ["cytoplasmic", "ORGANISM_SUBSTANCE", 155, 166], ["tail Golgi", "CELLULAR_COMPONENT", 167, 177], ["membrane", "CELLULAR_COMPONENT", 206, 214], ["vacuoles", "CELLULAR_COMPONENT", 287, 295], ["aromatic-based motif", "PROTEIN", 4, 24], ["cytoplasmic domain", "PROTEIN", 32, 50], ["DPAP A molecules", "PROTEIN", 68, 84], ["cytoplasmic tail", "PROTEIN", 155, 171], ["membrane proteins", "PROTEIN", 206, 223], ["mediates retrieval", "TREATMENT", 90, 108], ["these membrane proteins", "PROBLEM", 200, 223], ["late", "OBSERVATION_MODIFIER", 121, 125], ["Golgi", "OBSERVATION_MODIFIER", 126, 131]]], ["Loss of the clathrin heavy chain gene, CHC1, in yeast results in mislocalisation of Kex2p and DPAP A, indicating clathrin is necessary for either retention of these proteins in the TGN or recycling from the prevacuolar compartment back to the TGN (Seeger and Payne 1992a, b; Wilsbach and Payne 1993) .Golgi-localised viral proteinsRecently, Bryant and Stevens (1997) identified a second independent localisation signal in the cytoplasmic tail of DPAP A by employing an assay which uncoupled retrieval-based localisation from active Golgi retention.", [["TGN", "ANATOMY", 181, 184], ["prevacuolar compartment", "ANATOMY", 207, 230], ["TGN", "ANATOMY", 243, 246], ["cytoplasmic tail", "ANATOMY", 426, 442], ["Golgi", "ANATOMY", 532, 537], ["clathrin heavy chain", "GENE_OR_GENE_PRODUCT", 12, 32], ["CHC1", "GENE_OR_GENE_PRODUCT", 39, 43], ["Kex2p", "GENE_OR_GENE_PRODUCT", 84, 89], ["DPAP A", "GENE_OR_GENE_PRODUCT", 94, 100], ["clathrin", "GENE_OR_GENE_PRODUCT", 113, 121], ["TGN", "GENE_OR_GENE_PRODUCT", 181, 184], ["TGN", "CELLULAR_COMPONENT", 243, 246], ["cytoplasmic", "ORGANISM_SUBSTANCE", 426, 437], ["DPAP A", "GENE_OR_GENE_PRODUCT", 446, 452], ["Golgi", "CELLULAR_COMPONENT", 532, 537], ["clathrin heavy chain gene", "DNA", 12, 37], ["CHC1", "DNA", 39, 43], ["Kex2p", "PROTEIN", 84, 89], ["DPAP A", "PROTEIN", 94, 100], ["clathrin", "PROTEIN", 113, 121], ["TGN", "PROTEIN", 181, 184], ["Golgi-localised viral proteins", "PROTEIN", 301, 331], ["cytoplasmic tail", "PROTEIN", 426, 442], ["DPAP A", "PROTEIN", 446, 452], ["yeast", "SPECIES", 48, 53], ["yeast", "SPECIES", 48, 53], ["Loss of the clathrin heavy chain gene", "PROBLEM", 0, 37], ["clathrin", "TREATMENT", 113, 121], ["these proteins", "PROBLEM", 159, 173], ["Golgi-localised viral proteins", "PROBLEM", 301, 331], ["a second independent localisation signal", "PROBLEM", 378, 418], ["an assay", "TEST", 466, 474], ["active Golgi retention", "PROBLEM", 525, 547], ["clathrin", "OBSERVATION_MODIFIER", 12, 20], ["heavy", "OBSERVATION_MODIFIER", 21, 26], ["chain gene", "OBSERVATION", 27, 37], ["localised", "OBSERVATION_MODIFIER", 307, 316], ["viral proteins", "OBSERVATION", 317, 331], ["cytoplasmic tail", "OBSERVATION", 426, 442], ["active", "OBSERVATION_MODIFIER", 525, 531], ["Golgi retention", "OBSERVATION", 532, 547]]], ["These investigators have proposed that this second signal slows the rate of exit at the TGN whereas the aromatic motif directs retrieval from the prevacuolar compartment.Golgi-localised viral proteinsA large group of novel Saccharomyces cerevisiae mutants have been generated which are Golgi Retention Defective (grd) (Nothwehr et al. 1996) .", [["TGN", "ANATOMY", 88, 91], ["prevacuolar compartment", "ANATOMY", 146, 169], ["Golgi", "ANATOMY", 170, 175], ["Golgi", "ANATOMY", 286, 291], ["TGN", "CELLULAR_COMPONENT", 88, 91], ["Golgi", "CELLULAR_COMPONENT", 170, 175], ["Saccharomyces cerevisiae", "ORGANISM", 223, 247], ["Golgi", "CELLULAR_COMPONENT", 286, 291], ["TGN", "PROTEIN", 88, 91], ["aromatic motif", "PROTEIN", 104, 118], ["Golgi-localised viral proteins", "PROTEIN", 170, 200], ["Saccharomyces cerevisiae mutants", "PROTEIN", 223, 255], ["Saccharomyces cerevisiae", "SPECIES", 223, 247], ["Saccharomyces cerevisiae", "SPECIES", 223, 247], ["Golgi", "TEST", 170, 175], ["localised viral proteins", "PROBLEM", 176, 200], ["novel Saccharomyces cerevisiae mutants", "TREATMENT", 217, 255], ["localised", "OBSERVATION_MODIFIER", 176, 185], ["viral proteins", "OBSERVATION", 186, 200], ["large", "OBSERVATION_MODIFIER", 202, 207], ["Retention Defective", "OBSERVATION", 292, 311]]], ["Many of these mutants appear to be specifically defective in the retention of DPAP A and Kex2p and therefore should prove useful in defining the machinery involved in Golgi retention of this class of TGN protein.Golgi-localised viral proteinsTGN recycling proteins share the same Golgi compartment as the glycosyltransferases \u03b12,6ST and \u03b21,4GalT.", [["Golgi", "ANATOMY", 167, 172], ["TGN", "ANATOMY", 200, 203], ["Golgi", "ANATOMY", 212, 217], ["Golgi compartment", "ANATOMY", 280, 297], ["DPAP A", "GENE_OR_GENE_PRODUCT", 78, 84], ["Kex2p", "GENE_OR_GENE_PRODUCT", 89, 94], ["Golgi", "CELLULAR_COMPONENT", 167, 172], ["TGN", "GENE_OR_GENE_PRODUCT", 200, 203], ["Golgi", "CELLULAR_COMPONENT", 212, 217], ["TGN", "GENE_OR_GENE_PRODUCT", 242, 245], ["Golgi compartment", "CELLULAR_COMPONENT", 280, 297], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 326, 332], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 337, 345], ["DPAP A", "PROTEIN", 78, 84], ["Kex2p", "PROTEIN", 89, 94], ["TGN protein", "PROTEIN", 200, 211], ["Golgi-localised viral proteins", "PROTEIN", 212, 242], ["TGN recycling proteins", "PROTEIN", 242, 264], ["glycosyltransferases", "PROTEIN", 305, 325], ["\u03b1", "PROTEIN", 326, 327], ["2,6ST", "PROTEIN", 327, 332], ["\u03b21,4GalT", "PROTEIN", 337, 345], ["Golgi-localised viral proteins", "TEST", 212, 242], ["the glycosyltransferases", "TEST", 301, 325], ["appear to be", "UNCERTAINTY", 22, 34], ["defective", "OBSERVATION", 48, 57], ["retention", "OBSERVATION_MODIFIER", 65, 74], ["Golgi retention", "OBSERVATION", 167, 182]]], ["Although the recycling of furin and TGN38 clearly demonstrates that an efficient pathway exists for the recapture of TGN proteins from the cell surface of mammalian cells, experimental data argue against the recycling of \u03b12,6ST and \u03b21,4GalT from post-Golgi compartments Chapman and Munro 1994b; Teasdale et al. 1994) , nonetheless these glycosyltransferases are very efficiently retained within the Golgi.", [["TGN", "ANATOMY", 117, 120], ["cell surface", "ANATOMY", 139, 151], ["cells", "ANATOMY", 165, 170], ["Golgi compartments", "ANATOMY", 251, 269], ["Golgi", "ANATOMY", 399, 404], ["furin", "GENE_OR_GENE_PRODUCT", 26, 31], ["TGN38", "GENE_OR_GENE_PRODUCT", 36, 41], ["TGN", "GENE_OR_GENE_PRODUCT", 117, 120], ["cell surface", "CELLULAR_COMPONENT", 139, 151], ["mammalian cells", "CELL", 155, 170], ["\u03b12,6ST", "GENE_OR_GENE_PRODUCT", 221, 227], ["\u03b21,4GalT", "GENE_OR_GENE_PRODUCT", 232, 240], ["Golgi", "CELLULAR_COMPONENT", 399, 404], ["furin", "PROTEIN", 26, 31], ["TGN38", "PROTEIN", 36, 41], ["TGN proteins", "PROTEIN", 117, 129], ["mammalian cells", "CELL_TYPE", 155, 170], ["\u03b12,6ST", "PROTEIN", 221, 227], ["\u03b21,4GalT", "PROTEIN", 232, 240], ["glycosyltransferases", "PROTEIN", 337, 357], ["TGN proteins", "TEST", 117, 129], ["experimental data", "TEST", 172, 189], ["the recycling", "TEST", 204, 217], ["these glycosyltransferases", "TREATMENT", 331, 357], ["mammalian cells", "OBSERVATION", 155, 170]]], ["Thus there are two sets of membrane proteins within the same Golgi compartment with very different mechanisms of localisation.", [["membrane", "ANATOMY", 27, 35], ["Golgi compartment", "ANATOMY", 61, 78], ["membrane", "CELLULAR_COMPONENT", 27, 35], ["Golgi compartment", "CELLULAR_COMPONENT", 61, 78], ["membrane proteins", "PROTEIN", 27, 44], ["membrane proteins", "TEST", 27, 44], ["membrane proteins", "OBSERVATION", 27, 44], ["very different", "OBSERVATION_MODIFIER", 84, 98]]], ["Clearly we need to understand why some TGN-localised proteins can enter exocytic vesicles more efficiently than others.", [["TGN", "ANATOMY", 39, 42], ["exocytic vesicles", "ANATOMY", 72, 89], ["TGN", "GENE_OR_GENE_PRODUCT", 39, 42], ["exocytic vesicles", "CELLULAR_COMPONENT", 72, 89], ["TGN-localised proteins", "PROTEIN", 39, 61]]], ["One possibility is that the TGN consists of distinct membrane subdomains (Ladinsky et al. 1994) with the two classes of resident proteins localised to separate subdomains.Other Golgi-resident proteinsOther groups of Golgi-resident proteins include retrieval receptors, matrix and cytoskeletal-binding proteins and components of the vesicular transport machinery (Table 1) .Other Golgi-resident proteinsA number of ER proteins are retrieved from the Golgi apparatus by the interaction with specific receptors followed by retrograde transport to the ER.", [["TGN", "ANATOMY", 28, 31], ["membrane subdomains", "ANATOMY", 53, 72], ["matrix", "ANATOMY", 269, 275], ["cytoskeletal", "ANATOMY", 280, 292], ["vesicular", "ANATOMY", 332, 341], ["Golgi apparatus", "ANATOMY", 449, 464], ["ER", "ANATOMY", 548, 550], ["TGN", "CELLULAR_COMPONENT", 28, 31], ["membrane subdomains", "CELLULAR_COMPONENT", 53, 72], ["Golgi-resident proteins", "GENE_OR_GENE_PRODUCT", 216, 239], ["matrix", "CELLULAR_COMPONENT", 269, 275], ["cytoskeletal-binding proteins", "GENE_OR_GENE_PRODUCT", 280, 309], ["vesicular", "MULTI-TISSUE_STRUCTURE", 332, 341], ["ER", "GENE_OR_GENE_PRODUCT", 414, 416], ["Golgi apparatus", "CELLULAR_COMPONENT", 449, 464], ["ER", "GENE_OR_GENE_PRODUCT", 548, 550], ["TGN", "PROTEIN", 28, 31], ["membrane subdomains", "PROTEIN", 53, 72], ["resident proteins", "PROTEIN", 120, 137], ["Golgi-resident proteins", "PROTEIN", 216, 239], ["retrieval receptors", "PROTEIN", 248, 267], ["matrix and cytoskeletal-binding proteins", "PROTEIN", 269, 309], ["Golgi-resident proteins", "PROTEIN", 379, 402], ["ER proteins", "PROTEIN", 414, 425], ["specific receptors", "PROTEIN", 489, 507], ["ER", "PROTEIN", 548, 550], ["distinct membrane subdomains", "PROBLEM", 44, 72], ["retrieval receptors", "TREATMENT", 248, 267], ["cytoskeletal-binding proteins", "TREATMENT", 280, 309], ["ER proteins", "PROBLEM", 414, 425], ["distinct", "OBSERVATION_MODIFIER", 44, 52], ["membrane subdomains", "OBSERVATION", 53, 72], ["binding proteins", "OBSERVATION", 293, 309]]], ["These include the multimembrane-spanning KDEL/HDEL receptor, which resides predominantly in the early Golgi but is also found throughout the Golgi stack (Lewis and Pelham 1992; Tang et al. 1993) .", [["Golgi", "ANATOMY", 102, 107], ["Golgi stack", "ANATOMY", 141, 152], ["KDEL", "GENE_OR_GENE_PRODUCT", 41, 45], ["HDEL receptor", "GENE_OR_GENE_PRODUCT", 46, 59], ["Golgi", "CELLULAR_COMPONENT", 102, 107], ["Golgi stack", "CELLULAR_COMPONENT", 141, 152], ["KDEL", "PROTEIN", 41, 45], ["HDEL receptor", "PROTEIN", 46, 59], ["the multimembrane", "TEST", 14, 31], ["predominantly", "OBSERVATION_MODIFIER", 75, 88]]], ["As KDEL receptors only recycle back to the ER after binding to ligand (Lewis and Pelham 1992) , this receptor is likely to have signals for Golgi localisation, however, the nature of these signals is not known.", [["ER", "ANATOMY", 43, 45], ["Golgi", "ANATOMY", 140, 145], ["KDEL", "GENE_OR_GENE_PRODUCT", 3, 7], ["ER", "GENE_OR_GENE_PRODUCT", 43, 45], ["Golgi", "CELLULAR_COMPONENT", 140, 145], ["KDEL receptors", "PROTEIN", 3, 17], ["ER", "PROTEIN", 43, 45], ["Golgi localisation", "TEST", 140, 158]]], ["The retrieval of Sec12p from the Golgi to the ER in yeast is mediated by the Golgi-localised multimembrane-spanning Rer1p (Sato et al. 1995 (Sato et al. , 1996 .", [["Golgi", "ANATOMY", 33, 38], ["ER", "ANATOMY", 46, 48], ["Sec12p", "GENE_OR_GENE_PRODUCT", 17, 23], ["Golgi", "CELLULAR_COMPONENT", 33, 38], ["ER", "GENE_OR_GENE_PRODUCT", 46, 48], ["Rer1p", "GENE_OR_GENE_PRODUCT", 116, 121], ["Sec12p", "PROTEIN", 17, 23], ["ER", "PROTEIN", 46, 48], ["Golgi-localised multimembrane", "PROTEIN", 77, 106], ["Rer1p", "DNA", 116, 121], ["yeast", "SPECIES", 52, 57], ["yeast", "SPECIES", 52, 57]]], ["Although the precise role of Rer1p in the recycling process of Sec12p is not clear, in view of the previous discussion on glycosyltransferases, it is of particular interest that the Rer1p dependent retrieval mechanism requires the transmembrane domain of Sec12p (Boehm et al. 1994; Sato et al. 1996) .", [["transmembrane", "ANATOMY", 231, 244], ["Rer1p", "GENE_OR_GENE_PRODUCT", 29, 34], ["Sec12p", "GENE_OR_GENE_PRODUCT", 63, 69], ["Rer1p", "GENE_OR_GENE_PRODUCT", 182, 187], ["transmembrane", "CELLULAR_COMPONENT", 231, 244], ["Sec12p", "GENE_OR_GENE_PRODUCT", 255, 261], ["Rer1p", "PROTEIN", 29, 34], ["Sec12p", "PROTEIN", 63, 69], ["glycosyltransferases", "PROTEIN", 122, 142], ["Rer1p", "PROTEIN", 182, 187], ["transmembrane domain", "PROTEIN", 231, 251], ["Sec12p", "PROTEIN", 255, 261], ["glycosyltransferases", "TREATMENT", 122, 142], ["the Rer1p dependent retrieval mechanism", "TREATMENT", 178, 217]]], ["This finding raises the possibility that transmembrane domain-mediated retention may involve an interaction with sorting and/or retrieval receptors.Other Golgi-resident proteinsA number of Golgi matrix proteins have been described, including giantin (Linstedt and Hauri 1993) and GM130 (Nakamura et al. 1995) , as well as Golgi-localised cytoskeletal-associated proteins such as the dynein heavy chain isoform DHC2 (Vaisberg et al. 1996) , the actin-binding protein comitin (Weiner et al. 1993; Jung et al. 1996) and isoforms of ankyrin (Devarajan et al. 1996) and spectrin (Beck et al. 1994) .", [["transmembrane", "ANATOMY", 41, 54], ["Golgi matrix", "ANATOMY", 189, 201], ["Golgi", "ANATOMY", 322, 327], ["cytoskeletal", "ANATOMY", 338, 350], ["transmembrane", "CELLULAR_COMPONENT", 41, 54], ["Golgi matrix", "CELLULAR_COMPONENT", 189, 201], ["giantin", "GENE_OR_GENE_PRODUCT", 242, 249], ["GM130", "GENE_OR_GENE_PRODUCT", 280, 285], ["Golgi", "CELLULAR_COMPONENT", 322, 327], ["cytoskeletal", "CELLULAR_COMPONENT", 338, 350], ["dynein heavy chain", "GENE_OR_GENE_PRODUCT", 383, 401], ["comitin", "GENE_OR_GENE_PRODUCT", 466, 473], ["ankyrin", "GENE_OR_GENE_PRODUCT", 529, 536], ["spectrin", "GENE_OR_GENE_PRODUCT", 565, 573], ["transmembrane domain", "PROTEIN", 41, 61], ["sorting and/or retrieval receptors", "PROTEIN", 113, 147], ["Golgi-resident proteinsA", "PROTEIN", 154, 178], ["Golgi matrix proteins", "PROTEIN", 189, 210], ["GM130", "PROTEIN", 280, 285], ["Golgi-localised cytoskeletal-associated proteins", "PROTEIN", 322, 370], ["dynein heavy chain isoform DHC2", "PROTEIN", 383, 414], ["actin-binding protein comitin", "PROTEIN", 444, 473], ["ankyrin", "PROTEIN", 529, 536], ["spectrin", "PROTEIN", 565, 573], ["transmembrane domain-mediated retention", "PROBLEM", 41, 80], ["Golgi matrix proteins", "PROBLEM", 189, 210], ["associated proteins", "PROBLEM", 351, 370], ["the actin-binding protein comitin", "TREATMENT", 440, 473], ["raises the possibility", "UNCERTAINTY", 13, 35], ["Golgi matrix", "OBSERVATION", 189, 201]]], ["Again, the basis of Golgi residency of these protein has not been defined.Other Golgi-resident proteinsNumerous proteins associated with the machinery of vesicular transport are localised specifically (or are enriched) on Golgi membranes, for example \u03b2-COP (Oprins et al. 1993; Griffiths et al. 1995) , the monomeric GTPases rab6 (Gould et al. 1990 ) and ypt31p/32p (Benli et al. 1996) , heterotrimeric G proteins (Stow et al. 1991; Pimplikar and Simons 1993) , dynamin (Henley and McNiven 1996) , AP-1 adaptors (Pearse and Robinson 1990) , p230 (Kooy et al. 1991; Gleeson et al. 1996) , p200 (Narula et al. 1992; Narula and Stow 1995) , sec 7 (Franzusoff et al. 1991) , SNARE-like molecules (Banfied et al. 1995; Subramaniam et al. 1996) and VIP36 (Fiedler et al. 1994 ) ( Table 1 ).", [["Golgi", "ANATOMY", 20, 25], ["vesicular", "ANATOMY", 154, 163], ["Golgi membranes", "ANATOMY", 222, 237], ["Golgi", "CELLULAR_COMPONENT", 20, 25], ["vesicular", "MULTI-TISSUE_STRUCTURE", 154, 163], ["Golgi membranes", "CELLULAR_COMPONENT", 222, 237], ["\u03b2-COP", "GENE_OR_GENE_PRODUCT", 251, 256], ["GTPases", "GENE_OR_GENE_PRODUCT", 317, 324], ["heterotrimeric G proteins", "GENE_OR_GENE_PRODUCT", 388, 413], ["dynamin", "GENE_OR_GENE_PRODUCT", 462, 469], ["Golgi-resident proteins", "PROTEIN", 80, 103], ["monomeric GTPases", "PROTEIN", 307, 324], ["rab6", "PROTEIN", 325, 329], ["heterotrimeric G proteins", "PROTEIN", 388, 413], ["AP", "PROTEIN", 498, 500], ["SNARE", "PROTEIN", 671, 676], ["the monomeric GTPases rab6", "TEST", 303, 329], ["heterotrimeric G proteins", "TEST", 388, 413], ["AP", "TEST", 498, 500], ["Numerous", "OBSERVATION_MODIFIER", 103, 111], ["proteins", "OBSERVATION", 112, 120], ["vesicular", "ANATOMY_MODIFIER", 154, 163]]], ["Many of these are peripheral membrane proteins associated with the cytosolic face of Golgi membranes which recycle between a cytosolic pool and Golgi membranes.", [["peripheral membrane", "ANATOMY", 18, 37], ["cytosolic face", "ANATOMY", 67, 81], ["Golgi membranes", "ANATOMY", 85, 100], ["cytosolic pool", "ANATOMY", 125, 139], ["Golgi membranes", "ANATOMY", 144, 159], ["cytosolic face", "CELLULAR_COMPONENT", 67, 81], ["Golgi membranes", "CELLULAR_COMPONENT", 85, 100], ["cytosolic pool", "CELLULAR_COMPONENT", 125, 139], ["Golgi membranes", "CELLULAR_COMPONENT", 144, 159], ["peripheral membrane proteins", "PROTEIN", 18, 46], ["peripheral membrane proteins", "PROBLEM", 18, 46], ["Golgi membranes", "PROBLEM", 85, 100], ["peripheral membrane proteins", "OBSERVATION", 18, 46], ["Golgi membranes", "OBSERVATION", 85, 100], ["cytosolic pool", "OBSERVATION", 125, 139], ["Golgi membranes", "OBSERVATION", 144, 159]]], ["In some cases, for example COPI and AP1 adaptor, there is evidence that the proteins interact with motifs on the cytoplasmic domains of membrane proteins (see review by Robinson 1997) .", [["cytoplasmic", "ANATOMY", 113, 124], ["membrane", "ANATOMY", 136, 144], ["COPI", "GENE_OR_GENE_PRODUCT", 27, 31], ["AP1", "GENE_OR_GENE_PRODUCT", 36, 39], ["cytoplasmic", "ORGANISM_SUBSTANCE", 113, 124], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["COPI", "PROTEIN", 27, 31], ["AP1 adaptor", "PROTEIN", 36, 47], ["cytoplasmic domains", "PROTEIN", 113, 132], ["membrane proteins", "PROTEIN", 136, 153], ["example COPI and AP1 adaptor", "TEST", 19, 47], ["the proteins", "PROBLEM", 72, 84]]], ["Other components have complex intracellular locations perhaps due to membrane trafficking back and forth from the Golgi.", [["intracellular", "ANATOMY", 30, 43], ["membrane", "ANATOMY", 69, 77], ["Golgi", "ANATOMY", 114, 119], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 43], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["Golgi", "CELLULAR_COMPONENT", 114, 119], ["complex intracellular locations", "PROBLEM", 22, 53], ["membrane trafficking", "PROBLEM", 69, 89], ["intracellular locations", "OBSERVATION", 30, 53]]], ["The identification of the precise nature of the targeting signals and the mechanism of localisation of these periperal and membrane proteins will be important to the understanding of the organisation of the Golgi apparatus and vesicular transport.Concluding remarks: the way forwardIn the past decade, many resident Golgi proteins have been defined and some progress made toward understanding the molecular basis of Golgi localisation.", [["membrane", "ANATOMY", 123, 131], ["Golgi apparatus", "ANATOMY", 207, 222], ["vesicular", "ANATOMY", 227, 236], ["Golgi", "ANATOMY", 316, 321], ["Golgi", "ANATOMY", 416, 421], ["membrane", "CELLULAR_COMPONENT", 123, 131], ["Golgi apparatus", "CELLULAR_COMPONENT", 207, 222], ["vesicular", "MULTI-TISSUE_STRUCTURE", 227, 236], ["Golgi", "CELLULAR_COMPONENT", 316, 321], ["Golgi", "CELLULAR_COMPONENT", 416, 421], ["periperal and membrane proteins", "PROTEIN", 109, 140], ["resident Golgi proteins", "PROTEIN", 307, 330], ["these periperal and membrane proteins", "PROBLEM", 103, 140], ["Golgi localisation", "OBSERVATION", 416, 434]]], ["Overall, the situation is highly complex.", [["highly", "OBSERVATION_MODIFIER", 26, 32], ["complex", "OBSERVATION", 33, 40]]], ["Firstly, there are a number of distinct groups of Golgi-resident proteins; secondly, from studies on glycosyltransferases and recycling TGN proteins, it is clear that the localisation of individual proteins can involve multiple signals; thirdly, the localisation of Golgi glycosyltransferases and recycling TGN proteins could involve more than one mechanism; and fourthly, there is increasing evidence that resident Golgi proteins are involved in maintenance of the Golgi structure itself.Concluding remarks: the way forwardAlthough much has been learnt from the localisation of chimeric glycosyltransferase molecules, the approaches remain relatively crude.", [["Golgi", "ANATOMY", 266, 271], ["Golgi", "ANATOMY", 416, 421], ["Golgi", "ANATOMY", 466, 471], ["TGN", "GENE_OR_GENE_PRODUCT", 136, 139], ["Golgi", "CELLULAR_COMPONENT", 266, 271], ["TGN", "GENE_OR_GENE_PRODUCT", 307, 310], ["Golgi", "CELLULAR_COMPONENT", 416, 421], ["Golgi", "CELLULAR_COMPONENT", 466, 471], ["Golgi-resident proteins", "PROTEIN", 50, 73], ["glycosyltransferases", "PROTEIN", 101, 121], ["TGN proteins", "PROTEIN", 136, 148], ["Golgi glycosyltransferases", "PROTEIN", 266, 292], ["TGN proteins", "PROTEIN", 307, 319], ["resident Golgi proteins", "PROTEIN", 407, 430], ["chimeric glycosyltransferase molecules", "PROTEIN", 579, 617], ["glycosyltransferases", "TREATMENT", 101, 121], ["recycling TGN proteins", "TEST", 126, 148], ["individual proteins", "PROBLEM", 187, 206], ["Golgi glycosyltransferases", "TREATMENT", 266, 292], ["recycling TGN proteins", "TREATMENT", 297, 319], ["Golgi proteins", "PROBLEM", 416, 430], ["chimeric glycosyltransferase molecules", "TREATMENT", 579, 617], ["distinct", "OBSERVATION_MODIFIER", 31, 39], ["increasing", "OBSERVATION_MODIFIER", 382, 392], ["Golgi proteins", "OBSERVATION", 416, 430], ["Golgi structure", "OBSERVATION", 466, 481]]], ["The systems need to be better defined to analyse single localisation sequences using systems which uncouple the potential retention mechanisms, i.e. oligomerisation from intra-Golgi recycling.", [["intra-Golgi", "SIMPLE_CHEMICAL", 170, 181], ["intra-Golgi recycling", "TREATMENT", 170, 191], ["retention mechanisms", "OBSERVATION", 122, 142]]], ["More information is required about the precise organisation of enzymes within Golgi membranes and their possible interactions with other components of glycosylation machinery such as nucleotide-sugar transporters, and with molecules that may be important in mediating retention.", [["Golgi membranes", "ANATOMY", 78, 93], ["nucleotide", "CHEMICAL", 183, 193], ["nucleotide", "CHEMICAL", 183, 193], ["sugar", "CHEMICAL", 194, 199], ["Golgi membranes", "CELLULAR_COMPONENT", 78, 93], ["enzymes", "PROTEIN", 63, 70], ["nucleotide-sugar transporters", "PROTEIN", 183, 212], ["glycosylation machinery", "TREATMENT", 151, 174], ["nucleotide-sugar transporters", "TREATMENT", 183, 212]]], ["In addition, the conditions which induce aggregation of glycosyltransferase need to be identified and the precise role of kin recognition in the localisation process defined.", [["glycosyltransferase", "GENE_OR_GENE_PRODUCT", 56, 75], ["glycosyltransferase", "PROTEIN", 56, 75], ["the conditions", "PROBLEM", 13, 27], ["aggregation of glycosyltransferase", "PROBLEM", 41, 75]]], ["Further, the role of the transmembrane domain of glycosyltransferase in localisation, either by lipid-mediated sorting or through interactions with sorting proteins, needs to be clarified.Concluding remarks: the way forwardKnowledge of Golgi retention and biogenesis of Golgi membranes requires a combined biochemical and genetic approach.", [["transmembrane", "ANATOMY", 25, 38], ["Golgi", "ANATOMY", 236, 241], ["Golgi membranes", "ANATOMY", 270, 285], ["transmembrane", "CELLULAR_COMPONENT", 25, 38], ["glycosyltransferase", "GENE_OR_GENE_PRODUCT", 49, 68], ["lipid", "SIMPLE_CHEMICAL", 96, 101], ["Golgi", "CELLULAR_COMPONENT", 236, 241], ["Golgi membranes", "CELLULAR_COMPONENT", 270, 285], ["transmembrane domain", "PROTEIN", 25, 45], ["glycosyltransferase", "PROTEIN", 49, 68], ["sorting proteins", "PROTEIN", 148, 164], ["the transmembrane domain of glycosyltransferase", "TREATMENT", 21, 68], ["Golgi retention", "PROBLEM", 236, 251], ["Golgi membranes", "PROBLEM", 270, 285], ["a combined biochemical and genetic approach", "TREATMENT", 295, 338], ["Golgi retention", "OBSERVATION", 236, 251], ["Golgi membranes", "OBSERVATION", 270, 285]]], ["Yeast vps and grd mutants will continue to provide insight into the nature of the components involved in the retention machinery and recycling of TGN proteins and the identification of common localisation mechanisms.", [["TGN", "ANATOMY", 146, 149], ["Yeast vps", "GENE_OR_GENE_PRODUCT", 0, 9], ["grd", "GENE_OR_GENE_PRODUCT", 14, 17], ["TGN", "GENE_OR_GENE_PRODUCT", 146, 149], ["Yeast vps and grd mutants", "PROTEIN", 0, 25], ["TGN proteins", "PROTEIN", 146, 158], ["Yeast", "SPECIES", 0, 5], ["Yeast", "SPECIES", 0, 5], ["Yeast vps", "PROBLEM", 0, 9], ["grd mutants", "PROBLEM", 14, 25], ["the retention machinery", "TREATMENT", 105, 128], ["TGN proteins", "TREATMENT", 146, 158], ["vps", "OBSERVATION", 6, 9], ["grd mutants", "OBSERVATION", 14, 25]]], ["However, there is increasing evidence that Golgi retention is intimately associated with maintenance of membrane structure and a major drawback of Saccharomyces is the poor morphology of the Golgi apparatus.", [["Golgi", "ANATOMY", 43, 48], ["membrane", "ANATOMY", 104, 112], ["Golgi apparatus", "ANATOMY", 191, 206], ["Golgi", "CELLULAR_COMPONENT", 43, 48], ["membrane", "CELLULAR_COMPONENT", 104, 112], ["Golgi apparatus", "CELLULAR_COMPONENT", 191, 206], ["Golgi retention", "PROBLEM", 43, 58], ["membrane structure", "PROBLEM", 104, 122], ["a major drawback of Saccharomyces", "PROBLEM", 127, 160], ["increasing", "OBSERVATION_MODIFIER", 18, 28], ["Golgi retention", "OBSERVATION", 43, 58], ["membrane structure", "OBSERVATION", 104, 122], ["poor morphology", "OBSERVATION_MODIFIER", 168, 183], ["Golgi apparatus", "OBSERVATION", 191, 206]]], ["Genetically manipulable systems are required where Golgi structure can be readily monitored.", [["Golgi", "ANATOMY", 51, 56], ["Golgi", "CELLULAR_COMPONENT", 51, 56]]], ["Protozoan parasites may provide a very useful model system as the Golgi structure is highly developed in a number of these eukaryotic parasites and, furthermore, in some parasites, for example Leishmania and Giardia, the induction of Golgi structure is developmentally regulated (Pimenta et al. 1991; Winter et al. 1994; Luj\u00e1n et al. 1995) .", [["Golgi structure", "ANATOMY", 66, 81], ["Golgi", "ANATOMY", 234, 239], ["Golgi", "CELLULAR_COMPONENT", 66, 71], ["Leishmania", "ORGANISM", 193, 203], ["Golgi", "CELLULAR_COMPONENT", 234, 239], ["Protozoan parasites", "PROBLEM", 0, 19], ["Leishmania", "PROBLEM", 193, 203], ["Giardia", "PROBLEM", 208, 215], ["parasites", "OBSERVATION", 10, 19], ["eukaryotic parasites", "OBSERVATION", 123, 143], ["Leishmania", "OBSERVATION", 193, 203], ["Giardia", "OBSERVATION", 208, 215]]], ["Thus, these organisms offer the potential to understand the biogenesis of Golgi membranes.", [["Golgi membranes", "ANATOMY", 74, 89], ["Golgi membranes", "CELLULAR_COMPONENT", 74, 89], ["Golgi membranes", "PROBLEM", 74, 89], ["Golgi membranes", "OBSERVATION", 74, 89]]]], "PMC7205696": [["Disproportionate representation in sectors most affected by COVID-19Some of the employment sectors most affected by the social distancing protocols set in place in the United States are restaurants/bars, travel and transportation, entertainment, personal services, and certain types of retail and manufacturing (Vavra, 2020).", [["COVID", "TEST", 60, 65]]], ["These sectors employ a higher percentage of women and African American/Black, LatinX, and Native American employees (Bureau of Labor Statistics, 2020) resulting in a disproportionate number of employees of color and women being displaced from their jobs during the COVID-19 pandemic.", [["women", "ORGANISM", 44, 49], ["women", "ORGANISM", 216, 221], ["women", "SPECIES", 44, 49], ["women", "SPECIES", 216, 221], ["the COVID", "TEST", 261, 270], ["pandemic", "PROBLEM", 274, 282], ["disproportionate", "OBSERVATION_MODIFIER", 166, 182]]], ["A study by Mongey, Pilossoph, and Weinberg (2020) found that workers most likely to be affected by unemployment due to COVID-19 are less educated, have lower economic resources, and lower levels of liquid assets.", [["A study", "TEST", 0, 7]]], ["Considering that African American/Black, Native Americans, and LatinX are underrepresented in professional occupations (Bureau of Labor Statistics, 2020), they may be experiencing the adverse economic consequences of COVID-19 at an increased intensity when compared to White, upper, middle-class Americans.", [["COVID", "TEST", 217, 222], ["an increased intensity", "PROBLEM", 229, 251], ["upper", "ANATOMY_MODIFIER", 276, 281], ["middle", "ANATOMY_MODIFIER", 283, 289]]], ["How are structural barriers impeding workers of color in accessing employment during the COVID-19 pandemic?", [["the COVID", "TEST", 85, 94]]], ["Communities of color already have higher unemployment rates than White communities in the United States (Bureau of Labor Statistics, 2019a); will these differential rates be further perpetuated after COVID-19 resulting in even greater economic disparities?Decent workThe COVID-19 pandemic has highlighted the lack of decent work for \u201cessential\u201d employees in the United States.", [["COVID", "TEST", 200, 205], ["higher", "OBSERVATION_MODIFIER", 34, 40]]], ["For example, employees who work in essential services, such as grocery stores, may not be provided with the necessary safety equipment to keep them safe from contracting the virus.", [["safety equipment", "TREATMENT", 118, 134]]], ["A recent article in the Washington Post highlighted that many workers employed in grocery stores are experiencing stress and anxiety going to work, resulting in some workers staying home or quitting their jobs (Bhattarai, 2020).", [["anxiety", "DISEASE", 125, 132], ["stress", "PROBLEM", 114, 120], ["anxiety", "PROBLEM", 125, 132]]], ["This is particularly important because many of the employees who are working essential jobs are the most vulnerable to exploitation through precarious work.Asian American discriminationThe epicenter of the origin of the COVID-19 virus occurred in Wuhan, a city in China (Centers for Disease Control & Prevention, 2020).", [["COVID-19 virus", "CHEMICAL", 220, 234], ["COVID-19 virus", "ORGANISM", 220, 234], ["COVID-19 virus", "SPECIES", 220, 234], ["the COVID-19 virus", "PROBLEM", 216, 234], ["Disease Control", "TREATMENT", 283, 298], ["epicenter", "OBSERVATION_MODIFIER", 189, 198], ["origin", "ANATOMY_MODIFIER", 206, 212], ["19 virus", "OBSERVATION", 226, 234]]], ["Since the outbreak, Asians/Asian Americans have been scapegoated for the introduction of the virus.", [["Americans", "ORGANISM", 33, 42], ["the virus", "PROBLEM", 89, 98]]], ["For example, the Asian Pacific Policy and Planning Council launched a website for Asian Americans to report incidents of discrimination during COVID-19.", [["COVID", "TEST", 143, 148]]], ["Similarly, a recent poll of over 1000 adults conducted by IPSOS on behalf of the Center for Public Integrity found approximately 30% of Americans blame China or Chinese people for COVID-19, and approximately one-third (32%) of respondents have witnessed someone blaming Asians for the pandemic (IPSOS, 2020).", [["people", "SPECIES", 169, 175], ["COVID", "TEST", 180, 185]]], ["Combined, these findings provide evidence of the increased discrimination Asians and Asian Americans are currently experiencing in the United States.", [["increased", "OBSERVATION_MODIFIER", 49, 58], ["discrimination", "OBSERVATION_MODIFIER", 59, 73]]], ["The uptick of discrimination prompted a message from Janet Dhillon, chair of the United States Equal Employment Opportunity Commission, urging employers and employees to be attentive to instances of workplace discrimination against people of Asian descent, a reminder that these actions can result in unlawful discrimination in the workplace (U.S. Equal Employment Opportunity Commission, 2020),Asian American discriminationThe fact that Asian Americans are experiencing workplace discrimination due to COVID-19 is concerning not only because their civil rights are being violated but also because research has indicated that Asian Americans have already experienced workplace discrimination prior to the pandemic.", [["people", "ORGANISM", 232, 238], ["people", "SPECIES", 232, 238], ["COVID", "TEST", 503, 508], ["the pandemic", "PROBLEM", 701, 713]]], ["An experimental research study published in 2012 found that Asian Americans were perceived to be less socially skilled and were less likely to be selected and promoted in positions that involve social skills (Lai & Babcock, 2013).", [["An experimental research study", "TEST", 0, 30]]], ["Another recent study found that approximately one in four Asian American adults experienced discrimination in employment, both in job applications and in equal pay/promotions (McMurtry et al., 2019).", [["Another recent study", "TEST", 0, 20]]], ["Discrimination related to equal pay was close to double for Asian American respondents (25%) when compared to White respondents (13%).Asian American discriminationConsidering the well-documented increase in overall discrimination directed at Asian Americans during COVID-19, it is plausible that workplace discrimination has also increased during the pandemic.", [["COVID", "TEST", 265, 270], ["increase", "OBSERVATION_MODIFIER", 195, 203], ["increased", "OBSERVATION_MODIFIER", 330, 339]]], ["Social distancing has also universally changed the American way of life, resulting in many Asian Americans having to adapt to a new way of living and working while also coping with increased discrimination.", [["increased discrimination", "PROBLEM", 181, 205]]], ["These compounded stressors may result in Asian Americans lacking resources to manage the increased strain, particularly in the workplace.", [["the increased strain", "PROBLEM", 85, 105]]], ["Additionally, more research needs to examine the short-term and long-term consequences of this discrimination.Multiple role conflict for womenMultiple role conflict, or conflict between multiple life roles such as work and family, is a relevant construct as it relates to the differential impact of the COVID-19 pandemic for individuals who have historically been marginalized within the labor force.", [["individuals", "ORGANISM", 325, 336], ["long-term", "OBSERVATION_MODIFIER", 64, 73]]], ["Multiple role management is particularly relevant for women because women continue to engage in more household and caretaking responsibilities when compared to men.", [["women", "ORGANISM", 54, 59], ["women", "ORGANISM", 68, 73], ["men", "ORGANISM", 160, 163], ["women", "SPECIES", 54, 59], ["women", "SPECIES", 68, 73], ["men", "SPECIES", 160, 163], ["Multiple role management", "TREATMENT", 0, 24]]], ["The American Time Use Survey examined the division of household labor across gender and found that a greater percentage of women spent daily time on household activities when compared to men (84% compared to 69% respectively), and women also spent more hours (2.6 h) per day than men (2.0 h) on household activities (Bureau of Labor Statistics, 2019b).", [["women", "ORGANISM", 123, 128], ["men", "ORGANISM", 187, 190], ["women", "ORGANISM", 231, 236], ["men", "ORGANISM", 280, 283], ["women", "SPECIES", 123, 128], ["men", "SPECIES", 187, 190], ["women", "SPECIES", 231, 236], ["men", "SPECIES", 280, 283]]], ["The survey also found that women spent almost double the time providing care for children in the home than men (Bureau of Labor Statistics, 2019b).", [["women", "ORGANISM", 27, 32], ["children", "ORGANISM", 81, 89], ["men", "ORGANISM", 107, 110], ["women", "SPECIES", 27, 32], ["children", "SPECIES", 81, 89], ["men", "SPECIES", 107, 110]]], ["As schools and daycares across the United States close to facilitate social distancing, dual-earner parents of children are now being asked to work full-time jobs while also educating and providing 24-hour care to their children.", [["children", "ORGANISM", 111, 119], ["children", "ORGANISM", 220, 228], ["children", "SPECIES", 111, 119], ["children", "SPECIES", 220, 228]]], ["Since women engage in child caring and household responsibilities more than men, they are shouldering a higher amount of this burden, which has the potential to increase multiple role conflict for women in the workforce.", [["women", "ORGANISM", 6, 11], ["men", "ORGANISM", 76, 79], ["women", "ORGANISM", 197, 202], ["women", "SPECIES", 6, 11], ["men", "SPECIES", 76, 79], ["women", "SPECIES", 197, 202]]], ["Research has found that role conflict is related to strain and well-being in a reciprocal manner (Nohe, Meier, Sonntag, & Michel, 2015) and is also bidirectional in nature where conflict in one role can be related to the other role (Kulik, Shilo-Levin, & Liberman, 2015).", [["conflict", "OBSERVATION", 29, 37]]], ["Due to economic disparities in wages between men and women, workplace expectations, and social norms related to parenting and household responsibilities, women may be experiencing additional strain during COVID-19 to manage and/or balance multiple roles.Multiple role conflict for womenThis is problematic both for women who have the privilege to work from home and even more so for women who are essential employees.", [["men", "ORGANISM", 45, 48], ["women", "ORGANISM", 53, 58], ["women", "ORGANISM", 154, 159], ["women", "ORGANISM", 281, 286], ["women", "ORGANISM", 315, 320], ["women", "ORGANISM", 383, 388], ["men", "SPECIES", 45, 48], ["women", "SPECIES", 53, 58], ["women", "SPECIES", 154, 159], ["women", "SPECIES", 281, 286], ["women", "SPECIES", 315, 320], ["women", "SPECIES", 383, 388], ["additional strain", "PROBLEM", 180, 197], ["COVID", "TEST", 205, 210], ["conflict", "OBSERVATION", 268, 276]]], ["For those that can work from home, the expectations on women to manage domestic family needs while also managing full-time careers and work may be unreasonable or even impossible.", [["women", "ORGANISM", 55, 60], ["women", "SPECIES", 55, 60]]], ["Dual-career families may find that women are prioritizing their increased domestic responsibilities over their professional roles and placing professional responsibilities on the backburner due to the unmanageable nature of accomplishing both.", [["women", "ORGANISM", 35, 40], ["women", "SPECIES", 35, 40]]], ["It would be short-sighted to not discuss how income inequality may play a role in women compromising their work goals in the current context; if women are making less money for equal work, they may compromise their work desires and goals when faced with the task of having to suddenly manage child care, education, and domestic responsibilities.", [["women", "ORGANISM", 82, 87], ["women", "ORGANISM", 145, 150], ["women", "SPECIES", 82, 87], ["women", "SPECIES", 145, 150]]], ["This may be particularly heightened by an economy that has seen extreme job loss in such a short time span due to COVID-19.", [["COVID-19", "DNA", 114, 122], ["extreme job loss", "PROBLEM", 64, 80], ["COVID", "TEST", 114, 119], ["extreme", "OBSERVATION_MODIFIER", 64, 71], ["job loss", "OBSERVATION", 72, 80]]], ["This may also be particularly true for women of color, who earn less than White women, and are employed in service sectors that are being hit hard by current societal changes in social distancing (Bureau of Labor Statistics, 2019a).Multiple role conflict for womenEssential employees, on the other hand, are being asked to go to work without access to either formal or informal childcare.", [["women", "ORGANISM", 39, 44], ["women", "ORGANISM", 80, 85], ["women", "SPECIES", 39, 44], ["women", "SPECIES", 80, 85], ["may also be", "UNCERTAINTY", 5, 16]]], ["The burden placed on women to accommodate the lack of childcare is even more striking when considering that women comprise 74.9% of hospital employees (Bureau of Labor Statistics, 2020) and can be single parents or the primary earners for their families.", [["women", "ORGANISM", 21, 26], ["women", "ORGANISM", 108, 113], ["women", "SPECIES", 21, 26], ["women", "SPECIES", 108, 113]]], ["Future research could examine both the short-term and long-term consequences of how the closing of education systems and child care agencies affects women's vocational development.", [["women", "ORGANISM", 149, 154], ["women", "SPECIES", 149, 154]]], ["How are women navigating multiple roles, and what compromises are being made to accommodate to the impossible requirements of full-time work and full-time parenting at the same time?", [["women", "ORGANISM", 8, 13], ["women", "SPECIES", 8, 13]]], ["What are some of the long-term consequences of women shouldering most of the domestic responsibilities during the COVID-19 outbreak?", [["women", "ORGANISM", 47, 52], ["women", "SPECIES", 47, 52], ["the COVID", "TEST", 110, 119]]], ["Are we seeing women more dissatisfied with their work and/or parenting responsibilities?", [["women", "ORGANISM", 14, 19], ["women", "SPECIES", 14, 19]]], ["Similar to other crises, the COVID-19 pandemic has shed light on not just income inequalities but very large inequalities in access to decent work in the United States.", [["other crises", "PROBLEM", 11, 23], ["the COVID", "TEST", 25, 34], ["large", "OBSERVATION_MODIFIER", 103, 108], ["inequalities", "OBSERVATION", 109, 121]]], ["While there is a high percentage of the U.S. workforce that has the opportunity to work safely from home, that privilege is not accessible to all workers, many of whom are already vulnerable to economic and structural inequalities in the United States and who have historically experienced marginalization and discrimination in the workforce.", [["high", "OBSERVATION_MODIFIER", 17, 21], ["percentage", "OBSERVATION_MODIFIER", 22, 32]]], ["I also advocate for more research with individuals who are experiencing increased discrimination and/or workload due to the pandemic.", [["increased discrimination", "PROBLEM", 72, 96], ["the pandemic", "PROBLEM", 120, 132]]], ["Perhaps if vocational psychologists conduct meaningful research that helps serve marginalized communities more effectively and advocate for a labor market that is built on the foundation of decent work for all, we can emerge from COVID-19 with a shared goal to create a more equitable labor market that protects vulnerable workers.", [["a labor market", "TREATMENT", 140, 154]]], ["This is the premise that David Blustein et al. (2019) argue is needed for applied psychologists to contribute to the many challenges related to access to decent work and basic human rights for workers in the United States.", [["human", "ORGANISM", 176, 181], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181]]]], "47b91e17565bab446ececd3faf5788b90327d6ff": [["Idiopathic dilated cardiomyopathy (IDC) accounts for 25% of cases of heart failure in the United States.", [["IDC", "ANATOMY", 35, 38], ["heart", "ANATOMY", 69, 74], ["Idiopathic dilated cardiomyopathy", "DISEASE", 0, 33], ["IDC", "DISEASE", 35, 38], ["heart failure", "DISEASE", 69, 82], ["IDC", "CANCER", 35, 38], ["heart", "ORGAN", 69, 74], ["Idiopathic dilated cardiomyopathy", "PROBLEM", 0, 33], ["heart failure", "PROBLEM", 69, 82], ["dilated", "OBSERVATION_MODIFIER", 11, 18], ["cardiomyopathy", "OBSERVATION", 19, 33], ["heart", "ANATOMY", 69, 74], ["failure", "OBSERVATION", 75, 82]]], ["Understanding the relationship between an inciting event or agent and the development of IDC has progressed only recently.", [["IDC", "ANATOMY", 89, 92], ["IDC", "DISEASE", 89, 92], ["IDC", "CANCER", 89, 92], ["agent", "TREATMENT", 60, 65], ["IDC", "PROBLEM", 89, 92], ["IDC", "OBSERVATION", 89, 92]]], ["Once IDC has developed, treatment is palliative and little can be done to alter the natural course of the disease.", [["IDC", "ANATOMY", 5, 8], ["IDC", "CANCER", 5, 8], ["treatment", "TREATMENT", 24, 33], ["palliative", "TREATMENT", 37, 47], ["the disease", "PROBLEM", 102, 113], ["disease", "OBSERVATION", 106, 113]]], ["Active myocarditis, a suspected precursor of IDC, is myocardial inflammation and injury without ischemia.", [["IDC", "ANATOMY", 45, 48], ["myocardial", "ANATOMY", 53, 63], ["myocarditis", "DISEASE", 7, 18], ["IDC", "DISEASE", 45, 48], ["myocardial inflammation", "DISEASE", 53, 76], ["ischemia", "DISEASE", 96, 104], ["IDC", "CANCER", 45, 48], ["myocardial", "MULTI-TISSUE_STRUCTURE", 53, 63], ["Active myocarditis", "PROBLEM", 0, 18], ["IDC", "PROBLEM", 45, 48], ["myocardial inflammation", "PROBLEM", 53, 76], ["injury", "PROBLEM", 81, 87], ["ischemia", "PROBLEM", 96, 104], ["myocarditis", "OBSERVATION", 7, 18], ["myocardial", "ANATOMY", 53, 63], ["inflammation", "OBSERVATION", 64, 76], ["injury", "OBSERVATION", 81, 87], ["without", "UNCERTAINTY", 88, 95], ["ischemia", "OBSERVATION", 96, 104]]], ["The disease ranges from a self-limited flulike illness to one of serious consequence with arrhythmias, heart failure, or death.", [["heart", "ANATOMY", 103, 108], ["illness", "DISEASE", 47, 54], ["arrhythmias", "DISEASE", 90, 101], ["heart failure", "DISEASE", 103, 116], ["death", "DISEASE", 121, 126], ["heart", "ORGAN", 103, 108], ["The disease ranges", "PROBLEM", 0, 18], ["a self-limited flulike illness", "PROBLEM", 24, 54], ["arrhythmias", "PROBLEM", 90, 101], ["heart failure", "PROBLEM", 103, 116], ["death", "PROBLEM", 121, 126], ["disease", "OBSERVATION", 4, 11], ["arrhythmias", "OBSERVATION", 90, 101], ["heart", "ANATOMY", 103, 108], ["failure", "OBSERVATION", 109, 116]]], ["Many agents have been associated with myocarditis, and the clinical manifestations depend on an interplay between the inciting agent and the host response.", [["myocarditis", "DISEASE", 38, 49], ["myocarditis", "PROBLEM", 38, 49], ["the clinical manifestations", "PROBLEM", 55, 82], ["the inciting agent", "TREATMENT", 114, 132], ["associated with", "UNCERTAINTY", 22, 37], ["myocarditis", "OBSERVATION", 38, 49]]], ["The development of a murine model and the expanded use of endomyocardial biopsy using the Dallas criteria have increased our understanding of myocarditis and its sequelae.", [["endomyocardial", "ANATOMY", 58, 72], ["myocarditis", "DISEASE", 142, 153], ["murine", "ORGANISM", 21, 27], ["endomyocardial biopsy", "MULTI-TISSUE_STRUCTURE", 58, 79], ["murine", "SPECIES", 21, 27], ["endomyocardial biopsy", "TEST", 58, 79], ["myocarditis", "PROBLEM", 142, 153], ["its sequelae", "PROBLEM", 158, 170], ["myocarditis", "OBSERVATION", 142, 153], ["sequelae", "OBSERVATION_MODIFIER", 162, 170]]], ["Therapy consists of managing symptoms using conventional medical regimens for heart failure.", [["heart", "ANATOMY", 78, 83], ["heart failure", "DISEASE", 78, 91], ["heart", "ORGAN", 78, 83], ["Therapy", "TREATMENT", 0, 7], ["managing symptoms", "PROBLEM", 20, 37], ["conventional medical regimens", "TREATMENT", 44, 73], ["heart failure", "PROBLEM", 78, 91], ["heart", "ANATOMY", 78, 83], ["failure", "OBSERVATION", 84, 91]]], ["Immunosuppressive therapy should be reserved for patients with biopsy-proven disease who have failed conventional therapy.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Immunosuppressive therapy", "TREATMENT", 0, 25], ["biopsy", "TEST", 63, 69], ["disease", "PROBLEM", 77, 84], ["conventional therapy", "TREATMENT", 101, 121]]], ["Continued deterioration warrants ventricular assistance and consideration of cardiac transplantation.", [["ventricular", "ANATOMY", 33, 44], ["cardiac", "ANATOMY", 77, 84], ["ventricular", "MULTI-TISSUE_STRUCTURE", 33, 44], ["cardiac", "ORGAN", 77, 84], ["Continued deterioration", "PROBLEM", 0, 23], ["ventricular assistance", "TREATMENT", 33, 55], ["cardiac transplantation", "TREATMENT", 77, 100], ["deterioration", "OBSERVATION", 10, 23], ["ventricular", "ANATOMY", 33, 44], ["cardiac", "ANATOMY", 77, 84], ["transplantation", "OBSERVATION", 85, 100]]], ["M ore than 3 million people in the United States are affected by heart failure, with more than 750,000 new cases diagnosed and 250,000 deaths each year. '", [["heart", "ANATOMY", 65, 70], ["heart failure", "DISEASE", 65, 78], ["deaths", "DISEASE", 135, 141], ["people", "ORGANISM", 21, 27], ["heart", "ORGAN", 65, 70], ["people", "SPECIES", 21, 27], ["heart failure", "PROBLEM", 65, 78], ["heart", "ANATOMY", 65, 70], ["failure", "OBSERVATION", 71, 78]]], ["The economic effect is great: The expenditure of approximately $38 billion dollars in 1991 represented 5.4% of federal health care dollars spent that year.", [["great", "OBSERVATION_MODIFIER", 23, 28]]], ["The true impact of the additional disability and loss of productivity", [["disability", "DISEASE", 34, 44], ["loss of productivity", "DISEASE", 49, 69], ["loss of productivity", "PROBLEM", 49, 69], ["productivity", "OBSERVATION_MODIFIER", 57, 69]]]], "0e2cda1ba312950d53365c757ce038aeef15fce8": [], "79bf548351001ca5e4dd82e2c4a2c944277f1997": [["IntroductionCoronaviruses (CoVs) are members of the subfamily Orthocoronavirinae in the family Coronaviridae (1), and consist of four genera, i.e., alpha-, beta-, gamma-and deltacoronaviruses, as classified by the International Committee on Taxonomy of Viruses (ICTV) (2) (3) (4) (5) .", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 62, 80], ["alpha-", "GENE_OR_GENE_PRODUCT", 148, 154], ["beta-", "GENE_OR_GENE_PRODUCT", 156, 161], ["gamma", "GENE_OR_GENE_PRODUCT", 163, 168], ["CoVs", "PROTEIN", 27, 31], ["gamma", "PROTEIN", 163, 168], ["alpha-", "TEST", 148, 154], ["deltacoronaviruses", "TREATMENT", 173, 191]]], ["All CoVs characterized so far are known to only infect vertebrates, and lead to various zoonotic diseases.", [["zoonotic diseases", "DISEASE", 88, 105], ["CoVs", "GENE_OR_GENE_PRODUCT", 4, 8], ["CoVs", "PROTEIN", 4, 8], ["All CoVs", "PROBLEM", 0, 8], ["various zoonotic diseases", "PROBLEM", 80, 105], ["CoVs", "OBSERVATION", 4, 8], ["various", "OBSERVATION_MODIFIER", 80, 87], ["zoonotic", "OBSERVATION_MODIFIER", 88, 96], ["diseases", "OBSERVATION", 97, 105]]], ["Among them, three beta-CoVs are responsible for three major outbreaks of this century (6-10), i.e., the severe acute respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS), and the ongoing global COVID-19 pandemic.", [["acute respiratory syndrome", "DISEASE", 111, 137], ["SARS", "DISEASE", 139, 143], ["Middle East respiratory syndrome", "DISEASE", 150, 182], ["MERS", "DISEASE", 184, 188], ["beta-CoVs", "GENE_OR_GENE_PRODUCT", 18, 27], ["beta-CoVs", "PROTEIN", 18, 27], ["the severe acute respiratory syndrome", "PROBLEM", 100, 137], ["SARS", "PROBLEM", 139, 143], ["the Middle East respiratory syndrome", "PROBLEM", 146, 182], ["the ongoing global COVID", "TEST", 195, 219], ["pandemic", "PROBLEM", 223, 231], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["respiratory syndrome", "OBSERVATION", 117, 137], ["Middle", "ANATOMY_MODIFIER", 150, 156], ["respiratory syndrome", "OBSERVATION", 162, 182]]], ["Several alpha-CoVs and gamma-CoVs can also greatly affect livestock (11) (12) (13) .", [["alpha-CoVs", "CHEMICAL", 8, 18], ["gamma-CoVs", "CHEMICAL", 23, 33], ["alpha-CoVs", "GENE_OR_GENE_PRODUCT", 8, 18], ["gamma-CoVs", "GENE_OR_GENE_PRODUCT", 23, 33], ["alpha-CoVs and gamma-CoVs", "DNA", 8, 33], ["alpha", "OBSERVATION_MODIFIER", 8, 13], ["gamma", "ANATOMY", 23, 28]]], ["For example, in 2017, the swine acute diarrhea syndrome coronavirus, an alpha-CoV, led to the death of more than 24,000 piglets in Guangdong, China (11) .IntroductionCharacteristic features of CoVs include a high genetic diversity (7, 14) , frequent 3 mutation (15) , recombination (16, 17) , and most importantly, frequent cross-host transmissions (11, (18) (19) (20) which is facilitated by the spike protein (21) (22) (23) .", [["acute diarrhea syndrome coronavirus", "DISEASE", 32, 67], ["death", "DISEASE", 94, 99], ["alpha-CoV", "GENE_OR_GENE_PRODUCT", 72, 81], ["piglets", "ORGANISM", 120, 127], ["CoVs", "GENE_OR_GENE_PRODUCT", 193, 197], ["swine", "SPECIES", 26, 31], ["piglets", "SPECIES", 120, 127], ["swine acute diarrhea syndrome coronavirus", "SPECIES", 26, 67], ["the swine acute diarrhea syndrome coronavirus", "PROBLEM", 22, 67], ["an alpha-CoV", "PROBLEM", 69, 81], ["the death", "PROBLEM", 90, 99], ["CoVs", "PROBLEM", 193, 197], ["a high genetic diversity", "PROBLEM", 206, 230], ["frequent 3 mutation", "PROBLEM", 241, 260], ["the spike protein", "TEST", 393, 410], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["diarrhea syndrome coronavirus", "OBSERVATION", 38, 67], ["CoVs", "OBSERVATION", 193, 197], ["high genetic", "OBSERVATION_MODIFIER", 208, 220], ["diversity", "OBSERVATION_MODIFIER", 221, 230]]], ["These features pose serious challenges for the eradication and mitigation campaigns in case of epidemics, and make even the taxonomic classification of these viruses a challenging task.", [["the eradication", "TREATMENT", 43, 58], ["mitigation campaigns", "TREATMENT", 63, 83], ["epidemics", "PROBLEM", 95, 104], ["serious", "OBSERVATION_MODIFIER", 20, 27]]], ["The traditional classification of CoVs (2-5) relies on phenotypic information such as the host range, and takes into account of the phylogeny of the viruses.", [["CoVs", "CANCER", 34, 38], ["viruses", "OBSERVATION", 149, 156]]], ["Most of these phylogenetic analyses performed on CoVs rely on one of these two approaches (3) : (i) analyses based on the whole genome sequences; (ii) analyses based on individual conserved proteins, most prominently ORF1a/1b, spike, envelope, nucleocapsid, and membrane proteins.", [["membrane", "ANATOMY", 262, 270], ["ORF1a/1b", "GENE_OR_GENE_PRODUCT", 217, 225], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 244, 256], ["membrane", "CELLULAR_COMPONENT", 262, 270], ["CoVs", "DNA", 49, 53], ["whole genome sequences", "DNA", 122, 144], ["ORF1a", "PROTEIN", 217, 222], ["1b", "PROTEIN", 223, 225], ["spike, envelope, nucleocapsid, and membrane proteins", "PROTEIN", 227, 279], ["these phylogenetic analyses", "TEST", 8, 35], ["the whole genome sequences", "TEST", 118, 144], ["individual conserved proteins", "TEST", 169, 198], ["spike", "PROBLEM", 227, 232], ["nucleocapsid", "PROBLEM", 244, 256], ["membrane proteins", "PROBLEM", 262, 279], ["membrane proteins", "OBSERVATION", 262, 279]]], ["These analyses are useful for closely related species/lineages, but become problematic for more distant relationships (24).", [["These analyses", "TEST", 0, 14], ["closely related species/lineages", "PROBLEM", 30, 62]]], ["For example, the node robustness of phylogenetic trees built on the basis of whole genomes of distantly related species is often unreliable as can be judged by their bootstrap values (25) .", [["node", "ANATOMY", 17, 21], ["the node robustness of phylogenetic trees", "PROBLEM", 13, 54], ["node", "OBSERVATION", 17, 21], ["phylogenetic trees", "OBSERVATION", 36, 54]]], ["As a result, no comprehensive classification of coronaviruses is currently available.IntroductionIn this study, we adopted a different approach based on the identification and use of a set of five concatenated CoVs protein clusters to create an Orthocoronavirinae species tree, by using the Markov Cluster Algorithm (MCL, https://www.micans.org/mcl/) (26) .IntroductionThis phylogenetic species tree is robust, and is consistent with the current ICTV classification, and thus should be useful for the classification of future new CoV isolates.IntroductionFurthermore, through reconciliation with the corresponding gene trees (27) (28) (29) , this species tree allowed us to infer the apparent \"horizontal gene transfer\" (HGT) events 4 for each of the five protein clusters, which we surmised can serve as a marker for crosshost transmissions.", [["coronaviruses", "DISEASE", 48, 61], ["coronaviruses", "ORGANISM", 48, 61], ["CoVs", "GENE_OR_GENE_PRODUCT", 210, 214], ["CoV", "ORGANISM", 530, 533], ["CoVs protein clusters", "PROTEIN", 210, 231], ["coronaviruses", "PROBLEM", 48, 61], ["this study", "TEST", 100, 110], ["a different approach", "TREATMENT", 123, 143], ["five concatenated CoVs protein clusters", "PROBLEM", 192, 231], ["an Orthocoronavirinae species tree", "PROBLEM", 242, 276], ["new CoV isolates", "TREATMENT", 526, 542], ["this species tree", "PROBLEM", 642, 659], ["coronaviruses", "OBSERVATION", 48, 61], ["species tree", "OBSERVATION", 264, 276], ["species tree", "OBSERVATION", 387, 399], ["robust", "OBSERVATION_MODIFIER", 403, 409], ["consistent with", "UNCERTAINTY", 418, 433]]], ["The specific cases of SARS-CoV, MERS-CoV, and SARS-CoV-2 are discussed.Results and DiscussionWe searched through 3,880 genomes of coronaviruses from three databases NCBI, NGDC, and GISAID (https://www.ncbi.nlm.nih.gov/; https://bigd.big.ac.cn/; https://www.gisaid.org), and compiled 396 complete genomes with sequence identity lower than 95% (Supplementary Table S1 ).", [["SARS", "DISEASE", 22, 26], ["SARS", "DISEASE", 46, 50], ["SARS-CoV", "ORGANISM", 22, 30], ["MERS-CoV", "ORGANISM", 32, 40], ["SARS-CoV-2", "ORGANISM", 46, 56], ["coronaviruses", "ORGANISM", 130, 143], ["SARS-CoV", "SPECIES", 22, 30], ["MERS-CoV", "SPECIES", 32, 40], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "PROBLEM", 22, 26], ["CoV", "TEST", 27, 30], ["coronaviruses", "PROBLEM", 130, 143], ["sequence identity", "TEST", 309, 326]]], ["The predicted protein sequences were fed to the subsequent MCL analysis using graph clustering (26) .", [["The predicted protein sequences", "TEST", 0, 31], ["the subsequent MCL analysis", "TEST", 44, 71], ["graph clustering", "TEST", 78, 94]]], ["In total, 116 protein clusters were identified, among which five clusters, i.e., ORF1b, ORF1a, spike, membrane, and nucleocapsid proteins were found to be the most prevalent (Table 1 , Supplementary Fig. S1 ).", [["membrane", "ANATOMY", 102, 110], ["ORF1b", "GENE_OR_GENE_PRODUCT", 81, 86], ["ORF1a", "GENE_OR_GENE_PRODUCT", 88, 93], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["nucleocapsid proteins", "GENE_OR_GENE_PRODUCT", 116, 137], ["S1", "GENE_OR_GENE_PRODUCT", 204, 206], ["ORF1b", "PROTEIN", 81, 86], ["ORF1a", "PROTEIN", 88, 93], ["spike, membrane, and nucleocapsid proteins", "PROTEIN", 95, 137], ["S1", "PROTEIN", 204, 206], ["116 protein clusters", "PROBLEM", 10, 30], ["spike", "PROBLEM", 95, 100], ["nucleocapsid proteins", "PROBLEM", 116, 137]]], ["In this step, we added other 26 genome sequences isolated from different hosts, albeit with identity greater than 95% to the 396 sequences mentioned above (Supplementary Table S2 ).", [["26 genome sequences", "DNA", 29, 48], ["396 sequences", "DNA", 125, 138], ["other 26 genome sequences", "TREATMENT", 23, 48]]], ["The bovine torovirus (NC_007447) from Tobaniviridae (31, 32) was selected as the outgroup.", [["NC_007447", "CHEMICAL", 22, 31], ["bovine", "ORGANISM", 4, 10], ["torovirus", "GENE_OR_GENE_PRODUCT", 11, 20], ["NC_007447", "CELL", 22, 31], ["bovine", "SPECIES", 4, 10], ["bovine torovirus (NC_007447)", "SPECIES", 4, 32], ["The bovine torovirus", "TEST", 0, 20], ["Tobaniviridae", "TREATMENT", 38, 51], ["bovine torovirus", "OBSERVATION", 4, 20]]], ["The virus genera (according to ICTV classification), the host families and host receptors (if available), and the size of genomes are also included in Fig. 1 , in order to provide a comprehensive view of these metadata (3, 4) .", [["host receptors", "PROTEIN", 75, 89], ["The virus genera", "PROBLEM", 0, 16], ["virus genera", "OBSERVATION", 4, 16], ["size", "OBSERVATION_MODIFIER", 114, 118]]], ["5 As can be seen in Fig. 1 , this analysis yields genera and species that are largely congruous with the current ICTV classification (5) , but the interpretation of the results is far more straightforward and requires just genome sequences.", [["genome sequences", "DNA", 223, 239], ["this analysis", "TEST", 29, 42], ["genera and species", "PROBLEM", 50, 68], ["Fig", "OBSERVATION", 20, 23]]], ["The resulting phylogenetic tree has a high degree of robustness, compared to those obtained using whole genome sequences, or the ORF1a/1b proteins or domains (see Methods).", [["ORF1a/1b", "GENE_OR_GENE_PRODUCT", 129, 137], ["whole genome sequences", "DNA", 98, 120], ["ORF1a/1b proteins", "PROTEIN", 129, 146], ["a high degree of robustness", "PROBLEM", 36, 63], ["whole genome sequences", "TEST", 98, 120], ["the ORF1a", "TEST", 125, 134], ["phylogenetic tree", "OBSERVATION", 14, 31], ["high degree", "OBSERVATION_MODIFIER", 38, 49], ["robustness", "OBSERVATION", 53, 63]]], ["For example, nodes of branches of the most ancestral lineages of the tree were supported by bootstrap values \u226580%.", [["nodes", "ANATOMY", 13, 18], ["bootstrap values", "TEST", 92, 108], ["nodes", "OBSERVATION", 13, 18], ["branches", "ANATOMY_MODIFIER", 22, 30], ["most", "ANATOMY_MODIFIER", 38, 42], ["ancestral", "ANATOMY_MODIFIER", 43, 52], ["lineages", "ANATOMY_MODIFIER", 53, 61], ["tree", "ANATOMY_MODIFIER", 69, 73]]], ["Moreover, this phylogenetic tree can clearly distinguish different species of the viruses for the subfamily Orthocoronavirinae, while the phylogeny based on the ORF1a/b domains alone, which is better suited for classification at the order level (33), cannot do it.Results and DiscussionNotably, this circular map format clearly shows the viruses along the same or closely related evolutionary branches can infect different hosts.", [["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 108, 126], ["ORF1a/b domains", "DNA", 161, 176], ["this circular map format", "TEST", 295, 319], ["the viruses", "PROBLEM", 334, 345], ["viruses", "OBSERVATION", 82, 89], ["viruses", "OBSERVATION", 338, 345], ["branches", "OBSERVATION_MODIFIER", 393, 401]]], ["For instance, in the specific case of SARS-CoV, 29 viruses clustered into a monophyletic clade, which included 22 strains isolated from Chiroptera (bats), four from Viverridae (palm civets), and three from Hominidae (humans).", [["SARS", "DISEASE", 38, 42], ["SARS-CoV", "ORGANISM", 38, 46], ["humans", "ORGANISM", 217, 223], ["humans", "SPECIES", 217, 223], ["SARS-CoV", "SPECIES", 38, 46], ["humans", "SPECIES", 217, 223], ["SARS", "PROBLEM", 38, 42], ["CoV", "PROBLEM", 43, 46], ["29 viruses", "PROBLEM", 48, 58], ["a monophyletic clade", "PROBLEM", 74, 94]]], ["Similarly, several MERS-CoVs that form a monophyletic clade in the inferred tree were isolated from Chiroptera, Camelidae (dromedary camels), and Hominidae.", [["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 19, 28], ["MERS-CoVs", "DNA", 19, 28], ["several MERS-CoVs", "PROBLEM", 11, 28], ["a monophyletic clade", "PROBLEM", 39, 59], ["Chiroptera", "TREATMENT", 100, 110], ["Camelidae (dromedary camels)", "TREATMENT", 112, 140], ["Hominidae", "TREATMENT", 146, 155], ["several", "OBSERVATION_MODIFIER", 11, 18], ["MERS", "OBSERVATION", 19, 23], ["monophyletic clade", "OBSERVATION", 41, 59], ["tree", "ANATOMY_MODIFIER", 76, 80]]], ["In the section containing the coronaviruses Human_CoV_OC43 which are responsible for a common human flu, several hosts appear in the map (34, 35) , reflecting the considerable promiscuity of their hosts including Bovidae (cattle), Leporidae (rabbits), Camelidae, Suidae (swine), and Equidae (horses).", [["coronaviruses", "ORGANISM", 30, 43], ["Human_CoV_OC43", "GENE_OR_GENE_PRODUCT", 44, 58], ["human", "ORGANISM", 94, 99], ["Bovidae", "ORGANISM", 213, 220], ["cattle", "ORGANISM", 222, 228], ["Leporidae", "ORGANISM", 231, 240], ["rabbits", "ORGANISM", 242, 249], ["Camelidae", "GENE_OR_GENE_PRODUCT", 252, 261], ["horses", "ORGANISM_SUBDIVISION", 292, 298], ["coronaviruses Human_CoV_OC43", "DNA", 30, 58], ["human", "SPECIES", 94, 99], ["cattle", "SPECIES", 222, 228], ["Leporidae", "SPECIES", 231, 240], ["rabbits", "SPECIES", 242, 249], ["Camelidae", "SPECIES", 252, 261], ["swine", "SPECIES", 271, 276], ["human flu", "SPECIES", 94, 103], ["cattle", "SPECIES", 222, 228], ["a common human flu", "PROBLEM", 85, 103], ["the map", "TEST", 129, 136], ["Bovidae (cattle)", "TREATMENT", 213, 229], ["Leporidae (rabbits)", "TREATMENT", 231, 250], ["coronaviruses", "OBSERVATION", 30, 43], ["responsible for", "UNCERTAINTY", 69, 84], ["flu", "OBSERVATION", 100, 103]]], ["6 We next determined the apparent HGT events among the viruses, which we assumed would indicate their cross-host transmissions.", [["the apparent HGT events", "PROBLEM", 21, 44], ["the viruses", "PROBLEM", 51, 62], ["viruses", "OBSERVATION", 55, 62]]], ["To this end, the reconciliations between the concatenated phylogeny and the related gene trees for the five protein clusters was performed, using RANGER-DTL version 2.0 (36) .", [["the five protein clusters", "TEST", 99, 124]]], ["Within the same host, HGT occurred most frequently for Phasianidae, followed by Felidae and Hominidae (Fig. 2B) .", [["Phasianidae", "TREATMENT", 55, 66], ["Felidae", "TREATMENT", 80, 87], ["Hominidae", "TREATMENT", 92, 101]]], ["Transfer events across different hosts for clusters 3, 4, 5 (spike, membrane, and nucleocapsid proteins, respectively) were more frequent than for the other two clusters.", [["membrane", "ANATOMY", 68, 76], ["5", "GENE_OR_GENE_PRODUCT", 58, 59], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["nucleocapsid proteins", "PROTEIN", 82, 103], ["spike, membrane, and nucleocapsid proteins", "PROBLEM", 61, 103]]], ["Among different hosts, bats were the most frequent donor or receiver, followed by Suidae, Camelidae, Hominidae, and Phasianidae (Fig. 2C) .", [["bats", "ORGANISM", 23, 27], ["Camelidae", "TREATMENT", 90, 99], ["Hominidae", "TREATMENT", 101, 110], ["Phasianidae (Fig", "TREATMENT", 116, 132]]], ["This immediately suggests an urgent need for erecting ecological barriers between livestock and wild animals, and between humans and wild animals, as well as for worldwide monitoring of coronaviruses.Results and DiscussionWe then examined in more details the inferred HGT events for SARS-CoV, MERS-CoV and SARS-CoV-2.", [["SARS", "DISEASE", 283, 287], ["humans", "ORGANISM", 122, 128], ["coronaviruses", "ORGANISM", 186, 199], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 283, 291], ["MERS-CoV", "ORGANISM", 293, 301], ["SARS-CoV-2", "ORGANISM", 306, 316], ["humans", "SPECIES", 122, 128], ["humans", "SPECIES", 122, 128], ["SARS-CoV", "SPECIES", 283, 291], ["MERS-CoV", "SPECIES", 293, 301], ["SARS-CoV", "SPECIES", 306, 314], ["erecting ecological barriers", "TREATMENT", 45, 73], ["coronaviruses", "PROBLEM", 186, 199], ["SARS", "PROBLEM", 283, 287], ["CoV", "TEST", 288, 291], ["MERS", "TEST", 293, 297], ["CoV", "TEST", 311, 314]]], ["For this analysis, an expanded dataset of 269 complete genomes of the beta-CoVs with sequence identity lower than 99.8% was used, except that only four SARS-CoV-2 genomes of human origin were included (37) , to reduce the redundancy (Supplementary Table S3 ).", [["beta-CoVs", "GENE_OR_GENE_PRODUCT", 70, 79], ["SARS-CoV-2", "ORGANISM", 152, 162], ["human", "ORGANISM", 174, 179], ["beta-CoVs", "DNA", 70, 79], ["SARS-CoV-2 genomes", "DNA", 152, 170], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["this analysis", "TEST", 4, 17], ["sequence identity", "TEST", 85, 102], ["four SARS", "TEST", 147, 156], ["CoV", "TEST", 157, 160], ["redundancy", "OBSERVATION", 222, 232]]], ["The Human_CoV_229E (NC_002645) from alpha-CoVs (3) was selected as the outgroup.", [["NC_002645", "CHEMICAL", 20, 29], ["alpha-CoVs", "CHEMICAL", 36, 46], ["alpha-CoVs (3)", "GENE_OR_GENE_PRODUCT", 36, 50], ["The Human_CoV_229E (NC", "TREATMENT", 0, 22]]], ["For SARS-CoV (Fig. 3A) , there were apparent transfer links among Chiroptera, Viverridae and Hominidae.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8], ["Viverridae", "TREATMENT", 78, 88], ["Hominidae", "TREATMENT", 93, 102]]], ["This result is consistent with the current knowledge concerning the evolution of SARS-CoVs, with 7 the palm civet as the likely intermediate host (16, 38, 39) .", [["SARS-CoVs", "DISEASE", 81, 90], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 81, 90], ["SARS", "PROBLEM", 81, 85], ["consistent with", "UNCERTAINTY", 15, 30], ["likely", "UNCERTAINTY", 121, 127], ["intermediate host", "OBSERVATION_MODIFIER", 128, 145]]], ["As there is no evidence for direct transmission of this virus between Chiroptera and Hominidae, the gene transfer between Hominidae and Chiroptera as depicted in Fig. 3A might be an indirect result of separated transfer events between Chiroptera and Viverridae, and between Viverridae and Hominidae.", [["Viverridae", "GENE_OR_GENE_PRODUCT", 250, 260], ["Hominidae", "GENE_OR_GENE_PRODUCT", 289, 298], ["this virus", "PROBLEM", 51, 61], ["Chiroptera", "TREATMENT", 70, 80], ["Hominidae", "TREATMENT", 85, 94], ["Hominidae and Chiroptera", "TREATMENT", 122, 146], ["Chiroptera", "TREATMENT", 235, 245], ["Viverridae", "TREATMENT", 250, 260], ["Viverridae", "TREATMENT", 274, 284], ["no evidence for", "UNCERTAINTY", 12, 27]]], ["The pattern found for MERS-CoV (Fig. 3B) is again consistent with accumulated evidence indicating the dromedary camel as a probable vector for human infections (8, 40, 41) .", [["infections", "DISEASE", 149, 159], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 22, 30], ["camel", "ORGANISM", 112, 117], ["human", "ORGANISM", 143, 148], ["human", "SPECIES", 143, 148], ["MERS-CoV", "SPECIES", 22, 30], ["camel", "SPECIES", 112, 117], ["human", "SPECIES", 143, 148], ["MERS", "PROBLEM", 22, 26], ["the dromedary camel", "PROBLEM", 98, 117], ["human infections", "PROBLEM", 143, 159], ["consistent with", "UNCERTAINTY", 50, 65]]], ["For SARS-CoV-2 (Fig. 3C) , transfer links were found between Chiroptera and Hominidae, and between Chiroptera and Manidae (pangolins).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["Manidae", "GENE_OR_GENE_PRODUCT", 114, 121], ["pangolins", "GENE_OR_GENE_PRODUCT", 123, 132], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8], ["CoV", "TEST", 9, 12], ["Chiroptera", "TREATMENT", 61, 71], ["Hominidae", "TREATMENT", 76, 85], ["Chiroptera", "TREATMENT", 99, 109], ["Manidae (pangolins)", "TREATMENT", 114, 133]]], ["Interestingly, no gene transfer between Hominidae and Manidae can be inferred from our analysis.", [["Manidae", "GENE_OR_GENE_PRODUCT", 54, 61], ["our analysis", "TEST", 83, 95], ["no", "UNCERTAINTY", 15, 17]]], ["Pangolins were suggested to be involved in the species jump of SARS-CoV-2 to humans (37, 42) .", [["Pangolins", "CHEMICAL", 0, 9], ["SARS", "DISEASE", 63, 67], ["Pangolins", "CHEMICAL", 0, 9], ["Pangolins", "GENE_OR_GENE_PRODUCT", 0, 9], ["SARS-CoV-2", "ORGANISM", 63, 73], ["humans", "ORGANISM", 77, 83], ["Pangolins", "PROTEIN", 0, 9], ["humans", "SPECIES", 77, 83], ["SARS-CoV", "SPECIES", 63, 71], ["humans", "SPECIES", 77, 83], ["CoV", "TEST", 68, 71], ["suggested to be", "UNCERTAINTY", 15, 30]]], ["Finally, while the links among Hominidae, Mustelidae (minks), and Felidae (tigers) were deduced, it remains to be seen how SARS-CoV-2 viruses were transmitted among them.", [["SARS", "DISEASE", 123, 127], ["Felidae", "GENE_OR_GENE_PRODUCT", 66, 73], ["SARS-CoV-2 viruses", "ORGANISM", 123, 141], ["SARS-CoV-2 viruses", "SPECIES", 123, 141], ["Mustelidae (minks)", "TREATMENT", 42, 60], ["Felidae (tigers)", "TREATMENT", 66, 82]]], ["Taken together, we argue that these inferred apparent HGT events can serve as a possible marker for cross-host transmissions of coronaviruses.Results and DiscussionIn summary, based on the analysis of concatenated protein clusters of the viral genome sequences, we present a framework to produce robust phylogeny and classification for CoVs, and to infer the apparent HGT events and cross host transmissions for the Orthocoronavirinae subfamily.", [["coronaviruses", "ORGANISM", 128, 141], ["CoVs", "GENE_OR_GENE_PRODUCT", 336, 340], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 416, 434], ["viral genome sequences", "DNA", 238, 260], ["CoVs", "PROTEIN", 336, 340], ["Orthocoronavirinae subfamily", "PROTEIN", 416, 444], ["coronaviruses", "PROBLEM", 128, 141], ["the analysis", "TEST", 185, 197], ["the viral genome sequences", "PROBLEM", 234, 260], ["CoVs", "PROBLEM", 336, 340], ["viral genome", "OBSERVATION", 238, 250]]], ["This should help to understand how CoVs are transmitted to humans, and aid in devising strategies to combat the severe global health threat posed by these viruses.", [["CoVs", "GENE_OR_GENE_PRODUCT", 35, 39], ["humans", "ORGANISM", 59, 65], ["CoVs", "PROTEIN", 35, 39], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["the severe global health threat", "PROBLEM", 108, 139], ["viruses", "OBSERVATION", 155, 162]]], ["8Genome sequence collection and marker selectionGenome datasets were compiled with CD-HIT version 4.7 (45) .", [["HIT", "DISEASE", 86, 89], ["8Genome sequence collection", "PROBLEM", 0, 27], ["Genome datasets", "TEST", 48, 63], ["HIT version", "TEST", 86, 97]]], ["Open reading frames (ORFs) in the datasets were predicted by using GeneMarkS version 4.32 (46) , and then annotated using BLAST against the NR database (https://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/) with e-value \u2264 10 -5 .Genome sequence collection and marker selectionMarker selections were performed with the Markov Cluster algorithm of OrthoMCL, with the parameter of '-I 1.5' (26) .", [["Open reading frames", "DNA", 0, 19], ["ORFs", "DNA", 21, 25], ["NR database", "DNA", 140, 151], ["e-value \u2264 10 -5", "DNA", 204, 219], ["Genome sequence", "DNA", 221, 236], ["the NR database", "TEST", 136, 151], ["e-value", "TEST", 204, 211], ["Genome sequence collection", "TEST", 221, 247]]], ["The 20 protein clusters with abundancy in a genus higher than 30% are listed in Supplementary Fig. S1 .", [["S1", "GENE_OR_GENE_PRODUCT", 99, 101], ["S1", "PROTEIN", 99, 101], ["The 20 protein clusters", "TREATMENT", 0, 23], ["abundancy", "TREATMENT", 29, 38], ["20 protein", "OBSERVATION_MODIFIER", 4, 14]]], ["For comparison of robustness, two other phylogenetic trees were also built, based on 9 the full genome, and the five concatenated domains of ORF1a/b that are used in the ICTV classification approach by the Coronaviridae Study Group (e.g., 3CLpro, NiRAN, RdRp, ZBD, and HEL1) (3, 33) .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 141, 146], ["NiRAN", "GENE_OR_GENE_PRODUCT", 247, 252], ["ZBD", "GENE_OR_GENE_PRODUCT", 260, 263], ["ORF1a", "DNA", 141, 146], ["NiRAN", "DNA", 247, 252], ["RdRp", "DNA", 254, 258], ["ZBD", "DNA", 260, 263], ["HEL1", "DNA", 269, 273], ["robustness", "PROBLEM", 18, 28], ["ORF1a/b", "TREATMENT", 141, 148], ["3CLpro", "TEST", 239, 245], ["RdRp", "TEST", 254, 258], ["phylogenetic trees", "OBSERVATION", 40, 58]]], ["The phylogenetic tree based on the full genome was constructed using RAxML with the GTRGAMMA model and 1,000 bootstrap replicates.", [["RAxML", "DNA", 69, 74], ["GTRGAMMA model", "DNA", 84, 98], ["RAxML", "TREATMENT", 69, 74], ["the GTRGAMMA model", "TREATMENT", 80, 98], ["phylogenetic tree", "OBSERVATION", 4, 21]]], ["The phylogenetic tree based on the five concatenated domains of ORF1a/1b was built using the same method as that based on the five concatenated protein clusters described above.", [["ORF1a", "DNA", 64, 69], ["phylogenetic", "OBSERVATION_MODIFIER", 4, 16], ["tree", "OBSERVATION_MODIFIER", 17, 21], ["protein clusters", "OBSERVATION", 144, 160]]]], "d4ed23e27273cac6ae20d080e586a80f6029d4e5": [["INTRODUCTIONThe production of heterologous monoclonal antibodies by fusion of murine plasmacytoma cells with lymphocytes from other species is particularly useful when no homologous myeloma cell lines are available for the species to be studied, such as cattle.", [["plasmacytoma cells", "ANATOMY", 85, 103], ["lymphocytes", "ANATOMY", 109, 120], ["myeloma cell lines", "ANATOMY", 182, 200], ["plasmacytoma", "DISEASE", 85, 97], ["murine", "ORGANISM", 78, 84], ["plasmacytoma cells", "CELL", 85, 103], ["lymphocytes", "CELL", 109, 120], ["myeloma cell lines", "CELL", 182, 200], ["cattle", "ORGANISM", 254, 260], ["heterologous monoclonal antibodies", "PROTEIN", 30, 64], ["murine plasmacytoma cells", "CELL_TYPE", 78, 103], ["lymphocytes", "CELL_TYPE", 109, 120], ["homologous myeloma cell lines", "CELL_LINE", 171, 200], ["murine", "SPECIES", 78, 84], ["cattle", "SPECIES", 254, 260], ["cattle", "SPECIES", 254, 260], ["heterologous monoclonal antibodies", "TREATMENT", 30, 64], ["murine plasmacytoma cells", "PROBLEM", 78, 103], ["lymphocytes", "PROBLEM", 109, 120], ["other species", "PROBLEM", 126, 139], ["homologous myeloma cell lines", "PROBLEM", 171, 200], ["monoclonal antibodies", "OBSERVATION", 43, 64], ["plasmacytoma cells", "OBSERVATION", 85, 103], ["myeloma cell lines", "OBSERVATION", 182, 200]]], ["Srikumaran et al. (1983a Srikumaran et al. ( , 1983b Srikumaran et al. ( , 1987 have produced several mouse-bovine hybrids that produce monoclonal immunoglobulins with the major characteristics of bovine immunoglobulins.", [["hybrids", "ANATOMY", 115, 122], ["mouse", "ORGANISM", 102, 107], ["bovine", "ORGANISM", 108, 114], ["hybrids", "CELL", 115, 122], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 147, 162], ["bovine", "ORGANISM", 197, 203], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 204, 219], ["monoclonal immunoglobulins", "PROTEIN", 136, 162], ["bovine immunoglobulins", "PROTEIN", 197, 219], ["mouse", "SPECIES", 102, 107], ["bovine", "SPECIES", 108, 114], ["bovine", "SPECIES", 197, 203], ["mouse", "SPECIES", 102, 107], ["bovine", "SPECIES", 197, 203], ["several mouse-bovine hybrids", "TREATMENT", 94, 122], ["monoclonal immunoglobulins", "TREATMENT", 136, 162], ["bovine immunoglobulins", "TREATMENT", 197, 219], ["bovine immunoglobulins", "OBSERVATION", 197, 219]]], ["These reagents are valuable in immunochemical studies and some cell lines were reported to secrete products that reacted with Streptococcus sp. or Staphylococcus sp. thus furnishing tools for antigen-antibody interaction studies with bovine immunoglobulins.", [["cell lines", "ANATOMY", 63, 73], ["cell lines", "CELL", 63, 73], ["Streptococcus sp", "ORGANISM", 126, 142], ["Staphylococcus sp", "ORGANISM", 147, 164], ["antigen-antibody", "GENE_OR_GENE_PRODUCT", 192, 208], ["bovine", "ORGANISM", 234, 240], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 241, 256], ["cell lines", "CELL_LINE", 63, 73], ["bovine immunoglobulins", "PROTEIN", 234, 256], ["bovine", "SPECIES", 234, 240], ["bovine", "SPECIES", 234, 240], ["immunochemical studies", "TEST", 31, 53], ["some cell lines", "TREATMENT", 58, 73], ["Streptococcus sp", "PROBLEM", 126, 142], ["Staphylococcus sp", "PROBLEM", 147, 164], ["furnishing tools", "TEST", 171, 187], ["antigen-antibody interaction studies", "TEST", 192, 228], ["bovine immunoglobulins", "TREATMENT", 234, 256], ["cell lines", "OBSERVATION", 63, 73], ["Staphylococcus sp", "OBSERVATION", 147, 164]]], ["Similarly, mouse X bovine hybrids have been developed which produce antibody to the K99 pilus ofE. coli (Anderson et al., 1987) or to the bovine enteric coronavirus (Raybould et al., 1985) .", [["hybrids", "ANATOMY", 26, 33], ["enteric coronavirus", "DISEASE", 145, 164], ["mouse", "ORGANISM", 11, 16], ["bovine", "ORGANISM", 19, 25], ["hybrids", "CELL", 26, 33], ["coli", "ORGANISM", 99, 103], ["bovine", "ORGANISM", 138, 144], ["enteric coronavirus", "ORGANISM", 145, 164], ["mouse X bovine hybrids", "CELL_LINE", 11, 33], ["K99 pilus ofE", "PROTEIN", 84, 97], ["mouse", "SPECIES", 11, 16], ["bovine", "SPECIES", 19, 25], ["coli", "SPECIES", 99, 103], ["bovine", "SPECIES", 138, 144], ["coronavirus", "SPECIES", 153, 164], ["mouse", "SPECIES", 11, 16], ["coli", "SPECIES", 99, 103], ["bovine enteric coronavirus", "SPECIES", 138, 164], ["mouse X bovine hybrids", "TREATMENT", 11, 33], ["the bovine enteric coronavirus", "PROBLEM", 134, 164], ["enteric coronavirus", "ANATOMY", 145, 164]]], ["In addition, mouse X ovine monoclonal antibodies to testosterone have been made (Groves et al., 1987) and mouse X porcine hybridomas have been reported (Raybould et al., 1984) .INTRODUCTIONWhile mouse X mouse monoclonal antibodies to Brucella abortus have been prepared (Bundle et al., 1984; Holman et al., 1984; Quinn et al., 1984; Schurig et al., 1984; Bundesen et al., 1985; Greiser-Wilke and Moennig, 1987; Roop et al., 1987; Vendrell et al., 1987) and have proved to be useful reagents in Brucellosis serology, no mouse X bovine hybrids with antibody activity to B. abortus have been reported.", [["hybridomas", "ANATOMY", 122, 132], ["hybrids", "ANATOMY", 534, 541], ["testosterone", "CHEMICAL", 52, 64], ["Brucellosis", "DISEASE", 494, 505], ["testosterone", "CHEMICAL", 52, 64], ["mouse", "ORGANISM", 13, 18], ["testosterone", "SIMPLE_CHEMICAL", 52, 64], ["mouse", "ORGANISM", 106, 111], ["mouse", "ORGANISM", 195, 200], ["mouse", "ORGANISM", 203, 208], ["Brucella abortus", "ORGANISM", 234, 250], ["mouse", "ORGANISM", 519, 524], ["X", "ORGANISM", 525, 526], ["bovine", "ORGANISM", 527, 533], ["B. abortus", "ORGANISM", 568, 578], ["mouse X ovine monoclonal antibodies", "PROTEIN", 13, 48], ["mouse X porcine hybridomas", "CELL_LINE", 106, 132], ["mouse X mouse monoclonal antibodies", "PROTEIN", 195, 230], ["mouse X bovine hybrids", "CELL_LINE", 519, 541], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 106, 111], ["porcine", "SPECIES", 114, 121], ["mouse", "SPECIES", 195, 200], ["mouse", "SPECIES", 203, 208], ["Brucella abortus", "SPECIES", 234, 250], ["mouse", "SPECIES", 519, 524], ["bovine", "SPECIES", 527, 533], ["B. abortus", "SPECIES", 568, 578], ["mouse", "SPECIES", 13, 18], ["ovine", "SPECIES", 21, 26], ["mouse", "SPECIES", 106, 111], ["mouse", "SPECIES", 195, 200], ["mouse", "SPECIES", 203, 208], ["Brucella abortus", "SPECIES", 234, 250], ["mouse", "SPECIES", 519, 524], ["bovine", "SPECIES", 527, 533], ["B. abortus", "SPECIES", 568, 578], ["mouse X ovine monoclonal antibodies", "TREATMENT", 13, 48], ["testosterone", "TREATMENT", 52, 64], ["mouse X porcine hybridomas", "TREATMENT", 106, 132], ["mouse X mouse monoclonal antibodies", "TREATMENT", 195, 230], ["Brucellosis serology", "TEST", 494, 514], ["mouse X bovine hybrids", "TREATMENT", 519, 541], ["Brucellosis", "OBSERVATION", 494, 505]]], ["Such a reagent would be highly useful as a positive control in serological tests, such as enzyme linked immunosorbent assay (ELISA), the complement fixation test (CFT), agglutination and precipitation tests as well as for immunochemical studies.", [["a reagent", "TREATMENT", 5, 14], ["serological tests", "TEST", 63, 80], ["enzyme linked immunosorbent assay", "TEST", 90, 123], ["ELISA", "TEST", 125, 130], ["the complement fixation test", "TEST", 133, 161], ["CFT", "TEST", 163, 166], ["agglutination", "TEST", 169, 182], ["precipitation tests", "TEST", 187, 206], ["immunochemical studies", "TEST", 222, 244]]], ["This report deals with the development and characterization of a murine X bovine hybrid which produces bovine monoclonal IgG1 to B. abortus lipopolysaccharide (LPS).MATERIALS AND METHODSBovine lymphocytes.", [["lymphocytes", "ANATOMY", 193, 204], ["lipopolysaccharide", "CHEMICAL", 140, 158], ["LPS", "CHEMICAL", 160, 163], ["murine", "ORGANISM", 65, 71], ["bovine", "ORGANISM", 74, 80], ["bovine", "ORGANISM", 103, 109], ["IgG1", "GENE_OR_GENE_PRODUCT", 121, 125], ["B. abortus", "ORGANISM", 129, 139], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 140, 158], ["LPS", "SIMPLE_CHEMICAL", 160, 163], ["METHODSBovine lymphocytes", "CELL", 179, 204], ["murine X bovine hybrid", "CELL_LINE", 65, 87], ["bovine monoclonal IgG1", "PROTEIN", 103, 125], ["murine", "SPECIES", 65, 71], ["bovine", "SPECIES", 74, 80], ["bovine", "SPECIES", 103, 109], ["B. abortus", "SPECIES", 129, 139], ["bovine", "SPECIES", 103, 109], ["B. abortus", "SPECIES", 129, 139], ["a murine X bovine hybrid", "TREATMENT", 63, 87], ["bovine monoclonal IgG1", "TREATMENT", 103, 125], ["METHODSBovine lymphocytes", "OBSERVATION", 179, 204]]], ["An adult Holstein Friesian cow was immunized intramuscularly with 1.0 ml of 8% v/v of heat-killed and washed B. abortus cells.", [["intramuscularly", "ANATOMY", 45, 60], ["cells", "ANATOMY", 120, 125], ["cow", "ORGANISM", 27, 30], ["B. abortus cells", "CELL", 109, 125], ["cow", "SPECIES", 27, 30], ["B. abortus", "SPECIES", 109, 119], ["Holstein Friesian", "SPECIES", 9, 26], ["cow", "SPECIES", 27, 30], ["B. abortus", "SPECIES", 109, 119], ["An adult Holstein Friesian cow", "TREATMENT", 0, 30], ["heat-killed", "TREATMENT", 86, 97], ["abortus cells", "OBSERVATION", 112, 125]]], ["Additional similar injections were given 42 and 62 days later.", [["Additional similar injections", "TREATMENT", 0, 29]]], ["On day 67, blood was aseptically collected in EDTA and the lymphocytes were separated using Ficoll-paque.MATERIALS AND METHODSHybridization.", [["blood", "ANATOMY", 11, 16], ["lymphocytes", "ANATOMY", 59, 70], ["EDTA", "CHEMICAL", 46, 50], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["EDTA", "SIMPLE_CHEMICAL", 46, 50], ["lymphocytes", "CELL", 59, 70], ["lymphocytes", "CELL_TYPE", 59, 70], ["Ficoll-paque", "TREATMENT", 92, 104], ["METHODSHybridization", "TREATMENT", 119, 139], ["lymphocytes", "ANATOMY", 59, 70]]], ["Bovine lymphocytes ( 1 X 107 viable cells) were fused with mouse plasmacytoma cells (S/P 2, 1X 17 viable cells) using polyethylene glycol as described by Kennett et al. (1978) .", [["lymphocytes", "ANATOMY", 7, 18], ["cells", "ANATOMY", 36, 41], ["plasmacytoma cells", "ANATOMY", 65, 83], ["cells", "ANATOMY", 105, 110], ["plasmacytoma", "DISEASE", 65, 77], ["polyethylene glycol", "CHEMICAL", 118, 137], ["polyethylene glycol", "CHEMICAL", 118, 137], ["Bovine", "ORGANISM", 0, 6], ["lymphocytes", "CELL", 7, 18], ["cells", "CELL", 36, 41], ["mouse", "ORGANISM", 59, 64], ["plasmacytoma cells", "CELL", 65, 83], ["S/P 2", "CELL", 85, 90], ["cells", "CELL", 105, 110], ["polyethylene glycol", "SIMPLE_CHEMICAL", 118, 137], ["Bovine lymphocytes", "CELL_TYPE", 0, 18], ["1 X 107 viable cells", "CELL_LINE", 21, 41], ["mouse plasmacytoma cells", "CELL_LINE", 59, 83], ["1X 17 viable cells", "CELL_LINE", 92, 110], ["Bovine", "SPECIES", 0, 6], ["mouse", "SPECIES", 59, 64], ["Bovine", "SPECIES", 0, 6], ["mouse", "SPECIES", 59, 64], ["Bovine lymphocytes", "TEST", 0, 18], ["viable cells", "TEST", 29, 41], ["mouse plasmacytoma cells", "PROBLEM", 59, 83], ["1X 17 viable cells", "TREATMENT", 92, 110], ["polyethylene glycol", "TREATMENT", 118, 137], ["lymphocytes", "ANATOMY", 7, 18], ["plasmacytoma cells", "OBSERVATION", 65, 83], ["polyethylene glycol", "OBSERVATION", 118, 137]]], ["Two to 3 weeks after the fusion and removal of unfused S/P 2 cells by addition of HAT and several changes of the culture medium, the cell supernates were tested for antibody activity.MATERIALS AND METHODSHybridoma screening.", [["S/P 2 cells", "ANATOMY", 55, 66], ["cell", "ANATOMY", 133, 137], ["S/P 2 cells", "CELL", 55, 66], ["cell supernates", "CELL", 133, 148], ["unfused S/P 2 cells", "CELL_LINE", 47, 66], ["HAT", "PROTEIN", 82, 85], ["the fusion", "TREATMENT", 21, 31], ["removal of unfused S/P 2 cells", "TREATMENT", 36, 66], ["HAT", "PROBLEM", 82, 85], ["the culture medium", "TREATMENT", 109, 127], ["the cell supernates", "TEST", 129, 148], ["antibody activity", "PROBLEM", 165, 182], ["METHODSHybridoma screening", "TEST", 197, 223]]], ["An indirect ELISA procedure was used.", [["An indirect ELISA procedure", "TREATMENT", 0, 27]]], ["Polystyrene 96well plates were coated passively with 200 ng of B. abortus LPS in 200 #l of carbonate buffer (0.06 M, pH 9.6) overnight at room temperature (RT).", [["LPS", "CHEMICAL", 74, 77], ["Polystyrene", "CHEMICAL", 0, 11], ["carbonate", "CHEMICAL", 91, 100], ["B. abortus", "ORGANISM", 63, 73], ["LPS", "SIMPLE_CHEMICAL", 74, 77], ["carbonate", "SIMPLE_CHEMICAL", 91, 100], ["B. abortus", "SPECIES", 63, 73], ["B. abortus", "SPECIES", 63, 73], ["Polystyrene 96well plates", "TREATMENT", 0, 25], ["carbonate buffer", "TREATMENT", 91, 107], ["pH", "TEST", 117, 119]]], ["After washing four times with 0.1 M tris-HCl, pH 8.0, containing 0.15 M NaC1 and 0.05% Tween 20 (tris/T), 200 ttl of culture supernate was added to each well for 1 h at RT.", [["tris-HCl", "CHEMICAL", 36, 44], ["NaC1", "CHEMICAL", 72, 76], ["tris", "CHEMICAL", 36, 40], ["HCl", "CHEMICAL", 41, 44], ["NaC1", "CHEMICAL", 72, 76], ["Tween 20", "CHEMICAL", 87, 95], ["tris-HCl", "SIMPLE_CHEMICAL", 36, 44], ["NaC1", "SIMPLE_CHEMICAL", 72, 76], ["supernate", "SIMPLE_CHEMICAL", 125, 134], ["pH", "TEST", 46, 48], ["0.15 M NaC1", "TREATMENT", 65, 76], ["culture supernate", "TREATMENT", 117, 134]]], ["After four washes, 200/tl of murine monoclonal antibody to bovine L-chain conjugated with horseradish peroxidase (HRPO, type VI from Sigma Chem., St. Louis, MO, U.S.A.), appropriately diluted in tris/T were added for 1 h at RT.", [["murine", "ORGANISM", 29, 35], ["bovine", "ORGANISM", 59, 65], ["L-chain conjugated", "SIMPLE_CHEMICAL", 66, 84], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 90, 112], ["HRPO", "SIMPLE_CHEMICAL", 114, 118], ["St. Louis", "ORGANISM", 146, 155], ["tris/T", "SIMPLE_CHEMICAL", 195, 201], ["murine monoclonal antibody", "PROTEIN", 29, 55], ["bovine L-chain", "PROTEIN", 59, 73], ["horseradish peroxidase", "PROTEIN", 90, 112], ["HRPO", "PROTEIN", 114, 118], ["murine", "SPECIES", 29, 35], ["bovine", "SPECIES", 59, 65], ["horseradish", "SPECIES", 90, 101], ["four washes", "TREATMENT", 6, 17], ["murine monoclonal antibody", "TREATMENT", 29, 55], ["bovine L-chain conjugated", "TREATMENT", 59, 84], ["horseradish peroxidase", "TREATMENT", 90, 112], ["appropriately diluted in tris/T", "TREATMENT", 170, 201]]], ["Following four further washes in tris/T, 200 ]~l of substrate-chromogen containing lmM hydrogen peroxide and 4mM 2,2'-azinobis(3-ethylbenz-thiazoline sulfonic acid) (ABTS) were added and incubated at RT with constant orbital shaking.", [["hydrogen peroxide", "CHEMICAL", 87, 104], ["2,2'-azinobis(3-ethylbenz-thiazoline sulfonic acid", "CHEMICAL", 113, 163], ["ABTS", "CHEMICAL", 166, 170], ["tris", "CHEMICAL", 33, 37], ["chromogen", "CHEMICAL", 62, 71], ["hydrogen peroxide", "CHEMICAL", 87, 104], ["2,2'-azinobis(3-ethylbenz-thiazoline sulfonic acid)", "CHEMICAL", 113, 164], ["ABTS", "CHEMICAL", 166, 170], ["substrate-chromogen", "SIMPLE_CHEMICAL", 52, 71], ["lmM hydrogen peroxide", "SIMPLE_CHEMICAL", 83, 104], ["2,2'-azinobis(3-ethylbenz-thiazoline sulfonic acid", "SIMPLE_CHEMICAL", 113, 163], ["ABTS", "SIMPLE_CHEMICAL", 166, 170], ["substrate", "TEST", 52, 61], ["chromogen", "TREATMENT", 62, 71], ["lmM hydrogen peroxide", "TREATMENT", 83, 104], ["azinobis", "TREATMENT", 118, 126], ["ethylbenz-thiazoline sulfonic acid", "TREATMENT", 129, 163], ["ABTS)", "TREATMENT", 166, 171], ["constant orbital shaking", "PROBLEM", 208, 232], ["orbital", "ANATOMY", 217, 224], ["shaking", "OBSERVATION", 225, 232]]], ["After 10 min of development, optical densities were assessed with a spectrophotometer.", [["optical densities", "PROBLEM", 29, 46], ["a spectrophotometer", "TEST", 66, 85], ["optical", "OBSERVATION_MODIFIER", 29, 36], ["densities", "OBSERVATION", 37, 46]]], ["An arbitrary OD value of 0.100 or greater, based on OD values of negative controls, was considered positive.MATERIALS AND METHODSCloning.", [["An arbitrary OD value", "TEST", 0, 21], ["OD values", "TEST", 52, 61], ["METHODSCloning", "TREATMENT", 122, 136], ["arbitrary OD", "OBSERVATION_MODIFIER", 3, 15]]], ["Cells from wells giving a positive result on the screening test were cloned twice by the soft agar technique.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["the screening test", "TEST", 45, 63]]], ["The clone producing the highest OD in the screening test was selected for propagation.MATERIALS AND METHODSProduction of ascitic fluid.", [["ascitic fluid", "ANATOMY", 121, 134], ["clone", "CELL", 4, 9], ["ascitic fluid", "ORGANISM_SUBSTANCE", 121, 134], ["The clone", "PROBLEM", 0, 9], ["the screening test", "TEST", 38, 56], ["ascitic fluid", "PROBLEM", 121, 134], ["ascitic fluid", "OBSERVATION", 121, 134]]], ["Nu/nu mice, pristane treated 2 weeks previously by injection of 0.5 ml intraperitoneally (i.p.), were injected i.p. with 3.3 X 106 viable hybridoma cells.", [["hybridoma cells", "ANATOMY", 138, 153], ["pristane", "CHEMICAL", 12, 20], ["pristane", "CHEMICAL", 12, 20], ["Nu/nu mice", "ORGANISM", 0, 10], ["hybridoma cells", "CELL", 138, 153], ["hybridoma cells", "CELL_LINE", 138, 153], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["Nu/nu mice, pristane", "TREATMENT", 0, 20], ["nu mice", "OBSERVATION_MODIFIER", 3, 10], ["hybridoma cells", "OBSERVATION", 138, 153]]], ["Approximately 10 days later and every 2 days thereafter, ascites fluid was drawn from the peritoneal cavities.", [["ascites fluid", "ANATOMY", 57, 70], ["peritoneal cavities", "ANATOMY", 90, 109], ["ascites", "DISEASE", 57, 64], ["ascites fluid", "ORGANISM_SUBSTANCE", 57, 70], ["peritoneal cavities", "MULTI-TISSUE_STRUCTURE", 90, 109], ["ascites fluid", "PROBLEM", 57, 70], ["ascites", "ANATOMY", 57, 64], ["fluid", "OBSERVATION", 65, 70], ["peritoneal", "ANATOMY", 90, 100], ["cavities", "ANATOMY_MODIFIER", 101, 109]]], ["Usually three collections were taken from each mouse.", [["mouse", "ORGANISM", 47, 52], ["mouse", "SPECIES", 47, 52], ["mouse", "SPECIES", 47, 52], ["collections", "OBSERVATION", 14, 25]]], ["All ascites aliquants were pooled, clarified by centrifugation (10 000 Xg for 10 min), filter sterilized and frozen at -20 \u00b0 C.MATERIALS AND METHODSIsotyping.", [["ascites", "ANATOMY", 4, 11], ["ascites", "DISEASE", 4, 11], ["All ascites aliquants", "PROBLEM", 0, 21], ["filter", "TREATMENT", 87, 93], ["ascites", "OBSERVATION", 4, 11]]], ["The bovine isotype of clones producing antibody to B. abortus LPS was tested by an indirect ELISA in which LPS was used as the antigen, as above, but murine monoclonal antibody to bovine IgM, IgG1, IgG2 and IgA, conjugated with HRPO were used as detection reagents.", [["clones", "ANATOMY", 22, 28], ["LPS", "CHEMICAL", 62, 65], ["LPS", "CHEMICAL", 107, 110], ["HRPO", "CHEMICAL", 228, 232], ["bovine", "ORGANISM", 4, 10], ["clones", "CELL", 22, 28], ["B. abortus", "ORGANISM", 51, 61], ["LPS", "ORGANISM", 62, 65], ["LPS", "SIMPLE_CHEMICAL", 107, 110], ["murine", "ORGANISM", 150, 156], ["bovine", "ORGANISM", 180, 186], ["IgM", "GENE_OR_GENE_PRODUCT", 187, 190], ["IgG1", "GENE_OR_GENE_PRODUCT", 192, 196], ["IgG2", "GENE_OR_GENE_PRODUCT", 198, 202], ["IgA", "GENE_OR_GENE_PRODUCT", 207, 210], ["HRPO", "SIMPLE_CHEMICAL", 228, 232], ["murine monoclonal antibody", "PROTEIN", 150, 176], ["bovine IgM", "PROTEIN", 180, 190], ["IgG1", "PROTEIN", 192, 196], ["IgG2", "PROTEIN", 198, 202], ["IgA", "PROTEIN", 207, 210], ["HRPO", "PROTEIN", 228, 232], ["bovine", "SPECIES", 4, 10], ["B. abortus", "SPECIES", 51, 61], ["murine", "SPECIES", 150, 156], ["bovine", "SPECIES", 180, 186], ["B. abortus", "SPECIES", 51, 61], ["bovine", "SPECIES", 180, 186], ["The bovine isotype of clones", "TREATMENT", 0, 28], ["B. abortus LPS", "TEST", 51, 65], ["an indirect ELISA", "TEST", 80, 97], ["LPS", "TEST", 107, 110], ["the antigen", "TEST", 123, 134], ["murine monoclonal antibody", "TEST", 150, 176], ["bovine IgM", "TEST", 180, 190], ["IgG1", "TEST", 192, 196], ["IgG2", "TEST", 198, 202], ["IgA", "TEST", 207, 210], ["HRPO", "TEST", 228, 232], ["bovine isotype", "OBSERVATION", 4, 18]]], ["The ELISA procedure was described above.MATERIALS AND METHODSAffinity purification.", [["The ELISA procedure", "TREATMENT", 0, 19], ["METHODSAffinity purification", "TREATMENT", 54, 82]]], ["Murine monoclonal antibody to bovine IgG1 was covalently bound to agarose beads with cyanogen bromide using the technique of Johnson and Garvey (1977) and packed into a column which was run reverse to gravity with a peristaltic pump.", [["cyanogen bromide", "CHEMICAL", 85, 101], ["cyanogen bromide", "CHEMICAL", 85, 101], ["Murine", "ORGANISM", 0, 6], ["bovine", "ORGANISM", 30, 36], ["IgG1", "GENE_OR_GENE_PRODUCT", 37, 41], ["agarose beads", "SIMPLE_CHEMICAL", 66, 79], ["cyanogen bromide", "SIMPLE_CHEMICAL", 85, 101], ["Murine monoclonal antibody", "PROTEIN", 0, 26], ["bovine IgG1", "PROTEIN", 30, 41], ["Murine", "SPECIES", 0, 6], ["bovine", "SPECIES", 30, 36], ["Murine", "SPECIES", 0, 6], ["bovine", "SPECIES", 30, 36], ["Murine monoclonal antibody to bovine IgG1", "TREATMENT", 0, 41], ["cyanogen bromide", "TREATMENT", 85, 101], ["the technique of Johnson and Garvey", "TREATMENT", 108, 143], ["a peristaltic pump", "TREATMENT", 214, 232], ["monoclonal antibody", "OBSERVATION", 7, 26], ["peristaltic pump", "OBSERVATION", 216, 232]]], ["Amounts of bovine monoclonal antibody were percolated through the column.", [["bovine", "ORGANISM", 11, 17], ["bovine monoclonal antibody", "PROTEIN", 11, 37], ["bovine", "SPECIES", 11, 17], ["bovine", "SPECIES", 11, 17], ["bovine monoclonal antibody", "TEST", 11, 37], ["bovine", "OBSERVATION_MODIFIER", 11, 17], ["monoclonal antibody", "OBSERVATION", 18, 37], ["column", "ANATOMY", 66, 72]]], ["Unbound materials were washed out with 0.1 M tris-HC1, pH 7.2, containing 1 mM EDTA and 0.15 M NaC1 until the OD of the effluent was less than 0.01 at 280 nm.", [["NaC1", "CHEMICAL", 95, 99], ["tris-HC1", "CHEMICAL", 45, 53], ["EDTA", "CHEMICAL", 79, 83], ["NaC1", "CHEMICAL", 95, 99], ["tris-HC1", "SIMPLE_CHEMICAL", 45, 53], ["EDTA", "SIMPLE_CHEMICAL", 79, 83], ["NaC1", "SIMPLE_CHEMICAL", 95, 99], ["Unbound materials", "PROBLEM", 0, 17], ["pH", "TEST", 55, 57], ["1 mM EDTA", "TREATMENT", 74, 83], ["NaC1", "TREATMENT", 95, 99], ["effluent", "OBSERVATION", 120, 128]]], ["Bound materials were then eluted from the column with 0.1 M glycine-HCl buffer, pH 2.4 and neutralized immediately by addition of 0.5 M tris-HC1, pH 8.0.MATERIALS AND METHODSBound and unbound proteins eluted from the column were tested for antibody activity to B. abortus LPS by ELISA.", [["glycine-HCl", "CHEMICAL", 60, 71], ["LPS", "CHEMICAL", 272, 275], ["glycine", "CHEMICAL", 60, 67], ["HCl", "CHEMICAL", 68, 71], ["tris-HC1", "CHEMICAL", 136, 144], ["glycine-HCl", "SIMPLE_CHEMICAL", 60, 71], ["tris-HC1", "SIMPLE_CHEMICAL", 136, 144], ["B. abortus", "ORGANISM", 261, 271], ["LPS", "ORGANISM", 272, 275], ["B. abortus", "SPECIES", 261, 271], ["B. abortus", "SPECIES", 261, 271], ["0.1 M glycine-HCl buffer", "TREATMENT", 54, 78], ["pH", "TEST", 80, 82], ["pH", "TEST", 146, 148], ["unbound proteins", "TEST", 184, 200], ["the column", "TEST", 213, 223], ["antibody activity", "PROBLEM", 240, 257], ["column", "ANATOMY", 217, 223]]], ["Fractions containing antibody were pooled, dialized against 0.15 M NaCI and concentrated to 1.0 mg/ml.", [["NaCI", "CHEMICAL", 67, 71], ["NaCI", "CHEMICAL", 67, 71], ["NaCI", "SIMPLE_CHEMICAL", 67, 71], ["0.15 M NaCI", "TREATMENT", 60, 71]]], ["IgG1 was obtained by the same methods as the monoclonal antibody from serum from a cow infected with B. abortus which had a high complement fixation test titer.", [["serum", "ANATOMY", 70, 75], ["IgG1", "GENE_OR_GENE_PRODUCT", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["cow", "ORGANISM", 83, 86], ["B. abortus", "ORGANISM", 101, 111], ["IgG1", "PROTEIN", 0, 4], ["monoclonal antibody", "PROTEIN", 45, 64], ["cow", "SPECIES", 83, 86], ["B. abortus", "SPECIES", 101, 111], ["cow", "SPECIES", 83, 86], ["B. abortus", "SPECIES", 101, 111], ["IgG1", "TEST", 0, 4], ["the monoclonal antibody", "TEST", 41, 64], ["B. abortus", "PROBLEM", 101, 111], ["a high complement fixation test titer", "PROBLEM", 122, 159]]], ["The affinity purified IgG1 was further affinity purified with B. abortus LPS (Stiller and Nielsen, 1983) .", [["IgG1", "GENE_OR_GENE_PRODUCT", 22, 26], ["B. abortus", "ORGANISM", 62, 72], ["LPS", "ORGANISM", 73, 76], ["IgG1", "PROTEIN", 22, 26], ["B. abortus", "SPECIES", 62, 72], ["B. abortus", "SPECIES", 62, 72], ["B. abortus LPS", "TEST", 62, 76]]], ["These reagents were used for serological testing.MATERIALS AND METHODSSerological tests.", [["These reagents", "TREATMENT", 0, 14], ["serological testing", "TEST", 29, 48], ["METHODSSerological tests", "TEST", 63, 87]]], ["The indirect ELISA was performed as described by Nielsen et al. (1984) using a timing procedure (Wright et al., 1985) .", [["The indirect ELISA", "TEST", 0, 18], ["a timing procedure", "TREATMENT", 77, 95]]], ["A competitive ELISA for detection of antibody to B. abortus was used as described by Nielsen et al. (1987) .", [["B. abortus", "ORGANISM", 49, 59], ["B. abortus", "SPECIES", 49, 59], ["B. abortus", "SPECIES", 49, 59], ["antibody to B. abortus", "PROBLEM", 37, 59]]], ["In both cases, monoclonal detection reagents were conjugated with HRPO as per Henning and Nielsen (1987) .", [["HRPO", "CHEMICAL", 66, 70], ["HRPO", "CHEMICAL", 66, 70], ["HRPO", "SIMPLE_CHEMICAL", 66, 70], ["monoclonal detection reagents", "TREATMENT", 15, 44], ["HRPO", "TREATMENT", 66, 70]]], ["The CFT as outlined by Samagh and Boulanger (1978) was used.", [["The CFT", "TEST", 0, 7]]], ["Agglutination tests at a neutral or acid pH were done using doubling dilutions of the monoclonal antibody, mixing with appropriately diluted antigen (whole cell, 8% v/v, used at 1 : 200 or undi-luted 12% v/v whole cells at a final pH of 3.65, respectively), incubating for 48 h or 10 min, respectively, and then assessing agglutination visually.MATERIALS AND METHODSOther tests.", [["whole cell", "ANATOMY", 150, 160], ["cells", "ANATOMY", 214, 219], ["cell", "CELL", 156, 160], ["cells", "CELL", 214, 219], ["monoclonal antibody", "PROTEIN", 86, 105], ["Agglutination tests", "TEST", 0, 19], ["a neutral or acid pH", "TEST", 23, 43], ["doubling dilutions", "TREATMENT", 60, 78], ["the monoclonal antibody", "TEST", 82, 105], ["whole cell", "TEST", 150, 160], ["8% v/v", "TREATMENT", 162, 168], ["a final pH", "TEST", 223, 233], ["METHODSOther tests", "TEST", 359, 377]]], ["Immunoelectrophoresis and double gel immunodiffusion were done using standard techniques using BM-8 and control IgG1 at 1.0 and 0.1 mg/ml.", [["BM-8", "ANATOMY", 95, 99], ["BM-8", "CELL", 95, 99], ["IgG1", "GENE_OR_GENE_PRODUCT", 112, 116], ["IgG1", "PROTEIN", 112, 116], ["Immunoelectrophoresis", "TEST", 0, 21], ["double gel immunodiffusion", "TEST", 26, 52], ["standard techniques", "TREATMENT", 69, 88], ["BM", "TEST", 95, 97], ["IgG1", "TREATMENT", 112, 116]]], ["Polyacrylamide gels containing sodium dodecyl sulfate ( SDS-PAGE ) were run with purified BM-8 preparations at 1.0, 0.1 and 0.01 mg/ml as described by Towbin et al. (1979) .RESULTSScreening hybrid cultures from several fusions resulted in one positive cell line, BM-8, which had antibody activity to B. abortus LPS.", [["cell line", "ANATOMY", 252, 261], ["BM-8", "ANATOMY", 263, 267], ["sodium dodecyl sulfate", "CHEMICAL", 31, 53], ["SDS-PAGE", "CHEMICAL", 56, 64], ["LPS", "CHEMICAL", 311, 314], ["sodium dodecyl sulfate", "CHEMICAL", 31, 53], ["SDS-PAGE", "CHEMICAL", 56, 64], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 31, 53], ["SDS-PAGE", "SIMPLE_CHEMICAL", 56, 64], ["hybrid cultures", "CELL", 190, 205], ["cell line", "CELL", 252, 261], ["BM-8", "CELL", 263, 267], ["B. abortus", "ORGANISM", 300, 310], ["LPS", "ORGANISM", 311, 314], ["RESULTSScreening hybrid cultures", "CELL_LINE", 173, 205], ["positive cell line", "CELL_LINE", 243, 261], ["BM-8", "CELL_LINE", 263, 267], ["B. abortus", "SPECIES", 300, 310], ["B. abortus", "SPECIES", 300, 310], ["Polyacrylamide gels", "TREATMENT", 0, 19], ["sodium dodecyl sulfate", "TREATMENT", 31, 53], ["purified BM", "TREATMENT", 81, 92], ["hybrid cultures", "TEST", 190, 205], ["several fusions", "TEST", 211, 226], ["BM", "TEST", 263, 265], ["positive cell line", "OBSERVATION", 243, 261]]], ["The ascites fluid produced from twice cloned cells was tested by ELISA and found to contain antibody of the IgG1 subclass.", [["ascites fluid", "ANATOMY", 4, 17], ["cells", "ANATOMY", 45, 50], ["ascites", "DISEASE", 4, 11], ["ascites fluid", "ORGANISM_SUBSTANCE", 4, 17], ["cells", "CELL", 45, 50], ["IgG1", "GENE_OR_GENE_PRODUCT", 108, 112], ["IgG1 subclass", "PROTEIN", 108, 121], ["The ascites fluid", "PROBLEM", 0, 17], ["ELISA", "TEST", 65, 70], ["ascites", "OBSERVATION", 4, 11], ["antibody", "OBSERVATION", 92, 100]]], ["No reactivity was apparent with antibody to mouse IgG (H and L) or mouse IgM.", [["mouse", "ORGANISM", 44, 49], ["IgG", "GENE_OR_GENE_PRODUCT", 50, 53], ["mouse", "ORGANISM", 67, 72], ["mouse IgG", "PROTEIN", 44, 53], ["H and L)", "PROTEIN", 55, 63], ["mouse", "SPECIES", 44, 49], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 44, 49], ["mouse", "SPECIES", 67, 72], ["reactivity", "PROBLEM", 3, 13], ["antibody", "TEST", 32, 40], ["mouse IgG", "TEST", 44, 53], ["reactivity", "OBSERVATION", 3, 13]]], ["Antibody was prepared from pools of ascites fluid by affinity chromatography.", [["ascites fluid", "ANATOMY", 36, 49], ["ascites", "DISEASE", 36, 43], ["ascites fluid", "ORGANISM_SUBSTANCE", 36, 49], ["Antibody", "TEST", 0, 8], ["ascites fluid", "PROBLEM", 36, 49], ["affinity chromatography", "TEST", 53, 76], ["ascites", "OBSERVATION", 36, 43]]], ["Several batches were pooled, dialyzed and concentrated.", [["batches", "OBSERVATION_MODIFIER", 8, 15]]], ["A typical affinity chromatography run is presented in Fig. 1 .", [["A typical affinity chromatography", "TEST", 0, 33], ["affinity chromatography", "OBSERVATION", 10, 33]]], ["Immunoelectrophoresis (Fig. 2 ) revealed a single precitipin arc when developed with rabbit anti-bovine gamma globulin.", [["gamma globulin", "CHEMICAL", 104, 118], ["rabbit", "ORGANISM", 85, 91], ["anti-bovine gamma globulin", "GENE_OR_GENE_PRODUCT", 92, 118], ["rabbit anti-bovine gamma globulin", "PROTEIN", 85, 118], ["rabbit", "SPECIES", 85, 91], ["rabbit", "SPECIES", 85, 91], ["Immunoelectrophoresis", "TEST", 0, 21], ["a single precitipin arc", "PROBLEM", 41, 64], ["rabbit anti-bovine gamma globulin", "TREATMENT", 85, 118]]], ["This arc was fairly long, indicating some heterogeneity, although not as extensive as IgG1 prepared from serum (also by affinity chromatography).", [["serum", "ANATOMY", 105, 110], ["IgG1", "GENE_OR_GENE_PRODUCT", 86, 90], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["IgG1", "PROTEIN", 86, 90], ["some heterogeneity", "PROBLEM", 37, 55], ["serum", "TEST", 105, 110], ["affinity chromatography", "TEST", 120, 143], ["some", "OBSERVATION_MODIFIER", 37, 41], ["heterogeneity", "OBSERVATION", 42, 55]]], ["Double agar gel immunodiffusion with antisera specific for the heavy chains revealed reactivity with anti-IgG1 only and anti-A antisera (results not illustrated).RESULTSSDS-PAGE gave two bands when stained with Coomassie blue, one at 55 000 D and one at 25 000 D, indicating the appropriate molecular weights for heavy and light chains (see Fig. 3 ).RESULTSThe BM-8 antibody was not able to agglutinate B. abortus cells at a neutral pH at concentrations of antibody of less than 25/~g/ml.", [["cells", "ANATOMY", 414, 419], ["Coomassie blue", "CHEMICAL", 211, 225], ["Coomassie blue", "CHEMICAL", 211, 225], ["anti-IgG1", "SIMPLE_CHEMICAL", 101, 110], ["anti-A antisera", "GENE_OR_GENE_PRODUCT", 120, 135], ["Coomassie", "SIMPLE_CHEMICAL", 211, 220], ["B. abortus cells", "CELL", 403, 419], ["heavy chains", "PROTEIN", 63, 75], ["anti-IgG1", "PROTEIN", 101, 110], ["heavy and light chains", "PROTEIN", 313, 335], ["BM-8 antibody", "PROTEIN", 361, 374], ["B. abortus cells", "CELL_TYPE", 403, 419], ["B. abortus", "SPECIES", 403, 413], ["Coomassie blue", "SPECIES", 211, 225], ["B. abortus", "SPECIES", 403, 413], ["Double agar gel immunodiffusion", "TEST", 0, 31], ["anti-IgG1", "TREATMENT", 101, 110], ["anti-A antisera", "TEST", 120, 135], ["RESULTSSDS", "TEST", 162, 172], ["Coomassie blue", "TEST", 211, 225], ["RESULTSThe BM-8 antibody", "TEST", 350, 374], ["a neutral pH", "TEST", 423, 435], ["antibody", "TEST", 457, 465]]], ["Above 25/lg/ml a very fine, \"powdery\" agglutinate could be visualized but no increase in clumping was seen with increased concentrations of antibody.", [["\"powdery\" agglutinate", "TREATMENT", 28, 49], ["increase in clumping", "PROBLEM", 77, 97], ["increased concentrations of antibody", "PROBLEM", 112, 148], ["no", "UNCERTAINTY", 74, 76], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["clumping", "OBSERVATION", 89, 97]]], ["Similarly, control IgG1 antibody to B. abortus LPS did not cause agglutination at concentrations below 20/~g/ml.", [["LPS", "CHEMICAL", 47, 50], ["IgG1", "GENE_OR_GENE_PRODUCT", 19, 23], ["B. abortus", "ORGANISM", 36, 46], ["LPS", "ORGANISM", 47, 50], ["IgG1 antibody", "PROTEIN", 19, 32], ["B. abortus", "SPECIES", 36, 46], ["B. abortus", "SPECIES", 36, 46], ["control IgG1 antibody", "TEST", 11, 32], ["B. abortus LPS", "TEST", 36, 50], ["agglutination", "PROBLEM", 65, 78]]], ["Agglutination at pH 3.65 occurred with both BM-8 and control IgG1 to concentrations of 500 ng/ml in 10 min.", [["BM-8", "ANATOMY", 44, 48], ["BM-8", "CELL", 44, 48], ["IgG1", "GENE_OR_GENE_PRODUCT", 61, 65], ["IgG1", "PROTEIN", 61, 65], ["Agglutination", "TEST", 0, 13], ["pH", "TEST", 17, 19]]], ["The BM-8 antibody did not appear capable of precipitating B. abortus LPS in agar containing 1.0 M NaCl at the levels tested while the control IgG1 preparation did give a diffuse precipitin band at 1.0 mg/ml.", [["LPS", "CHEMICAL", 69, 72], ["NaCl", "CHEMICAL", 98, 102], ["NaCl", "CHEMICAL", 98, 102], ["B. abortus", "ORGANISM", 58, 68], ["LPS", "SIMPLE_CHEMICAL", 69, 72], ["IgG1", "GENE_OR_GENE_PRODUCT", 142, 146], ["BM-8 antibody", "PROTEIN", 4, 17], ["IgG1", "PROTEIN", 142, 146], ["B. abortus", "SPECIES", 58, 68], ["B. abortus", "SPECIES", 58, 68], ["The BM", "TEST", 0, 6], ["agar", "TEST", 76, 80], ["NaCl", "TREATMENT", 98, 102], ["the control IgG1 preparation", "TREATMENT", 130, 158], ["a diffuse precipitin band", "TREATMENT", 168, 193], ["BM", "ANATOMY", 4, 6]]], ["The BM-8 antibody was capable of fixing guinea pig complement.", [["BM-8 antibody", "GENE_OR_GENE_PRODUCT", 4, 17], ["guinea pig", "ORGANISM", 40, 50], ["BM-8 antibody", "PROTEIN", 4, 17], ["guinea pig", "SPECIES", 40, 50], ["guinea pig", "SPECIES", 40, 50], ["The BM", "TEST", 0, 6], ["fixing guinea pig complement", "TREATMENT", 33, 61], ["BM", "ANATOMY", 4, 6]]], ["In the diagnostic CFT, 200 ng/ml of the antibody gave 50% activation of three CHso units of complement (Fig. 4) .", [["CHso units", "PROTEIN", 78, 88], ["the antibody", "TREATMENT", 36, 48]]], ["Similarly, in the diagnostic indirect ELISA, using B. abortus LPS as the antigen and mouse monoclonal antibody to bovine IgG1, conjugated with HRPO, as the detection reagent, 25 ng/ml of BM-8 could be detected after 10 min of development at an OD of 1.0 at 414 nm.", [["LPS", "CHEMICAL", 62, 65], ["HRPO", "CHEMICAL", 143, 147], ["B. abortus", "ORGANISM", 51, 61], ["LPS", "ORGANISM", 62, 65], ["mouse", "ORGANISM", 85, 90], ["bovine", "ORGANISM", 114, 120], ["IgG1", "GENE_OR_GENE_PRODUCT", 121, 125], ["HRPO", "SIMPLE_CHEMICAL", 143, 147], ["BM-8", "CELL", 187, 191], ["mouse monoclonal antibody", "PROTEIN", 85, 110], ["bovine IgG1", "PROTEIN", 114, 125], ["HRPO", "PROTEIN", 143, 147], ["B. abortus", "SPECIES", 51, 61], ["mouse", "SPECIES", 85, 90], ["bovine", "SPECIES", 114, 120], ["B. abortus", "SPECIES", 51, 61], ["mouse", "SPECIES", 85, 90], ["bovine", "SPECIES", 114, 120], ["B. abortus LPS", "TREATMENT", 51, 65], ["the antigen", "TEST", 69, 80], ["mouse monoclonal antibody to bovine IgG1", "TREATMENT", 85, 125], ["HRPO", "TREATMENT", 143, 147], ["the detection reagent", "TEST", 152, 173], ["BM", "TEST", 187, 189]]], ["In the competitive ELISA, the BM-8 antibody was unable to compete with the monoclonal antibody to B. abortus LPS.DISCUSSIONThe development and characterization of a bovine monoclonal antibody to B. abortus LPS from fusion of bovine peripheral blood lymphocytes and a mufine plasmacytoma cell line has been described.", [["peripheral blood lymphocytes", "ANATOMY", 232, 260], ["plasmacytoma cell line", "ANATOMY", 274, 296], ["LPS", "CHEMICAL", 109, 112], ["LPS", "CHEMICAL", 206, 209], ["plasmacytoma", "DISEASE", 274, 286], ["B. abortus", "ORGANISM", 98, 108], ["LPS", "ORGANISM", 109, 112], ["bovine", "ORGANISM", 165, 171], ["B. abortus LPS", "ORGANISM", 195, 209], ["bovine", "ORGANISM", 225, 231], ["peripheral blood lymphocytes", "CELL", 232, 260], ["plasmacytoma cell line", "CELL", 274, 296], ["BM-8 antibody", "PROTEIN", 30, 43], ["monoclonal antibody", "PROTEIN", 75, 94], ["bovine monoclonal antibody", "PROTEIN", 165, 191], ["bovine peripheral blood lymphocytes", "CELL_TYPE", 225, 260], ["mufine plasmacytoma cell line", "CELL_LINE", 267, 296], ["B. abortus", "SPECIES", 98, 108], ["bovine", "SPECIES", 165, 171], ["B. abortus", "SPECIES", 195, 205], ["bovine", "SPECIES", 225, 231], ["B. abortus", "SPECIES", 98, 108], ["bovine", "SPECIES", 165, 171], ["B. abortus", "SPECIES", 195, 205], ["bovine", "SPECIES", 225, 231], ["the BM", "TEST", 26, 32], ["the monoclonal antibody", "TEST", 71, 94], ["a bovine monoclonal antibody", "TREATMENT", 163, 191], ["B. abortus LPS", "TEST", 195, 209], ["fusion of bovine peripheral blood lymphocytes", "TREATMENT", 215, 260], ["a mufine plasmacytoma cell line", "TREATMENT", 265, 296], ["BM", "ANATOMY", 30, 32], ["peripheral", "ANATOMY_MODIFIER", 232, 242], ["blood lymphocytes", "ANATOMY", 243, 260], ["plasmacytoma cell line", "OBSERVATION", 274, 296]]], ["It is notable that, in spite of a high hybridization rate (approximately 60% of the wells contained growing hybrid cells), only one fusion product produced antibody of the desired specificity.", [["cells", "ANATOMY", 115, 120], ["hybrid cells", "CELL", 108, 120], ["hybrid cells", "CELL_LINE", 108, 120], ["fusion product", "PROTEIN", 132, 146], ["a high hybridization rate", "PROBLEM", 32, 57], ["growing hybrid cells", "PROBLEM", 100, 120], ["notable", "OBSERVATION_MODIFIER", 6, 13], ["hybrid cells", "OBSERVATION", 108, 120]]], ["This may reflect a lack of specific B-cells in the peripheral blood at a particular time, in spite of high levels of serum antibody.", [["B-cells", "ANATOMY", 36, 43], ["peripheral blood", "ANATOMY", 51, 67], ["serum", "ANATOMY", 117, 122], ["B-cells", "CELL", 36, 43], ["peripheral blood", "ORGANISM_SUBSTANCE", 51, 67], ["serum", "ORGANISM_SUBSTANCE", 117, 122], ["B-cells", "CELL_TYPE", 36, 43], ["serum antibody", "PROTEIN", 117, 131], ["high levels of serum antibody", "PROBLEM", 102, 131], ["may reflect", "UNCERTAINTY", 5, 16], ["peripheral", "ANATOMY_MODIFIER", 51, 61], ["blood", "ANATOMY", 62, 67]]], ["Thus the immunization schedule in relation to the time of bleeding for lymphocyte harvest is of importance.", [["lymphocyte", "ANATOMY", 71, 81], ["bleeding", "DISEASE", 58, 66], ["lymphocyte", "CELL", 71, 81], ["the immunization schedule", "TREATMENT", 5, 30], ["bleeding", "PROBLEM", 58, 66], ["lymphocyte harvest", "TREATMENT", 71, 89], ["bleeding", "OBSERVATION", 58, 66], ["lymphocyte harvest", "OBSERVATION", 71, 89]]], ["This is unlike the mouse system in which normally the spleen is used as a source of lymphocytes.", [["spleen", "ANATOMY", 54, 60], ["lymphocytes", "ANATOMY", 84, 95], ["mouse", "ORGANISM", 19, 24], ["spleen", "ORGAN", 54, 60], ["lymphocytes", "CELL", 84, 95], ["lymphocytes", "CELL_TYPE", 84, 95], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 19, 24], ["lymphocytes", "PROBLEM", 84, 95], ["mouse system", "OBSERVATION", 19, 31], ["spleen", "ANATOMY", 54, 60]]], ["Alternate approaches would be to biopsy lymph nodes that drain the immunization site (Tucker et al., 1984; Anderson et al., 1987) or spleen cells (Srikumaran et al., 1983a,b) .", [["biopsy lymph nodes", "ANATOMY", 33, 51], ["spleen cells", "ANATOMY", 133, 145], ["biopsy", "MULTI-TISSUE_STRUCTURE", 33, 39], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 40, 51], ["spleen cells", "CELL", 133, 145], ["spleen cells", "CELL_TYPE", 133, 145], ["Alternate approaches", "TREATMENT", 0, 20], ["biopsy lymph nodes", "TREATMENT", 33, 51], ["drain the immunization site", "TREATMENT", 57, 84], ["lymph nodes", "OBSERVATION", 40, 51], ["spleen", "ANATOMY", 133, 139]]], ["Cell line stability with interspecies-fusion partners may be a problem as the murine chromosomes are lost and as a result immunoglobulin secretion ceases or diminishes with culture time.", [["Cell line", "ANATOMY", 0, 9], ["chromosomes", "ANATOMY", 85, 96], ["Cell line", "CELL", 0, 9], ["murine", "ORGANISM", 78, 84], ["chromosomes", "CELLULAR_COMPONENT", 85, 96], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 122, 136], ["murine chromosomes", "DNA", 78, 96], ["immunoglobulin", "PROTEIN", 122, 136], ["murine", "SPECIES", 78, 84], ["Cell line stability", "TREATMENT", 0, 19], ["interspecies-fusion partners", "TREATMENT", 25, 53], ["the murine chromosomes", "TEST", 74, 96], ["a result immunoglobulin secretion ceases", "PROBLEM", 113, 153], ["culture time", "TEST", 173, 185], ["stability", "OBSERVATION_MODIFIER", 10, 19], ["fusion", "OBSERVATION", 38, 44]]], ["In the case of BM-8 this has not been a problem.", [["BM-8", "CELL", 15, 19], ["BM", "TEST", 15, 17], ["BM", "ANATOMY", 15, 17]]], ["The cell line appears stable in culture and several subcultures stored in liquid nitrogen prior to propagation have produced immunoglobulin in quantities comparable to the parent cell line.", [["cell line", "ANATOMY", 4, 13], ["cell line", "ANATOMY", 179, 188], ["nitrogen", "CHEMICAL", 81, 89], ["cell line", "CELL", 4, 13], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 125, 139], ["cell line", "CELL", 179, 188], ["cell line", "CELL_LINE", 4, 13], ["immunoglobulin", "PROTEIN", 125, 139], ["parent cell line", "CELL_LINE", 172, 188], ["The cell line", "TREATMENT", 0, 13], ["culture", "TEST", 32, 39], ["several subcultures", "PROBLEM", 44, 63], ["liquid nitrogen", "TREATMENT", 74, 89], ["immunoglobulin in quantities", "PROBLEM", 125, 153], ["the parent cell line", "TREATMENT", 168, 188], ["cell line", "OBSERVATION", 4, 13], ["stable", "OBSERVATION_MODIFIER", 22, 28], ["several", "OBSERVATION_MODIFIER", 44, 51], ["subcultures", "OBSERVATION_MODIFIER", 52, 63], ["cell line", "OBSERVATION", 179, 188]]], ["Production of ascitic fluid in large volumes alleviates some of the long term culture problems.", [["ascitic fluid", "ANATOMY", 14, 27], ["ascitic fluid", "ORGANISM_SUBSTANCE", 14, 27], ["ascitic fluid", "PROBLEM", 14, 27], ["large volumes", "PROBLEM", 31, 44], ["the long term culture problems", "PROBLEM", 64, 94], ["ascitic fluid", "OBSERVATION", 14, 27], ["large", "OBSERVATION_MODIFIER", 31, 36], ["volumes", "OBSERVATION_MODIFIER", 37, 44], ["long term", "OBSERVATION_MODIFIER", 68, 77]]], ["An alternate approach to enhance stability of immunoglobulin production might be to re-fuse the hybridoma cell line with bovine lymph node cells obtained from immunized animals (Tucker et al., 1984 ) .DISCUSSIONWhile several reports of bovine X mouse fusions are in the literature, including some reporting production of antibody of known specificity (see above for references), to our knowledge, none that produce antibody to B. abortus have been reported.", [["hybridoma cell line", "ANATOMY", 96, 115], ["lymph node cells", "ANATOMY", 128, 144], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 46, 60], ["hybridoma cell line", "CELL", 96, 115], ["bovine", "ORGANISM", 121, 127], ["lymph node cells", "CELL", 128, 144], ["bovine", "ORGANISM", 236, 242], ["X mouse", "ORGANISM", 243, 250], ["B. abortus", "ORGANISM", 427, 437], ["immunoglobulin", "PROTEIN", 46, 60], ["hybridoma cell line", "CELL_LINE", 96, 115], ["bovine lymph node cells", "CELL_TYPE", 121, 144], ["bovine X mouse fusions", "DNA", 236, 258], ["bovine", "SPECIES", 121, 127], ["bovine", "SPECIES", 236, 242], ["mouse", "SPECIES", 245, 250], ["B. abortus", "SPECIES", 427, 437], ["bovine", "SPECIES", 121, 127], ["mouse", "SPECIES", 245, 250], ["B. abortus", "SPECIES", 427, 437], ["An alternate approach", "TREATMENT", 0, 21], ["immunoglobulin production", "PROBLEM", 46, 71], ["the hybridoma cell line", "TREATMENT", 92, 115], ["bovine lymph node cells", "TREATMENT", 121, 144], ["bovine X mouse fusions", "TREATMENT", 236, 258], ["hybridoma cell line", "OBSERVATION", 96, 115], ["lymph node cells", "OBSERVATION", 128, 144]]], ["This reagent could be valuable as a source for continuous quality control and standardization inherent to mass serological testing.", [["continuous quality control", "TREATMENT", 47, 73], ["mass serological testing", "TEST", 106, 130]]], ["In the past, individual sera or pools have been relied on as positive reagents in diagnostic serology, but in spite of large volumes on hand, these reagents eventually run out, necessitating the need for others which were never identical.", [["sera", "ANATOMY", 24, 28], ["sera", "ORGANISM_SUBSTANCE", 24, 28], ["hand", "ORGANISM_SUBDIVISION", 136, 140], ["individual sera or pools", "PROBLEM", 13, 37], ["diagnostic serology", "TEST", 82, 101], ["large", "OBSERVATION_MODIFIER", 119, 124], ["volumes", "OBSERVATION", 125, 132]]], ["The BM-8 monoclonal antibody could provide such a reagent for the CFT and ELISA.", [["BM-8 monoclonal antibody", "PROTEIN", 4, 28], ["The BM", "TEST", 0, 6], ["monoclonal antibody", "TEST", 9, 28], ["a reagent", "TREATMENT", 48, 57], ["the CFT", "TEST", 62, 69], ["ELISA", "TEST", 74, 79], ["BM", "ANATOMY", 4, 6]]], ["It is of interest to note that the BM-8 antibody fixes guinea pig complement as efficiently as does polyclonal affinity purified IgG1 (Fig. 4 ) ; however, it is considerably more active in the indirect ELISA than polyclonal IgG1 (Fig. 5) .DISCUSSIONThere are some limitations to its use, including the use of mice for ascites production and the inability of BM-8 to compete for antigen epitopes in the competitive ELISA used to distinguish sera from B. abortus S19 vaccinated and field infected cattle .", [["ascites", "ANATOMY", 318, 325], ["sera", "ANATOMY", 440, 444], ["ascites", "DISEASE", 318, 325], ["guinea pig", "ORGANISM", 55, 65], ["IgG1", "GENE_OR_GENE_PRODUCT", 129, 133], ["IgG1", "GENE_OR_GENE_PRODUCT", 224, 228], ["mice", "ORGANISM", 309, 313], ["BM-8", "CELL", 358, 362], ["sera", "ORGANISM_SUBSTANCE", 440, 444], ["B. abortus S19", "ORGANISM", 450, 464], ["cattle", "ORGANISM", 495, 501], ["BM-8 antibody", "PROTEIN", 35, 48], ["IgG1", "PROTEIN", 129, 133], ["Fig. 4", "PROTEIN", 135, 141], ["polyclonal IgG1", "PROTEIN", 213, 228], ["antigen epitopes", "PROTEIN", 378, 394], ["guinea pig", "SPECIES", 55, 65], ["mice", "SPECIES", 309, 313], ["B. abortus", "SPECIES", 450, 460], ["cattle", "SPECIES", 495, 501], ["pig", "SPECIES", 62, 65], ["mice", "SPECIES", 309, 313], ["B. abortus", "SPECIES", 450, 460], ["cattle", "SPECIES", 495, 501], ["the BM", "TEST", 31, 37], ["guinea pig complement", "TREATMENT", 55, 76], ["ascites production", "PROBLEM", 318, 336], ["the inability of BM", "PROBLEM", 341, 360], ["antigen epitopes", "PROBLEM", 378, 394], ["the competitive ELISA", "TEST", 398, 419], ["sera from B. abortus", "PROBLEM", 440, 460], ["active", "OBSERVATION_MODIFIER", 179, 185], ["ascites", "OBSERVATION", 318, 325]]], ["This discriminatory assay which uses the O-chain of B. abortus LPS as the antigen, appears to be based on at least three premises: (1) the antibody response of infected cattle differing from that of $19 vaccinated cattle; $19 vaccinated animals lack antibody to the 'length' epitope of the O-chain while infected cattle develop antibody specific for both the 'tip' and the 'length' epitopes; (2) that the antibody affinity of vaccinated cattle is less than that of infected cattle and (3) that the antigen presented on the polystyrene 96-well plate has the 'tip' epitope occluded {Nielsen et al., 1988) .", [["LPS", "CHEMICAL", 63, 66], ["polystyrene", "CHEMICAL", 523, 534], ["B. abortus", "ORGANISM", 52, 62], ["LPS", "ORGANISM", 63, 66], ["cattle", "ORGANISM", 169, 175], ["cattle", "ORGANISM", 214, 220], ["cattle", "ORGANISM", 313, 319], ["cattle", "ORGANISM", 437, 443], ["cattle", "ORGANISM", 474, 480], ["antigen", "GENE_OR_GENE_PRODUCT", 498, 505], ["O-chain", "PROTEIN", 41, 48], ["O-chain", "PROTEIN", 290, 297], ["epitopes", "PROTEIN", 382, 390], ["B. abortus", "SPECIES", 52, 62], ["cattle", "SPECIES", 169, 175], ["cattle", "SPECIES", 214, 220], ["cattle", "SPECIES", 313, 319], ["cattle", "SPECIES", 437, 443], ["cattle", "SPECIES", 474, 480], ["B. abortus", "SPECIES", 52, 62], ["cattle", "SPECIES", 169, 175], ["cattle", "SPECIES", 214, 220], ["cattle", "SPECIES", 313, 319], ["cattle", "SPECIES", 437, 443], ["cattle", "SPECIES", 474, 480], ["This discriminatory assay", "TEST", 0, 25], ["the 'length' epitopes", "TREATMENT", 369, 390], ["the antibody affinity", "TEST", 401, 422], ["vaccinated cattle", "PROBLEM", 426, 443], ["the antigen", "TEST", 494, 505], ["the polystyrene", "TEST", 519, 534], ["the 'tip' epitope occluded", "TREATMENT", 553, 579]]], ["The BM-8 antibody, derived from an immunized rather than infected animal would appear to lack specificity for the 'tip' determinant of B. abortus O-chain or perhaps a determinant not recognized by the murine monoclonal antibody.", [["BM-8 antibody", "GENE_OR_GENE_PRODUCT", 4, 17], ["animal", "ORGANISM", 66, 72], ["B. abortus", "ORGANISM", 135, 145], ["murine", "ORGANISM", 201, 207], ["BM-8 antibody", "PROTEIN", 4, 17], ["B. abortus O-chain", "PROTEIN", 135, 153], ["murine monoclonal antibody", "PROTEIN", 201, 227], ["B. abortus", "SPECIES", 135, 145], ["murine", "SPECIES", 201, 207], ["B. abortus", "SPECIES", 135, 145], ["The BM", "TEST", 0, 6], ["BM", "ANATOMY", 4, 6]]], ["A third disadvantage is the price of nu/nu mice.DISCUSSIONIn spite of these problems, bovine monoclonal antibody to B. abortus LPS should be highly useful in standardizing the CFT and the indirect ELISA for detection of antibody to B. abortus in cattle and for immunochemical studies of immune complexes and their biological functions.", [["nu/nu mice", "ORGANISM", 37, 47], ["bovine", "ORGANISM", 86, 92], ["B. abortus", "ORGANISM", 116, 126], ["LPS", "ORGANISM", 127, 130], ["B. abortus", "ORGANISM", 232, 242], ["cattle", "ORGANISM", 246, 252], ["bovine monoclonal antibody", "PROTEIN", 86, 112], ["immune complexes", "PROTEIN", 287, 303], ["mice", "SPECIES", 43, 47], ["bovine", "SPECIES", 86, 92], ["B. abortus", "SPECIES", 116, 126], ["B. abortus", "SPECIES", 232, 242], ["cattle", "SPECIES", 246, 252], ["bovine", "SPECIES", 86, 92], ["B. abortus", "SPECIES", 116, 126], ["B. abortus", "SPECIES", 232, 242], ["cattle", "SPECIES", 246, 252], ["nu/nu mice", "TREATMENT", 37, 47], ["these problems", "PROBLEM", 70, 84], ["bovine monoclonal antibody", "TREATMENT", 86, 112], ["B. abortus LPS", "TEST", 116, 130], ["the CFT", "TEST", 172, 179], ["the indirect ELISA", "TEST", 184, 202], ["antibody", "PROBLEM", 220, 228], ["immunochemical studies", "TEST", 261, 283], ["immune complexes", "PROBLEM", 287, 303]]]], "55d762875ac9c5b43832336f3a88d0e70ff8ab9c": [["BackgroundIn controlled trials, vitamin C has improved endothelial function, lowered blood pressure, increased left ventricular ejection fraction, decreased the incidence of atrial fibrillation, decreased bronchoconstriction, prevented pain, shortened the duration of colds, and decreased the incidence of colds in physically stressed people, and it may also have beneficial effects against pneumonia, see reference [1] .BackgroundThe average person, in good health, maintains normal plasma vitamin C levels with a daily intake of about 0.1 g/day.", [["endothelial", "ANATOMY", 55, 66], ["blood", "ANATOMY", 85, 90], ["left ventricular", "ANATOMY", 111, 127], ["atrial", "ANATOMY", 174, 180], ["plasma", "ANATOMY", 484, 490], ["vitamin C", "CHEMICAL", 32, 41], ["atrial fibrillation", "DISEASE", 174, 193], ["pain", "DISEASE", 236, 240], ["colds", "DISEASE", 268, 273], ["colds", "DISEASE", 306, 311], ["pneumonia", "DISEASE", 391, 400], ["vitamin C", "CHEMICAL", 491, 500], ["vitamin C", "CHEMICAL", 32, 41], ["vitamin C", "CHEMICAL", 491, 500], ["vitamin C", "SIMPLE_CHEMICAL", 32, 41], ["endothelial", "CELL", 55, 66], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["ventricular", "MULTI-TISSUE_STRUCTURE", 116, 127], ["atrial", "MULTI-TISSUE_STRUCTURE", 174, 180], ["people", "ORGANISM", 335, 341], ["plasma", "ORGANISM_SUBSTANCE", 484, 490], ["vitamin C", "SIMPLE_CHEMICAL", 491, 500], ["people", "SPECIES", 335, 341], ["person", "SPECIES", 443, 449], ["BackgroundIn controlled trials", "TREATMENT", 0, 30], ["vitamin C", "TREATMENT", 32, 41], ["blood pressure", "TEST", 85, 99], ["increased left ventricular ejection fraction", "PROBLEM", 101, 145], ["atrial fibrillation", "PROBLEM", 174, 193], ["decreased bronchoconstriction", "PROBLEM", 195, 224], ["pain", "PROBLEM", 236, 240], ["colds", "PROBLEM", 268, 273], ["colds", "PROBLEM", 306, 311], ["pneumonia", "PROBLEM", 391, 400], ["normal plasma vitamin C levels", "TREATMENT", 477, 507], ["left ventricular", "ANATOMY", 111, 127], ["ejection fraction", "OBSERVATION", 128, 145], ["decreased", "OBSERVATION_MODIFIER", 147, 156], ["atrial", "ANATOMY", 174, 180], ["fibrillation", "OBSERVATION", 181, 193], ["decreased", "OBSERVATION_MODIFIER", 195, 204], ["bronchoconstriction", "OBSERVATION", 205, 224], ["decreased", "OBSERVATION_MODIFIER", 279, 288]]], ["However, much higher doses, in the order of grams per day, are needed for critically ill patients to reach normal plasma vitamin C levels [2] [3] [4] [5] .", [["plasma", "ANATOMY", 114, 120], ["critically ill", "DISEASE", 74, 88], ["vitamin C", "CHEMICAL", 121, 130], ["vitamin C", "CHEMICAL", 121, 130], ["[2] [3] [4]", "CHEMICAL", 138, 149], ["patients", "ORGANISM", 89, 97], ["plasma", "ORGANISM_SUBSTANCE", 114, 120], ["vitamin C", "SIMPLE_CHEMICAL", 121, 130], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 138, 153], ["patients", "SPECIES", 89, 97], ["critically ill", "PROBLEM", 74, 88], ["plasma vitamin C levels", "TEST", 114, 137]]], ["Without supplementation, plasma vitamin C levels are particularly low in critically ill patients [6] [7] [8] [9] [10] , indicating that the body may have a greater need for vitamin C when under severe stress such as illness requiring intensive care.", [["plasma", "ANATOMY", 25, 31], ["body", "ANATOMY", 140, 144], ["vitamin C", "CHEMICAL", 32, 41], ["critically ill", "DISEASE", 73, 87], ["vitamin C", "CHEMICAL", 173, 182], ["illness", "DISEASE", 216, 223], ["vitamin C", "CHEMICAL", 32, 41], ["vitamin C", "CHEMICAL", 173, 182], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["vitamin C", "SIMPLE_CHEMICAL", 32, 41], ["patients", "ORGANISM", 88, 96], ["body", "ORGANISM_SUBDIVISION", 140, 144], ["vitamin C", "SIMPLE_CHEMICAL", 173, 182], ["patients", "SPECIES", 88, 96], ["supplementation", "TREATMENT", 8, 23], ["plasma vitamin C levels", "TEST", 25, 48], ["vitamin C", "TREATMENT", 173, 182], ["severe stress", "PROBLEM", 194, 207], ["intensive care", "TREATMENT", 234, 248]]], ["It seems evident that there are gradual changes in vitamin C metabolism according to the severity of disease, in that the sicker a patient is, the greater the consumption of vitamin C. This further suggests that the sicker a patient is, the more they are likely to benefit from additional vitamin C.BackgroundGiven this background, we previously examined whether vitamin C administration has an effect on practical outcomes such as the length of ICU stay, without looking at specific medical conditions.", [["vitamin C", "CHEMICAL", 51, 60], ["vitamin C.", "CHEMICAL", 174, 184], ["vitamin C.Background", "CHEMICAL", 289, 309], ["vitamin C", "CHEMICAL", 363, 372], ["vitamin C", "CHEMICAL", 51, 60], ["vitamin C.", "CHEMICAL", 174, 184], ["vitamin C.Background", "CHEMICAL", 289, 309], ["vitamin C", "CHEMICAL", 363, 372], ["vitamin C", "SIMPLE_CHEMICAL", 51, 60], ["patient", "ORGANISM", 131, 138], ["vitamin", "SIMPLE_CHEMICAL", 174, 181], ["patient", "ORGANISM", 225, 232], ["vitamin C.Background", "SIMPLE_CHEMICAL", 289, 309], ["vitamin C", "SIMPLE_CHEMICAL", 363, 372], ["patient", "SPECIES", 131, 138], ["patient", "SPECIES", 225, 232], ["gradual changes", "PROBLEM", 32, 47], ["vitamin C metabolism", "TREATMENT", 51, 71], ["disease", "PROBLEM", 101, 108], ["vitamin C.", "TREATMENT", 174, 184], ["additional vitamin C.Background", "TREATMENT", 278, 309], ["vitamin C administration", "TREATMENT", 363, 387], ["gradual", "OBSERVATION_MODIFIER", 32, 39], ["disease", "OBSERVATION", 101, 108]]], ["From the results of 12 trials with 1766 patients, we calculated that vitamin C reduced the length of ICU stay on average by 7.8% (P < 0.001) [1] .BackgroundWe also found that in trials in which the control groups were ventilated for 24 h or more, vitamin C shortened the duration of mechanical ventilation by 18% (P = 0.001) [1] .", [["vitamin C", "CHEMICAL", 69, 78], ["vitamin C", "CHEMICAL", 247, 256], ["vitamin C", "CHEMICAL", 69, 78], ["vitamin C", "CHEMICAL", 247, 256], ["patients", "ORGANISM", 40, 48], ["vitamin C", "SIMPLE_CHEMICAL", 69, 78], ["vitamin C", "SIMPLE_CHEMICAL", 247, 256], ["patients", "SPECIES", 40, 48], ["vitamin C", "TREATMENT", 69, 78], ["vitamin C", "TREATMENT", 247, 256], ["mechanical ventilation", "TREATMENT", 283, 305]]], ["However, vitamin C did not have an effect on the duration of mechanical ventilation in trials in which control groups were ventilated for less than 24 h, i.e., trials in patients with less severe illness.BackgroundIn this study, we hypothesize that there is a continuous relationship between disease severity and the beneficial effect of vitamin C administration.", [["vitamin C", "CHEMICAL", 9, 18], ["vitamin C", "CHEMICAL", 338, 347], ["vitamin C", "CHEMICAL", 9, 18], ["vitamin C", "CHEMICAL", 338, 347], ["vitamin C", "SIMPLE_CHEMICAL", 9, 18], ["patients", "ORGANISM", 170, 178], ["vitamin C", "SIMPLE_CHEMICAL", 338, 347], ["patients", "SPECIES", 170, 178], ["vitamin C", "TREATMENT", 9, 18], ["mechanical ventilation", "TREATMENT", 61, 83], ["less severe illness", "PROBLEM", 184, 203], ["this study", "TEST", 217, 227], ["a continuous relationship between disease severity", "PROBLEM", 258, 308], ["vitamin C administration", "TREATMENT", 338, 362], ["mechanical ventilation", "OBSERVATION", 61, 83]]], ["We used metaregression to analyze the gradual relationship between the effect of vitamin C in the treatment group and the duration of mechanical ventilation in untreated patients of the control group, which we used as a proxy for the severity of the disease.MethodsWe included controlled trials that compared the length of mechanical ventilation between vitamin C and control groups.", [["vitamin C", "CHEMICAL", 81, 90], ["vitamin C", "CHEMICAL", 354, 363], ["vitamin C", "CHEMICAL", 81, 90], ["vitamin C", "CHEMICAL", 354, 363], ["vitamin C", "SIMPLE_CHEMICAL", 81, 90], ["patients", "ORGANISM", 170, 178], ["vitamin C", "SIMPLE_CHEMICAL", 354, 363], ["patients", "SPECIES", 170, 178], ["metaregression", "TREATMENT", 8, 22], ["vitamin C", "TREATMENT", 81, 90], ["the treatment group", "TREATMENT", 94, 113], ["mechanical ventilation", "TREATMENT", 134, 156], ["the disease", "PROBLEM", 246, 257], ["MethodsWe", "TREATMENT", 258, 267], ["controlled trials", "TREATMENT", 277, 294], ["mechanical ventilation", "TREATMENT", 323, 345], ["vitamin C and control groups", "TREATMENT", 354, 382], ["mechanical ventilation", "OBSERVATION", 134, 156], ["disease", "OBSERVATION", 250, 257], ["mechanical ventilation", "OBSERVATION", 323, 345]]], ["We included trials in which the administration of vitamin C was the only difference between the study groups; trials that administered other therapies as well as vitamin C were included only if the other therapies were the same for both trial groups.", [["vitamin C", "CHEMICAL", 50, 59], ["vitamin C", "CHEMICAL", 162, 171], ["vitamin C", "CHEMICAL", 50, 59], ["vitamin C", "CHEMICAL", 162, 171], ["vitamin C", "SIMPLE_CHEMICAL", 50, 59], ["vitamin C", "SIMPLE_CHEMICAL", 162, 171], ["trials", "TREATMENT", 12, 18], ["vitamin C", "TREATMENT", 50, 59], ["the study groups", "TEST", 92, 108], ["trials", "TREATMENT", 110, 116], ["other therapies", "TREATMENT", 135, 150], ["vitamin C", "TREATMENT", 162, 171], ["the other therapies", "TREATMENT", 194, 213]]], ["We did not limit our search to randomized trials and did not require placebo control.", [["placebo control", "TREATMENT", 69, 84]]], ["We included all doses and all durations of vitamin C administration.MethodsWe searched MEDLINE, Scopus, and the Cochrane Register on 13 Nov 2019 with the search phrases described in Fig. 1 .", [["vitamin C", "CHEMICAL", 43, 52], ["vitamin C", "CHEMICAL", 43, 52], ["vitamin C", "SIMPLE_CHEMICAL", 43, 52], ["all doses", "TREATMENT", 12, 21], ["vitamin C administration", "TREATMENT", 43, 67]]], ["We had previously searched the same databases for trials on vitamin C and ICU length of stay on 20 Jan 2019 [1] ; from that search, we found trials that were not well indexed and so not identified in our new search specifically for trials on vitamin C and mechanical ventilation.", [["vitamin C", "CHEMICAL", 60, 69], ["vitamin C", "CHEMICAL", 242, 251], ["vitamin C", "CHEMICAL", 60, 69], ["vitamin C", "CHEMICAL", 242, 251], ["vitamin C", "SIMPLE_CHEMICAL", 60, 69], ["vitamin C", "SIMPLE_CHEMICAL", 242, 251], ["vitamin C", "TREATMENT", 60, 69], ["vitamin C", "TREATMENT", 242, 251], ["mechanical ventilation", "TREATMENT", 256, 278], ["mechanical ventilation", "OBSERVATION", 256, 278]]], ["We identified nine trials satisfying our selection criteria [11] [12] [13] [14] [15] [16] [17] [18] [19] .", [["[11] [12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 60, 104], ["our selection criteria", "TEST", 37, 59]]], ["We did not include two further trials that reported \"ventilator-free days\" since we were unable to convert this to our outcome of interest, \"duration of mechanical ventilation\" [20, 21] .MethodsTanaka et al. administered vitamin C continuously with a dosage of 66 mg/kg/h for the first 24 h only, with the reported mean weight of patients being 57 kg [17] .", [["vitamin C", "CHEMICAL", 221, 230], ["vitamin C", "CHEMICAL", 221, 230], ["vitamin C", "SIMPLE_CHEMICAL", 221, 230], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 330, 338], ["mechanical ventilation", "TREATMENT", 153, 175], ["vitamin C", "TREATMENT", 221, 230]]], ["The searches identified nine trials that we included in our systematic review analysis [11] [12] [13] [14] [15] [16] [17] [18] [19] and eight of them were included in our meta-analysis [11] [12] [13] [14] [15] [16] [17] [18] calculated that the average dose was 90 g/day in the Tanaka trial.", [["[11] [12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 87, 131], ["[11] [12] [13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 185, 224], ["our systematic review analysis", "TEST", 56, 86], ["our meta-analysis", "TEST", 167, 184]]], ["Zabet et al. administered 25 mg/kg every 6 h, but the mean weight was not reported [18] .", [["the mean weight", "TEST", 50, 65]]], ["Assuming a mean weight of 60 kg, we estimated that the average dose was 6 g/day in the Zabet trial.", [["a mean weight", "TEST", 9, 22], ["the Zabet trial", "TREATMENT", 83, 98]]], ["We use these estimates in our text.MethodsThe outcome in this analysis is the length of mechanical ventilation, which we analyzed on the relative scale.", [["this analysis", "TEST", 57, 70], ["mechanical ventilation", "TREATMENT", 88, 110], ["mechanical ventilation", "OBSERVATION", 88, 110]]], ["The relative scale is usually more informative than the absolute scale for the analysis of treatment effects on continuous outcomes, in particular, for the analysis of duration data [1, [22] [23] [24] .", [["the absolute scale", "TREATMENT", 52, 70], ["treatment effects", "TREATMENT", 91, 108], ["duration data", "TEST", 168, 181]]], ["We used the ratio of means (RoM) to estimate the effect of vitamin C, and the Taylor series-based approach to calculate the log(RoM) [22] .MethodsWe pooled the selected trials with the metagen function of the meta package of the R statistical software [25] [26] [27] , using the inverse variance, fixed effect options.", [["vitamin C", "CHEMICAL", 59, 68], ["vitamin C", "CHEMICAL", 59, 68], ["vitamin C", "SIMPLE_CHEMICAL", 59, 68], ["the ratio of means (RoM)", "TREATMENT", 8, 32], ["vitamin C", "TREATMENT", 59, 68], ["the Taylor series-based approach", "TREATMENT", 74, 106], ["MethodsWe", "TREATMENT", 139, 148], ["the inverse variance", "TEST", 275, 295]]], ["For metaregression, we used the metareg function of the meta package.", [["the meta package", "TREATMENT", 52, 68]]], ["We used the \u03c7 2 test and the I 2 statistic to assess statistical heterogeneity among the trials in the metaanalysis [28] .", [["the \u03c7 2 test", "TEST", 8, 20], ["statistical heterogeneity", "PROBLEM", 53, 78]]], ["Values of I 2 range from 0% to 100%.", [["Values", "TEST", 0, 6], ["I", "TEST", 10, 11]]], ["A value close to 0% indicates very low-level heterogeneity.", [["A value", "TEST", 0, 7], ["very low-level heterogeneity", "PROBLEM", 30, 58], ["very", "OBSERVATION_MODIFIER", 30, 34], ["low-level", "OBSERVATION_MODIFIER", 35, 44], ["heterogeneity", "OBSERVATION", 45, 58]]], ["A value of more than approximately 50% indicates moderate heterogeneity, and a value over 75% indicates highlevel heterogeneity.", [["A value", "TEST", 0, 7], ["moderate heterogeneity", "PROBLEM", 49, 71], ["a value", "TEST", 77, 84], ["highlevel heterogeneity", "PROBLEM", 104, 127], ["moderate", "OBSERVATION_MODIFIER", 49, 57], ["heterogeneity", "OBSERVATION", 58, 71], ["highlevel heterogeneity", "OBSERVATION", 104, 127]]], ["Our calculations are described in Additional files 1 and 2.Description of the included trialsNine controlled trials have reported on vitamin C administration and the length of mechanical ventilation (Table 1 ; see Additional file 1: Table S1 for further details of the trials).", [["vitamin C", "CHEMICAL", 133, 142], ["vitamin C", "CHEMICAL", 133, 142], ["vitamin C", "SIMPLE_CHEMICAL", 133, 142], ["Our calculations", "TEST", 0, 16], ["vitamin C administration", "TREATMENT", 133, 157], ["mechanical ventilation", "TREATMENT", 176, 198]]], ["The flow diagram of our search is shown in Fig. 1 .Description of the included trialsThe total number of patients was 975, with 810 patients in six cardiac surgery trials, 128 patients in two sepsis trials, and 37 patients in one trial with burns patients (Table 1 ).", [["cardiac", "ANATOMY", 148, 155], ["sepsis", "DISEASE", 192, 198], ["burns", "DISEASE", 241, 246], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 214, 222], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 214, 222], ["patients", "SPECIES", 247, 255], ["The flow diagram", "TEST", 0, 16], ["our search", "TEST", 20, 30], ["flow diagram", "OBSERVATION", 4, 16], ["total", "OBSERVATION_MODIFIER", 89, 94], ["sepsis", "OBSERVATION", 192, 198]]], ["Vitamin C was administered orally in four trials and intravenously in five trials.", [["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin C", "TREATMENT", 0, 9]]], ["Safaei et al. [15] and Tanaka et al. [17] administered vitamin C on a single day only, six trials administered for 2-5 days [11-13, 16, 18, 19] , and one administered \"until ICU discharge\" for septic shock patients [14] .", [["vitamin C", "CHEMICAL", 55, 64], ["septic shock", "DISEASE", 193, 205], ["vitamin C", "CHEMICAL", 55, 64], ["vitamin C", "SIMPLE_CHEMICAL", 55, 64], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["vitamin C", "TREATMENT", 55, 64], ["septic shock", "PROBLEM", 193, 205]]], ["There is a 250-fold variation in the average length of mechanical ventilation in the untreated groups from 2 h [16] to 511 h [17] , which reflects great variation in the severity of the baseline medical condition (Table 1) .Description of the included trialsSix trials were randomized [11-13, 15, 18, 19] , two used alternative allocation [14, 17] , and one did not describe the allocation method [16] .", [["mechanical ventilation", "TREATMENT", 55, 77], ["250-fold", "OBSERVATION_MODIFIER", 11, 19], ["variation", "OBSERVATION_MODIFIER", 20, 29], ["average", "OBSERVATION_MODIFIER", 37, 44], ["length", "OBSERVATION_MODIFIER", 45, 51], ["mechanical ventilation", "OBSERVATION", 55, 77], ["great", "OBSERVATION_MODIFIER", 147, 152], ["variation", "OBSERVATION_MODIFIER", 153, 162]]], ["The reported baseline variables for the treatment groups were balanced in all trials (Additional file 1: Table S1 ).", [["the treatment groups", "TREATMENT", 36, 56]]], ["The risk of bias assessment of the trials is shown in Fig. 2 .", [["bias assessment", "TEST", 12, 27]]], ["Four trials used an explicit placebo [11, 16, 18, 19] .", [["an explicit placebo", "TREATMENT", 17, 36]]], ["The trial by Sadeghpour et al. [19] had a high dropout rate, with 500 participants recruited, but results were reported for just 290 participants [1] .", [["participants", "SPECIES", 70, 82], ["participants", "SPECIES", 133, 145], ["a high dropout rate", "PROBLEM", 40, 59]]], ["We did not include this trial in our statistical models, but the results are presented separately.Results of the included trialsIn our standard meta-analyses, we pooled the results of the trials on the relative scale, calculating the ratio of means The trials are listed by the number of patients (N).", [["patients", "ORGANISM", 288, 296], ["patients", "SPECIES", 288, 296], ["the relative scale", "TREATMENT", 198, 216]]], ["The proportion of males varied from 58% to 75%.", [["males", "OBSERVATION", 18, 23]]], ["The Amini trial [12] results are modified as described previously [1] *Estimated vitamin C dose, see the \"Methods\" section **Sadeghpour et al. [19] recruited 500 participants but reported the results for just 290 participants [1] .", [["vitamin C", "CHEMICAL", 81, 90], ["vitamin C", "CHEMICAL", 81, 90], ["vitamin C", "SIMPLE_CHEMICAL", 81, 90], ["participants", "SPECIES", 162, 174], ["participants", "SPECIES", 213, 225], ["The Amini trial", "TREATMENT", 0, 15], ["Estimated vitamin C dose", "TREATMENT", 71, 95]]], ["Because of the high dropout rate (42%), we did not include this trial in our calculations, but we overlay the findings in Fig. 4 iv intravenous, po per oral, RoM ratio of means [22] : e.g., for the Bjordahl trial [11] , RoM = 0.86, based on 28.8/33.6, and RoM = 0.86 indicates that ventilation time in the vitamin C group was 14% shorter than in the placebo group (RoM) [22] .", [["intravenous", "ANATOMY", 132, 143], ["oral", "ANATOMY", 152, 156], ["vitamin C", "CHEMICAL", 306, 315], ["vitamin C", "CHEMICAL", 306, 315], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 132, 143], ["oral", "ORGANISM_SUBDIVISION", 152, 156], ["vitamin C", "SIMPLE_CHEMICAL", 306, 315], ["the high dropout rate", "PROBLEM", 11, 32], ["our calculations", "TEST", 73, 89], ["iv intravenous", "TREATMENT", 129, 143], ["the Bjordahl trial", "TEST", 194, 212], ["RoM", "TEST", 220, 223], ["RoM", "TEST", 256, 259], ["ventilation time", "TEST", 282, 298], ["the vitamin C group", "TEST", 302, 321]]], ["For example, in the Bjordahl trial [11] , the length of mechanical ventilation was 28.8 h in the vitamin C group and 33.6 h in the placebo group, which corresponds to RoM = 0.86 (28.8/33.6) ( Table 1 ).", [["vitamin C", "CHEMICAL", 97, 106], ["vitamin C", "CHEMICAL", 97, 106], ["vitamin C", "SIMPLE_CHEMICAL", 97, 106], ["mechanical ventilation", "TREATMENT", 56, 78], ["the vitamin C group", "TEST", 93, 112], ["RoM", "TEST", 167, 170], ["mechanical ventilation", "OBSERVATION", 56, 78]]], ["This represents a 14% shorter ventilation time in the vitamin C group.Results of the included trialsOver the eight included trials with 685 patients in total, vitamin C shortened the length of mechanical ventilation on average by 14% (P = 10 \u22125 ) (Fig. 3) .", [["vitamin C", "CHEMICAL", 54, 63], ["vitamin C", "CHEMICAL", 159, 168], ["vitamin C", "CHEMICAL", 54, 63], ["vitamin C", "CHEMICAL", 159, 168], ["vitamin C", "SIMPLE_CHEMICAL", 54, 63], ["patients", "ORGANISM", 140, 148], ["vitamin C", "SIMPLE_CHEMICAL", 159, 168], ["patients", "SPECIES", 140, 148], ["a 14% shorter ventilation time", "TREATMENT", 16, 46], ["the vitamin C group", "TREATMENT", 50, 69], ["vitamin C shortened the length of mechanical ventilation", "TREATMENT", 159, 215], ["mechanical ventilation", "OBSERVATION", 193, 215]]], ["However, there was highly significant heterogeneity in the vitamin C effect between the trials with I 2 = 83% (P = 4.8 \u00d7 10 \u22127 ).", [["vitamin C", "CHEMICAL", 59, 68], ["vitamin C", "CHEMICAL", 59, 68], ["vitamin C", "SIMPLE_CHEMICAL", 59, 68], ["the vitamin C effect", "TREATMENT", 55, 75], ["P", "TEST", 111, 112], ["highly", "OBSERVATION_MODIFIER", 19, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["heterogeneity", "OBSERVATION", 38, 51]]], ["This indicates that the calculated average effect of 14% is not consistent over all the included trials.Results of the included trialsIn a meta-regression analysis, we found that the heterogeneity between the trials was explained by the length of mechanical ventilation in the untreated control group (Fig. 4) .", [["a meta-regression analysis", "TEST", 137, 163], ["mechanical ventilation", "TREATMENT", 247, 269], ["mechanical ventilation", "OBSERVATION", 247, 269]]], ["The evidence for modification of the vitamin C effect by the untreated ventilation time was very strong (P = 10 \u22127 ).", [["vitamin C", "CHEMICAL", 37, 46], ["vitamin C", "CHEMICAL", 37, 46], ["vitamin C", "SIMPLE_CHEMICAL", 37, 46], ["the vitamin C effect", "TREATMENT", 33, 53], ["the untreated ventilation time", "TEST", 57, 87]]], ["There is little residual heterogeneity around the regression line with I 2 = 12% (P = 0.3), which indicates that the meta-regression in Fig. 4 much better captures the findings of the trials compared with the standard meta-analysis shown in Fig. 3 .", [["little residual heterogeneity", "PROBLEM", 9, 38], ["the meta-regression in Fig", "PROBLEM", 113, 139], ["the standard meta-analysis", "TEST", 205, 231], ["little", "OBSERVATION_MODIFIER", 9, 15], ["residual", "OBSERVATION_MODIFIER", 16, 24], ["heterogeneity", "OBSERVATION", 25, 38], ["regression", "OBSERVATION_MODIFIER", 50, 60], ["line", "OBSERVATION_MODIFIER", 61, 65], ["Fig", "OBSERVATION_MODIFIER", 136, 139]]], ["The confidence intervals of all included trials are consistent with the regression line in Fig. 4 .", [["the regression line in Fig", "PROBLEM", 68, 94], ["consistent with", "UNCERTAINTY", 52, 67], ["regression line", "OBSERVATION", 72, 87], ["Fig", "OBSERVATION_MODIFIER", 91, 94]]], ["The Habib [14] trial contributed considerable weight to the effect of vitamin C in Fig. 4 .", [["vitamin C", "CHEMICAL", 70, 79], ["vitamin C", "CHEMICAL", 70, 79], ["vitamin C", "SIMPLE_CHEMICAL", 70, 79], ["considerable weight", "PROBLEM", 33, 52], ["vitamin C in Fig", "TREATMENT", 70, 86]]], ["However, even if both the Habib [14] and Tanaka [17] trials are excluded, there is strong evidence from the six remaining trials that the effect of vitamin C is modified by the ventilation time in the untreated control group (P = 0.004) (see Additional file 1).", [["vitamin C", "CHEMICAL", 148, 157], ["vitamin C", "CHEMICAL", 148, 157], ["vitamin C", "SIMPLE_CHEMICAL", 148, 157], ["vitamin C", "TREATMENT", 148, 157]]], ["Figure 4 indicates that no meaningful benefit from vitamin C is expected for patients whose ventilation time is shorter than 10 h.", [["vitamin C", "CHEMICAL", 51, 60], ["vitamin C", "CHEMICAL", 51, 60], ["vitamin C", "SIMPLE_CHEMICAL", 51, 60], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["vitamin C", "TREATMENT", 51, 60], ["no", "UNCERTAINTY", 24, 26]]], ["On the other hand, the regression line in Fig. 4 predicts that for patients ventilated for 100 h, vitamin C reduces the ventilation time on average by 31% (RoM = 0.69).", [["vitamin C", "CHEMICAL", 98, 107], ["vitamin C", "CHEMICAL", 98, 107], ["patients", "ORGANISM", 67, 75], ["vitamin C", "SIMPLE_CHEMICAL", 98, 107], ["patients", "SPECIES", 67, 75], ["the regression line in Fig", "PROBLEM", 19, 45], ["vitamin C", "TREATMENT", 98, 107], ["RoM", "TEST", 156, 159], ["regression line", "OBSERVATION", 23, 38], ["Fig", "OBSERVATION_MODIFIER", 42, 45]]], ["Three trials administered vitamin C orally and five intravenously, but both methods are consistent with the single regression line in Fig. 4 .Results of the included trialsTanaka et al. [17] used by far the highest dose of vitamin C, 90 g/day.", [["intravenously", "ANATOMY", 52, 65], ["vitamin C", "CHEMICAL", 26, 35], ["vitamin C", "CHEMICAL", 223, 232], ["vitamin C", "CHEMICAL", 26, 35], ["vitamin C", "CHEMICAL", 223, 232], ["vitamin C", "SIMPLE_CHEMICAL", 26, 35], ["vitamin C", "SIMPLE_CHEMICAL", 223, 232], ["vitamin C orally", "TREATMENT", 26, 42], ["the single regression line in Fig", "TREATMENT", 104, 137], ["vitamin C", "TREATMENT", 223, 232], ["consistent with", "UNCERTAINTY", 88, 103], ["regression line", "OBSERVATION", 115, 130], ["Fig", "OBSERVATION_MODIFIER", 134, 137]]], ["Figure 4 indicates that the substantial benefit observed in that trial may be explained by the particularly sick patients with burns requiring very long ventilation, rather than by the very high vitamin C dose.", [["burns", "DISEASE", 127, 132], ["vitamin C", "CHEMICAL", 195, 204], ["vitamin C", "CHEMICAL", 195, 204], ["patients", "ORGANISM", 113, 121], ["vitamin C", "SIMPLE_CHEMICAL", 195, 204], ["patients", "SPECIES", 113, 121], ["very long ventilation", "TREATMENT", 143, 164], ["the very high vitamin C dose", "TREATMENT", 181, 209]]], ["We found that vitamin C shortened the length of ventilation on average by 25% (P = 10 \u221210 ) when the Tanaka trial was excluded and the analysis was restricted to the five trials with dosage from 1 to 6 g/day for patients ventilated for over 10 h [11, [13] [14] [15] 18] .", [["vitamin C", "CHEMICAL", 14, 23], ["vitamin C", "CHEMICAL", 14, 23], ["vitamin C", "SIMPLE_CHEMICAL", 14, 23], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["vitamin C", "PROBLEM", 14, 23], ["P", "TEST", 79, 80], ["the Tanaka trial", "TEST", 97, 113], ["the analysis", "TEST", 131, 143]]], ["The Sadeghpour trial [19] is not included in our statistical models because of the high dropout rate, but the results are shown in Fig. 4 by the dashed line and they are consistent with the findings of the other trials.Secondary analysis of vitamin C and E combination trialsOur meta-regression analysis above was restricted to studies in which vitamin C was administered as the only difference between the study groups.", [["vitamin C", "CHEMICAL", 241, 250], ["vitamin C", "CHEMICAL", 345, 354], ["vitamin C and E", "CHEMICAL", 241, 256], ["vitamin C", "CHEMICAL", 345, 354], ["vitamin C", "SIMPLE_CHEMICAL", 241, 250], ["E", "SIMPLE_CHEMICAL", 255, 256], ["vitamin C", "SIMPLE_CHEMICAL", 345, 354], ["the high dropout rate", "PROBLEM", 79, 100], ["Secondary analysis", "TEST", 219, 237], ["vitamin C", "TREATMENT", 241, 250], ["E combination trials", "TREATMENT", 255, 275], ["Our meta-regression analysis", "TEST", 275, 303], ["studies", "TEST", 328, 335], ["vitamin C", "TREATMENT", 345, 354], ["the study groups", "TEST", 403, 419], ["line", "OBSERVATION", 152, 156], ["consistent with", "UNCERTAINTY", 170, 185]]], ["We did not carry out a systematic search for trials on the combination of vitamins C and E, but in our search for Fig. 2 Risk of bias summary.", [["vitamins C", "CHEMICAL", 74, 84], ["vitamins C and E", "CHEMICAL", 74, 90], ["vitamins C", "SIMPLE_CHEMICAL", 74, 84], ["E", "SIMPLE_CHEMICAL", 89, 90], ["trials", "TREATMENT", 45, 51], ["vitamins C and E", "TREATMENT", 74, 90]]], ["A green plus sign (+) indicates that there is no substantial concern for bias in the particular quality item.", [["A green plus sign", "TEST", 0, 17], ["bias in the particular quality item", "PROBLEM", 73, 108], ["no", "UNCERTAINTY", 46, 48], ["substantial", "OBSERVATION_MODIFIER", 49, 60]]], ["A red minus sign (\u2212) indicates that there is an explicit concern regarding bias.", [["A red minus sign", "TEST", 0, 16]]], ["In the Sadeghpour trial, the dropout rate was very high (42%), justifying the minus sign [1] .", [["the dropout rate", "TEST", 25, 41]]], ["The reference numbers to the trials are shown in Table 1 the vitamin C trials, we found three trials that administered vitamins C and E together to critically ill patients [29] [30] [31] .", [["vitamin C", "CHEMICAL", 61, 70], ["vitamins C", "CHEMICAL", 119, 129], ["critically ill", "DISEASE", 148, 162], ["vitamin C", "CHEMICAL", 61, 70], ["vitamins C and E", "CHEMICAL", 119, 135], ["vitamin C", "SIMPLE_CHEMICAL", 61, 70], ["vitamins C", "SIMPLE_CHEMICAL", 119, 129], ["E", "SIMPLE_CHEMICAL", 134, 135], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["the vitamin C trials", "TREATMENT", 57, 77], ["vitamins C", "TREATMENT", 119, 129]]], ["Given that our search for vitamin C also identifies any combinations of vitamins C and E, it is unlikely that there are many more combination trials.", [["vitamin C", "CHEMICAL", 26, 35], ["vitamins C", "CHEMICAL", 72, 82], ["vitamin C", "CHEMICAL", 26, 35], ["vitamins C and E", "CHEMICAL", 72, 88], ["vitamin C", "SIMPLE_CHEMICAL", 26, 35], ["vitamins C", "SIMPLE_CHEMICAL", 72, 82], ["E", "SIMPLE_CHEMICAL", 87, 88], ["vitamin C", "TREATMENT", 26, 35], ["vitamins C", "TREATMENT", 72, 82]]], ["As a secondary analysis, we compared the findings of the three vitamin C and E trials with our meta-regression model based on the eight trials using vitamin C alone (Fig. 5 ).Secondary analysis of vitamin C and E combination trialsNathens et al. administered 1 g/day vitamin C intravenously and 1000 IU/day vitamin E enterally [29] .", [["vitamin C", "CHEMICAL", 63, 72], ["vitamin C", "CHEMICAL", 149, 158], ["vitamin C", "CHEMICAL", 197, 206], ["vitamin C", "CHEMICAL", 267, 276], ["vitamin E", "CHEMICAL", 307, 316], ["vitamin C and E", "CHEMICAL", 63, 78], ["vitamin C", "CHEMICAL", 149, 158], ["vitamin C and E", "CHEMICAL", 197, 212], ["vitamin C", "CHEMICAL", 267, 276], ["vitamin E", "CHEMICAL", 307, 316], ["vitamin C", "SIMPLE_CHEMICAL", 63, 72], ["vitamin C", "SIMPLE_CHEMICAL", 149, 158], ["vitamin C", "SIMPLE_CHEMICAL", 197, 206], ["E", "SIMPLE_CHEMICAL", 211, 212], ["vitamin C", "SIMPLE_CHEMICAL", 267, 276], ["vitamin E", "SIMPLE_CHEMICAL", 307, 316], ["a secondary analysis", "TEST", 3, 23], ["the three vitamin C", "TREATMENT", 53, 72], ["E trials", "TREATMENT", 77, 85], ["our meta-regression model", "TREATMENT", 91, 116], ["vitamin C", "TREATMENT", 149, 158], ["Secondary analysis", "TEST", 175, 193], ["vitamin C", "TREATMENT", 197, 206], ["E combination trials", "TREATMENT", 211, 231], ["vitamin C intravenously", "TREATMENT", 267, 290], ["vitamin E enterally", "TREATMENT", 307, 326]]], ["The duration of mechanical ventilation in the control group was 110 h, for which our model predicts a 32% decrease in the vitamin C group.", [["vitamin C", "CHEMICAL", 122, 131], ["vitamin C", "CHEMICAL", 122, 131], ["vitamin C", "SIMPLE_CHEMICAL", 122, 131], ["mechanical ventilation", "TREATMENT", 16, 38], ["the vitamin C group", "TREATMENT", 118, 137], ["mechanical ventilation", "OBSERVATION", 16, 38]]], ["The observed decrease in the vitamins C and E group was 20% (95% CI 13% to 26%).Secondary analysis of vitamin C and E combination trialsCrimi et al. administered 0.5 g/day vitamin C and 400 IU/day vitamin E enterally [30] .", [["vitamins C", "CHEMICAL", 29, 39], ["vitamin C", "CHEMICAL", 102, 111], ["vitamin C", "CHEMICAL", 172, 181], ["vitamin E", "CHEMICAL", 197, 206], ["vitamins C and E", "CHEMICAL", 29, 45], ["vitamin C and E", "CHEMICAL", 102, 117], ["vitamin C", "CHEMICAL", 172, 181], ["vitamin E", "CHEMICAL", 197, 206], ["vitamins C", "SIMPLE_CHEMICAL", 29, 39], ["E", "SIMPLE_CHEMICAL", 44, 45], ["vitamin C", "SIMPLE_CHEMICAL", 102, 111], ["E", "SIMPLE_CHEMICAL", 116, 117], ["vitamin C", "SIMPLE_CHEMICAL", 172, 181], ["vitamin E", "SIMPLE_CHEMICAL", 197, 206], ["the vitamins C", "TEST", 25, 39], ["CI", "TEST", 65, 67], ["Secondary analysis", "TEST", 80, 98], ["vitamin C", "TREATMENT", 102, 111], ["E combination trials", "TREATMENT", 116, 136], ["vitamin C", "TREATMENT", 172, 181], ["vitamin E enterally", "TREATMENT", 197, 216], ["decrease", "OBSERVATION_MODIFIER", 13, 21]]], ["Ventilation time in the control group was 213 h, for which our model predicts a Fig. 3 Effect of vitamin C on the duration of ventilation.", [["vitamin C", "CHEMICAL", 97, 106], ["vitamin C", "CHEMICAL", 97, 106], ["vitamin C", "SIMPLE_CHEMICAL", 97, 106], ["Ventilation time", "TREATMENT", 0, 16], ["vitamin C", "TREATMENT", 97, 106], ["ventilation", "TREATMENT", 126, 137]]], ["The horizontal lines indicate the 95% CI for the vitamin C effect and the blue squares in the middle of the horizontal lines indicate the point estimate of the effect in the particular trial.", [["vitamin C", "CHEMICAL", 49, 58], ["vitamin C", "CHEMICAL", 49, 58], ["horizontal lines", "CELL", 4, 20], ["vitamin C", "SIMPLE_CHEMICAL", 49, 58], ["horizontal lines", "CELL_LINE", 108, 124], ["The horizontal lines", "TREATMENT", 0, 20], ["the vitamin C effect", "TREATMENT", 45, 65], ["the blue squares", "TREATMENT", 70, 86], ["horizontal lines", "OBSERVATION", 4, 20], ["middle", "ANATOMY_MODIFIER", 94, 100], ["horizontal lines", "OBSERVATION", 108, 124]]], ["The red diamond shape indicates the pooled effect and its 95% CI.", [["The red diamond shape", "PROBLEM", 0, 21], ["red diamond", "OBSERVATION_MODIFIER", 4, 15], ["shape", "OBSERVATION_MODIFIER", 16, 21], ["pooled effect", "OBSERVATION", 36, 49]]], ["The Sadeghpour trial [19] is not included in the meta-analysis, since the dropout rate was high (42%) [1] .", [["the dropout rate", "TEST", 70, 86]]], ["RoM ratio of means [22] [19] is not included in the statistical model, since the dropout rate was high; however, it is overlaid here for information.", [["RoM ratio", "TEST", 0, 9], ["the dropout rate", "TEST", 77, 93]]], ["RoM ratio of means [22] 37% decrease in the vitamin C group.", [["vitamin C", "CHEMICAL", 44, 53], ["vitamin C", "CHEMICAL", 44, 53], ["RoM", "SIMPLE_CHEMICAL", 0, 3], ["vitamin C", "SIMPLE_CHEMICAL", 44, 53], ["RoM ratio", "TEST", 0, 9], ["means", "TEST", 13, 18], ["the vitamin C group", "TREATMENT", 40, 59]]], ["The observed decrease was 30% (95% CI 0% to 61%).Secondary analysis of vitamin C and E combination trialsHowe et al. administered 1 g/day vitamin C and 1000 IU/day vitamin E enterally [31] .", [["vitamin C", "CHEMICAL", 71, 80], ["vitamin C", "CHEMICAL", 138, 147], ["vitamin E", "CHEMICAL", 164, 173], ["vitamin C and E", "CHEMICAL", 71, 86], ["vitamin C", "CHEMICAL", 138, 147], ["vitamin E", "CHEMICAL", 164, 173], ["vitamin C", "SIMPLE_CHEMICAL", 71, 80], ["E", "SIMPLE_CHEMICAL", 85, 86], ["vitamin C", "SIMPLE_CHEMICAL", 138, 147], ["vitamin E", "SIMPLE_CHEMICAL", 164, 173], ["CI", "TEST", 35, 37], ["Secondary analysis", "TEST", 49, 67], ["vitamin C", "TREATMENT", 71, 80], ["E combination trials", "TREATMENT", 85, 105], ["vitamin C", "TREATMENT", 138, 147], ["vitamin E enterally", "TREATMENT", 164, 183], ["decrease", "OBSERVATION_MODIFIER", 13, 21]]], ["Ventilation time in the control group was 456 h, and our model predicts a 42% decrease in the vitamin C group.", [["vitamin C", "CHEMICAL", 94, 103], ["vitamin C", "CHEMICAL", 94, 103], ["vitamin C", "SIMPLE_CHEMICAL", 94, 103], ["Ventilation time", "TREATMENT", 0, 16], ["the vitamin C group", "TREATMENT", 90, 109]]], ["The observed decrease was 47% (95% CI 7% to 87%).", [["CI", "TEST", 35, 37], ["decrease", "OBSERVATION_MODIFIER", 13, 21]]], ["In all three vitamin C and E trials, the observed effect of treatment was quite close to the effect predicted by the trials using only vitamin C (Fig. 5 ; see Additional files 1 and 2 for the calculations).DiscussionThere is significant variation in the severity of disease in patients who are mechanically ventilated.", [["vitamin C", "CHEMICAL", 13, 22], ["vitamin C", "CHEMICAL", 135, 144], ["vitamin C and E", "CHEMICAL", 13, 28], ["vitamin C", "CHEMICAL", 135, 144], ["vitamin C", "SIMPLE_CHEMICAL", 13, 22], ["E", "SIMPLE_CHEMICAL", 27, 28], ["vitamin C", "SIMPLE_CHEMICAL", 135, 144], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 277, 285], ["vitamin C and E trials", "TREATMENT", 13, 35], ["treatment", "TREATMENT", 60, 69], ["vitamin C (Fig. 5", "TREATMENT", 135, 152], ["the calculations", "TEST", 188, 204], ["disease", "PROBLEM", 266, 273], ["mechanically ventilated", "PROBLEM", 294, 317], ["significant", "OBSERVATION_MODIFIER", 225, 236], ["variation", "OBSERVATION_MODIFIER", 237, 246], ["disease", "OBSERVATION", 266, 273], ["mechanically ventilated", "OBSERVATION", 294, 317]]], ["One measure of severity is the mechanical ventilation time required by the patient, which we used as a proxy for severity.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["the mechanical ventilation time", "TREATMENT", 27, 58], ["severity", "PROBLEM", 113, 121], ["severity", "OBSERVATION_MODIFIER", 15, 23], ["mechanical ventilation", "OBSERVATION", 31, 53]]], ["In this study, we found that the duration of ventilation in the untreated control group explained most of the variation in the reported effects of vitamin C on the mechanical ventilation time.", [["vitamin C", "CHEMICAL", 147, 156], ["vitamin C", "CHEMICAL", 147, 156], ["vitamin C", "SIMPLE_CHEMICAL", 147, 156], ["this study", "TEST", 3, 13], ["ventilation", "TREATMENT", 45, 56], ["the untreated control group", "TREATMENT", 60, 87], ["vitamin C", "TREATMENT", 147, 156], ["the mechanical ventilation time", "TREATMENT", 160, 191], ["mechanical ventilation", "OBSERVATION", 164, 186]]], ["In the standard meta-analysis, there is high-level heterogeneity with I 2 = 83% (Fig. 3) , whereas in the meta-regression of the vitamin C effect by the control group duration of ventilation, the residual heterogeneity is small with I 2 = 12% (Fig. 4) .DiscussionSome of the included trials examined elective surgical patients.", [["vitamin C", "CHEMICAL", 129, 138], ["vitamin C", "CHEMICAL", 129, 138], ["vitamin C", "SIMPLE_CHEMICAL", 129, 138], ["patients", "ORGANISM", 318, 326], ["patients", "SPECIES", 318, 326], ["high-level heterogeneity", "PROBLEM", 40, 64], ["the vitamin C effect", "TREATMENT", 125, 145], ["ventilation", "TREATMENT", 179, 190], ["the residual heterogeneity", "PROBLEM", 192, 218], ["elective surgical patients", "TREATMENT", 300, 326], ["high", "OBSERVATION_MODIFIER", 40, 44], ["-level", "OBSERVATION_MODIFIER", 44, 50], ["heterogeneity", "OBSERVATION_MODIFIER", 51, 64], ["residual", "OBSERVATION_MODIFIER", 196, 204], ["heterogeneity", "OBSERVATION", 205, 218], ["small", "OBSERVATION_MODIFIER", 222, 227]]], ["These patients are not usually critically ill; however, as a result of their surgery, they are routinely ventilated in the ICU for a period of time.", [["critically ill", "DISEASE", 31, 45], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["their surgery", "TREATMENT", 71, 84]]], ["In the metaregression, such patients are located on the left-hand side of Fig. 4 which means that the analysis takes into account the low level of illness severity.", [["left-hand", "ANATOMY", 56, 65], ["illness", "DISEASE", 147, 154], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["the analysis", "TEST", 98, 110], ["illness severity", "PROBLEM", 147, 163], ["left", "ANATOMY_MODIFIER", 56, 60], ["hand", "ANATOMY", 61, 65], ["Fig", "OBSERVATION", 74, 77], ["low level", "OBSERVATION_MODIFIER", 134, 143], ["illness", "OBSERVATION", 147, 154]]], ["In contrast, the inclusion of patients with less severe disease in the standard meta-analysis decreases the average effect of vitamin C, so that the greater effect on the sicker patients is masked (Fig. 3) .DiscussionThe substantial benefit observed in the Tanaka [17] trial seems to be explained by the particularly long mechanical ventilation in the untreated control patients (which reflects the greater illness severity), rather than the particularly high vitamin C dosage of 90 g/day in that trial.", [["vitamin C", "CHEMICAL", 126, 135], ["illness", "DISEASE", 407, 414], ["vitamin C", "CHEMICAL", 460, 469], ["vitamin C", "CHEMICAL", 126, 135], ["vitamin C", "CHEMICAL", 460, 469], ["patients", "ORGANISM", 30, 38], ["vitamin C", "SIMPLE_CHEMICAL", 126, 135], ["patients", "ORGANISM", 178, 186], ["patients", "ORGANISM", 370, 378], ["vitamin C", "SIMPLE_CHEMICAL", 460, 469], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 370, 378], ["less severe disease", "PROBLEM", 44, 63], ["vitamin C", "TREATMENT", 126, 135], ["long mechanical ventilation", "TREATMENT", 317, 344], ["high vitamin C dosage", "TREATMENT", 455, 476], ["less", "OBSERVATION_MODIFIER", 44, 48], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["disease", "OBSERVATION", 56, 63], ["greater", "OBSERVATION_MODIFIER", 149, 156], ["effect", "OBSERVATION_MODIFIER", 157, 163]]], ["All the other trials used 6 g/day or less, but there is no evidence that the benefit was less than in the Tanaka trial when taking into account the ventilation time in the untreated control group (Fig. 4 ).", [["the ventilation time", "TREATMENT", 144, 164], ["no evidence", "UNCERTAINTY", 56, 67]]], ["There are a few reports of deaths caused by intravenous vitamin C in doses of 80 to 224 g/day [32, 33] .", [["intravenous", "ANATOMY", 44, 55], ["deaths", "DISEASE", 27, 33], ["vitamin C", "CHEMICAL", 56, 65], ["vitamin C", "CHEMICAL", 56, 65], ["intravenous vitamin C", "SIMPLE_CHEMICAL", 44, 65], ["intravenous vitamin C", "TREATMENT", 44, 65], ["few", "OBSERVATION_MODIFIER", 12, 15]]], ["Therefore, the interpretation that the benefit in the Tanaka trial may be caused by the type of patients and not by the very high vitamin C dose is important for planning further trials.DiscussionOur previous analysis of the length of ICU stay also found that the effect of vitamin C appeared greater for the sicker patients.", [["vitamin C", "CHEMICAL", 130, 139], ["vitamin C", "CHEMICAL", 274, 283], ["vitamin C", "CHEMICAL", 130, 139], ["vitamin C", "CHEMICAL", 274, 283], ["patients", "ORGANISM", 96, 104], ["vitamin C", "SIMPLE_CHEMICAL", 130, 139], ["vitamin C", "SIMPLE_CHEMICAL", 274, 283], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 316, 324], ["the Tanaka trial", "TREATMENT", 50, 66], ["the very high vitamin C dose", "TREATMENT", 116, 144], ["vitamin C", "TREATMENT", 274, 283]]], ["The length of ICU stay was reduced by 10.1% (P = 0.0001) in patients who required an ICU stay of 3 days or longer, but by just 5.7% (P = 0.03) in those who needed only 1-2 days in the ICU [1] .DiscussionThere are also other findings that are consistent with vitamin C having a greater effect on patients with more severe medical conditions.", [["vitamin C", "CHEMICAL", 258, 267], ["vitamin C", "CHEMICAL", 258, 267], ["patients", "ORGANISM", 60, 68], ["vitamin C", "SIMPLE_CHEMICAL", 258, 267], ["patients", "ORGANISM", 295, 303], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 295, 303], ["vitamin C", "TREATMENT", 258, 267], ["more severe medical conditions", "PROBLEM", 309, 339], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["A meta-analysis of vitamin C effect on exercise-induced bronchoconstriction found that vitamin C halved FEV 1 decline caused by exercise [34] .", [["vitamin C", "CHEMICAL", 19, 28], ["vitamin C", "CHEMICAL", 87, 96], ["vitamin C", "CHEMICAL", 19, 28], ["vitamin C", "CHEMICAL", 87, 96], ["vitamin C", "SIMPLE_CHEMICAL", 19, 28], ["vitamin C", "SIMPLE_CHEMICAL", 87, 96], ["FEV 1", "GENE_OR_GENE_PRODUCT", 104, 109], ["vitamin C effect", "TREATMENT", 19, 35], ["exercise", "TEST", 39, 47], ["bronchoconstriction", "PROBLEM", 56, 75], ["vitamin C", "TREATMENT", 87, 96]]], ["The constant relative effect indicates that the absolute effect was greatest for patients who had the greatest bronchoconstriction in the exercise test.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["the exercise test", "TEST", 134, 151]]], ["RoM ratio of means [22] with common cold patients indicated that the bronchodilatory effect of vitamin C was most beneficial for those with the greatest bronchial hypersensitivity to histamine [35, 36] .DiscussionThere is much evidence indicating that vitamins C and E have an interaction in vitro and in vivo [37] [38] [39] [40] [41] , and three trials have examined the effect of the combination of vitamins C and E on the duration of mechanical ventilation [29] [30] [31] .", [["bronchial", "ANATOMY", 153, 162], ["vitamin C", "CHEMICAL", 95, 104], ["bronchial hypersensitivity", "DISEASE", 153, 179], ["histamine", "CHEMICAL", 183, 192], ["vitamins C", "CHEMICAL", 252, 262], ["vitamins C", "CHEMICAL", 401, 411], ["vitamin C", "CHEMICAL", 95, 104], ["histamine", "CHEMICAL", 183, 192], ["vitamins C and E", "CHEMICAL", 252, 268], ["vitamins C and E", "CHEMICAL", 401, 417], ["RoM", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 41, 49], ["vitamin C", "SIMPLE_CHEMICAL", 95, 104], ["bronchial", "MULTI-TISSUE_STRUCTURE", 153, 162], ["histamine", "SIMPLE_CHEMICAL", 183, 192], ["vitamins C", "SIMPLE_CHEMICAL", 252, 262], ["E", "SIMPLE_CHEMICAL", 267, 268], ["[37] [38] [39] [40] [41]", "SIMPLE_CHEMICAL", 310, 334], ["vitamins C", "SIMPLE_CHEMICAL", 401, 411], ["E", "SIMPLE_CHEMICAL", 416, 417], ["patients", "SPECIES", 41, 49], ["common cold patients", "PROBLEM", 29, 49], ["the bronchodilatory effect", "TREATMENT", 65, 91], ["vitamin C", "TREATMENT", 95, 104], ["the greatest bronchial hypersensitivity", "PROBLEM", 140, 179], ["histamine", "TEST", 183, 192], ["vitamins C and E", "PROBLEM", 252, 268], ["vitamins C", "TREATMENT", 401, 411], ["mechanical ventilation", "TREATMENT", 437, 459], ["bronchial", "ANATOMY", 153, 162], ["hypersensitivity", "OBSERVATION", 163, 179]]], ["The reported effects from the three trials are largely consistent with the meta-regression model based on the eight trials using vitamin C alone (Fig. 5) , though the confidence interval of the Nathens et al. trial does not cross the regression line.", [["vitamin C", "CHEMICAL", 129, 138], ["vitamin C", "CHEMICAL", 129, 138], ["vitamin C", "SIMPLE_CHEMICAL", 129, 138], ["vitamin C", "TREATMENT", 129, 138]]], ["Thus, the statistically significant benefit observed in each of these three trials might be explained by the long ventilation time in the control groups, indicating greater severity of illness in the patients, rather than by the addition of vitamin E to the intervention.", [["illness", "DISEASE", 185, 192], ["vitamin E", "CHEMICAL", 241, 250], ["vitamin E", "CHEMICAL", 241, 250], ["patients", "ORGANISM", 200, 208], ["vitamin E", "SIMPLE_CHEMICAL", 241, 250], ["patients", "SPECIES", 200, 208], ["illness", "PROBLEM", 185, 192], ["vitamin E", "TREATMENT", 241, 250], ["the intervention", "TREATMENT", 254, 270], ["greater", "OBSERVATION_MODIFIER", 165, 172], ["severity", "OBSERVATION_MODIFIER", 173, 181], ["illness", "OBSERVATION", 185, 192]]], ["To test the possible additional benefit of vitamin E over vitamin C would require 2 \u00d7 2 factorial trials.DiscussionAlthough our meta-regression analysis by the ventilation time in the control group explains the heterogeneity in the published trials, it seems evident that other variables influence the effects of vitamin C. For example, there are indications that treatment effects can differ between less and more developed countries.", [["vitamin E", "CHEMICAL", 43, 52], ["vitamin C", "CHEMICAL", 58, 67], ["vitamin C.", "CHEMICAL", 313, 323], ["vitamin E", "CHEMICAL", 43, 52], ["vitamin C", "CHEMICAL", 58, 67], ["vitamin C.", "CHEMICAL", 313, 323], ["vitamin E", "SIMPLE_CHEMICAL", 43, 52], ["vitamin C", "SIMPLE_CHEMICAL", 58, 67], ["vitamin", "SIMPLE_CHEMICAL", 313, 320], ["vitamin E over vitamin C", "TREATMENT", 43, 67], ["our meta-regression analysis", "TEST", 124, 152], ["the ventilation time", "TREATMENT", 156, 176], ["vitamin C.", "TREATMENT", 313, 323]]], ["Panagiotou et al. identified several studies that reported greater treatment effects in less developed countries than in more developed countries [42] .", [["several studies", "TEST", 29, 44], ["greater", "OBSERVATION_MODIFIER", 59, 66]]], ["Although methodological variations may explain some of the differences, there can also be genuine treatment differences between substantially different cultures, since wealth is strongly correlated with life-style factors including nutrition and with differences in hospital treatments.", [["genuine treatment differences", "PROBLEM", 90, 119], ["substantially different cultures", "PROBLEM", 128, 160], ["hospital treatments", "TREATMENT", 266, 285], ["treatment", "OBSERVATION", 98, 107]]], ["Previously, vitamin C was found to prevent post-operative atrial fibrillation in non-US trials, but not in US-based trials [43] , which may also indicate that the effects of vitamin C can depend on cultural context.", [["atrial", "ANATOMY", 58, 64], ["vitamin C", "CHEMICAL", 12, 21], ["atrial fibrillation", "DISEASE", 58, 77], ["vitamin C", "CHEMICAL", 174, 183], ["vitamin C", "CHEMICAL", 12, 21], ["vitamin C", "CHEMICAL", 174, 183], ["vitamin C", "SIMPLE_CHEMICAL", 12, 21], ["atrial", "MULTI-TISSUE_STRUCTURE", 58, 64], ["vitamin C", "SIMPLE_CHEMICAL", 174, 183], ["vitamin C", "TREATMENT", 12, 21], ["post-operative atrial fibrillation", "PROBLEM", 43, 77], ["vitamin C", "TREATMENT", 174, 183], ["atrial", "ANATOMY", 58, 64], ["fibrillation", "OBSERVATION", 65, 77]]], ["Thus, although the fit of the meta-regression line in Fig. 4 is good, the findings should not be extrapolated directly to other contexts.DiscussionTwo recent meta-analyses concluded that vitamin C is not beneficial for critically ill patients [44, 45] , whereas a third concluded that vitamin C was beneficial for sepsis patients [46] .", [["vitamin C", "CHEMICAL", 187, 196], ["critically ill", "DISEASE", 219, 233], ["vitamin C", "CHEMICAL", 285, 294], ["sepsis", "DISEASE", 314, 320], ["vitamin C", "CHEMICAL", 187, 196], ["vitamin C", "CHEMICAL", 285, 294], ["vitamin C", "SIMPLE_CHEMICAL", 187, 196], ["patients", "ORGANISM", 234, 242], ["vitamin C", "SIMPLE_CHEMICAL", 285, 294], ["patients", "ORGANISM", 321, 329], ["patients", "SPECIES", 234, 242], ["patients", "SPECIES", 321, 329], ["the meta-regression line", "TREATMENT", 26, 50], ["vitamin C", "TREATMENT", 187, 196], ["vitamin C", "TREATMENT", 285, 294], ["sepsis", "PROBLEM", 314, 320], ["good", "OBSERVATION_MODIFIER", 64, 68]]], ["However, all three meta-analyses included studies that administered vitamin C in combination with numerous other substances, such as vitamins A, B, and E, selenium, and zinc [47] [48] [49] .", [["vitamin C", "CHEMICAL", 68, 77], ["vitamins A, B, and E", "CHEMICAL", 133, 153], ["selenium", "CHEMICAL", 155, 163], ["zinc", "CHEMICAL", 169, 173], ["vitamin C", "CHEMICAL", 68, 77], ["vitamins A, B, and E", "CHEMICAL", 133, 153], ["selenium", "CHEMICAL", 155, 163], ["zinc", "CHEMICAL", 169, 173], ["vitamin C", "SIMPLE_CHEMICAL", 68, 77], ["vitamins A", "SIMPLE_CHEMICAL", 133, 143], ["B", "SIMPLE_CHEMICAL", 145, 146], ["E", "SIMPLE_CHEMICAL", 152, 153], ["selenium", "SIMPLE_CHEMICAL", 155, 163], ["zinc [47] [48] [49]", "SIMPLE_CHEMICAL", 169, 188], ["studies", "TEST", 42, 49], ["vitamin C", "TREATMENT", 68, 77]]], ["Such trials do not test the specific effect of vitamin C. The other substances can have negative or positive effects, and they can also modify the effect of vitamin C. The three meta-analyses also had statistical shortcomings [47] [48] [49] .", [["vitamin C.", "CHEMICAL", 47, 57], ["vitamin C.", "CHEMICAL", 157, 167], ["vitamin C.", "CHEMICAL", 47, 57], ["vitamin C.", "CHEMICAL", 157, 167], ["vitamin C.", "SIMPLE_CHEMICAL", 47, 57], ["vitamin", "SIMPLE_CHEMICAL", 157, 164], ["vitamin C.", "TREATMENT", 47, 57], ["vitamin C.", "TREATMENT", 157, 167]]], ["Our current metaanalysis was restricted to trials that tested vitamin C alone.", [["vitamin C", "CHEMICAL", 62, 71], ["vitamin C", "CHEMICAL", 62, 71], ["vitamin C", "SIMPLE_CHEMICAL", 62, 71], ["trials", "TREATMENT", 43, 49], ["vitamin C", "TREATMENT", 62, 71]]], ["A fourth recent meta-analysis concluded that vitamin C shortens ventilation time in cardiac surgery patients [50] ; however, the study was shown to contain several substantial statistical errors [51] .DiscussionIn systematic reviews, one potential concern is publication bias, in that negative trials may remain unpublished.", [["cardiac", "ANATOMY", 84, 91], ["vitamin C", "CHEMICAL", 45, 54], ["vitamin C", "CHEMICAL", 45, 54], ["vitamin C", "SIMPLE_CHEMICAL", 45, 54], ["cardiac", "ORGAN", 84, 91], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["A fourth recent meta-analysis", "TEST", 0, 29], ["vitamin C shortens ventilation", "TREATMENT", 45, 75], ["cardiac surgery", "TREATMENT", 84, 99], ["the study", "TEST", 125, 134]]], ["To explain this association by publication bias would require that positive studies with less ill patients remain unpublished, and negative studies with severely ill patients also remain unpublished.", [["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 166, 174], ["positive studies", "TEST", 67, 83], ["severely ill patients", "PROBLEM", 153, 174]]], ["Five trials did not use an explicit placebo [12] [13] [14] [15] 17 ], but we do not consider that the lack of placebo undermines the validity of those trials, since ICU patients receive numerous treatments and it is unlikely that one additional tablet or infusion would cause a substantial placebo effect for ventilated patients.", [["[12] [13] [14] [15] 17", "SIMPLE_CHEMICAL", 44, 66], ["patients", "ORGANISM", 169, 177], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 169, 177], ["patients", "SPECIES", 320, 328], ["an explicit placebo", "TREATMENT", 24, 43], ["numerous treatments", "TREATMENT", 186, 205], ["infusion", "TREATMENT", 255, 263], ["ventilated patients", "TREATMENT", 309, 328]]], ["The lack of a placebo may cause bias in research on subjective outcomes, but less so on objective outcomes [52] .", [["a placebo", "TREATMENT", 12, 21], ["bias", "PROBLEM", 32, 36]]], ["Thus, it is unlikely to bias studies with outcomes such as the duration of mechanical ventilation.ConclusionsIt may not be worthwhile to carry out further research on the effects of vitamin C on mechanical ventilation for patient groups that require on average less than 10 h of ventilation.", [["vitamin C", "CHEMICAL", 182, 191], ["vitamin C", "CHEMICAL", 182, 191], ["vitamin C", "SIMPLE_CHEMICAL", 182, 191], ["patient", "ORGANISM", 222, 229], ["patient", "SPECIES", 222, 229], ["bias studies", "TEST", 24, 36], ["mechanical ventilation", "TREATMENT", 75, 97], ["vitamin C", "TREATMENT", 182, 191], ["mechanical ventilation", "TREATMENT", 195, 217], ["ventilation", "TREATMENT", 279, 290], ["mechanical ventilation", "OBSERVATION", 75, 97]]], ["The level of sickness severity should be taken into account in future studies, for example, by evaluating prognostic scores at the start of the trial.", [["sickness severity", "PROBLEM", 13, 30]]], ["Our analysis did not find differences between oral and intravenous vitamin C, but oral administration is rarely an option for the sickest patients, for whom the effects of vitamin C appear greatest.", [["oral", "ANATOMY", 46, 50], ["intravenous", "ANATOMY", 55, 66], ["oral", "ANATOMY", 82, 86], ["vitamin C", "CHEMICAL", 67, 76], ["vitamin C", "CHEMICAL", 172, 181], ["vitamin C", "CHEMICAL", 67, 76], ["vitamin C", "CHEMICAL", 172, 181], ["oral", "ORGANISM_SUBDIVISION", 46, 50], ["intravenous vitamin C", "SIMPLE_CHEMICAL", 55, 76], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["patients", "ORGANISM", 138, 146], ["vitamin C", "SIMPLE_CHEMICAL", 172, 181], ["patients", "SPECIES", 138, 146], ["Our analysis", "TEST", 0, 12], ["oral and intravenous vitamin C", "TREATMENT", 46, 76], ["oral administration", "TREATMENT", 82, 101], ["vitamin C", "TREATMENT", 172, 181]]], ["Our analysis is not informative about the optimal dosage of vitamin C. Future trials should directly compare different dosage levels.Supplementary informationSupplementary information accompanies this paper at https://doi.org/10.", [["vitamin C.", "CHEMICAL", 60, 70], ["vitamin C.", "CHEMICAL", 60, 70], ["vitamin", "SIMPLE_CHEMICAL", 60, 67], ["Our analysis", "TEST", 0, 12], ["vitamin C.", "TREATMENT", 60, 70], ["Future trials", "TREATMENT", 71, 84]]], ["The data set used in this analysis.Supplementary informationAuthors' contributions HH and EC planned the study and searched the literature and selected the trials to be included.", [["EC", "CELL", 90, 92], ["EC", "CELL_TYPE", 90, 92], ["The data", "TEST", 0, 8], ["this analysis", "TEST", 21, 34], ["the study", "TEST", 101, 110]]], ["HH entered the data into a spreadsheet and carried out the statistical analysis.", [["the statistical analysis", "TEST", 55, 79]]], ["EC checked that the entered data were consistent with original reports.", [["EC", "ANATOMY", 0, 2], ["EC", "CELL", 0, 2], ["EC", "CELL_TYPE", 0, 2], ["consistent with", "UNCERTAINTY", 38, 53]]], ["HH wrote the draft manuscript and EC participated in the critical revision of the manuscript.", [["EC", "ANATOMY", 34, 36], ["EC", "CELL", 34, 36], ["EC", "CELL_TYPE", 34, 36]]], ["Both authors read and approved the final manuscript.No external fundingAvailability of data and materials Descriptions of the included trials, and the risk of bias assessment, and the analyzed data are available as Additional files 1 and 2.", [["bias assessment", "TEST", 159, 174], ["the analyzed data", "TEST", 180, 197], ["external", "OBSERVATION_MODIFIER", 55, 63], ["funding", "OBSERVATION", 64, 71]]]], "2a02bb8a26542f9c2905429399f964b650ad784f": [["Title: May Parkinson's disease be a protective factor against CNS involvement by SARS-CoV2?", [["CNS", "ANATOMY", 62, 65], ["Parkinson's disease", "DISEASE", 11, 30], ["SARS", "DISEASE", 81, 85], ["CNS", "ANATOMICAL_SYSTEM", 62, 65], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 81, 90], ["Parkinson's disease", "PROBLEM", 11, 30]]], ["Spina Tensini, F.* 1 , Spina Tensini, T. 2 , Franklin, G.L. 1 However, considering the above, it is postulated that, regardless of the severity of the systemic condition and possible higher mortality, in these patients there will be no virus spreading to the CNS due to the previous destruction of structures that would serve as their gateway.", [["CNS", "ANATOMY", 259, 262], ["patients", "ORGANISM", 210, 218], ["CNS", "ANATOMICAL_SYSTEM", 259, 262], ["patients", "SPECIES", 210, 218], ["Spina Tensini", "TEST", 23, 36], ["the systemic condition", "PROBLEM", 147, 169], ["higher mortality", "PROBLEM", 183, 199], ["virus", "PROBLEM", 236, 241], ["the previous destruction of structures", "PROBLEM", 270, 308], ["Spina Tensini", "ANATOMY", 23, 36], ["destruction", "OBSERVATION", 283, 294]]]], "PMC4030737": [["BackgroundTransmission of viruses from wildlife to humans continues to cause outbreaks of disease in humans.", [["humans", "ORGANISM", 51, 57], ["humans", "ORGANISM", 101, 107], ["humans", "SPECIES", 51, 57], ["humans", "SPECIES", 101, 107], ["humans", "SPECIES", 51, 57], ["humans", "SPECIES", 101, 107], ["viruses", "PROBLEM", 26, 33], ["disease in humans", "PROBLEM", 90, 107], ["viruses", "OBSERVATION", 26, 33], ["disease", "OBSERVATION", 90, 97]]], ["Examples of recent outbreaks are the Middle East Respiratory Syndrome-coronavirus (MERS-CoV) that may have originated from bats and/or camelids and the influenza A (H7N9) virus that originated from wild birds [1-5].", [["Respiratory Syndrome-coronavirus", "DISEASE", 49, 81], ["Middle East Respiratory Syndrome-coronavirus", "ORGANISM", 37, 81], ["MERS-CoV", "ORGANISM", 83, 91], ["influenza A (H7N9) virus", "ORGANISM", 152, 176], ["-coronavirus", "SPECIES", 69, 81], ["Middle East Respiratory Syndrome-coronavirus", "SPECIES", 37, 81], ["MERS-CoV", "SPECIES", 83, 91], ["influenza A (H7N9) virus", "SPECIES", 152, 176], ["recent outbreaks", "PROBLEM", 12, 28], ["the Middle East Respiratory Syndrome", "PROBLEM", 33, 69], ["coronavirus", "PROBLEM", 70, 81], ["camelids", "PROBLEM", 135, 143], ["the influenza A (H7N9) virus", "PROBLEM", 148, 176], ["outbreaks", "OBSERVATION", 19, 28], ["Middle", "ANATOMY_MODIFIER", 37, 43], ["Respiratory Syndrome", "OBSERVATION", 49, 69]]], ["A systematic exploration of viruses present in several key host species of wild animals might provide important information to find the original host or carriers of viruses of future outbreaks of viral disease among domestic animals, endangered animal species, and humans [6].", [["viral disease", "DISEASE", 196, 209], ["humans", "ORGANISM", 265, 271], ["humans", "SPECIES", 265, 271], ["humans", "SPECIES", 265, 271], ["A systematic exploration", "TEST", 0, 24], ["viruses", "PROBLEM", 28, 35], ["viral disease", "PROBLEM", 196, 209], ["viruses", "OBSERVATION", 28, 35], ["viral disease", "OBSERVATION", 196, 209]]], ["Furthermore, information about the presence of viruses in healthy hosts provides a baseline level for viruses present in these animals in case an outbreak of disease occurs.", [["viruses in healthy hosts", "PROBLEM", 47, 71], ["viruses", "PROBLEM", 102, 109], ["disease", "PROBLEM", 158, 165], ["viruses", "OBSERVATION", 47, 54], ["disease", "OBSERVATION", 158, 165]]], ["In previous viral metagenomics studies, high numbers of new viruses have been identified [7-10].", [["previous viral metagenomics studies", "TEST", 3, 38], ["new viruses", "PROBLEM", 56, 67], ["viral metagenomics", "OBSERVATION", 12, 30], ["new", "OBSERVATION_MODIFIER", 56, 59], ["viruses", "OBSERVATION", 60, 67]]], ["The results of these studies have highlighted that our knowledge of the viral reservoir is far from complete and many, as yet, unidentified viruses circulate among humans and wild and domestic animals.", [["humans", "ORGANISM", 164, 170], ["humans", "SPECIES", 164, 170], ["humans", "SPECIES", 164, 170], ["these studies", "TEST", 15, 28], ["the viral reservoir", "PROBLEM", 68, 87], ["viral reservoir", "OBSERVATION", 72, 87], ["viruses", "OBSERVATION", 140, 147]]], ["However, there is an enormous diversity of viral sequences and viral metagenomics efforts should be focused on outbreaks of disease and viral metagenomics on samples collected from a selected number of key species [11].BackgroundWild carnivores are known carriers of several viral pathogens that can affect domestic animals and humans, including rabies and canine distemper virus [12,13].", [["samples", "ANATOMY", 158, 165], ["rabies", "DISEASE", 346, 352], ["canine distemper", "DISEASE", 357, 373], ["BackgroundWild carnivores", "ORGANISM", 219, 244], ["humans", "ORGANISM", 328, 334], ["rabies", "ORGANISM", 346, 352], ["canine distemper virus", "ORGANISM", 357, 379], ["humans", "SPECIES", 328, 334], ["canine distemper virus", "SPECIES", 357, 379], ["humans", "SPECIES", 328, 334], ["canine distemper virus", "SPECIES", 357, 379], ["an enormous diversity of viral sequences", "PROBLEM", 18, 58], ["viral metagenomics efforts", "TREATMENT", 63, 89], ["disease", "PROBLEM", 124, 131], ["viral metagenomics on samples", "PROBLEM", 136, 165], ["several viral pathogens", "PROBLEM", 267, 290], ["rabies and canine distemper virus", "PROBLEM", 346, 379], ["enormous", "OBSERVATION_MODIFIER", 21, 29], ["diversity", "OBSERVATION", 30, 39], ["viral sequences", "OBSERVATION", 43, 58], ["viral metagenomics", "OBSERVATION", 63, 81]]], ["In addition, in previous studies various previously unknown viruses have been detected in European badgers, red foxes and European pine martens in the Netherlands [9,14].", [["red foxes", "ORGANISM", 108, 117], ["European badgers", "SPECIES", 90, 106], ["red foxes", "SPECIES", 108, 117], ["European pine martens", "SPECIES", 122, 143], ["previous studies", "TEST", 16, 32], ["red foxes", "TEST", 108, 117], ["viruses", "OBSERVATION", 60, 67], ["pine martens", "OBSERVATION", 131, 143]]], ["In the present study, we evaluated the viral diversity of fecal swabs or fecal specimens collected from 10 different small carnivore species of the Mustelidae, Canidae, Viverridae and Felidae families inhabiting northern Spain.Metagenomic overview ::: Results and discussionUsing random amplification in combination with next-generation sequencing, more than 320,000 trimmed sequence reads were obtained of fecal samples collected from the carnivores of the present study (Figure 1).", [["fecal swabs", "ANATOMY", 58, 69], ["fecal specimens", "ANATOMY", 73, 88], ["fecal samples", "ANATOMY", 407, 420], ["fecal swabs", "ORGANISM_SUBSTANCE", 58, 69], ["fecal specimens", "ORGANISM_SUBSTANCE", 73, 88], ["fecal samples", "ORGANISM_SUBSTANCE", 407, 420], ["the present study", "TEST", 3, 20], ["fecal swabs", "TEST", 58, 69], ["fecal specimens", "TEST", 73, 88], ["the Mustelidae", "TREATMENT", 144, 158], ["Canidae", "TREATMENT", 160, 167], ["Viverridae", "TREATMENT", 169, 179], ["fecal samples", "TEST", 407, 420], ["the present study", "TEST", 454, 471], ["fecal swabs", "ANATOMY", 58, 69], ["small", "OBSERVATION_MODIFIER", 117, 122], ["carnivore species", "OBSERVATION", 123, 140], ["fecal", "ANATOMY", 407, 412]]], ["Reads were classified into eukaryotic viruses, phages, bacteria and eukaryotes.", [["bacteria", "PROBLEM", 55, 63], ["eukaryotic viruses", "OBSERVATION", 27, 45]]], ["Many of the identified sequences were of bacterial or eukaryotic origin.", [["bacterial or eukaryotic origin", "PROBLEM", 41, 71], ["bacterial", "OBSERVATION_MODIFIER", 41, 50], ["eukaryotic origin", "OBSERVATION", 54, 71]]], ["A substantial proportion of the reads did not have any significant hits for nucleotide or amino acid sequences in GenBank.", [["nucleotide", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 90, 100], ["nucleotide", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 90, 100], ["amino acid", "AMINO_ACID", 90, 100], ["nucleotide or amino acid sequences", "PROBLEM", 76, 110], ["substantial", "OBSERVATION_MODIFIER", 2, 13]]], ["In addition, several reads were detected that had the closest similarity to viruses.", [["viruses", "OBSERVATION", 76, 83]]], ["In the majority of the samples, sequences of the order Caudovirales were detected and in 26 out of 42 samples, sequences were detected that had the closest similarity to viruses known to infect eukaryotes (Figure 2A, Table 1).", [["samples", "ANATOMY", 23, 30], ["samples", "ANATOMY", 102, 109], ["samples", "CANCER", 23, 30], ["Caudovirales", "GENE_OR_GENE_PRODUCT", 55, 67], ["samples", "CANCER", 102, 109], ["the order Caudovirales", "TEST", 45, 67], ["sequences", "TEST", 111, 120]]], ["Viruses belonging to the families of Anelloviridae, Astroviridae, Bunyaviridae, Caliciviridae, Circoviridiae, Parvoviridae subfamily Parvovirinae, Picobirnaviridae, Picornaviridae, Rhabdoviridae, and Retroviridae were detected (Figure 2B).", [["Bunyaviridae", "DISEASE", 66, 78], ["Anelloviridae", "GENE_OR_GENE_PRODUCT", 37, 50], ["Astroviridae", "GENE_OR_GENE_PRODUCT", 52, 64], ["Bunyaviridae", "ORGANISM", 66, 78], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 80, 93], ["Circoviridiae", "GENE_OR_GENE_PRODUCT", 95, 108], ["Parvoviridae subfamily Parvovirinae", "ORGANISM", 110, 145], ["Picobirnaviridae", "GENE_OR_GENE_PRODUCT", 147, 163], ["Picornaviridae", "GENE_OR_GENE_PRODUCT", 165, 179], ["Rhabdoviridae", "GENE_OR_GENE_PRODUCT", 181, 194], ["Retroviridae", "GENE_OR_GENE_PRODUCT", 200, 212], ["Parvovirinae", "SPECIES", 133, 145], ["Viruses", "PROBLEM", 0, 7], ["Anelloviridae", "TREATMENT", 37, 50], ["Astroviridae", "TREATMENT", 52, 64], ["Bunyaviridae", "TREATMENT", 66, 78], ["Caliciviridae", "TREATMENT", 80, 93], ["Circoviridiae", "TREATMENT", 95, 108], ["Parvoviridae subfamily Parvovirinae", "TREATMENT", 110, 145], ["Picobirnaviridae", "TREATMENT", 147, 163], ["Picornaviridae", "TREATMENT", 165, 179], ["Rhabdoviridae", "TREATMENT", 181, 194], ["Retroviridae", "TREATMENT", 200, 212]]], ["Furthermore, sequences were detected that had the closest similarity to the recently proposed family of Breviviridae and the recently described hybrid DNA virus NIH-CQV/PHV which was identified as a contaminant of silica column-based nucleic acid extraction kits [9,15,16].", [["silica", "CHEMICAL", 214, 220], ["nucleic acid", "CHEMICAL", 234, 246], ["silica", "CHEMICAL", 214, 220], ["Breviviridae", "CANCER", 104, 116], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["NIH-CQV", "ORGANISM", 161, 168], ["silica", "SIMPLE_CHEMICAL", 214, 220], ["nucleic acid", "SIMPLE_CHEMICAL", 234, 246], ["Breviviridae", "TREATMENT", 104, 116], ["hybrid DNA virus NIH", "PROBLEM", 144, 164], ["PHV", "PROBLEM", 169, 172], ["silica column", "TREATMENT", 214, 227], ["nucleic acid extraction kits", "TREATMENT", 234, 262], ["silica column", "OBSERVATION", 214, 227]]], ["No sequences were detected that were identical to currently known zoonotic viruses.", [["zoonotic viruses", "DISEASE", 66, 82], ["zoonotic", "OBSERVATION_MODIFIER", 66, 74], ["viruses", "OBSERVATION", 75, 82]]], ["A proportion of the detected viral sequences had the closest similarity to viruses previously detected in birds and rodents.", [["viral sequences", "DNA", 29, 44], ["the detected viral sequences", "PROBLEM", 16, 44], ["viruses", "PROBLEM", 75, 82]]], ["For example, in an European mink (sample 26), sequences were detected with >95% homology on the nucleotide level with Turkey parvovirus and in a stone marten (sample 41), sequences were detected with 94-96% homology on the nucleotide level with Encephalomyocarditis virus type 2 isolate RD 1338 (D28/05) detected in a wood mouse (Apodemus sylvaticus) [17].", [["nucleotide", "CHEMICAL", 96, 106], ["Turkey parvovirus", "DISEASE", 118, 135], ["nucleotide", "CHEMICAL", 223, 233], ["nucleotide", "CHEMICAL", 96, 106], ["nucleotide", "CHEMICAL", 223, 233], ["Encephalomyocarditis virus type 2", "ORGANISM", 245, 278], ["mouse", "ORGANISM", 323, 328], ["Apodemus sylvaticus", "ORGANISM", 330, 349], ["mouse", "SPECIES", 323, 328], ["Apodemus sylvaticus", "SPECIES", 330, 349], ["European mink", "SPECIES", 19, 32], ["Turkey parvovirus", "SPECIES", 118, 135], ["Encephalomyocarditis virus type 2 isolate RD 1338", "SPECIES", 245, 294], ["mouse", "SPECIES", 323, 328], ["Apodemus sylvaticus", "SPECIES", 330, 349], ["sequences", "TEST", 46, 55], ["the nucleotide level", "TEST", 92, 112], ["Turkey parvovirus", "TEST", 118, 135], ["a stone marten", "TEST", 143, 157], ["sequences", "TEST", 171, 180], ["the nucleotide level", "TEST", 219, 239], ["stone", "OBSERVATION", 145, 150]]], ["These viruses most likely originate from the diet of the animals.", [["These viruses", "PROBLEM", 0, 13], ["viruses", "OBSERVATION", 6, 13]]], ["In addition, sequences with >95% identity on the nucleotide level to viruses that are known to infect mink were detected in European and American mink, including Mink calicivirus strain MCV-DL/2007/CN [18] (samples 1 and 8) and Aleutian mink disease virus (sample 30).", [["nucleotide", "CHEMICAL", 49, 59], ["Aleutian mink disease", "DISEASE", 228, 249], ["nucleotide", "CHEMICAL", 49, 59], ["mink", "ORGANISM", 102, 106], ["mink", "ORGANISM", 146, 150], ["Mink calicivirus", "ORGANISM", 162, 178], ["MCV-DL", "ORGANISM", 186, 192], ["Aleutian mink disease virus", "ORGANISM", 228, 255], ["mink", "SPECIES", 102, 106], ["mink", "SPECIES", 146, 150], ["Mink calicivirus", "SPECIES", 162, 178], ["Aleutian mink disease virus", "SPECIES", 228, 255], ["mink", "SPECIES", 102, 106], ["American mink", "SPECIES", 137, 150], ["Mink calicivirus strain MCV-DL/2007/CN", "SPECIES", 162, 200], ["Aleutian mink disease virus", "SPECIES", 228, 255], ["sequences", "TEST", 13, 22], ["viruses", "PROBLEM", 69, 76], ["Mink calicivirus strain MCV", "TEST", 162, 189], ["samples", "TEST", 207, 214], ["Aleutian mink disease virus", "PROBLEM", 228, 255], ["Aleutian mink disease", "OBSERVATION", 228, 249]]], ["Antibodies to Aleutian mink disease parvovirus have been detected in a cohort of free-ranging European mink in southwestern France and northern Spain previously, but not in another cohort of free-ranging European mink in Navarra, Spain [19-21].", [["Aleutian mink disease parvovirus", "DISEASE", 14, 46], ["Aleutian mink disease parvovirus", "ORGANISM", 14, 46], ["mink", "ORGANISM", 103, 107], ["mink", "ORGANISM", 213, 217], ["Aleutian mink disease parvovirus", "SPECIES", 14, 46], ["mink", "SPECIES", 103, 107], ["Aleutian mink disease parvovirus", "SPECIES", 14, 46], ["European mink", "SPECIES", 94, 107], ["European mink", "SPECIES", 204, 217], ["Aleutian mink disease parvovirus", "PROBLEM", 14, 46], ["Aleutian mink disease", "OBSERVATION", 14, 35]]], ["Additional sampling and confirmation by specific PCR is necessary to indeed confirm that the Aleutian mink disease parvovirus is circulating among these animals.", [["mink disease parvovirus", "DISEASE", 102, 125], ["Aleutian mink disease parvovirus", "ORGANISM", 93, 125], ["mink", "SPECIES", 102, 106], ["Aleutian mink disease parvovirus", "SPECIES", 93, 125], ["Additional sampling", "TEST", 0, 19], ["specific PCR", "TEST", 40, 52], ["the Aleutian mink disease parvovirus", "PROBLEM", 89, 125], ["Aleutian mink disease", "OBSERVATION", 93, 114]]], ["Besides these sequences that had high homology with known viruses, also sequences were detected that had the closest similarity to viruses, but with only low homology.", [["these sequences", "TEST", 8, 23], ["high homology with known viruses", "PROBLEM", 33, 65], ["viruses", "OBSERVATION", 58, 65], ["viruses", "OBSERVATION", 131, 138]]], ["A number of sequences of potentially novel viruses or virus variants, including a theilovirus, phleboviruses, an amdovirus, a kobuvirus and picobirnaviruses, were further characterized in the present manuscript, while sequences of the other viruses are preliminary and need further characterization.Genet fecal theilovirus ::: Results and discussionPicornaviruses are small, positive-stranded non-enveloped RNA viruses.", [["picobirnaviruses", "GENE_OR_GENE_PRODUCT", 140, 156], ["potentially novel viruses", "PROBLEM", 25, 50], ["virus variants", "PROBLEM", 54, 68], ["a theilovirus, phleboviruses", "PROBLEM", 80, 108], ["an amdovirus", "PROBLEM", 110, 122], ["a kobuvirus and picobirnaviruses", "PROBLEM", 124, 156], ["the other viruses", "PROBLEM", 231, 248], ["further characterization", "TEST", 274, 298], ["Picornaviruses", "TEST", 349, 363], ["stranded non-enveloped RNA viruses", "PROBLEM", 384, 418], ["small", "OBSERVATION_MODIFIER", 368, 373], ["stranded non-enveloped", "OBSERVATION_MODIFIER", 384, 406], ["RNA viruses", "OBSERVATION", 407, 418]]], ["The genus Cardiovirus of the family Picornaviridae currently consists of two species, Theilovirus and Encephalomyocarditis virus (EMCV) [22].", [["Theilovirus", "ORGANISM", 86, 97], ["Encephalomyocarditis virus", "ORGANISM", 102, 128], ["EMCV", "ORGANISM", 130, 134], ["Encephalomyocarditis virus", "SPECIES", 102, 128], ["Encephalomyocarditis virus", "SPECIES", 102, 128], ["EMCV", "SPECIES", 130, 134], ["Picornaviridae", "TREATMENT", 36, 50], ["two species", "PROBLEM", 73, 84], ["Theilovirus", "PROBLEM", 86, 97], ["Encephalomyocarditis virus", "PROBLEM", 102, 128], ["genus Cardiovirus", "OBSERVATION", 4, 21]]], ["Viruses belonging to the species Theilovirus were detected initially mainly in rodents.", [["Theilovirus", "GENE_OR_GENE_PRODUCT", 33, 44], ["Viruses", "PROBLEM", 0, 7], ["the species Theilovirus", "TEST", 21, 44]]], ["In these animals, viruses cause primarily infection of the digestive tract without clinical signs, but extra-intestinal infection occurs and can cause an acute encephalomyelitis and a chronic demyelinating infection of the central nervous system [23].", [["digestive tract", "ANATOMY", 59, 74], ["central nervous system", "ANATOMY", 223, 245], ["infection of the digestive tract", "DISEASE", 42, 74], ["extra-intestinal infection", "DISEASE", 103, 129], ["encephalomyelitis", "DISEASE", 160, 177], ["demyelinating infection of the central nervous system", "DISEASE", 192, 245], ["digestive tract", "ORGAN", 59, 74], ["central nervous system", "ANATOMICAL_SYSTEM", 223, 245], ["viruses", "PROBLEM", 18, 25], ["primarily infection of the digestive tract", "PROBLEM", 32, 74], ["clinical signs", "PROBLEM", 83, 97], ["extra-intestinal infection", "PROBLEM", 103, 129], ["an acute encephalomyelitis", "PROBLEM", 151, 177], ["a chronic demyelinating infection of the central nervous system", "PROBLEM", 182, 245], ["viruses", "OBSERVATION", 18, 25], ["infection", "OBSERVATION", 42, 51], ["digestive tract", "ANATOMY", 59, 74], ["extra-intestinal", "ANATOMY", 103, 119], ["infection", "OBSERVATION", 120, 129], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["encephalomyelitis", "OBSERVATION", 160, 177], ["chronic", "OBSERVATION_MODIFIER", 184, 191], ["demyelinating", "OBSERVATION_MODIFIER", 192, 205], ["infection", "OBSERVATION", 206, 215], ["central", "ANATOMY_MODIFIER", 223, 230], ["nervous system", "ANATOMY", 231, 245]]], ["Vilyuisk human encephalomyelitis virus, another strain of the species Theilovirus, was isolated from humans with encephalomyelitis, but only after serial passage over mice brains [24,25].", [["brains", "ANATOMY", 172, 178], ["encephalomyelitis", "DISEASE", 15, 32], ["encephalomyelitis", "DISEASE", 113, 130], ["Vilyuisk human encephalomyelitis virus", "ORGANISM", 0, 38], ["Theilovirus", "ORGANISM", 70, 81], ["humans", "ORGANISM", 101, 107], ["mice", "ORGANISM", 167, 171], ["human encephalomyelitis virus", "SPECIES", 9, 38], ["humans", "SPECIES", 101, 107], ["mice", "SPECIES", 167, 171], ["Vilyuisk human encephalomyelitis virus", "SPECIES", 0, 38], ["humans", "SPECIES", 101, 107], ["mice", "SPECIES", 167, 171], ["Vilyuisk human encephalomyelitis virus", "PROBLEM", 0, 38], ["the species Theilovirus", "PROBLEM", 58, 81], ["encephalomyelitis", "PROBLEM", 113, 130], ["serial passage over mice brains", "TREATMENT", 147, 178], ["encephalomyelitis virus", "OBSERVATION", 15, 38], ["encephalomyelitis", "OBSERVATION", 113, 130]]], ["More recently, Saffold virus was discovered in a stool sample of a child with fever of unknown origin, and additional research revealed that infection with this virus was common [26-28].Genet fecal theilovirus ::: Results and discussionWe detected in fecal material of a stone marten (sample 41) sequences with high similarity to a novel Encephalomyocarditis type 2 virus detected recently in a wood mouse (Apodemus sylvaticus) [17].", [["stool sample", "ANATOMY", 49, 61], ["fecal material", "ANATOMY", 251, 265], ["fever", "DISEASE", 78, 83], ["infection", "DISEASE", 141, 150], ["Encephalomyocarditis type 2 virus", "DISEASE", 338, 371], ["Saffold virus", "ORGANISM", 15, 28], ["child", "ORGANISM", 67, 72], ["fecal", "ORGANISM_SUBSTANCE", 251, 256], ["Encephalomyocarditis type 2 virus", "ORGANISM", 338, 371], ["mouse", "ORGANISM", 400, 405], ["Apodemus sylvaticus", "ORGANISM", 407, 426], ["child", "SPECIES", 67, 72], ["mouse", "SPECIES", 400, 405], ["Apodemus sylvaticus", "SPECIES", 407, 426], ["Saffold virus", "SPECIES", 15, 28], ["Encephalomyocarditis type 2 virus", "SPECIES", 338, 371], ["mouse", "SPECIES", 400, 405], ["Apodemus sylvaticus", "SPECIES", 407, 426], ["Saffold virus", "PROBLEM", 15, 28], ["a stool sample", "TEST", 47, 61], ["fever", "PROBLEM", 78, 83], ["infection", "PROBLEM", 141, 150], ["this virus", "PROBLEM", 156, 166], ["a stone marten (sample 41) sequences", "TEST", 269, 305], ["high similarity", "PROBLEM", 311, 326], ["a novel Encephalomyocarditis type 2 virus", "PROBLEM", 330, 371], ["fever", "OBSERVATION", 78, 83], ["unknown origin", "OBSERVATION_MODIFIER", 87, 101], ["infection", "OBSERVATION", 141, 150], ["stone", "OBSERVATION", 271, 276]]], ["In addition, sequences were detected that had the closest similarity to viruses of the species Theilovirus in a rectal swab collected from a common genet (sample 14).", [["rectal swab", "ANATOMY", 112, 123], ["Theilovirus", "CHEMICAL", 95, 106], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 112, 123], ["the species Theilovirus", "PROBLEM", 83, 106], ["a rectal swab", "TEST", 110, 123], ["rectal", "ANATOMY", 112, 118]]], ["The obtained sequences were further analyzed by designing primers based on the obtained sequence reads and the partial sequence (6488 nt) of a novel theilovirus, tentatively called Genet fecal theilovirus (GFTV; Genbank accession KF823815), was obtained.", [["Genet fecal theilovirus", "ORGANISM", 181, 204], ["6488 nt", "DNA", 129, 136], ["Genet fecal theilovirus", "SPECIES", 181, 204], ["The obtained sequences", "TEST", 0, 22], ["the partial sequence", "TEST", 107, 127], ["a novel theilovirus", "PROBLEM", 141, 160], ["Genet fecal theilovirus", "TEST", 181, 204]]], ["Despite various attempts using degenerate primers and 3\u2019 RACE PCRs, no more sequences could be obtained of the 5\u2019 and 3\u2019 end, possibly due to low virus genome copy numbers present in the original material.", [["degenerate primers", "DNA", 31, 49], ["3\u2019 RACE PCRs", "DNA", 54, 66], ["5\u2019 and 3\u2019 end", "DNA", 111, 124], ["degenerate primers", "TEST", 31, 49], ["3\u2019 RACE PCRs", "TEST", 54, 66], ["low virus genome copy numbers", "PROBLEM", 142, 171], ["possibly due to", "UNCERTAINTY", 126, 141], ["low virus", "OBSERVATION", 142, 151]]], ["The obtained sequence contained the partial non-coding region of the 5\u2019end and the partial ORF encoding for the polyprotein gene.", [["partial non-coding region", "DNA", 36, 61], ["5\u2019end", "DNA", 69, 74], ["ORF", "DNA", 91, 94], ["polyprotein gene", "DNA", 112, 128], ["the partial ORF", "PROBLEM", 79, 94], ["the polyprotein gene", "TREATMENT", 108, 128], ["partial", "OBSERVATION_MODIFIER", 36, 43]]], ["Based on splice-site predictions and alignment with other theiloviruses, the complete coding sequence of the L protein (228 nt), the complete P1 (2462 nt) capsid-encoding regions, the complete P2 (1785 nt) non-structural coding region and the partial P3 (1455 nt) non-structural coding region were detected in the partial polyprotein.", [["theiloviruses", "DNA", 58, 71], ["L protein", "PROTEIN", 109, 118], ["P1 (2462 nt) capsid-encoding regions", "DNA", 142, 178], ["P2", "DNA", 193, 195], ["non-structural coding region", "DNA", 206, 234], ["P3", "DNA", 251, 253], ["the L protein", "TEST", 105, 118], ["the complete P1 (2462 nt) capsid-encoding regions", "TREATMENT", 129, 178], ["non-structural coding region", "PROBLEM", 206, 234], ["the partial P3 (1455 nt) non-structural coding region", "PROBLEM", 239, 292], ["the partial polyprotein", "PROBLEM", 310, 333], ["partial polyprotein", "OBSERVATION", 314, 333]]], ["Pairwise identity analysis and phylogenetic analysis of the nucleotide sequences of the complete Leader gene, P1, P2 and partial P3 gene showed that Genet fecal theilovirus probably belongs to a novel genotype, with maximum pairwise identities on the nucleotide (and deduced amino acid) level of respectively 69 (70), 63 (68), 62 (65) and 82 (65)% (Figure 3).", [["amino acid", "CHEMICAL", 275, 285], ["nucleotide", "CHEMICAL", 60, 70], ["nucleotide", "CHEMICAL", 251, 261], ["amino acid", "CHEMICAL", 275, 285], ["Leader", "GENE_OR_GENE_PRODUCT", 97, 103], ["P3", "GENE_OR_GENE_PRODUCT", 129, 131], ["Genet fecal theilovirus", "ORGANISM", 149, 172], ["amino acid", "AMINO_ACID", 275, 285], ["Leader gene", "DNA", 97, 108], ["P1", "DNA", 110, 112], ["P2", "DNA", 114, 116], ["P3 gene", "DNA", 129, 136], ["Pairwise identity analysis", "TEST", 0, 26], ["phylogenetic analysis", "TEST", 31, 52], ["the nucleotide sequences", "TEST", 56, 80], ["partial P3 gene", "TEST", 121, 136], ["Genet fecal theilovirus", "PROBLEM", 149, 172], ["a novel genotype", "PROBLEM", 193, 209], ["the nucleotide", "TEST", 247, 261], ["amino acid", "TEST", 275, 285]]], ["Additional alignment of the deduced amino acid sequence of the P1 gene with the major surface structures of other viruses of the species theilovirus (VP2 puffs A and B, the VP3 knob and VP1 loops 1 and 2) indeed shows the high divergence between the potential immunogenic sites of these viruses (Additional file 1: Figure S1) [29,30].", [["surface structures", "ANATOMY", 86, 104], ["amino acid", "CHEMICAL", 36, 46], ["amino acid", "CHEMICAL", 36, 46], ["amino acid", "AMINO_ACID", 36, 46], ["P1", "GENE_OR_GENE_PRODUCT", 63, 65], ["species theilovirus", "ORGANISM", 129, 148], ["VP2 puffs A", "ORGANISM", 150, 161], ["B", "GENE_OR_GENE_PRODUCT", 166, 167], ["VP3 knob", "GENE_OR_GENE_PRODUCT", 173, 181], ["VP1 loops 1", "GENE_OR_GENE_PRODUCT", 186, 197], ["P1 gene", "DNA", 63, 70], ["VP2", "PROTEIN", 150, 153], ["B", "PROTEIN", 166, 167], ["VP3 knob", "PROTEIN", 173, 181], ["VP1 loops 1 and 2", "PROTEIN", 186, 203], ["the deduced amino acid sequence", "TEST", 24, 55], ["the species theilovirus", "TEST", 125, 148], ["the VP3 knob and VP1 loops", "TEST", 169, 195], ["the high divergence", "PROBLEM", 218, 237], ["viruses", "OBSERVATION", 114, 121], ["VP3", "ANATOMY", 173, 176], ["knob", "ANATOMY_MODIFIER", 177, 181], ["VP1 loops", "ANATOMY", 186, 195], ["high divergence", "OBSERVATION", 222, 237], ["viruses", "OBSERVATION", 287, 294]]], ["In addition to the major ORF encoding the polyprotein, an alternative ORF of 423 nt (140AA) was present in the Genet fecal theilovirus sequence based on an alternative initiation codon 13 nt downstream of the authentic initiation codon, which indicates that the L* protein previously observed in Theiler\u2019s murine encephalomyocarditis virus and other strains of the species Theilovirus is also present in this novel virus [29,31].", [["encephalomyocarditis virus", "DISEASE", 313, 339], ["Theilovirus", "CHEMICAL", 373, 384], ["Theiler\u2019s murine encephalomyocarditis virus", "ORGANISM", 296, 339], ["ORF", "DNA", 25, 28], ["ORF", "DNA", 70, 73], ["Genet fecal theilovirus sequence", "DNA", 111, 143], ["alternative initiation codon", "DNA", 156, 184], ["authentic initiation codon", "DNA", 209, 235], ["L* protein", "PROTEIN", 262, 272], ["Theiler", "SPECIES", 296, 303], ["murine", "SPECIES", 306, 312], ["encephalomyocarditis virus", "SPECIES", 313, 339], ["Theiler\u2019s murine encephalomyocarditis virus", "SPECIES", 296, 339], ["the polyprotein", "TREATMENT", 38, 53], ["an alternative ORF", "TEST", 55, 73], ["an alternative initiation codon", "TREATMENT", 153, 184], ["the L* protein", "TEST", 258, 272], ["murine encephalomyocarditis virus", "PROBLEM", 306, 339], ["the species Theilovirus", "PROBLEM", 361, 384], ["this novel virus", "PROBLEM", 404, 420], ["encephalomyocarditis virus", "OBSERVATION", 313, 339]]], ["Since this animal was found dead, possibly due to a car accident, and the carcass was stored at \u221220 for a few months, a necropsy could be performed.", [["carcass", "ORGANISM_SUBDIVISION", 74, 81], ["dead", "PROBLEM", 28, 32], ["a necropsy", "TEST", 118, 128], ["possibly due to", "UNCERTAINTY", 34, 49]]], ["The carcass was defrosted but no abnormalities were detected in this animal upon macroscopic and microscopic examination of various tissues, including the brain.", [["carcass", "ANATOMY", 4, 11], ["tissues", "ANATOMY", 132, 139], ["brain", "ANATOMY", 155, 160], ["carcass", "ORGANISM_SUBDIVISION", 4, 11], ["tissues", "TISSUE", 132, 139], ["brain", "ORGAN", 155, 160], ["abnormalities", "PROBLEM", 33, 46], ["macroscopic and microscopic examination of various tissues", "TEST", 81, 139], ["carcass", "ANATOMY", 4, 11], ["no", "UNCERTAINTY", 30, 32], ["abnormalities", "OBSERVATION", 33, 46], ["various tissues", "ANATOMY", 124, 139], ["brain", "ANATOMY", 155, 160]]], ["This indicates that the novel Genet fecal theilovirus has not caused any significant disease.", [["theilovirus", "CHEMICAL", 42, 53], ["Genet fecal theilovirus", "ORGANISM", 30, 53], ["the novel Genet fecal theilovirus", "PROBLEM", 20, 53], ["any significant disease", "PROBLEM", 69, 92], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["disease", "OBSERVATION", 85, 92]]], ["Since picornaviruses are known to be very resistant to a low pH, further research needs to be performed to elucidate whether the detected virus is derived from the prey species of this animal or is a novel theilovirus of the common genet.Novel phleboviruses in feces of a red fox and an eurasian otter ::: Results and discussionBunyaviruses are segmented, negative-sense single stranded RNA viruses.", [["picornaviruses", "ORGANISM", 6, 20], ["genet", "CANCER", 232, 237], ["feces", "ORGANISM_SUBSTANCE", 261, 266], ["red fox", "SPECIES", 272, 279], ["picornaviruses", "PROBLEM", 6, 20], ["a low pH", "PROBLEM", 55, 63], ["the detected virus", "PROBLEM", 125, 143], ["Bunyaviruses", "TEST", 328, 340], ["sense single stranded RNA viruses", "PROBLEM", 365, 398], ["picornaviruses", "OBSERVATION", 6, 20], ["low pH", "OBSERVATION_MODIFIER", 57, 63], ["virus", "OBSERVATION", 138, 143], ["RNA viruses", "OBSERVATION", 387, 398]]], ["Genomes consist of three different segments, the Large (L), Medium (M) and Small (S) segment.", [["Small (S) segment", "PROBLEM", 75, 92], ["three different", "OBSERVATION_MODIFIER", 19, 34], ["segments", "ANATOMY_MODIFIER", 35, 43], ["Large", "OBSERVATION_MODIFIER", 49, 54], ["L", "ANATOMY_MODIFIER", 56, 57], ["Medium", "OBSERVATION_MODIFIER", 60, 66], ["Small", "OBSERVATION_MODIFIER", 75, 80], ["segment", "ANATOMY_MODIFIER", 85, 92]]], ["At present the ICTV has recognized five different genera, Orthobunyavirus, Hantavirus, Nairovirus, Phlebovirus, and Tospovirus[22].", [["Hantavirus", "DISEASE", 75, 85], ["ICTV", "CANCER", 15, 19], ["Orthobunyavirus", "TEST", 58, 73], ["Hantavirus", "PROBLEM", 75, 85], ["Nairovirus", "PROBLEM", 87, 97], ["Phlebovirus", "PROBLEM", 99, 110], ["Hantavirus", "OBSERVATION", 75, 85], ["Phlebovirus", "ANATOMY", 99, 110]]], ["The genus Phlebovirus consists of a genetically diverse group of viruses, some of which were described very recently [32-34].", [["The genus Phlebovirus", "PROBLEM", 0, 21], ["a genetically diverse group of viruses", "PROBLEM", 34, 72], ["genus", "ANATOMY", 4, 9], ["Phlebovirus", "OBSERVATION", 10, 21], ["viruses", "OBSERVATION", 65, 72]]], ["A few members of this genus were identified as important pathogens in humans and domestic animals, including Rift valley fever virus and the Severe fever with thrombocytopenia syndrome virus or Huaiyangshan virus [35,36].Novel phleboviruses in feces of a red fox and an eurasian otter ::: Results and discussionIn fecal material of an Eurasian otter (sample 22) and a red fox (sample 37) sequences were detected that had the closest similarity to viruses of the genus Phlebovirus (Table 1).", [["Rift valley fever", "DISEASE", 109, 126], ["fever", "DISEASE", 148, 153], ["thrombocytopenia syndrome", "DISEASE", 159, 184], ["humans", "ORGANISM", 70, 76], ["Rift valley fever virus", "ORGANISM", 109, 132], ["Huaiyangshan virus", "ORGANISM", 194, 212], ["feces", "ORGANISM_SUBSTANCE", 244, 249], ["red fox (sample 37) sequences", "DNA", 368, 397], ["humans", "SPECIES", 70, 76], ["Rift valley fever virus", "SPECIES", 109, 132], ["Huaiyangshan virus", "SPECIES", 194, 212], ["humans", "SPECIES", 70, 76], ["Rift valley fever virus", "SPECIES", 109, 132], ["Severe fever with thrombocytopenia syndrome virus", "SPECIES", 141, 190], ["Huaiyangshan virus", "SPECIES", 194, 212], ["red fox", "SPECIES", 255, 262], ["Eurasian otter", "SPECIES", 335, 349], ["red fox", "SPECIES", 368, 375], ["this genus", "PROBLEM", 17, 27], ["Rift valley fever virus", "PROBLEM", 109, 132], ["the Severe fever", "PROBLEM", 137, 153], ["thrombocytopenia syndrome virus", "PROBLEM", 159, 190], ["Huaiyangshan virus", "PROBLEM", 194, 212], ["a red fox (sample 37) sequences", "TEST", 366, 397], ["few", "OBSERVATION_MODIFIER", 2, 5], ["Severe", "OBSERVATION_MODIFIER", 141, 147], ["fever", "OBSERVATION", 148, 153], ["thrombocytopenia", "OBSERVATION", 159, 175], ["genus Phlebovirus", "ANATOMY", 462, 479]]], ["Additional virus reads were obtained of the samples of these animals (total 43,584 of sample 22 and 30,064 reads of sample 37).", [["samples", "ANATOMY", 44, 51], ["Additional virus reads", "TEST", 0, 22], ["sample", "TEST", 86, 92], ["sample", "TEST", 116, 122]]], ["By analysis of the additional obtained sequences of sample 22, the partial viral nucleoprotein (NP) gene (S segment) and partial glycoprotein (G) gene (M segment) of a novel phlebovirus, tentatively called Otter fecal phlebovirus (NP gene 699 nt, covered by 16 reads, G gene 984 nt, covered by 59 reads, Genbank accessions KF823816 and KF823817), were identified.", [["partial glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 121, 145], ["phlebovirus", "CANCER", 174, 185], ["Otter fecal phlebovirus", "ORGANISM", 206, 229], ["sample 22", "DNA", 52, 61], ["partial viral nucleoprotein (NP) gene", "DNA", 67, 104], ["S segment", "DNA", 106, 115], ["partial glycoprotein (G) gene", "DNA", 121, 150], ["Otter fecal phlebovirus", "DNA", 206, 229], ["NP gene 699 nt", "DNA", 231, 245], ["16 reads", "DNA", 258, 266], ["G gene 984 nt", "DNA", 268, 281], ["sample", "TEST", 52, 58], ["the partial viral nucleoprotein (NP) gene (S segment)", "PROBLEM", 63, 116], ["partial glycoprotein (G) gene (M segment)", "PROBLEM", 121, 162], ["a novel phlebovirus", "PROBLEM", 166, 185], ["Otter fecal phlebovirus", "PROBLEM", 206, 229], ["Genbank accessions", "TEST", 304, 322], ["KF823817", "TEST", 336, 344], ["phlebovirus", "OBSERVATION", 174, 185], ["fecal phlebovirus", "ANATOMY", 212, 229]]], ["In addition, by analysis of the additional obtained sequences of sample 37, the partial viral nucleoprotein (NP) gene (S segment) and partial glycoprotein (G) gene (M segment) of another novel phlebovirus, tentatively called Red fox fecal phlebovirus (NP gene: 606 nt, covered by 33 reads, G gene: 1110 nt, covered by 63 reads, Genbank accessions KF823818 and KF823819) were identified (Figure 4A, B).", [["partial glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 134, 158], ["phlebovirus", "CANCER", 193, 204], ["Red fox fecal phlebovirus", "ORGANISM", 225, 250], ["G gene", "GENE_OR_GENE_PRODUCT", 290, 296], ["partial viral nucleoprotein (NP) gene", "DNA", 80, 117], ["S segment", "DNA", 119, 128], ["partial glycoprotein (G) gene", "DNA", 134, 163], ["Red fox fecal phlebovirus", "DNA", 225, 250], ["NP gene", "DNA", 252, 259], ["G gene", "DNA", 290, 296], ["KF823819", "DNA", 360, 368], ["fox fecal phlebovirus", "SPECIES", 229, 250], ["Red fox fecal phlebovirus", "SPECIES", 225, 250], ["sample", "TEST", 65, 71], ["the partial viral nucleoprotein", "TEST", 76, 107], ["partial glycoprotein (G) gene (M segment)", "PROBLEM", 134, 175], ["another novel phlebovirus", "PROBLEM", 179, 204], ["Red fox fecal phlebovirus", "PROBLEM", 225, 250], ["Genbank accessions", "TEST", 328, 346], ["KF823819", "TEST", 360, 368], ["phlebovirus", "OBSERVATION", 193, 204], ["fecal phlebovirus", "ANATOMY", 233, 250]]], ["Also sequences were detected with the closest similarity to sequences of the large segment of phleboviruses, but with a lower coverage of reads.", [["phleboviruses", "DNA", 94, 107], ["a lower coverage of reads", "TREATMENT", 118, 143], ["large", "OBSERVATION_MODIFIER", 77, 82], ["segment", "OBSERVATION_MODIFIER", 83, 90], ["phleboviruses", "OBSERVATION", 94, 107]]], ["Pairwise identity and phylogenetic analysis of the deduced amino acid sequence of the partial NP and G1 genes with various other viruses of the genus Phlebovirus suggest that both viruses are highly divergent viruses belonging to the genus Phlebovirus with pairwise identities of less than 34% on the deduced amino acid level of both viruses of both genes (Additional file 1: Table S1, Table S2, Figure 4C, D).", [["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 309, 319], ["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 309, 319], ["amino acid", "AMINO_ACID", 59, 69], ["Phlebovirus", "GENE_OR_GENE_PRODUCT", 150, 161], ["amino acid", "AMINO_ACID", 309, 319], ["partial NP and G1 genes", "DNA", 86, 109], ["phylogenetic analysis", "TEST", 22, 43], ["the deduced amino acid sequence", "TEST", 47, 78], ["various other viruses of the genus Phlebovirus", "PROBLEM", 115, 161], ["both viruses", "PROBLEM", 175, 187], ["highly divergent viruses", "PROBLEM", 192, 216], ["the genus Phlebovirus", "PROBLEM", 230, 251], ["pairwise identities", "TEST", 257, 276], ["the deduced amino acid level", "TEST", 297, 325], ["genus Phlebovirus", "OBSERVATION", 144, 161], ["viruses", "OBSERVATION", 180, 187], ["genus Phlebovirus", "ANATOMY", 234, 251], ["viruses", "OBSERVATION", 334, 341]]], ["Of interest, phleboviruses are transmitted by arthropods or ticks, but these viruses were detected in the fecal material of two animals in this study.", [["fecal material", "ANATOMY", 106, 120], ["phleboviruses", "GENE_OR_GENE_PRODUCT", 13, 26], ["fecal material", "MULTI-TISSUE_STRUCTURE", 106, 120], ["phleboviruses", "PROBLEM", 13, 26], ["ticks", "PROBLEM", 60, 65], ["these viruses", "PROBLEM", 71, 84], ["this study", "TEST", 139, 149], ["viruses", "OBSERVATION", 77, 84], ["fecal material", "OBSERVATION_MODIFIER", 106, 120]]], ["It has been demonstrated for Rift valley fever virus that after systemic infection virus can be detected in feces [37], therefore also these animals might have been infected systemically.", [["Rift valley fever", "DISEASE", 29, 46], ["systemic infection", "DISEASE", 64, 82], ["Rift valley fever virus", "ORGANISM", 29, 52], ["feces", "ORGANISM_SUBSTANCE", 108, 113], ["animals", "ORGANISM", 141, 148], ["Rift valley fever virus", "SPECIES", 29, 52], ["Rift valley fever virus", "SPECIES", 29, 52], ["Rift valley fever virus", "PROBLEM", 29, 52], ["systemic infection virus", "PROBLEM", 64, 88], ["infected", "OBSERVATION", 165, 173]]], ["However, the identification of these viruses in fecal content could be also due to the ingestion of preys (e.g. small mammals) with arthropods or ticks.Red fox fecal amdovirus ::: Results and discussionParvoviruses are small non-enveloped single-stranded DNA viruses.", [["fecal", "ANATOMY", 48, 53], ["fecal", "ORGANISM_SUBSTANCE", 48, 53], ["DNA", "CELLULAR_COMPONENT", 255, 258], ["Red fox", "SPECIES", 152, 159], ["these viruses in fecal content", "PROBLEM", 31, 61], ["Red fox", "TEST", 152, 159], ["small non-enveloped single-stranded DNA viruses", "PROBLEM", 219, 266], ["viruses", "OBSERVATION", 37, 44], ["fecal content", "OBSERVATION", 48, 61], ["fecal amdovirus", "OBSERVATION", 160, 175], ["small", "OBSERVATION_MODIFIER", 219, 224], ["non-enveloped", "OBSERVATION_MODIFIER", 225, 238]]], ["The family Parvoviridae has been subdivided into two different subfamilies, Parvovirinae and Densovirinae.", [["Parvoviridae", "CHEMICAL", 11, 23], ["Parvoviridae", "GENE_OR_GENE_PRODUCT", 11, 23], ["Densovirinae", "GENE_OR_GENE_PRODUCT", 93, 105], ["The family Parvoviridae", "TREATMENT", 0, 23], ["Parvovirinae", "TREATMENT", 76, 88], ["Densovirinae", "TREATMENT", 93, 105]]], ["Viruses of the Densovirinae infect arthropods, while viruses of the Parvovirinae infect vertebrates.", [["Densovirinae", "GENE_OR_GENE_PRODUCT", 15, 27], ["Parvovirinae", "GENE_OR_GENE_PRODUCT", 68, 80], ["the Densovirinae infect arthropods", "PROBLEM", 11, 45], ["the Parvovirinae infect vertebrates", "PROBLEM", 64, 99], ["Densovirinae infect arthropods", "OBSERVATION", 15, 45], ["infect vertebrates", "OBSERVATION", 81, 99]]], ["At present, the International Committee on Taxonomy of Viruses (ICTV) has recognized eight different genera of the subfamily Parvovirinae: Amdoparvovirus, Aveparvovirus, Bocaparvovirus, Copiparvovirus, Dependoparvovirus, Erythroparvovirus, Protoparvovirus and Tetraparvovirus[22].", [["Parvovirinae", "GENE_OR_GENE_PRODUCT", 125, 137], ["Amdoparvovirus", "GENE_OR_GENE_PRODUCT", 139, 153], ["Aveparvovirus", "GENE_OR_GENE_PRODUCT", 155, 168], ["Bocaparvovirus", "GENE_OR_GENE_PRODUCT", 170, 184], ["Copiparvovirus", "GENE_OR_GENE_PRODUCT", 186, 200], ["Dependoparvovirus", "GENE_OR_GENE_PRODUCT", 202, 219], ["Erythroparvovirus", "GENE_OR_GENE_PRODUCT", 221, 238], ["ICTV", "SPECIES", 64, 68], ["Amdoparvovirus", "TREATMENT", 139, 153], ["Aveparvovirus", "TREATMENT", 155, 168], ["Bocaparvovirus", "TREATMENT", 170, 184], ["Copiparvovirus", "TREATMENT", 186, 200], ["Dependoparvovirus", "TREATMENT", 202, 219], ["Erythroparvovirus", "TREATMENT", 221, 238], ["Protoparvovirus", "TREATMENT", 240, 255], ["Tetraparvovirus", "TREATMENT", 260, 275]]], ["The genus Amdoparvovirus currently has two members, Aleutian mink disease virus and Gray fox amdovirus.", [["Aleutian mink disease", "DISEASE", 52, 73], ["Aleutian mink disease virus", "ORGANISM", 52, 79], ["Gray fox amdovirus", "ORGANISM", 84, 102], ["Aleutian mink disease virus", "SPECIES", 52, 79], ["Aleutian mink disease virus", "SPECIES", 52, 79], ["Gray fox amdovirus", "SPECIES", 84, 102], ["Aleutian mink disease virus", "PROBLEM", 52, 79], ["genus Amdoparvovirus", "OBSERVATION", 4, 24], ["Aleutian mink disease", "OBSERVATION", 52, 73]]], ["Aleutian mink disease virus causes interstitial pneumonia in young mink and chronic immunological disorders in adult mink, but infection can also occur without clinical signs.", [["interstitial", "ANATOMY", 35, 47], ["mink disease", "DISEASE", 9, 21], ["interstitial pneumonia", "DISEASE", 35, 57], ["immunological disorders", "DISEASE", 84, 107], ["infection", "DISEASE", 127, 136], ["Aleutian mink disease virus", "ORGANISM", 0, 27], ["mink", "ORGANISM", 67, 71], ["mink", "ORGANISM", 117, 121], ["Aleutian mink disease virus", "SPECIES", 0, 27], ["mink", "SPECIES", 67, 71], ["mink", "SPECIES", 117, 121], ["Aleutian mink disease virus", "SPECIES", 0, 27], ["mink", "SPECIES", 67, 71], ["mink", "SPECIES", 117, 121], ["Aleutian mink disease virus", "PROBLEM", 0, 27], ["interstitial pneumonia", "PROBLEM", 35, 57], ["chronic immunological disorders", "PROBLEM", 76, 107], ["infection", "PROBLEM", 127, 136], ["interstitial", "OBSERVATION_MODIFIER", 35, 47], ["pneumonia", "OBSERVATION", 48, 57], ["young mink", "OBSERVATION_MODIFIER", 61, 71], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["immunological disorders", "OBSERVATION", 84, 107], ["adult mink", "OBSERVATION_MODIFIER", 111, 121], ["infection", "OBSERVATION", 127, 136]]], ["Gray fox amdovirus was identified in foxes with abnormal gait and muscle inflammation [38].", [["muscle", "ANATOMY", 66, 72], ["abnormal gait", "DISEASE", 48, 61], ["muscle inflammation", "DISEASE", 66, 85], ["Gray fox amdovirus", "ORGANISM", 0, 18], ["muscle", "ORGAN", 66, 72], ["Gray fox amdovirus", "SPECIES", 0, 18], ["Gray fox amdovirus", "TEST", 0, 18], ["abnormal gait", "PROBLEM", 48, 61], ["muscle inflammation", "PROBLEM", 66, 85], ["muscle", "ANATOMY", 66, 72], ["inflammation", "OBSERVATION", 73, 85]]], ["In fecal material of red fox sample 40, 11 sequences were detected that had the closest similarity to viruses belonging to the genus Amdovirus.", [["fecal material", "ANATOMY", 3, 17], ["fecal material", "MULTI-TISSUE_STRUCTURE", 3, 17], ["red fox", "SPECIES", 21, 28], ["red fox sample", "TEST", 21, 35], ["fecal", "ANATOMY", 3, 8], ["genus Amdovirus", "OBSERVATION", 127, 142]]], ["Based on these sequences, specific primers were designed and sequences of two partial ORFs (left ORF, putative non-structural gene 1 and 5\u2019 end; 633 nt and right ORF, putative viral protein 2; 830 nt, Genbank accessions KF823809 and KF823808) of this novel virus, tentatively called Red fox fecal amdovirus, were confirmed by Sanger sequencing (Figure 5A).", [["non-structural gene 1", "GENE_OR_GENE_PRODUCT", 111, 132], ["Red fox fecal amdovirus", "ORGANISM", 283, 306], ["ORFs", "DNA", 86, 90], ["left ORF", "DNA", 92, 100], ["putative non-structural gene 1", "DNA", 102, 132], ["5\u2019 end", "DNA", 137, 143], ["633 nt and right ORF", "DNA", 145, 165], ["putative viral protein 2", "DNA", 167, 191], ["830 nt", "DNA", 193, 199], ["Red fox fecal amdovirus", "SPECIES", 283, 306], ["these sequences", "TEST", 9, 24], ["specific primers", "TEST", 26, 42], ["two partial ORFs", "PROBLEM", 74, 90], ["left ORF", "TEST", 92, 100], ["putative non-structural gene", "TEST", 102, 130], ["nt and right ORF", "TEST", 149, 165], ["putative viral protein", "TEST", 167, 189], ["Genbank accessions", "TEST", 201, 219], ["this novel virus", "PROBLEM", 246, 262], ["Red fox fecal amdovirus", "TEST", 283, 306], ["left", "ANATOMY_MODIFIER", 92, 96], ["right", "ANATOMY_MODIFIER", 156, 161]]], ["Phylogenetic analysis and calculation of the pairwise identities of the deduced amino acid sequence of the partial VP2 gene revealed that this virus is most closely related to Grey fox amdovirus, with pairwise identities of respectively 83% on the amino acid level and 80% on the nucleotide level (Figure 5B).Red fox fecal kobuvirus ::: Results and discussionKobuviruses are small single stranded positive sense RNA viruses belonging to the family of Picornaviridae.", [["amino acid", "CHEMICAL", 80, 90], ["amino acid", "CHEMICAL", 248, 258], ["amino acid", "CHEMICAL", 80, 90], ["amino acid", "CHEMICAL", 248, 258], ["nucleotide", "CHEMICAL", 280, 290], ["amino acid", "AMINO_ACID", 80, 90], ["VP2", "GENE_OR_GENE_PRODUCT", 115, 118], ["Grey fox amdovirus", "ORGANISM", 176, 194], ["amino acid", "AMINO_ACID", 248, 258], ["VP2 gene", "DNA", 115, 123], ["fox amdovirus", "SPECIES", 181, 194], ["Grey fox amdovirus", "SPECIES", 176, 194], ["Red fox fecal kobuvirus", "SPECIES", 309, 332], ["Phylogenetic analysis", "TEST", 0, 21], ["the deduced amino acid sequence", "TEST", 68, 99], ["the partial VP2 gene", "TEST", 103, 123], ["this virus", "PROBLEM", 138, 148], ["Grey fox amdovirus", "TEST", 176, 194], ["the amino acid level", "TEST", 244, 264], ["the nucleotide level", "TEST", 276, 296], ["discussionKobuviruses", "TEST", 349, 370], ["small single stranded positive sense RNA viruses", "PROBLEM", 375, 423], ["Picornaviridae", "TREATMENT", 451, 465], ["fox amdovirus", "OBSERVATION", 181, 194], ["fecal kobuvirus", "OBSERVATION", 317, 332], ["small", "OBSERVATION_MODIFIER", 375, 380]]], ["At present, the genus Kobuvirus consists of three species, Aichivirus A, B and C. Aichivirus A, B and C were detected in enteric samples from humans, cows and pigs respectively [39-41].", [["samples", "ANATOMY", 129, 136], ["Aichivirus A", "ORGANISM", 59, 71], ["B", "GENE_OR_GENE_PRODUCT", 73, 74], ["C. Aichivirus A", "ORGANISM", 79, 94], ["B", "GENE_OR_GENE_PRODUCT", 96, 97], ["C", "GENE_OR_GENE_PRODUCT", 102, 103], ["enteric samples", "ORGANISM_SUBSTANCE", 121, 136], ["humans", "ORGANISM", 142, 148], ["cows", "ORGANISM_SUBDIVISION", 150, 154], ["pigs", "ORGANISM", 159, 163], ["humans", "SPECIES", 142, 148], ["cows", "SPECIES", 150, 154], ["pigs", "SPECIES", 159, 163], ["Aichivirus A", "SPECIES", 59, 71], ["humans", "SPECIES", 142, 148], ["pigs", "SPECIES", 159, 163], ["the genus Kobuvirus", "TEST", 12, 31], ["three species", "PROBLEM", 44, 57], ["genus Kobuvirus", "OBSERVATION", 16, 31]]], ["In addition, kobuviruses were detected in fecal samples of a number of other species recently [42].", [["fecal samples", "ANATOMY", 42, 55], ["kobuviruses", "GENE_OR_GENE_PRODUCT", 13, 24], ["fecal samples", "ORGANISM_SUBSTANCE", 42, 55], ["kobuviruses", "PROTEIN", 13, 24], ["kobuviruses", "TREATMENT", 13, 24], ["fecal samples", "TEST", 42, 55]]], ["Although seroprevalence studies suggest that infections with kobuviruses are common, their role as a primary pathogen is unknown [43,44].Red fox fecal kobuvirus ::: Results and discussionSequences with the closest similarity to kobuviruses were detected in a common genet (sample 13) and in two red foxes (samples 37 and 39) (Table 1).", [["infections", "DISEASE", 45, 55], ["kobuviruses", "DISEASE", 61, 72], ["kobuviruses", "CANCER", 228, 239], ["kobuviruses", "DNA", 228, 239], ["Red fox fecal kobuvirus", "SPECIES", 137, 160], ["red foxes", "SPECIES", 295, 304], ["seroprevalence studies", "TEST", 9, 31], ["infections with kobuviruses", "PROBLEM", 45, 72], ["infections", "OBSERVATION", 45, 55], ["fecal kobuvirus", "OBSERVATION", 145, 160]]], ["Kobuvirus sequences detected in the common genet had the closest similarity to kobuviruses detected in mice and sewage [7,45], while kobuvirus sequences detected in the foxes were nearly identical to kobuviruses detected in healthy and diarrheic dogs [43,46,47].", [["kobuviruses", "DISEASE", 79, 90], ["kobuviruses", "CANCER", 79, 90], ["mice", "ORGANISM", 103, 107], ["kobuvirus", "GENE_OR_GENE_PRODUCT", 133, 142], ["kobuviruses", "CANCER", 200, 211], ["Kobuvirus sequences", "DNA", 0, 19], ["kobuviruses", "DNA", 79, 90], ["kobuvirus sequences", "DNA", 133, 152], ["mice", "SPECIES", 103, 107], ["dogs", "SPECIES", 246, 250], ["mice", "SPECIES", 103, 107], ["Kobuvirus sequences", "TEST", 0, 19], ["kobuvirus sequences", "TEST", 133, 152]]], ["Using primers described previously [46], the partial 3D region of a variant kobuvirus detected in feces of a red fox (sample 37), tentatively called Red fox fecal kobuvirus (Genbank accession KF823813) was amplified and sequenced.", [["feces", "ANATOMY", 98, 103], ["feces", "ORGANISM_SUBDIVISION", 98, 103], ["red fox", "ORGANISM", 109, 116], ["Red fox fecal kobuvirus", "ORGANISM", 149, 172], ["partial 3D region", "DNA", 45, 62], ["fox fecal kobuvirus", "SPECIES", 153, 172], ["red fox", "SPECIES", 109, 116], ["Red fox fecal kobuvirus", "SPECIES", 149, 172], ["Genbank accession KF823813", "SPECIES", 174, 200], ["a variant kobuvirus", "PROBLEM", 66, 85], ["a red fox", "TEST", 107, 116], ["variant kobuvirus", "OBSERVATION", 68, 85]]], ["Alignment and phylogenetic analysis of this Red fox fecal kobuvirus with various other kobuviruses indeed confirmed that detected sequences were very similar to canine kobuviruses, with an identity of 97% on the nucleotide and 100% on the deduced amino acid level with Canine kobuviruses detected in Italy recently [46] (Figure 6).", [["nucleotide", "CHEMICAL", 212, 222], ["amino acid", "CHEMICAL", 247, 257], ["nucleotide", "CHEMICAL", 212, 222], ["amino acid", "CHEMICAL", 247, 257], ["Red fox", "ORGANISM", 44, 51], ["fecal kobuvirus", "ORGANISM", 52, 67], ["kobuviruses", "CANCER", 87, 98], ["canine", "ORGANISM", 161, 167], ["kobuviruses", "CANCER", 168, 179], ["amino acid", "AMINO_ACID", 247, 257], ["canine", "SPECIES", 161, 167], ["Red fox fecal kobuvirus", "SPECIES", 44, 67], ["canine kobuviruses", "SPECIES", 161, 179], ["Canine kobuviruses", "SPECIES", 269, 287], ["phylogenetic analysis", "TEST", 14, 35], ["this Red fox fecal kobuvirus", "PROBLEM", 39, 67], ["various other kobuviruses", "PROBLEM", 73, 98], ["an identity", "TEST", 186, 197], ["the nucleotide", "TEST", 208, 222], ["the deduced amino acid level", "TEST", 235, 263], ["Canine kobuviruses", "PROBLEM", 269, 287]]], ["The high similarity between kobuviruses detected in dogs and foxes suggest that kobuviruses of dogs and red foxes can be easily transmitted from one host to another or that transmission of these viruses has occurred relatively recently.Novel picobirnaviruses ::: Results and discussionPicobirnaviruses are small, non-enveloped, bisegmented double-stranded RNA viruses.", [["picobirnaviruses", "CHEMICAL", 242, 258], ["kobuviruses", "GENE_OR_GENE_PRODUCT", 28, 39], ["dogs", "ORGANISM", 52, 56], ["dogs", "ORGANISM", 95, 99], ["red foxes", "ORGANISM", 104, 113], ["picobirnaviruses", "SIMPLE_CHEMICAL", 242, 258], ["Picobirnaviruses", "GENE_OR_GENE_PRODUCT", 285, 301], ["dogs", "SPECIES", 52, 56], ["dogs", "SPECIES", 95, 99], ["red foxes", "SPECIES", 104, 113], ["red foxes", "PROBLEM", 104, 113], ["these viruses", "PROBLEM", 189, 202], ["bisegmented double-stranded RNA viruses", "PROBLEM", 328, 367], ["high similarity", "OBSERVATION_MODIFIER", 4, 19], ["viruses", "OBSERVATION", 195, 202], ["small", "OBSERVATION_MODIFIER", 306, 311], ["RNA viruses", "OBSERVATION", 356, 367]]], ["These viruses have been often detected in fecal samples of humans and various animal species with and without disease [7,14,48,49].", [["fecal samples", "ANATOMY", 42, 55], ["fecal samples", "ORGANISM_SUBSTANCE", 42, 55], ["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["These viruses", "PROBLEM", 0, 13], ["fecal samples", "TEST", 42, 55], ["various animal species", "PROBLEM", 70, 92], ["disease", "PROBLEM", 110, 117], ["viruses", "OBSERVATION", 6, 13]]], ["In the present study, sequences that had the closest similarity to viruses belonging to the family Picobirnaviridae were detected in fecal samples collected from two common genets, two European minks and two red foxes (Table 1).", [["fecal samples", "ANATOMY", 133, 146], ["Picobirnaviridae", "GENE_OR_GENE_PRODUCT", 99, 115], ["fecal samples", "ORGANISM_SUBSTANCE", 133, 146], ["red foxes", "SPECIES", 208, 217], ["the present study", "TEST", 3, 20], ["the family Picobirnaviridae", "TREATMENT", 88, 115], ["fecal samples", "TEST", 133, 146], ["fecal", "ANATOMY", 133, 138]]], ["Based on 454-sequencing reads, the (partial) coding sequences of the RNA-dependent RNA polymerase (RdRp) gene of a novel picobirnavirus detected in one common genet (sample 14; 811 nt, Genet fecal picobirnavirus, Genbank accession KF823812) and of two novel picobirnaviruses detected in a red fox (sample 40, Red fox fecal picobirnavirus 40\u20131; 1560 nt and 40\u20132; 1669 nt, Genbank accessions KF823810 and KF823811) were obtained (Figure 7A).", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 69, 97], ["picobirnavirus", "CANCER", 121, 135], ["picobirnaviruses", "CANCER", 258, 274], ["red fox", "ORGANISM", 289, 296], ["454-sequencing reads", "DNA", 9, 29], ["RNA-dependent RNA polymerase (RdRp) gene", "DNA", 69, 109], ["red fox", "SPECIES", 289, 296], ["Red fox fecal picobirnavirus 40\u20131", "SPECIES", 309, 342], ["the RNA", "TEST", 65, 72], ["a novel picobirnavirus", "PROBLEM", 113, 135], ["nt", "TEST", 181, 183], ["Genet fecal picobirnavirus", "TEST", 185, 211], ["two novel picobirnaviruses", "PROBLEM", 248, 274], ["a red fox", "TEST", 287, 296], ["Red fox fecal picobirnavirus", "TEST", 309, 337], ["Genbank accessions", "TEST", 371, 389]]], ["Alignment and phylogenetic analysis of these viruses with RdRp gene sequences of similar length of other picobirnaviruses showed that obtained sequences of the RdRp gene were most closely related to picobirnaviruses detected previously in rodents and otarines (Figure 7B).Novel picobirnaviruses ::: Results and discussionVarious sequences of known and novel viruses were identified but no known zoonotic viruses were detected.", [["zoonotic viruses", "DISEASE", 395, 411], ["picobirnaviruses", "CHEMICAL", 278, 294], ["picobirnaviruses", "CANCER", 105, 121], ["RdRp", "GENE_OR_GENE_PRODUCT", 160, 164], ["picobirnaviruses", "CANCER", 199, 215], ["picobirnaviruses", "SIMPLE_CHEMICAL", 278, 294], ["RdRp gene sequences", "DNA", 58, 77], ["RdRp gene", "DNA", 160, 169], ["picobirnaviruses", "DNA", 199, 215], ["phylogenetic analysis", "TEST", 14, 35], ["these viruses", "PROBLEM", 39, 52], ["RdRp gene sequences", "TEST", 58, 77], ["the RdRp gene", "PROBLEM", 156, 169], ["picobirnaviruses", "PROBLEM", 199, 215], ["discussionVarious sequences", "TEST", 311, 338], ["known and novel viruses", "PROBLEM", 342, 365], ["known zoonotic viruses", "PROBLEM", 389, 411], ["zoonotic", "OBSERVATION_MODIFIER", 395, 403], ["viruses", "OBSERVATION", 404, 411]]], ["In addition to the viral sequences characterized in the present manuscript, a novel rhabdovirus was discovered in feces of a red fox (nr 40, Bodewes et al., manuscript submitted for publication), which was divergent from currently known rhabdoviruses, with pairwise identities on the amino acid level of the L gene of this novel rhabdovirus with other viruses of the family Rhabdoviridae of only 35% or less.Novel picobirnaviruses ::: Results and discussionThe presence and detection of the obtained viral sequences is potentially biased by multiple factors, including ecological factors, virus concentrations, a PCR bias, a bioinformatics analysis bias and possible contamination of laboratory kits since we also identified sequences with the closest similarity with NIH-CQV/PHV, although only in one sample [16].", [["amino acid", "CHEMICAL", 284, 294], ["amino acid", "CHEMICAL", 284, 294], ["picobirnaviruses", "CHEMICAL", 414, 430], ["rhabdovirus", "CANCER", 84, 95], ["feces", "ORGANISM_SUBDIVISION", 114, 119], ["rhabdoviruses", "CANCER", 237, 250], ["amino acid", "AMINO_ACID", 284, 294], ["rhabdovirus", "CANCER", 329, 340], ["picobirnaviruses", "SIMPLE_CHEMICAL", 414, 430], ["viral sequences", "DNA", 19, 34], ["L gene", "DNA", 308, 314], ["viral sequences", "DNA", 500, 515], ["CQV", "DNA", 772, 775], ["red fox", "SPECIES", 125, 132], ["NIH-CQV/PHV", "SPECIES", 768, 779], ["the viral sequences", "TEST", 15, 34], ["a novel rhabdovirus", "PROBLEM", 76, 95], ["a red fox", "PROBLEM", 123, 132], ["known rhabdoviruses", "PROBLEM", 231, 250], ["the amino acid level", "TEST", 280, 300], ["this novel rhabdovirus", "PROBLEM", 318, 340], ["the family Rhabdoviridae", "TREATMENT", 363, 387], ["the obtained viral sequences", "PROBLEM", 487, 515], ["ecological factors", "PROBLEM", 569, 587], ["virus concentrations", "PROBLEM", 589, 609], ["a PCR bias", "TEST", 611, 621], ["a bioinformatics analysis bias", "TEST", 623, 653], ["laboratory kits", "TEST", 684, 699], ["NIH", "TEST", 768, 771], ["PHV", "TREATMENT", 776, 779], ["rhabdoviruses", "OBSERVATION", 237, 250], ["L", "ANATOMY_MODIFIER", 308, 309], ["rhabdovirus", "OBSERVATION", 329, 340]]], ["Since for almost all animals only fecal material was available, it is unknown whether these novel viruses have caused disease in the host or if they might potentially transmit to domestic animals or humans.", [["fecal material", "MULTI-TISSUE_STRUCTURE", 34, 48], ["humans", "ORGANISM", 199, 205], ["humans", "SPECIES", 199, 205], ["humans", "SPECIES", 199, 205], ["fecal material", "PROBLEM", 34, 48], ["these novel viruses", "PROBLEM", 86, 105], ["disease in the host", "PROBLEM", 118, 137]]], ["Additional studies based on collection of blood samples and complete necropsies are necessary to elucidate the pathogenicity and epidemiology of these viruses.", [["blood samples", "ANATOMY", 42, 55], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["Additional studies", "TEST", 0, 18], ["collection of blood samples", "TEST", 28, 55], ["complete necropsies", "TEST", 60, 79], ["the pathogenicity", "PROBLEM", 107, 124], ["these viruses", "PROBLEM", 145, 158], ["viruses", "OBSERVATION", 151, 158]]], ["Of interest, a number of species evaluated in the present study have been the focus of previous viral metagenomics studies in the Netherlands [9,14].", [["previous viral metagenomics studies", "TEST", 87, 122]]], ["Still, high numbers of previously unknown viruses were detected.", [["previously unknown viruses", "PROBLEM", 23, 49], ["high", "OBSERVATION_MODIFIER", 7, 11], ["numbers", "OBSERVATION_MODIFIER", 12, 19], ["viruses", "OBSERVATION", 42, 49]]], ["This might be due to the relatively low number of animals sampled in each study or due to the geographic distance between the Netherlands and Spain.", [["each study", "TEST", 69, 79], ["might be due to", "UNCERTAINTY", 5, 20], ["relatively", "OBSERVATION_MODIFIER", 25, 35], ["low", "OBSERVATION_MODIFIER", 36, 39], ["number", "OBSERVATION_MODIFIER", 40, 46]]], ["Further studies using samples of more countries are necessary to elucidate the geographical spread of each of these viruses among animals in Europe and beyond.", [["Further studies", "TEST", 0, 15], ["samples", "TEST", 22, 29], ["viruses", "OBSERVATION", 116, 123]]], ["In addition, in spite of their relevance as potential carriers of pathogens, only a few recent studies have conducted thorough metagenomic analysis of fecal material on wild carnivore species [9,14,50].ConclusionsThe present study highlights the viral diversity that is present in fecal material of wild carnivores.", [["fecal material", "ANATOMY", 281, 295], ["fecal material", "MULTI-TISSUE_STRUCTURE", 151, 165], ["fecal material", "MULTI-TISSUE_STRUCTURE", 281, 295], ["pathogens", "PROBLEM", 66, 75], ["a few recent studies", "TEST", 82, 102], ["thorough metagenomic analysis", "TEST", 118, 147], ["fecal material", "PROBLEM", 151, 165], ["The present study", "TEST", 213, 230], ["the viral diversity", "PROBLEM", 242, 261], ["fecal material", "OBSERVATION_MODIFIER", 151, 165], ["viral diversity", "OBSERVATION", 246, 261], ["fecal material", "OBSERVATION_MODIFIER", 281, 295], ["wild carnivores", "OBSERVATION", 299, 314]]], ["Results obtained in this study are a step forward in order to improve the limited knowledge about virus diversity present in wild carnivores in Europe and will help to get a better understanding of potential cross-species transmission of viruses between diverse hosts [51] and provide information about potential pathogens [52].Sample collection ::: Materials and methodsRectal swabs or fecal specimens were collected from 42 carnivores in the Basque Country and La Rioja regions, Spain (Figure 1; Table 1).", [["Rectal swabs", "ANATOMY", 371, 383], ["fecal specimens", "ANATOMY", 387, 402], ["Rectal swabs", "ORGANISM_SUBSTANCE", 371, 383], ["fecal specimens", "ORGANISM_SUBSTANCE", 387, 402], ["this study", "TEST", 20, 30], ["virus diversity", "PROBLEM", 98, 113], ["methods", "TEST", 364, 371], ["Rectal swabs", "TEST", 371, 383], ["fecal specimens", "TEST", 387, 402], ["Rectal", "ANATOMY", 371, 377], ["fecal", "ANATOMY", 387, 392]]], ["Samples from the Canidae, Mustelidae, Viverridae and Felidae families of the order Carnivora, including American mink (n = 10), Common genet (n = 7), Eurasian badger (n = 4), Eurasian otter (n = 1), European mink (n = 9), European pine marten (n = 2); European polecat (n = 3), red fox (n = 4), stone marten (n = 1), and European wild cat (n = 1) were analysed in the present study.", [["Samples", "ANATOMY", 0, 7], ["stone marten", "DISEASE", 295, 307], ["cat", "ORGANISM", 335, 338], ["mink", "SPECIES", 113, 117], ["Eurasian badger", "SPECIES", 150, 165], ["Eurasian otter", "SPECIES", 175, 189], ["mink", "SPECIES", 208, 212], ["cat", "SPECIES", 335, 338], ["American mink", "SPECIES", 104, 117], ["Eurasian badger", "SPECIES", 150, 165], ["Eurasian otter", "SPECIES", 175, 189], ["European mink", "SPECIES", 199, 212], ["European pine marten", "SPECIES", 222, 242], ["red fox", "SPECIES", 278, 285], ["European wild cat", "SPECIES", 321, 338], ["Samples", "TEST", 0, 7], ["Viverridae", "TREATMENT", 38, 48], ["Eurasian badger (n", "TREATMENT", 150, 168], ["European mink", "TEST", 199, 212], ["European pine marten", "TEST", 222, 242], ["European polecat", "TEST", 252, 268], ["red fox", "TEST", 278, 285], ["stone marten", "PROBLEM", 295, 307], ["the present study", "TEST", 364, 381], ["stone", "OBSERVATION", 295, 300]]], ["Carnivore samples were obtained from found-dead animals, (road casualties and/or poaching) collected by authorized veterinarian personnel of the Wildlife Rehabilitation Centre of Martioda (Alava Regional Council.", [["samples", "ANATOMY", 10, 17], ["Carnivore samples", "CANCER", 0, 17], ["Carnivore samples", "TEST", 0, 17]]], ["Department of Environment; Biodiversity section).", [["Biodiversity section", "TREATMENT", 27, 47]]], ["Additionally, samples from live trapped individuals were obtained in the framework of a systematic population study of the Endangered European mink (Mustela lutreola) and the control and eradication program of the invasive alien American mink in Spain, for other purposes than this study (Ref: 3088046-CONSERVISON.", [["samples", "ANATOMY", 14, 21], ["individuals", "ORGANISM", 40, 51], ["mink", "ORGANISM", 143, 147], ["Mustela", "ORGANISM", 149, 156], ["lutreola", "ORGANISM", 157, 165], ["mink", "ORGANISM", 238, 242], ["mink", "SPECIES", 143, 147], ["Mustela lutreola", "SPECIES", 149, 165], ["mink", "SPECIES", 238, 242], ["European mink", "SPECIES", 134, 147], ["Mustela lutreola", "SPECIES", 149, 165], ["American mink", "SPECIES", 229, 242], ["a systematic population study", "TEST", 86, 115], ["Mustela lutreola)", "TREATMENT", 149, 166], ["the control", "TREATMENT", 171, 182], ["eradication program", "TREATMENT", 187, 206], ["this study", "TEST", 277, 287], ["Endangered European mink", "OBSERVATION", 123, 147], ["invasive", "OBSERVATION_MODIFIER", 214, 222]]], ["Conservation actions for the Endangered European mink: National strategy development, ex-situ conservation program and American mink eradication.", [["mink", "SPECIES", 49, 53], ["European mink", "SPECIES", 40, 53], ["American mink", "SPECIES", 119, 132], ["ex-situ conservation program", "TREATMENT", 86, 114], ["American mink eradication", "TREATMENT", 119, 144]]], ["All the trapping, handling, sampling and American mink culling was performed by specialized wildlife researchers and veterinarians with the permission of regional wildlife authorities (La Rioja Government.", [["mink", "SPECIES", 50, 54], ["trapping", "OBSERVATION_MODIFIER", 8, 16]]], ["General Direction of Natural Environment.", [["Natural Environment", "OBSERVATION", 21, 40]]], ["Nature Conservation and Planning Service: Ref: LL/aic; Alava Regional Council.", [["LL", "ANATOMY", 47, 49], ["aic", "ANATOMY", 50, 53]]], ["No animals were sacrificed for the purposes of this study.", [["this study", "TEST", 47, 57]]], ["Following collection, samples were directly stored at \u221220\u00b0C and were stored at \u221270\u00b0C within 2 months after collection until further processing.Sequence independent RNA and DNA virus screening of collected samples ::: Materials and methodsSamples were processed for viral metagenomics as described previously [9,49].", [["samples", "ANATOMY", 22, 29], ["samples", "ANATOMY", 205, 212], ["C", "GENE_OR_GENE_PRODUCT", 58, 59], ["DNA", "CELLULAR_COMPONENT", 172, 175], ["samples", "TEST", 22, 29], ["collection", "PROBLEM", 107, 117], ["Sequence independent RNA", "TEST", 143, 167], ["DNA virus screening", "TEST", 172, 191], ["methodsSamples", "TEST", 231, 245], ["viral metagenomics", "PROBLEM", 265, 283]]], ["In brief, samples were depleted from host nucleic acids and filtered through a 0.45 \u03bcM filter.", [["samples", "ANATOMY", 10, 17], ["nucleic acids", "CHEMICAL", 42, 55], ["host nucleic acids", "TEST", 37, 55], ["a 0.45 \u03bcM filter", "TREATMENT", 77, 93]]], ["Subsequently, RNA and DNA were extracted using the Nucleospin RNA XS kit (Macherey-Nagel) and the High Pure viral nucleic acids kit (Roche).", [["DNA", "CELLULAR_COMPONENT", 22, 25], ["the Nucleospin RNA", "TREATMENT", 47, 65], ["nucleic acids", "OBSERVATION", 114, 127]]], ["First and second strand synthesis and random PCR amplification were performed.", [["second strand synthesis", "PROBLEM", 10, 33], ["random PCR amplification", "TEST", 38, 62]]], ["PCR products were purified and processed for next-generation sequencing with a 454 GS Junior Instrument (Roche).", [["PCR products", "TREATMENT", 0, 12]]], ["Obtained reads were assembled using de novo assembly in CLC Genomics Workbench 5 (CLC Bio) and contigs and individual reads were analyzed by BLASTN and BLASTX respectively.", [["CLC Genomics Workbench 5", "DNA", 56, 80], ["CLC Bio", "DNA", 82, 89], ["BLASTX", "DNA", 152, 158]]], ["Cut off E-values for significant virus hits for BLASTN and BLASTX were respectively 1.0 \u00d7 10\u22123 and 1.0 \u00d7 10\u221210.", [["significant virus hits", "PROBLEM", 21, 43], ["BLASTN", "TEST", 48, 54], ["BLASTX", "TEST", 59, 65]]], ["Based on the taxonomic origin of the best-hit sequence, classification of the sequences was performed in MEGAN 4.70.4 [53].", [["the sequences", "TEST", 74, 87], ["MEGAN", "TEST", 105, 110]]], ["Obtained reads were deposited at the European Nucleotide Archive under archive number PRJEB4910.PCR amplification and sequencing ::: Materials and methodsBased on obtained next-generation sequencing data, specific primers of the novel rhabdovirus, theilovirus, and amdovirus were designed to confirm and partially extend the obtained sequence data.", [["rhabdovirus", "GENE_OR_GENE_PRODUCT", 235, 246], ["theilovirus", "GENE_OR_GENE_PRODUCT", 248, 259], ["European Nucleotide Archive", "DNA", 37, 64], ["rhabdovirus", "DNA", 235, 246], ["PCR amplification", "TEST", 96, 113], ["the novel rhabdovirus", "TEST", 225, 246], ["theilovirus", "TEST", 248, 259], ["the obtained sequence data", "TEST", 321, 347]]], ["Products were sequenced as described previously and primer sequences are available upon request [49].Phylogenetic and protein analysis ::: Materials and methodsNucleotide and/or deduced amino acid sequences of the novel kobuvirus, theilovirus, amdovirus, and picobirnaviruses were aligned using ClustalW in MEGA5 with default parameters [54], while deduced amino acid sequences of the novel phleboviruses were aligned using MAFFT (vs 7; http://mafft.cbrc.jp/alignment/software/) with the E-INS-I algorithm and otherwise default parameters.", [["amino acid", "CHEMICAL", 186, 196], ["amino acid", "CHEMICAL", 357, 367], ["amino acid", "CHEMICAL", 186, 196], ["amino acid", "CHEMICAL", 357, 367], ["amino acid", "AMINO_ACID", 186, 196], ["kobuvirus", "GENE_OR_GENE_PRODUCT", 220, 229], ["theilovirus", "GENE_OR_GENE_PRODUCT", 231, 242], ["amdovirus", "GENE_OR_GENE_PRODUCT", 244, 253], ["picobirnaviruses", "GENE_OR_GENE_PRODUCT", 259, 275], ["amino acid", "AMINO_ACID", 357, 367], ["phleboviruses", "CANCER", 391, 404], ["primer sequences", "DNA", 52, 68], ["kobuvirus", "PROTEIN", 220, 229], ["MEGA5", "DNA", 307, 312], ["E-INS-I algorithm", "DNA", 488, 505], ["Phylogenetic and protein analysis", "TEST", 101, 134], ["methodsNucleotide", "TREATMENT", 153, 170], ["deduced amino acid sequences", "TEST", 178, 206], ["the novel kobuvirus", "PROBLEM", 210, 229], ["theilovirus", "TEST", 231, 242], ["amdovirus", "TREATMENT", 244, 253], ["picobirnaviruses", "TREATMENT", 259, 275], ["amino acid sequences", "TEST", 357, 377], ["MAFFT", "TEST", 424, 429], ["http:", "TEST", 437, 442], ["the E-INS-I algorithm", "TREATMENT", 484, 505]]], ["Phylogenetic analysis of the novel theilovirus, kobuvirus, amdovirus and picobirnaviruses were performed using a neighbor-joining tree with 1000 bootstrap replicates in MEGA5, while phylogenetic analysis of GP and NP genes of the novel phleboviruses was performed using a maximum-likelihood tree (WAG + F + I + G model) with 100 bootstrap replicates.", [["theilovirus", "GENE_OR_GENE_PRODUCT", 35, 46], ["kobuvirus", "GENE_OR_GENE_PRODUCT", 48, 57], ["amdovirus", "GENE_OR_GENE_PRODUCT", 59, 68], ["picobirnaviruses", "CANCER", 73, 89], ["GP", "GENE_OR_GENE_PRODUCT", 207, 209], ["phleboviruses", "CANCER", 236, 249], ["theilovirus, kobuvirus, amdovirus and picobirnaviruses", "DNA", 35, 89], ["neighbor-joining tree", "DNA", 113, 134], ["MEGA5", "DNA", 169, 174], ["GP and NP genes", "DNA", 207, 222], ["Phylogenetic analysis", "TEST", 0, 21], ["the novel theilovirus", "PROBLEM", 25, 46], ["kobuvirus", "TEST", 48, 57], ["amdovirus", "TREATMENT", 59, 68], ["picobirnaviruses", "TREATMENT", 73, 89], ["a neighbor-joining tree", "TREATMENT", 111, 134], ["MEGA5", "TREATMENT", 169, 174], ["phylogenetic analysis", "TEST", 182, 203], ["GP", "TEST", 207, 209], ["the novel phleboviruses", "PROBLEM", 226, 249]]], ["Alignment of the amino acids of the major surface structures of the theiloviruses was performed with JalView version 2 [55].", [["surface structures", "ANATOMY", 42, 60], ["amino acids", "CHEMICAL", 17, 28], ["amino acids", "CHEMICAL", 17, 28], ["amino acids", "AMINO_ACID", 17, 28], ["surface structures", "CELLULAR_COMPONENT", 42, 60], ["the amino acids", "TEST", 13, 28]]], ["Prediction of cleavage sites of picornaviral proteases was performed using NetPicoRNA 1.0 (http://www.cbs.dtu.dk/services/NetPicoRNA/).", [["picornaviral proteases", "PROTEIN", 32, 54], ["NetPicoRNA 1.0", "DNA", 75, 89], ["picornaviral proteases", "PROBLEM", 32, 54], ["NetPicoRNA", "TEST", 75, 85]]], ["Other conserved motifs were predicted with MEME 4.9.0 (http://meme.nbcr.net/meme/).", [["MEME 4.9.0", "DNA", 43, 53], ["MEME", "TEST", 43, 47]]], ["The presence of conserved domains was evaluated using the Conserved Domains Database [56].Competing interestsTwo authors of the manuscript have interests to declare: Prof. Dr. A.D.M.E. Osterhaus and Dr. S.L. Smits are part time chief scientific officer and senior scientist respectively of Viroclinics Biosciences B.V. There are no patents, products in development or marketed products to declare.", [["no", "UNCERTAINTY", 329, 331], ["patents", "OBSERVATION", 332, 339]]], ["JMAB and CMES performed the experiments and analyzed the data.", [["the data", "TEST", 53, 61]]], ["ADMEO designed the experiments and analyzed the data.", [["the data", "TEST", 44, 52]]]]}